metformin has been researched along with Obesity in 1238 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin." | 9.69 | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. ( Cai, H; Chen, Q; Duan, Y; Zhang, X; Zhao, Y, 2023) |
| "We aimed to determine the efficacy and safety of DDG combined with metformin for the treatment of T2DM patients with obesity." | 9.69 | Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial. ( Liu, Z; Wang, F; Wang, L; Wang, M; Zhang, J; Zhang, K; Zhang, Y; Zhou, S; Zhou, Y, 2023) |
| "Metformin showed favourable effect on GV in overweight/obese T1DM patients and reduction in systolic blood pressure, TDD insulin, fasting venous glucose and fructosamine." | 9.69 | Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes. ( Adam, NLB; Chin Voon, T; Long Bidin, MBB; Poh Shean, W, 2023) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 9.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 9.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 9.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 9.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "Among men with obesity and low testosterone concentrations, the combination of metformin plus testosterone, metformin only, and testosterone only, compared to placebo, reduced insulin resistance with no evidence of additive benefit." | 9.51 | Metformin, testosterone, or both in men with obesity and low testosterone: A double-blind, parallel-group, randomized controlled trial. ( Asenjo-Plaza, M; Barrios-Rodríguez, R; Fernández-García, JC; Guzmán-Guzmán, A; Jiménez-Moleón, JJ; Martínez-González, MÁ; Molina-Vega, M; Moreno-León, L; Ramos-Molina, B; Rius-Díaz, F; Tinahones, FJ; Valdés, S; Yubero-Serrano, EM, 2022) |
| "To observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS)." | 9.51 | Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. ( He, B; Xing, C; Zhang, J; Zhao, H, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| " The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate." | 9.51 | Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022) |
| "Metformin is widely used in pregnancy, despite lack of long-term safety for children." | 9.51 | Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood. ( Denison, FC; Dhaun, N; Drake, AJ; Lacey, L; Norman, JE; Quenby, S; Reynolds, RM; Whyte, S; Yang, L, 2022) |
| "Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks." | 9.41 | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. ( Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY, 2021) |
| "This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART)." | 9.41 | Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy. ( Bianchi, C; Burlina, S; Formoso, G; Manicardi, E; Resi, V; Sciacca, L; Sculli, MA, 2023) |
| "This is the first meta-analysis of the available literature about the efficacy of metformin exclusively in pediatric patients with non-alcoholic fatty liver disease (NAFLD)." | 9.41 | The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. ( Cheirakis, K; Christakopoulos, A; Fotoulaki, M; Gkiourtzis, N; Glava, A; Michou, P; Moutafi, M; Vouksinou, E, 2023) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 9.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment." | 9.41 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. ( Appel, LJ; Carducci, MA; Charleston, J; Dalcin, AT; Durkin, N; Hassoon, A; Jerome, GJ; Juraschek, SP; Kanarek, NF; Lansey, DG; Maruthur, NM; Miller, ER; Mueller, NT; Tseng, E; Wang, NY; White, K; Yeh, HC, 2021) |
| "This study aims to assess the therapeutic effects of a well-known component (puerarin) obtained from a Chinese herb root in patients with polycystic ovary syndrome (PCOS)." | 9.41 | Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. ( Hu, H; Li, F; Li, W; Liu, J; Ma, Z; Zou, G, 2021) |
| "We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention." | 9.41 | A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. ( Algotar, AM; Altbach, M; Centuori, S; Chalasani, P; Chow, HS; Galons, JP; Guillen-Rodriguez, J; Huang, C; Martinez, JA; Pinto, L; Roe, DJ; Tapia, E; Thomson, CA; Trujillo, J; Villa-Guillen, DE, 2021) |
| "To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.34 | Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. ( Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q, 2020) |
| "Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1." | 9.34 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. ( Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F, 2020) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 9.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| "Metformin treatment (1000-2000 mg/day) over 6 months in pubertal children and/or adolescents with obesity and hyperinsulinism is associated with a reduction in body mass index (BMI) and the insulin resistance index (HOMA-IR)." | 9.30 | Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Dorado-Ceballos, E; Ibáñez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Mas-Parés, B; Osiniri, I; Prats-Puig, A; Xargay-Torrent, S, 2019) |
| "To evaluate the impact of metformin on in vitro fertilization (IVF) outcomes in overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.30 | Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. ( Abbas, AM; Abdalmageed, OS; Abdelaleem, AA; Abdelmagied, AE; Ali, MK; Farghaly, TA, 2019) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 9.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 9.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| " We investigated the effect of liraglutide combined with metformin on LGI and lipoprotein density profiles in patients with stable coronary artery disease (CAD) and newly diagnosed T2DM." | 9.30 | Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. ( Anholm, C; Fenger, M; Haugaard, SB; Kristiansen, OP; Kumarathurai, P; Madsbad, S; Nielsen, OW; Pedersen, LR; Sajadieh, A; Samkani, A; Walzem, RL, 2019) |
| "Metformin prevents weight gain in patients with type 2 diabetes (T2D)." | 9.27 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. ( Jager-Wittenaar, H; Kooy, A; Krijnen, W; Lehert, P; Miedema, I; Out, M; Stehouwer, C; van der Schans, C, 2018) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 9.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet." | 9.27 | Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. ( Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E, 2018) |
| "Proof-of-concept study to investigate the amplifying effects of diazoxide (DZX)-mediated insulin suppression on lifestyle-induced weight loss in nondiabetic, hyperinsulinemic, obese men." | 9.27 | High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| " The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D." | 9.27 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. ( Beale, E; Buchanan, TA; Chow, T; Hendee, F; Katkhouda, N; Martinez, M; Montgomery, C; Nayak, KS; Trigo, E; Wang, X; Wu, J; Xiang, AH, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1." | 9.24 | Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. ( Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A, 2017) |
| " The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions." | 9.24 | Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. ( Barrett-Connor, E; Dabelea, DM; Edelstein, SL; Herman, WH; Horton, E; Kahn, SE; Knowler, WC; Lorenzo, C; Mather, KJ; Pan, Q; Perreault, L; Pi-Sunyer, X; Venditti, E; Ye, W, 2017) |
| "Steady-state population pharmacokinetics of a noncommercial immediate-release metformin (hydrochloride) drug product were characterized in 28 severely obese children with insulin resistance." | 9.24 | Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( Alfaro, RM; Calis, KA; Hon, YY; Reynolds, JC; Roza, O; Sam, WJ; Yanovski, JA, 2017) |
| "This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA) on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin pathway expression molecules in muscle biopsies of children with obesity." | 9.24 | Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial. ( Alvarez, F; Bustos, M; Cuevas, S; Duggirala, R; Fonseca-Sánchez, M; Garibay-Nieto, N; Jalife, A; Laresgoiti-Servitje, E; León, M; López-Alvarenga, JC; Macías, T; Queipo-García, G; Ramírez, F; Serratos, F; Villanueva, E, 2017) |
| "The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy." | 9.24 | The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J, 2017) |
| "Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity." | 9.22 | Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. ( Dolžan, V; Herman, R; Janež, A; Jensterle, M; Kravos, NA, 2022) |
| "Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial)." | 9.22 | Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.22 | The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. ( Ge, JJ; Ge, WH; Shen, SM; Song, W; Wang, DJ, 2022) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 9.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 9.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 9.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 9.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "Our results show that Metformin and acupuncture combined therapy significantly improves body weight, body mass index (BMI), fasting blood sugar (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and ceramides." | 9.22 | Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. ( Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 9.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "The study will evaluate whether metformin can result in favorable changes in breast density, select proteins and hormones, products of body metabolism, and body weight and composition." | 9.22 | Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. ( Altbach, M; Chalasani, P; Chow, HH; Galons, JP; Martinez, JA; Roe, D; Stopeck, A; Thompson, PA; Thomson, CA; Villa-Guillen, DE, 2016) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 9.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| "Conclusions on the effect of metformin on circulating anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous." | 9.20 | Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. ( Ingerslev, HJ; Lauszus, FF; Madsen, HN; Trolle, B; Tørring, N, 2015) |
| " This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM)." | 9.20 | Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. ( Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K, 2015) |
| "Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in obese PCOS." | 9.20 | Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. ( Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E, 2015) |
| "Previous observational studies have suggested that metformin in diabetes patients may reduce breast cancer risk more than the reductions from other anti-diabetes medications." | 9.20 | Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. ( Ahn, C; Cho, YM; Han, W; Hwang, Y; Ko, KP; Ma, SH; Noh, DY; Park, BJ; Park, SK; Yang, JJ, 2015) |
| " This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM." | 9.20 | Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. ( Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M, 2015) |
| "The effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory." | 9.19 | Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. ( Janez, A; Jensterle Sever, M; Kocjan, T; Kravos, NA; Pfeifer, M, 2014) |
| "We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients." | 9.19 | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. ( Ahmad, A; Cremers, S; Crew, KD; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, M; Refice, S; Taback, B; Wang, A; Xiao, T, 2014) |
| "Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response." | 9.19 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. ( Duran, J; Keefe, C; Pau, CT; Welt, CK, 2014) |
| "In obese, difficult-to-treat patients with T2DM inadequately controlled on high MDI insulin doses, empagliflozin improved glycemic control and reduced weight without increasing the risk of hypoglycemia and with lower insulin requirements." | 9.19 | Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. ( Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ, 2014) |
| " The primary aim is to determine the efficacy of: levonorgestrel intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with or without a weight loss intervention to achieve a pathological complete response (pCR) in EC at six months from study treatment initiation." | 9.19 | Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014) |
| "Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia." | 9.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| "The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder." | 9.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "The present study is the first prospective clinical trial evaluating the effect of combined therapy of metformin and insulin on the pool of oxidized and glycated low‑density lipoproteins (LDL) in young patients with type 1 diabetes and concomitant obesity." | 9.17 | Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. ( Burchardt, P; Kaczmarek, J; Marcinkaniec, J; Naskręt, D; Tabaczewski, P; Wierusz-Wysocka, B; Wysocki, H; Zawada, A, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 9.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| " We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer." | 9.17 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 9.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes." | 9.16 | [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. ( Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J, 2012) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "Metformin has no effect on blood pressure and blood glucose levels, but it does reduce total cholesterol, abdominal obesity and C-reactive protein levels in obese hypertensive patients without diabetes." | 9.16 | Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. ( Chen, J; He, H; Li, Y; Liu, D; Ni, Y; Pletcher, MJ; Yan, Z; Zhao, Z; Zhong, J; Zhu, Z, 2012) |
| "To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNFalpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR)." | 9.16 | The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. ( Apolinar-Jiménez, E; Evia-Viscarra, ML; Figueroa-Barrón, M; García-Morales, LM; Leaños-Pérez, C; Muñoz-Noriega, N; Reyes-García, JG; Rodea-Montero, ER; Sánchez-Fierros, D, 2012) |
| "To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated obesity." | 9.16 | Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. ( Balagopal, P; Bird, K; Damaso, L; DelGiorno, C; Hossain, J; Killen, K; Mauras, N; Merinbaum, D; Weltman, A, 2012) |
| " This study aimed to determine the effect of metformin on body weight, body composition, metabolic risk factors and reproductive hormone levels in overweight or obese young women compared to placebo and comprehensive lifestyle intervention." | 9.15 | The effect of comprehensive lifestyle intervention or metformin on obesity in young women. ( Clifton, PM; Lim, SS; Noakes, M; Norman, RJ, 2011) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 9.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program." | 9.15 | Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. ( Brady, SM; Calis, KA; Kozlosky, M; Krakoff, J; McDuffie, JR; Reynolds, JC; Salaita, CG; Sebring, NG; Yanovski, JA, 2011) |
| "There is no benefit from increased doses of metformin in PCOS but reduction of insulin resistance is more significant in those patients with a lower insulin sensitivity at baseline." | 9.15 | Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. ( Balen, AH; Barth, J; Glanville, J; Yasmin, E, 2011) |
| "Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome." | 9.15 | The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. ( Aflatoonian, A; Ghandi, S; Moghaddam, MH; Tabibnejad, N, 2011) |
| "Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance." | 9.15 | Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study. ( Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 9.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 9.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 9.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| " Obesity increased circulating fibrinogen levels, prothrombin activity and platelet counts, and reduced prothrombin and activated partial thromboplastin times." | 9.14 | Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. ( del Rey Sánchez, JM; Escobar-Morreale, HF; Luque-Ramírez, M; Matíes, M; Mendieta-Azcona, C, 2009) |
| "This study assessed the efficacy of adding metformin to a structured lifestyle intervention in reducing BMI in obese adolescents with insulin resistance." | 9.14 | Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. ( Baker, JE; Clark, HE; Clarson, CL; Hill, DJ; Mahmud, FH; McKay, WM; Schauteet, VD, 2009) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 9.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "We studied the effect of metformin or placebo in a lifestyle modification program combined with oral contraceptives (OC) on quality-of-life parameters measured by the polycystic ovary syndrome (PCOS) questionnaire in obese adolescent women with validated PCOS." | 9.14 | Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. ( Davidson, K; Guzick, D; Harris-Glocker, M; Hoeger, K; Kochman, L, 2010) |
| "The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction." | 9.14 | The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. ( Beckmann, MW; Cupisti, S; Dittrich, R; Jentsch, K; Kronawitter, D; Mueller, A; Oppelt, PG; Reissmann, C, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 9.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported." | 9.14 | Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. ( Abrams, SH; Aye, T; Feldman, HA; Lee, PD; Lenders, C; Lustig, RH; Osganian, SV; Wilson, DM, 2010) |
| "To measure the vascularization and ovarian volume with three-dimensional sonography in patients diagnosed of polycystic ovary syndrome with stimulated ovulation treatment, and to analyse the differences between the patients treated with clomiphen citrate versus clomiphen citrate and metformin." | 9.14 | [Sonographic ovarian vascularization and volume in women with polycystic ovary syndrome treated with clomiphene citrate and metformin]. ( Alvarez-Alvarez, P; Bajo-Arenas, JM; de la Fuente-Valero, J; Engels-Calvo, V; Orensanz-Fernández, I; Zapardiel-Gutiérrez, I, 2010) |
| "Forty patients with schizophrenia were randomly assigned to treatment for 12 weeks with olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or olanzapine, 15 mg/day, plus placebo (N=20)." | 9.13 | Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. ( Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Six hundred and ninety-four consecutive overweight and obese type 2 diabetic patients were evaluated and 56 patients were intolerant to metformin at maximum dosage." | 9.13 | Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA, 2008) |
| "Serum uric acid levels were measured in 40 polycystic ovary syndrome (PCOS) patients and 40 non-hyperandrogenic women matched for BMI and grade of obesity, and were followed-up in 34 PCOS patients who were randomized to an oral contraceptive containing 35 mg ethinyl-estradiol plus 2 mg cyproterone acetate (Diane(35) Diario) or metformin (850 mg twice daily) for 24 weeks." | 9.13 | Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. ( Alvarez-Blasco, F; Escobar-Morreale, HF; Luque-Ramírez, M; Uriol Rivera, MG, 2008) |
| "An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate." | 9.13 | Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? ( Bossuyt, PM; Korevaar, JC; Moll, E; van der Veen, F, 2008) |
| "In a randomized double-blind placebo controlled trial, 85 adolescents with insulin resistance were randomized to receive metformin (70%) or placebo (30%), along with monthly goal setting for diet and exercise modification." | 9.13 | Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. ( Love-Osborne, K; Sheeder, J; Zeitler, P, 2008) |
| " Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes." | 9.12 | Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 9.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "To determine if short courses of metformin (MET) administration in patients with polycystic ovary syndrome (PCOS) would reduce fasting insulin and improve the efficacy of clomiphene citrate (CC) to induce ovulation." | 9.12 | Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. ( Bonpane, CM; Helliwell, JP; Jaramillo, L; Katz, S; Khorram, O, 2006) |
| "We assessed the effect of metformin on body composition and insulin sensitivity in pediatric subjects with exogenous obesity." | 9.12 | Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. ( Ambler, GR; Baur, LA; Cowell, CT; Garnett, SP; Srinivasan, S; Tepsa, M; Ward, GM; Yap, F, 2006) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 9.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "To evaluate the therapeutic effect of metformin on the clinical features, hormonal and metabolic profile in obese women with a hyperinsulinemic polycystic ovary syndrome (PCOS)." | 9.12 | Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. ( Ahmeti, I; Dimitrovski, Ch; Dimova, Z; Krstevska, B; Misevska, S; Pemovska, G; Simeonova, S, 2006) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 9.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 9.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 9.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "Our findings suggest that metformin might reduce the rates or severity of liver dysfunction in selected high-risk adolescents." | 9.12 | Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. ( Freemark, M, 2007) |
| "Our aim was to assess the effects of metformin on menstrual frequency, fasting plasma glucose (FPG), insulin resistance assessed as HOMA-index, weight, waist/hip ratio, blood pressure (BP), serum lipids, and testosterone levels in women with polycystic ovary syndrome (PCOS) METHODS: In a randomized, controlled, double-blinded setup, 56 women aged 18-45 with PCOS were treated with either metformin 850 mg or placebo twice daily for 6 months." | 9.12 | Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. ( Flyvbjerg, A; Kesmodel, U; Lauszus, FF; Trolle, B, 2007) |
| "To compare the clinical results and reproductive outcome in obese women with polycystic ovary syndrome (PCOS) following dietary intervention or treatment with metformin." | 9.12 | Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. ( Al-Qudah, MA; El-Uri, FI; Qublan, HS; Yannakoula, EK, 2007) |
| " Objective To prospectively evaluate if administration of metformin to obese, diabetic patients with primary hypothyroidism on stable thyroxine replacement doses modifies TSH levels." | 9.12 | Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. ( Cordido, F; Isidro, ML; Nemiña, R; Penín, MA, 2007) |
| " Through its effect on RBP4 expression in adipocytes, metformin may improve total insulin sensitivity in obese individuals including those with MS and delay the onset of manifest DM." | 9.12 | [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin]. ( Donicová, V; Ivancová, G; Petrovicová, J; Semanová, Z; Tajtáková, M; Zemberová, E, 2007) |
| "Based on the known effect of metformin (MET) in improving insulin sensitivity in type 2 diabetes, with the scope to focus the effects on glycaemic and free fatty acids (FFA) levels, we studied the effects of a short-term treatment with this drug in obese subjects and obese patients with diabetes or family history of diabetes (FHD)." | 9.11 | Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. ( Belfiore, F; Bellomia, D; Camuto, M; Cavaleri, A; Iannello, S; Milazzo, P; Pisano, MG, 2004) |
| "To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS)." | 9.11 | Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. ( Abi Haidar, M; Alves da Motta, EL; Baracat, EC; de Lima, GR; Maciel, GA; Soares Júnior, JM, 2004) |
| "Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study." | 9.11 | Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. ( Balci, MK; Coban, E; Sari, R; Yazicioglu, G, 2004) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 9.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| " Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention." | 9.11 | A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. ( Craig, K; Guzick, DS; Hoeger, KM; Kochman, L; Miller, RK; Wixom, N, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| " The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance." | 9.11 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. ( Barrett-Connor, E; Crandall, J; Fowler, S; Goldberg, R; Haffner, S; Horton, E; Marcovina, S; Mather, K; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 9.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 9.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS)." | 9.10 | Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. ( Capp, E; Chou, KH; Spritzer, PM; von Eye Corleta, H, 2003) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 9.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "In 43 amenorrheic women with polycystic ovary syndrome (PCOS), 31 (74%) with fasting hyperinsulinemia (> or =20 microU/mL), our aim was to determine whether Metformin (Bristol-Myers Squibb, Princeton, NJ), which reduces hyperinsulinemia, would reverse the endocrinopathy of PCOS, allowing resumption of regular normal menses." | 9.09 | Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 1999) |
| "Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study." | 9.09 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. ( Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L, 1999) |
| "Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial." | 9.09 | Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2000) |
| "To determine the clinical, hormonal and biochemical effect of 4-5 months of insulin-sensitizing therapy (hypocaloric diet+metformin) in obese patients with polycystic ovary syndrome (PCOS)." | 9.09 | Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. ( Kinalska, I; Kinalski, M; Kowalska, I; Straczkowski, M; Wolczyski, S, 2001) |
| "To describe our clinical experience in using Metformin combined with a high protein-low carbohydrate diet to restore normal menstrual cycles in teenaged females with polycystic ovary syndrome (PCOS)." | 9.09 | Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 2001) |
| "Metformin often promotes weight loss in patients with obesity with non-insulin-dependent diabetes mellitus (NIDDM)." | 9.08 | Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. ( Lee, A; Morley, JE, 1998) |
| "To determine the clinical, hormonal, and biochemical effects of 4-6 months of metformin therapy in obese patients with polycystic ovary syndrome (PCOS)." | 9.08 | Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A, 1998) |
| "We performed oral glucose-tolerance tests before and after the administration of 500 mg of metformin or placebo three times daily for 35 days in 61 obese women with the polycystic ovary syndrome." | 9.08 | Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. ( Evans, WS; Jakubowicz, DJ; Nestler, JE; Pasquali, R, 1998) |
| "Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS)." | 9.08 | Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tomás, C, 1998) |
| "The aim of this study was to review TZD and metformin as pharmacological treatments for insulin resistance associated with obesity and cancer." | 9.05 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. ( Biondo, LA; de O S Ferreira, KC; Neto, JCR; Teixeira, AAS, 2020) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 9.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| "Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults." | 9.01 | Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. ( Hui, F; Li, X; Ren, T; Zhang, Y; Zhao, M; Zhao, Q, 2019) |
| "Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance." | 9.01 | Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. ( He, X; Hu, C; Liu, C; Liu, Y; Tang, W; Wu, D; Xu, B; Xu, T, 2019) |
| "There is a recent growing evidence that abnormalities in the microbiota composition can have a major role in the development of obesity and diabetes and that some actions of metformin may be mediated by gut bacteria." | 9.01 | The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. ( Coppola, A; Gazzaruso, C; Govoni, S; Marchesi, N; Pascale, A, 2019) |
| "Metformin has been reported to reduce the risk of pre-eclampsia." | 8.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy." | 8.98 | Metformin in Pregnancy: Mechanisms and Clinical Applications. ( Balani, J; Hyer, S; Shehata, H, 2018) |
| "To evaluate the efficacy of metformin versus a placebo in the treatment of patients with simple obesity without obesity related diseases." | 8.98 | The effects of metformin on simple obesity: a meta-analysis. ( Deng, B; Gao, PX; Le, J; Ning, HH; Qin, SL; Wang, Q; Young, CA; Zhang, HQ, 2018) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 8.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| "The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial." | 8.95 | Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. ( Chen, L; Chen, Y; Deng, H; Li, M; Li, N; Wang, Q; Wang, S; Xu, D, 2017) |
| "Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment." | 8.93 | Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. ( Apovian, CM; Aronne, LJ; Igel, LI; Saunders, KH; Sinha, A; Vojta, D, 2016) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 8.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug." | 8.90 | Effects of metformin on weight loss: potential mechanisms. ( Kashyap, SR; Malin, SK, 2014) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 8.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 8.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 8.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| "To assess the efficacy and safety of using metformin in overweight and obese adolescents without related morbidity." | 8.88 | Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. ( Amate, J; Bouza, C; Gutierrez-Torres, LF; López-Cuadrado, T, 2012) |
| "There are differences in opinion as to whether metformin should play a role in the primary treatment of anovulatory infertility for women with polycystic ovary syndrome (PCOS)." | 8.87 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. ( Johnson, N, 2011) |
| "Articles were identified by searching the MEDLINE database (from 1949 through January 2010) using the key words metformin, topiramate, antipsychotic, weight, weight gain, and obesity." | 8.86 | Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. ( Ellinger, LK; Ipema, HJ; Stachnik, JM, 2010) |
| "Metformin is widely used for treating patients with type 2 diabetes mellitus." | 8.86 | [New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010) |
| "Metformin has been used as a treatment in many studies of the infertility associated with polycystic ovary syndrome (PCOS)." | 8.82 | Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. ( Attia, GR; Carr, BR; Haas, DA, 2003) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "Metformin-associated lactic acidosis is not necessarily due to metformin accumulation." | 8.80 | [Current role of metformin in treatment of diabetes mellitus type 2]. ( Janssen, JA, 2000) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 8.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 8.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "The anti-diabetic drug metformin might reduce prevalence of chronic low back pain in people who are older, overweight, or less active." | 8.31 | The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank. ( Carvalho-E-Silva, AP; Ferreira, ML; Ferreira, PH; Harmer, AR; Hartvigsen, J, 2023) |
| "The high-fat diet-induced mouse model of obesity and insulin resistance of both sexes was developed in a randomized block experiment and bulk RNA-Seq of the ileum tissue was the method of choice for comparative transcriptional profiling after metformin intervention for ten weeks." | 8.31 | Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance. ( Ansone, L; Birzniece, L; Brīvība, M; Elbere, I; Jagare, L; Kalniņa, I; Kloviņš, J; Silamiķele, L; Silamiķelis, I, 2023) |
| "We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic." | 8.12 | Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. ( Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D, 2022) |
| "To evaluate and compare the effects of the combined intervention of metformin and exercise on the degeneration of cartilage and subchondral bone in a mouse model of osteoarthritis (OA) induced by estrogen deficiency and obesity." | 8.12 | Combination of metformin and exercise alleviates osteoarthritis in ovariectomized mice fed a high-fat diet. ( Gou, Y; Hu, Y; Li, H; Lian, Q; Tian, F; Zhang, L; Zhang, Y, 2022) |
| "Of those prescribed metformin, 83% were overweight or obese and 72% had elevated HOMA2-IR scores." | 8.12 | Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting. ( Carpenter, J; Hickie, IB; McHugh, C; Park, S; Scott, EM; Wilson, C, 2022) |
| " The aim of this study is the comparison of 3 mg liraglutide and metformin combination, metformin monotherapy on the blood glucose regulation, weight loss and lipid panel in the patients with Type 2 diabetes mellitus whose BMI is ≥ 30 kg/m2." | 8.12 | Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. ( Keskin, L; Yaprak, B, 2022) |
| "The US FDA required a Risk Evaluation and Mitigation Strategy (REMS) for phentermine/topiramate, an anti-obesity medication, to prevent congenital malformations." | 8.12 | Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2022) |
| "Metformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i." | 8.12 | Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. ( Afonso, J; Azócar-Gallardo, J; García-García, JM; González-Rojas, L; Granacher, U; Ojeda-Aravena, A; Ramirez-Campillo, R; Sá, M, 2022) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 8.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| " Metformin has potential effects on improving asthma airway inflammation." | 8.02 | Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. ( Chen, M; Guo, Y; Hong, L; Jiang, S; Liu, S; Shi, J; Wang, Q; Yuan, X, 2021) |
| " We have recently demonstrated that the combined treatment between moderate exercise and metformin slows sarcopenia's onset by a mechanism that includes adipose reduction and REDOX regulation." | 8.02 | Metformin and tBHQ Treatment Combined with an Exercise Regime Prevents Osteosarcopenic Obesity in Middle-Aged Wistar Female Rats. ( Hernández-Álvarez, D; Königsberg, M; Lopéz-Cervantes, SP; López-Diazguerrero, NE; Luna-López, A; Mena-Montes, B; Pedraza-Vázquez, G; Sánchez-Garibay, C; Toledo-Pérez, R, 2021) |
| "Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis." | 7.96 | Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. ( Aedo, S; Arriola-Montenegro, J; Arteaga, E; Belardo, A; Blümel, JE; Chedraui, P; Fighera, TM; López, M; Martino, M; Miranda, C; Miranda, O; Mostajo, D; Ñañez, M; Ojeda, E; Pilnik, S; Rojas, J; Salinas, C; Sosa, L; Spritzer, PM; Tserotas, K; Vallejo, MS, 2020) |
| "Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease." | 7.96 | Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. ( Avolio, T; Bachman, TN; Bai, Y; Baust, JJ; Bonetto, A; Considine, RV; Cook, T; Fisher, A; Gladwin, MT; Goncharov, DA; Goncharova, EA; Halliday, G; Hu, J; Huot, JR; Lai, YC; Machado, RF; McTiernan, CF; Mora, AL; Satoh, T; Sebastiani, A; Tan, J; Vanderpool, RR; Wang, L, 2020) |
| " Metformin is used for the treatment of type 2 diabetes and was reported to exert therapeutic effects against rheumatoid arthritis and obesity by improving mitochondrial dysfunction via the activation of fibroblast growth factor 21." | 7.96 | Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome. ( Cho, ML; Choi, JW; Jung, KA; Kim, DS; Kim, EK; Lee, SY; Min, HK; Na, HS; Park, SH; Ryu, JG, 2020) |
| "The aim of this study was to investigate the effects of metformin supplementation on metabolic dysfunction, testicular antioxidant capacity, apoptosis, inflammation and spermatogenesis in male mice with high-fat and high-cholesterol diet-induced obesity." | 7.96 | Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity. ( Cha, TL; Chang, TC; Lin, SH; Liu, CY; Tsao, CW; Wu, ST, 2020) |
| "This study aims to demonstrate the effects of metformin on epicardial adipose tissue and electromechanical delay in patients using metformin for insulin resistance." | 7.96 | Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance. ( Çelik, E; Güneş, H; Özmen, Ş; Temiz, F, 2020) |
| " The aims of this study were to evaluate the potential effect of metformin in GWG in overweight or obese women with GDM, to report our experience and to assess metformin's safety in this population." | 7.91 | Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. ( Belo, S; Bettencourt-Silva, R; Carvalho, D; Ferreira, MJ; Montenegro, N; Namora, G; Neves, JS; Oliveira, AI; Queirós, J; Souteiro, P, 2019) |
| "Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 7.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
| "In diet-induced obesity, metformin (MF) has weight-lowering effect and improves glucose homeostasis and insulin sensitivity." | 7.91 | The evidence of metabolic-improving effect of metformin in Ay/a mice with genetically-induced melanocortin obesity and the contribution of hypothalamic mechanisms to this effect. ( Bakhtyukov, A; Bayunova, L; Derkach, K; Romanova, I; Shpakov, A; Zakharova, I; Zorina, I, 2019) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 7.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 7.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " Metformin has been reported to have a therapeutic effect on RA and obesity." | 7.88 | Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. ( Cho, ML; Choi, JY; Jhun, JY; Kim, EK; Kim, JK; Kim, SY; Lee, SH; Lee, SY; Na, HS; Park, SH; Yang, CW, 2018) |
| "There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication." | 7.85 | Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. ( Galletly, C; Myles, H; Smith, C, 2017) |
| "To compare the therapeutic potential of TP-113, a unique molecular entity linking DHA with metformin, for alleviating insulin resistance in obese diabetic mice through the PDX/IL-6 pathway." | 7.85 | Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice. ( Barbier, O; Lachance, D; Marette, A; Mitchell, PL; Nachbar, R; St-Pierre, P; Trottier, J, 2017) |
| "The purpose of this study was to determine the effects of metformin on dysfunctional retinas in obesity-induced type 2 diabetic mice." | 7.85 | The Effects of Metformin on Obesity-Induced Dysfunctional Retinas. ( Chang, JY; Chang, RC; Kim, AJ; Ko, GY; Ko, ML; Shi, L, 2017) |
| "To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM)." | 7.83 | Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. ( Chen, J; Liao, L; Sun, W; Wang, Y; Zeng, C, 2016) |
| "A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily)." | 7.83 | Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. ( Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D, 2016) |
| " Here we show that treatment with the antidiabetic drug metformin inhibits excessive ECM deposition in WAT of ob/ob mice and mice with diet-induced obesity, as evidenced by decreased collagen deposition surrounding adipocytes and expression of fibrotic genes including the collagen cross-linking regulator LOX Inhibition of interstitial fibrosis by metformin is likely attributable to the activation of AMPK and the suppression of transforming growth factor-β1 (TGF-β1)/Smad3 signaling, leading to enhanced systemic insulin sensitivity." | 7.83 | AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. ( Fry, J; Han, J; Jiang, B; Li, Q; Luo, T; Nocon, A; Rui, X; Sherban, A; Xu, XJ; Yan, Y; Yang, Q; Zang, M, 2016) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| " This study is to investigate the role of apoA5 in obesity-associated hypertriglyceridemia and metformin-related hypotriglyceridemic actions." | 7.83 | Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. ( Chen, LZ; Huang, XS; Li, R; Zhao, SP; Zhao, W, 2016) |
| " Metformin is a first-line treatment of type 2 diabetes, with minimal weight loss in humans." | 7.81 | Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice. ( Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A, 2015) |
| " Leucine (Leu) activates Sirt1 by lowering its Km for NAD(+) and potentiates other sirtuin/AMPK-activators, resulting in improvement of insulin sensitivity." | 7.81 | Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice. ( Bruckbauer, A; Cao, Q; Cui, X; Fu, L; Li, F; Shi, H; Wu, R; Xue, B; Zemel, MB, 2015) |
| "Percentage of health plan enrollees with prediabetes who were prescribed metformin." | 7.81 | Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. ( Duru, OK; Ettner, S; Ho, S; Keckhafer, A; Li, J; Mangione, CM; Moin, T; Turk, N, 2015) |
| "To evaluate the effects of treatment with metformin on a murine model of obesity-associated erectile dysfunction." | 7.81 | Treatment With Metformin Improves Erectile Dysfunction in a Murine Model of Obesity Associated With Insulin Resistance. ( Alexandre, EC; Antunes, E; Calixto, MC; Calmasini, FB; Silva, FH, 2015) |
| "To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients." | 7.81 | IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. ( Gong, WJ; Han, XY; Ji, LN; Li, X; Lin, X; Liu, RR; Liu, ZQ; Tang, Q; Xiao, D; Xu, XJ; Yin, JY; Zhang, SM; Zhang, W; Zheng, Y; Zhou, HH, 2015) |
| "The aim of this retrospective observational study was to evaluate whether adding liraglutide to lifestyle changes, metformin (Met) and testosterone replacement therapy (TRT), by means of improving weight and glycaemic control, could boost erectile function in type 2 diabetic obese men with overt hypogonadism and erectile dysfunction (ED) in a 'real-life setting'." | 7.81 | Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. ( Carbone, MD; De Pergola, G; Giagulli, VA; Guastamacchia, E; Licchelli, B; Ramunni, MI; Sabbà, C; Triggiani, V, 2015) |
| "Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study." | 7.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| "To authenticate the effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome (PCOS) using 3-dimensional (3D) power Doppler." | 7.80 | Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome. ( El Sherbiny, M; Elkabarity, R; Makled, AK, 2014) |
| "In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet." | 7.80 | Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 7.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "Metformin and swimming exercise improved lipid profile, and increased insulin sensitivity and body weight reduction were observed." | 7.80 | Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. ( Gao, Y; Luo, L; Pan, T; Wang, C, 2014) |
| "To study the effect of Mudan Granule (MD) on the glucose metabolism and beta cell function in monosodium glutamate (MSG) induced obese mice with insulin resistance (IR)." | 7.80 | [Effect of Mudan Granule on islets beta cell function in monosodium glutamate induced obese mice with insulin resistance: an experimental study]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ, 2014) |
| "Global metabolite profiling of tissues and plasma from mice with diet-induced obesity chronically treated with either R118 or metformin revealed tissue-selective effects of each compound." | 7.80 | Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways. ( Boralsky, L; Goff, DA; Gross, L; Hitoshi, Y; Jenkins, Y; Li, Y; Markovtsov, V; Payan, DG; Shaw, SJ; Singh, R; Sun, TQ; Uy, G, 2014) |
| "In an experimental model of obesity and hyperglycemia in Drosophila melanogaster we studied the effect of diet modification and administration of metformin on systemic infection with Rhizopus, a common cause of mucormycosis in diabetic patients." | 7.80 | Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. ( Albert, N; Do, KA; Farmakiotis, D; Kim-Anh, D; Kontoyiannis, DP; Shirazi, F; Yan, Y, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 7.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 7.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| " The AMP-activated protein kinase (AMPK) activator metformin reverses obesity-associated insulin resistance (IR) and inhibits different types of inflammatory responses." | 7.79 | Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. ( André, DM; Anhê, GF; Antunes, E; Bordin, S; Calixto, MC; Ferreira, D; Landgraf, RG; Leiria, LO; Lellis-Santos, C; Lintomen, L, 2013) |
| "Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate." | 7.79 | Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography. ( Elkattan, E; Khattab, S; Mohsen, IA; Nabil, H, 2013) |
| "The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results." | 7.79 | Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. ( Schehler, B; Schneider, HJ; Seifarth, C, 2013) |
| "To observe the effects of metformin on epididymal sperm quality and antioxidant function of the testis in diet-induced obesity rats." | 7.78 | [Metformin improves epididymal sperm quality and antioxidant function of the testis in diet-induced obesity rats]. ( Fang, X; Jia, C; Peng, YF; Xu, QY, 2012) |
| "The objective was to explore the effects of metformin on the expression of endometrial glucose transporter 4 (GLUT4) and analyze the related factors of GLUT4 in patients with polycystic ovary syndrome (PCOS)." | 7.78 | Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. ( Jiang, QH; Liu, CX; Sun, YP; Tian, ZR; Zhai, J, 2012) |
| "Hyperuricemia may underlie obesity and related disorders, but the impact of weight reduction and metformin on serum uric acid (sUA) in Caucasian children/adolescents is unknown." | 7.77 | The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. ( Chrzanowska, J; Gamian, A; Krzystek-Korpacka, M; Kustrzeba-Wojcicka, I; Noczynska, A; Patryn, E, 2011) |
| "Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills." | 7.77 | [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011) |
| " Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study." | 7.77 | Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011) |
| "To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD)." | 7.76 | Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. ( Bachyrycz, AM; Cone, CJ; Murata, GH, 2010) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 7.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS)." | 7.74 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. ( Bednarek-Tupikowska, G; Bohdanowicz-Pawlak, A; Demissie, M; Jakubowska, J; Milewicz, A; Szymczak, J, 2008) |
| "7%) stopped metformin therapy due to excessive anorexia." | 7.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up." | 7.74 | Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. ( Fu, JF; Hong, F; Liang, L; Wang, CL; Wang, XM; Zhao, ZY; Zou, CC, 2007) |
| "The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin." | 7.74 | Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. ( Cowan, PA; Harden, KA; Patton, SB; Velasquez-Mieyer, P, 2007) |
| "Before and 3 months after low-dose metformin therapy, eight overweight/obese Japanese subjects [body mass index (BMI) >25 kg/m2] were studied with blood sampling, measurement of IHL and IMCL by 1H magnetic resonance spectroscopy and glucose infusion rate (GIR) during euglycaemic-hyperinsulinaemic clamp as an index of peripheral insulin sensitivity." | 7.74 | Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. ( Hirose, T; Kawamori, R; Kumashiro, N; Sakurai, Y; Sato, F; Tamura, Y; Tanaka, Y; Watada, H, 2008) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 7.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| "A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)." | 7.74 | Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007) |
| "This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)." | 7.73 | Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005) |
| " Obesity is the most important risk factor to develop this disease and metformin is considered as a first line drug in overweighted diabetic patients." | 7.73 | [Metformin in the treatment of type 2 diabetes in overweighted or obese patients]. ( Costa Zamora, P; Díaz, JM; González Alvaro, A; Martín Muñoz, MC; Muros Bayo, JM, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 7.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| " However, obese mares exhibited a significantly longer duration of the oestrous cycle, significant increases in circulating concentrations of leptin and insulin, and decreased insulin sensitivity and concentrations of thyroxine compared with feed-restricted mares throughout the experiment." | 7.73 | Obesity is associated with altered metabolic and reproductive activity in the mare: effects of metformin on insulin sensitivity and reproductive cyclicity. ( Fitzgerald, BP; Kennedy, EL; Murphy, BA; Reedy, SE; Sessions, DR; Vick, MM, 2006) |
| "We report 4 cases of lactic acidosis in diabetic patients usually treated with metformin." | 7.72 | [Metformin-associated lactic acidosis remains a serious complication of metformin therapy]. ( Giunti, C; Grimaud, D; Ichai, C; Levraut, J; Orban, JC, 2003) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 7.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| "The aim of the present study was to evaluate the effect of metformin on body weight, body fat mass, waist circumference, lipid parameters, insulin secretion and insulin resistance in obese subjects with normal glucose tolerance." | 7.72 | Metformin in the treatment of obesity in subjects with normal glucose tolerance. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2003) |
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 7.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "55 g/d for 28 weeks) would ameliorate morbid obesity and reduce centripetal obesity; lipid and lipoprotein cholesterol, insulin, and leptin levels; and plasminogen activator inhibitor activity (PAI-Fx), risk factors for coronary heart disease (CHD)." | 7.71 | Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. ( Fontaine, RN; Glueck, CJ; Illig, E; Lang, JE; McCullough, P; Sieve-Smith, L; Streicher, P; Subbiah, MT; Tracy, TM; Wang, P; Weber, K, 2001) |
| "The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it." | 7.71 | Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS, 2001) |
| "To evaluate the long-term effects of metformin on biochemical variables and body weight in polycystic ovary syndrome (PCOS)." | 7.71 | Biochemical and body weight changes with metformin in polycystic ovary syndrome. ( Batukan, C; Batukan, M; Baysal, B, 2001) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 7.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "HCl and metformin on diabetes and obesity were investigated in Wistar fatty rats, which are hyperglycaemic and hypertriglyceridaemic and have higher plasma levels of total ketone bodies than lean rats." | 7.71 | Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats. ( Ikeda, H; Odaka, H; Sugiyama, Y; Suzuki, M; Suzuki, N, 2002) |
| "The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years." | 7.69 | Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. ( Dailey, G; Gerich, JE; Nurjhan, N; Perriello, G; Stumvoll, M, 1995) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 7.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 7.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "To assess the effects of metformin on tissue insulin sensitivity in obese and hyperandrogenic women." | 7.69 | [Effects of metformin on insulin resistance in obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; López, G; Muñoz, S; Sir, T, 1997) |
| "To examine the cellular mechanism of the antihyperglycemic action of in vivo metformin (M) we used an animal model of severe insulin resistance, the genetically obese (fa/fa) Zucker rat." | 7.68 | In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. ( Benecke, H; Greten, H; Hamann, A; Häring, HU; Klein, HH; Matthaei, S; Reibold, JP, 1993) |
| "Bicalutamide 50 mg/day was added after 8 weeks to both arms." | 7.11 | A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). ( Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M, 2022) |
| " This review explored critical components including effective dosage and appropriate intervention period, consistent with the beneficial effects of metformin against obesity-associated complications." | 7.01 | Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target. ( Basson, AK; Dludla, PV; Jack, BU; Mabhida, SE; Mazibuko-Mbeje, SE; Mthembu, SXH; Nkambule, BB; Nyambuya, TM; Tiano, L; Ziqubu, K, 2023) |
| "Treatment with dapagliflozin and interval-based exercise lead to similar but small improvements in glycaemic variability compared with control and metformin therapy." | 7.01 | The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D, 2021) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | 6.94 | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| "Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes." | 6.90 | Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. ( Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T, 2019) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 6.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| "Metformin was administered in the dose of 50 mg daily to the overweight and obese participants." | 6.78 | Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention. ( Erzen, DJ; Hozo, I; Radman, M; Tesanović, D; Tesanović, S, 2013) |
| " Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks." | 6.76 | Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011) |
| "Treatment with cetilistat 80 or 120 mg t." | 6.75 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). ( Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010) |
| "The objective of this study was to assess the efficacy and safety of metformin at the dosage of 2,500 mg/day in the treatment of obese women with PCOS and also to evaluate its effect on weight, hormones, and lipid profile." | 6.75 | Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. ( Aghahosseini, M; Aleyaseen, A; Kashani, L; Moddaress-Hashemi, S; Mofid, B; Safdarian, L, 2010) |
| "Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)." | 6.74 | The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009) |
| "Metformin treatment induced a significant decrease in insulin levels (P < 0." | 6.73 | Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. ( Campagna, G; De Marinis, L; Guido, M; Lanzone, A; Proto, C; Romualdi, D, 2008) |
| "Obesity is often accompanied by insulin resistance and/or hyperinsulinemia." | 6.72 | Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. ( Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J, 2006) |
| "Metformin was well tolerated except for one case of flatulence." | 6.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Metformin has been shown to improve insulin sensitivity and fibrinolysis." | 6.69 | Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. ( André, P; Charles, MA; Eschwège, E; Juhan-Vague, I; Morange, P; Vague, P, 1998) |
| "Abdominal obesity is connoted by hyperinsulinism and insulin insensitivity, a trend toward glucose intolerance, hypoactivity of GH/IGF-I axis and alterations of hypothalamo-pituitary-adrenal (HPA) axis." | 6.69 | Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. ( Avogadri, E; Ganzaroli, C; Gauna, C; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M; Rossetto, R, 1999) |
| "Metformin was added progressively over a year in total doses of 1." | 6.69 | [The combination of insulin and metformin in obese patients with type-2 diabetes mellitus]. ( Ibarra Rueda, JM; Ruiz de Adana Pérez, R; Sánchez-Barba Izquierdo, MI, 1999) |
| "Metformin is a first-line therapy for type 2 diabetes." | 6.61 | Metformin: Mechanisms in Human Obesity and Weight Loss. ( Soukas, AA; Yerevanian, A, 2019) |
| "Obesity and insulin resistance have been associated with breast cancer risk, and breast cancer outcomes." | 6.47 | Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. ( Goodwin, PJ; Stambolic, V, 2011) |
| "Metformin has been shown to inhibit proliferation, invasion and angiogenesis of neoplastic cells and to overcome resistance of breast cancer to chemotherapy, hormonal therapy and HER2 inhibition." | 6.46 | Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. ( Wierusz-Wysocka, B; Wysocki, PJ, 2010) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 6.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Metformin is an antidiabetic drug that has been shown to cause weight loss in patients with diabetes mellitus, as well as in some individuals without diabetes." | 6.45 | Management of atypical antipsychotic drug-induced weight gain: focus on metformin. ( Miller, LJ, 2009) |
| "However, many antidiabetic treatments increase body weight." | 6.44 | Metformin and body weight. ( Golay, A, 2008) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 6.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| " They also suggest that long term administration of metformin might be helpful in treating insulin resistance, thus reducing risks of type 2 (non-insulin-dependent) diabetes and cardiovascular disease in these patients." | 6.40 | Insulin resistance, polycystic ovary syndrome and metformin. ( Ducluzeau, PH; Pugeat, M, 1999) |
| "Diabetes mellitus is a disease with no cure that can cause complications and even death." | 5.91 | Using Artificial Intelligence to Develop a Multivariate Model with a Machine Learning Model to Predict Complications in Mexican Diabetic Patients without Arterial Hypertension (National Nested Case-Control Study): Metformin and Elevated Normal Blood Press ( Canseco-Avila, LM; Ceja-Espiritu, G; Delgado-Enciso, I; Delgado-Enciso, J; Espinoza-Gomez, F; Garcia-Nevares, A; Guzman-Esquivel, J; Hernández-Suarez, CM; Lara-Esqueda, A; Martinez-Fierro, ML; Ochoa-Díaz-Lopez, H; Rodriguez-Sanchez, IP; Sanchez-Diaz, I; Zaizar-Fregoso, SA, 2023) |
| "Obesity has been linked to a higher risk of pancreatic cancer." | 5.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
| "Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on liver steatosis is unclear." | 5.91 | Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. ( Bahramzadeh, A; Goodarzi, G; Meshkani, R; Panahi, G; Tehrani, SS, 2023) |
| "Metformin (MTF) treatment improves insulin signaling in endometrial tissues, but its mechanism is not fully understood." | 5.72 | Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. ( Astorga, I; Carvajal, R; García, V; Oróstica, ML; Plaza-Parrochia, F; Poblete, C; Romero, C; Vega, M, 2022) |
| "Obesity has become a health threat and hard enough to deal with." | 5.72 | Metformin combats obesity by targeting FTO in an m ( Chen, W; Chen, Y; Guo, G; Huang, C; Liao, X; Liu, J; Liu, Y; Luo, Y; Wang, X; Wang, Y; Zeng, B, 2022) |
| "Metformin treatment reduced weight gain and visceral fat accumulation." | 5.72 | Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice. ( Appel, S; Bae-Gartz, I; Dötsch, J; Gellhaus, A; Gründemann, D; Handwerk, M; Hucklenbruch-Rother, E; Janoschek, R; Kammerer, MD; Köninger, A; Kretschmer, T; Schmitz, K; Turnwald, EM; Voßbrecher, K; Wohlfarth, M, 2022) |
| "Metformin may offer benefits to certain cancer populations experiencing metabolic abnormalities." | 5.72 | Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice. ( Chang, CY; Chen, CJ; Chen, WY; Li, JR; Liao, SL; Ou, YC; Wang, JD; Wu, CC, 2022) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 5.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity." | 5.69 | Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. ( Bianzano, S; Heise, T; Nordaby, M; Peil, B; Plum-Mörschel, L, 2023) |
| "In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin." | 5.69 | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. ( Cai, H; Chen, Q; Duan, Y; Zhang, X; Zhao, Y, 2023) |
| "We aimed to determine the efficacy and safety of DDG combined with metformin for the treatment of T2DM patients with obesity." | 5.69 | Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial. ( Liu, Z; Wang, F; Wang, L; Wang, M; Zhang, J; Zhang, K; Zhang, Y; Zhou, S; Zhou, Y, 2023) |
| "Metformin showed favourable effect on GV in overweight/obese T1DM patients and reduction in systolic blood pressure, TDD insulin, fasting venous glucose and fructosamine." | 5.69 | Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes. ( Adam, NLB; Chin Voon, T; Long Bidin, MBB; Poh Shean, W, 2023) |
| "To compare body composition, visceral adiposity, adipocytokines, and low-grade inflammation markers in prepubertal offspring of mothers who were treated with metformin or insulin for gestational diabetes mellitus (GDM)." | 5.69 | Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years. ( Koskensalo, K; Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Parkkola, R; Rönnemaa, T; Tertti, K; Tossavainen, P; Vääräsmäki, M; Veijola, R, 2023) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 5.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| "Metformin is an antidiabetic drug commonly used in obesity treatment." | 5.56 | Effect of high-fat diet-induced obesity on thyroid gland structure in female rats and the possible ameliorating effect of metformin therapy. ( El-Sayed, SM; Ibrahim, HM, 2020) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 5.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 5.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| " Behavioral weight loss and metformin have distinct effects on the gut microbiome, but their impact on gut permeability to lipopolysaccharides is unknown." | 5.51 | A behavioral weight-loss intervention, but not metformin, decreases a marker of gut barrier permeability: results from the SPIRIT randomized trial. ( Appel, LJ; Juraschek, SP; Maruthur, N; Miller, ER; Mueller, NT; Tilves, C; Yeh, HC, 2022) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 5.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 5.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "Among men with obesity and low testosterone concentrations, the combination of metformin plus testosterone, metformin only, and testosterone only, compared to placebo, reduced insulin resistance with no evidence of additive benefit." | 5.51 | Metformin, testosterone, or both in men with obesity and low testosterone: A double-blind, parallel-group, randomized controlled trial. ( Asenjo-Plaza, M; Barrios-Rodríguez, R; Fernández-García, JC; Guzmán-Guzmán, A; Jiménez-Moleón, JJ; Martínez-González, MÁ; Molina-Vega, M; Moreno-León, L; Ramos-Molina, B; Rius-Díaz, F; Tinahones, FJ; Valdés, S; Yubero-Serrano, EM, 2022) |
| "To observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS)." | 5.51 | Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. ( He, B; Xing, C; Zhang, J; Zhao, H, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| " The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate." | 5.51 | Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022) |
| "Metformin is widely used in pregnancy, despite lack of long-term safety for children." | 5.51 | Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood. ( Denison, FC; Dhaun, N; Drake, AJ; Lacey, L; Norman, JE; Quenby, S; Reynolds, RM; Whyte, S; Yang, L, 2022) |
| "Metformin (Met) was reported to possess positive effects on preventing muscle damage and promoting muscle mass maintenance." | 5.51 | Beneficial effects of metformin on muscle atrophy induced by obesity in rats. ( Abdelghany, EMA; El-Gendy, J; Hasan, MM; Shalaby, SM, 2019) |
| "Metformin treatment increased the levels of butyrylcarnitine and acylcarnitine C18:1 concentrations and decreased the levels of isoleucine concentrations compared to untreated HFD mice." | 5.51 | Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination. ( Bugáňová, M; Haluzík, M; Holubová, M; Kuneš, J; Kuzma, M; Maletínská, L; Pelantová, H; Šedivá, B; Tomášová, P; Železná, B, 2019) |
| "Metformin was administered for 7 weeks to high fat-fed C57/6J male mice in vivo." | 5.48 | Metformin improves obesity-associated inflammation by altering macrophages polarization. ( Jing, Y; Li, D; Li, Q; Li, R; Wu, F; Yang, L, 2018) |
| "Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)." | 5.48 | Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018) |
| "Obesity was not detrimental to trabecular bone in growing mice, but bone marrow medullary expansion was observed, likely resulting from inhibition of osteoblastogenesis, and this was partially reversed by metformin treatment." | 5.46 | Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. ( Baron, R; Bornstein, S; Bouxein, M; Brooks, D; Fairfield, H; Falank, C; Ghobrial, IM; Huynh, D; Kawano, Y; Manier, S; Moschetta, M; Nagano, K; Reagan, MR; Roccaro, AM; Rosen, CJ; Sacco, A; Vary, C, 2017) |
| "Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored." | 5.43 | Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016) |
| "Metformin was treated daily for 14 weeks in a high-fat dieting C57BL/6J mice." | 5.43 | Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. ( Byun, JK; Cho, ML; Choi, JY; Jeong, JH; Jhun, JY; Kim, EK; Kim, JK; Lee, SH; Lee, SY, 2016) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 5.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 5.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "The metformin treatment of Wistar rats with obesity induced by high-fat diet was carried out for 2 months (daily dose of 200 mg/kg)." | 5.42 | [THE EFFECTS OF LONG-TERM METFORMIN TREATMENT ON THE ACTIVITY OF ADENYLYL CYCLASE SYSTEM AND NO-SYNTHASES IN THE BRAIN AND THE MYOCARDIUM OF RATS WITH OBESITY]. ( Bondareva, VM; Derkach, KV; Ignatieva, PA; Kuznetsova, LA; Sharova, TS; Shpakov, AO, 2015) |
| "Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks." | 5.41 | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. ( Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY, 2021) |
| "A total of 27 RCTs with 12 interventions were included, and all therapies tended to increase clinical pregnancy, especially pioglitazone (PIO) (log OR 3." | 5.41 | The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. ( Li, J; Liu, Y; Ma, J; Peng, G; Tong, N; Wang, Y; Yan, Z, 2023) |
| "PubMed, EMBASE, Cochrane Library, CNKI, CNKI, and VIP databases were systematically searched for randomized controlled trials (RCTs) through January 1, 2015 to investigate the effectiveness of liraglutide combined with metformin treatment (LMT) in obesity patients with type 2 diabetes (ODP)." | 5.41 | Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis. ( Long, Y; Zhang, Y, 2023) |
| "This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART)." | 5.41 | Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy. ( Bianchi, C; Burlina, S; Formoso, G; Manicardi, E; Resi, V; Sciacca, L; Sculli, MA, 2023) |
| "This is the first meta-analysis of the available literature about the efficacy of metformin exclusively in pediatric patients with non-alcoholic fatty liver disease (NAFLD)." | 5.41 | The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. ( Cheirakis, K; Christakopoulos, A; Fotoulaki, M; Gkiourtzis, N; Glava, A; Michou, P; Moutafi, M; Vouksinou, E, 2023) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 5.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment." | 5.41 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. ( Appel, LJ; Carducci, MA; Charleston, J; Dalcin, AT; Durkin, N; Hassoon, A; Jerome, GJ; Juraschek, SP; Kanarek, NF; Lansey, DG; Maruthur, NM; Miller, ER; Mueller, NT; Tseng, E; Wang, NY; White, K; Yeh, HC, 2021) |
| "To determine the longer-term effects of metformin treatment and behavioral weight loss on gut microbiota and short-chain fatty acids (SCFAs)." | 5.41 | Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. ( Appel, LJ; Differding, MK; Juraschek, SP; Maruthur, NM; Miller, ER; Mueller, NT; Yeh, HC; Zhang, M, 2021) |
| "This study aims to assess the therapeutic effects of a well-known component (puerarin) obtained from a Chinese herb root in patients with polycystic ovary syndrome (PCOS)." | 5.41 | Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. ( Hu, H; Li, F; Li, W; Liu, J; Ma, Z; Zou, G, 2021) |
| "We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention." | 5.41 | A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. ( Algotar, AM; Altbach, M; Centuori, S; Chalasani, P; Chow, HS; Galons, JP; Guillen-Rodriguez, J; Huang, C; Martinez, JA; Pinto, L; Roe, DJ; Tapia, E; Thomson, CA; Trujillo, J; Villa-Guillen, DE, 2021) |
| "Obesity is a significant contributing factor to endometrial cancer risk." | 5.39 | Chemopreventive effects of metformin on obesity-associated endometrial proliferation. ( Broaddus, RR; Burzawa, JK; Celestino, J; Huang, M; Iglesias, D; Lu, KH; McCampbell, AS; Meyer, LA; Schmandt, R; Urbauer, DL; Yates, MS; Zhang, Q, 2013) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 5.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 5.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "GVHD had little effect." | 5.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| "To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.34 | Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. ( Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q, 2020) |
| "Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1." | 5.34 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. ( Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F, 2020) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 5.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| "Metformin was more effective in lowering glucose in those with a lower BMI (r = -0." | 5.33 | The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. ( Doney, AS; Donnelly, LA; Hattersley, AT; Morris, AD; Pearson, ER, 2006) |
| "Metformin was then administered." | 5.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| "There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease." | 5.31 | Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000) |
| "Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate." | 5.31 | Metformin for weight loss in pediatric patients taking psychotropic drugs. ( Barton, BA; Cottingham, EM; Morrison, JA, 2002) |
| ", the Diabetes Prevention Program) and metformin reduce type 2 diabetes risk among patients with prediabetes." | 5.30 | Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial. ( Castellon-Lopez, Y; Chon, JS; Duru, OK; Frosch, DL; Jeffers, KS; Mangione, CM; Martin, JM; Moin, T; Norris, K; Tseng, CH; Turk, N, 2019) |
| "Metformin treatment (1000-2000 mg/day) over 6 months in pubertal children and/or adolescents with obesity and hyperinsulinism is associated with a reduction in body mass index (BMI) and the insulin resistance index (HOMA-IR)." | 5.30 | Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Dorado-Ceballos, E; Ibáñez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Mas-Parés, B; Osiniri, I; Prats-Puig, A; Xargay-Torrent, S, 2019) |
| "To evaluate the impact of metformin on in vitro fertilization (IVF) outcomes in overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.30 | Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. ( Abbas, AM; Abdalmageed, OS; Abdelaleem, AA; Abdelmagied, AE; Ali, MK; Farghaly, TA, 2019) |
| " The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS-0200) on body weight and obesity comorbidities in a phase 2 randomized trial." | 5.30 | Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. ( Barritt, AS; Chalasani, N; Flores, O; Kolterman, O; Rinella, M; Siddiqui, M; Vuppalanchi, R; Zemel, MB, 2019) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 5.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "To evaluate the reproductive and metabolic effects of L-carnitine plus metformin in clomiphene citrate (CC) resistant obese polycystic ovary syndrome (PCOS) women." | 5.30 | l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. ( El Sharkwy, I; Sharaf El-Din, M, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 5.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| " We investigated the effect of liraglutide combined with metformin on LGI and lipoprotein density profiles in patients with stable coronary artery disease (CAD) and newly diagnosed T2DM." | 5.30 | Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. ( Anholm, C; Fenger, M; Haugaard, SB; Kristiansen, OP; Kumarathurai, P; Madsbad, S; Nielsen, OW; Pedersen, LR; Sajadieh, A; Samkani, A; Walzem, RL, 2019) |
| "Metformin prevents weight gain in patients with type 2 diabetes (T2D)." | 5.27 | Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. ( Jager-Wittenaar, H; Kooy, A; Krijnen, W; Lehert, P; Miedema, I; Out, M; Stehouwer, C; van der Schans, C, 2018) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 5.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet." | 5.27 | Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. ( Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E, 2018) |
| "Proof-of-concept study to investigate the amplifying effects of diazoxide (DZX)-mediated insulin suppression on lifestyle-induced weight loss in nondiabetic, hyperinsulinemic, obese men." | 5.27 | High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| " The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D." | 5.27 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. ( Beale, E; Buchanan, TA; Chow, T; Hendee, F; Katkhouda, N; Martinez, M; Montgomery, C; Nayak, KS; Trigo, E; Wang, X; Wu, J; Xiang, AH, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1." | 5.24 | Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. ( Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A, 2017) |
| " The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions." | 5.24 | Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. ( Barrett-Connor, E; Dabelea, DM; Edelstein, SL; Herman, WH; Horton, E; Kahn, SE; Knowler, WC; Lorenzo, C; Mather, KJ; Pan, Q; Perreault, L; Pi-Sunyer, X; Venditti, E; Ye, W, 2017) |
| "Steady-state population pharmacokinetics of a noncommercial immediate-release metformin (hydrochloride) drug product were characterized in 28 severely obese children with insulin resistance." | 5.24 | Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( Alfaro, RM; Calis, KA; Hon, YY; Reynolds, JC; Roza, O; Sam, WJ; Yanovski, JA, 2017) |
| "This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA) on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin pathway expression molecules in muscle biopsies of children with obesity." | 5.24 | Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial. ( Alvarez, F; Bustos, M; Cuevas, S; Duggirala, R; Fonseca-Sánchez, M; Garibay-Nieto, N; Jalife, A; Laresgoiti-Servitje, E; León, M; López-Alvarenga, JC; Macías, T; Queipo-García, G; Ramírez, F; Serratos, F; Villanueva, E, 2017) |
| "Eight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks." | 5.24 | Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study. ( Baur, LA; Cowell, CT; Garnett, SP; Gow, ML; Johnson, NA, 2017) |
| "Liraglutide 3 mg was recently approved as an anti-obesity drug." | 5.24 | Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. ( Goričar, K; Janez, A; Jensterle, M; Kravos, NA, 2017) |
| "The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy." | 5.24 | The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J, 2017) |
| "To investigate the effects of COVID-19 infection in DM patients, we reviewed literature from Google Scholar search engine and PubMed database from '2013 to 2020' using the terms "COVID-19; SARS-CoV-2; Diabetes mellitus; obesity; Angiotensin-converting enzyme 2; ACE2; Insulin and Metformin." | 5.22 | Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside. ( Ali Kazem, T; Filayih Hassan, A; Paridar, P; Pezeshki, SMS; Pezeshki, SP; Zeylabi, F, 2022) |
| "Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity." | 5.22 | Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. ( Dolžan, V; Herman, R; Janež, A; Jensterle, M; Kravos, NA, 2022) |
| "This meta-analysis focused on the slimming effect, safety, and correlation of metformin, orlistat, exenatide, liraglutide, and topiramate in children with obesity." | 5.22 | Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. ( Liu, H; Wu, F; Xie, Y; Yin, S; Zhang, Q; Zhao, G, 2022) |
| " One randomized clinical trial (RCT) (TODAY; n = 699 adolescents with obesity; mean age, 14 years) comparing metformin, metformin plus rosiglitazone, and metformin plus lifestyle intervention reported that 2 youths with recently diagnosed diabetes developed kidney impairment (0 vs 1 vs 1, respectively; P > ." | 5.22 | Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Ali, R; Allison, BA; Baker, C; Jonas, DE; LeBlanc, ES; Middleton, JC; Riley, S; Vander Schaaf, EB; Voisin, CE, 2022) |
| "Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial)." | 5.22 | Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.22 | The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. ( Ge, JJ; Ge, WH; Shen, SM; Song, W; Wang, DJ, 2022) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 5.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 5.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 5.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 5.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "Among women without diabetes who had a BMI of more than 35, the antenatal administration of metformin reduced maternal weight gain but not neonatal birth weight." | 5.22 | Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. ( Akolekar, R; Balani, J; Hyer, S; Kotecha, R; Nicolaides, KH; Pastides, A; Shehata, H; Syngelaki, A, 2016) |
| "Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration." | 5.22 | Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. ( Broedl, UC; Chilton, R; Crowe, S; Johansen, OE; Lund, SS; McGuire, DK; Neeland, IJ; Woerle, HJ, 2016) |
| "These results suggest that the effect of exenatide on weight loss may be related with the suppression of serum ghrelin levels, which is an orexigenic peptide." | 5.22 | Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. ( Cavun, S; Guclu, M; Gul, Z; Kisakol, G; Kiyici, S; Sigirli, D; Topyildiz, F, 2016) |
| "Our results show that Metformin and acupuncture combined therapy significantly improves body weight, body mass index (BMI), fasting blood sugar (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and ceramides." | 5.22 | Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. ( Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 5.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "The study will evaluate whether metformin can result in favorable changes in breast density, select proteins and hormones, products of body metabolism, and body weight and composition." | 5.22 | Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. ( Altbach, M; Chalasani, P; Chow, HH; Galons, JP; Martinez, JA; Roe, D; Stopeck, A; Thompson, PA; Thomson, CA; Villa-Guillen, DE, 2016) |
| "This study tests the effectiveness of expert guidelines for diabetes prevention: lifestyle intervention with addition of metformin, when required, among people with prediabetes." | 5.22 | The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial. ( Ali, MK; Anjana, RM; Mohan, V; Narayan, KM; Ranjani, H; Staimez, LR; Weber, MB, 2016) |
| "As adolescents with obesity and insulin resistance may be refractory to lifestyle intervention therapy alone, additional off-label metformin therapy is often used." | 5.22 | Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. ( Elst, MA; Knibbe, CA; van de Garde, EM; van der Aa, MP; van der Vorst, MM; van Mil, EG, 2016) |
| "Beneficial effects were observed on serum leptin concentration, weight loss, and body composition for all interventions and in all examined groups, with the greatest advantage being associated with the orlistat treatment." | 5.22 | Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial. ( Bogdański, P; Grzymisławska, M; Kargulewicz, A; Kręgielska-Narożna, M; Kujawska-Łuczak, M; Musialik, K; Swora-Cwynar, E; Szulińska, M, 2016) |
| " This study aimed to explore the association between the estimated insulin demand of the diet, as measured by glycemic and insulin load, weight loss, percentage body fat and insulin sensitivity index (ISI) in obese adolescents with clinical features of insulin resistance and/or prediabetes after a 3 month lifestyle and metformin intervention." | 5.20 | Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study. ( Buyken, AE; Cowell, CT; Garnett, SP; Goletzke, J; Gow, M; Halim, J; Ho, M; Joslowski, G; Louie, JC, 2015) |
| "This study was undertaken to determine whether metformin would ameliorate insulin resistance, reduce weight and waist circumference and improve lipids in obese, but not morbidly obese, euglycemic women." | 5.20 | Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. ( Bell, RJ; Davis, SR; Jane, F; Robinson, PJ; Worsley, R, 2015) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 5.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| " We present a protocol for a study to test the hypothesis that metformin will improve insulin sensitivity in obese pregnant women, thereby reducing the incidence of high birthweight babies and other pregnancy complications." | 5.20 | Efficacy of metformin in pregnant obese women: a randomised controlled trial. ( Chiswick, CA; Denison, FC; Drake, AJ; Forbes, S; Murray, GD; Newby, DE; Norman, JE; Quenby, S; Reynolds, RM; Walker, BR; Whyte, SA; Wray, S, 2015) |
| "Conclusions on the effect of metformin on circulating anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous." | 5.20 | Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. ( Ingerslev, HJ; Lauszus, FF; Madsen, HN; Trolle, B; Tørring, N, 2015) |
| " This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM)." | 5.20 | Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. ( Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K, 2015) |
| "Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in obese PCOS." | 5.20 | Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. ( Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E, 2015) |
| "Previous observational studies have suggested that metformin in diabetes patients may reduce breast cancer risk more than the reductions from other anti-diabetes medications." | 5.20 | Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. ( Ahn, C; Cho, YM; Han, W; Hwang, Y; Ko, KP; Ma, SH; Noh, DY; Park, BJ; Park, SK; Yang, JJ, 2015) |
| " This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM." | 5.20 | Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. ( Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M, 2015) |
| "The Diabetes Prevention Program randomized overweight or obese dysglycemic participants to lifestyle change with the goals of weight reduction of >7% of initial weight and 150 minutes per week of exercise, metformin, or placebo." | 5.19 | Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program. ( Barrett-Connor, E; Golden, SH; Kim, C; Kong, S; Mather, KJ; Nan, B; Randolph, JF, 2014) |
| "The effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory." | 5.19 | Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. ( Janez, A; Jensterle Sever, M; Kocjan, T; Kravos, NA; Pfeifer, M, 2014) |
| " Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n = 692), intensive lifestyle intervention (n = 832) or metformin (n = 887)." | 5.19 | Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. ( Barrett-Connor, E; Christophi, CA; Davis, J; Florez, JC; Goldberg, RB; Horton, E; Jarolim, P; Ma, Y; Mather, KJ; Walford, GA; Wang, TJ, 2014) |
| "We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients." | 5.19 | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. ( Ahmad, A; Cremers, S; Crew, KD; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, M; Refice, S; Taback, B; Wang, A; Xiao, T, 2014) |
| "Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response." | 5.19 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. ( Duran, J; Keefe, C; Pau, CT; Welt, CK, 2014) |
| "Roflumilast added to metformin reduced body weight in obese women with PCOS, primarily due to a loss of fat mass." | 5.19 | Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. ( Janez, A; Jensterle, M; Kocjan, T, 2014) |
| "In obese, difficult-to-treat patients with T2DM inadequately controlled on high MDI insulin doses, empagliflozin improved glycemic control and reduced weight without increasing the risk of hypoglycemia and with lower insulin requirements." | 5.19 | Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. ( Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ, 2014) |
| " The primary aim is to determine the efficacy of: levonorgestrel intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with or without a weight loss intervention to achieve a pathological complete response (pCR) in EC at six months from study treatment initiation." | 5.19 | Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014) |
| "To assess the effect of metformin (Met) or omega-3 (ω-3) polyunsaturated fatty acids (PUFA) on the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index, lipid profile, and body mass index (BMI) of obese children." | 5.17 | Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. ( Flores-Huerta, S; Juárez-López, C; Klünder-Klünder, M; Madrigal-Azcárate, A, 2013) |
| "Diabetes prevention program (DPP) participants (N = 3,819, of whom 3,356 were genotyped for baseline and 3,234 for longitudinal analyses) were randomized into intensive lifestyle modification (diet, exercise, weight loss), metformin or placebo control." | 5.17 | Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program. ( Delahanty, LM; Florez, JC; Franks, PW; Jablonski, KA; Kahn, SE; Knowler, WC; Pan, Q, 2013) |
| "Abdominal acupuncture and metformin improved the endocrine and metabolic function of patients with obesity-type PCOS." | 5.17 | Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial. ( Lai, MH; Liu, H; Ma, HX; Wang, XH; Yao, H; Zheng, YH, 2013) |
| "Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia." | 5.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| "The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder." | 5.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "The present study is the first prospective clinical trial evaluating the effect of combined therapy of metformin and insulin on the pool of oxidized and glycated low‑density lipoproteins (LDL) in young patients with type 1 diabetes and concomitant obesity." | 5.17 | Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. ( Burchardt, P; Kaczmarek, J; Marcinkaniec, J; Naskręt, D; Tabaczewski, P; Wierusz-Wysocka, B; Wysocki, H; Zawada, A, 2013) |
| "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years." | 5.17 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| "These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight." | 5.17 | The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes. ( Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 5.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| " We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer." | 5.17 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 5.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes." | 5.16 | [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. ( Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J, 2012) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "Metformin has no effect on blood pressure and blood glucose levels, but it does reduce total cholesterol, abdominal obesity and C-reactive protein levels in obese hypertensive patients without diabetes." | 5.16 | Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. ( Chen, J; He, H; Li, Y; Liu, D; Ni, Y; Pletcher, MJ; Yan, Z; Zhao, Z; Zhong, J; Zhu, Z, 2012) |
| "To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNFalpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR)." | 5.16 | The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. ( Apolinar-Jiménez, E; Evia-Viscarra, ML; Figueroa-Barrón, M; García-Morales, LM; Leaños-Pérez, C; Muñoz-Noriega, N; Reyes-García, JG; Rodea-Montero, ER; Sánchez-Fierros, D, 2012) |
| "To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated obesity." | 5.16 | Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. ( Balagopal, P; Bird, K; Damaso, L; DelGiorno, C; Hossain, J; Killen, K; Mauras, N; Merinbaum, D; Weltman, A, 2012) |
| "Exenatide demonstrated more beneficial effects on HbA(1C), weight reduction and insulin resistance during 26 weeks of treatment, but there were more hypoglycemic events and mild-to-moderate nausea compared with metformin." | 5.16 | Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. ( Gao, Y; Guo, XH; Huang, YY; Song, WL; Yuan, GH, 2012) |
| "The use of metformin throughout gestation by women with polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) significantly reduces the number of first-trimester spontaneous abortions and the rate of occurrence of gestational diabetes and hypertensive syndromes." | 5.16 | Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ( Cavalli, RC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL; Moisés, EC, 2012) |
| " This study aimed to determine the effect of metformin on body weight, body composition, metabolic risk factors and reproductive hormone levels in overweight or obese young women compared to placebo and comprehensive lifestyle intervention." | 5.15 | The effect of comprehensive lifestyle intervention or metformin on obesity in young women. ( Clifton, PM; Lim, SS; Noakes, M; Norman, RJ, 2011) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 5.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program." | 5.15 | Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. ( Brady, SM; Calis, KA; Kozlosky, M; Krakoff, J; McDuffie, JR; Reynolds, JC; Salaita, CG; Sebring, NG; Yanovski, JA, 2011) |
| "There is no benefit from increased doses of metformin in PCOS but reduction of insulin resistance is more significant in those patients with a lower insulin sensitivity at baseline." | 5.15 | Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. ( Balen, AH; Barth, J; Glanville, J; Yasmin, E, 2011) |
| "Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome." | 5.15 | The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. ( Aflatoonian, A; Ghandi, S; Moghaddam, MH; Tabibnejad, N, 2011) |
| "Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance." | 5.15 | Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study. ( Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 5.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 5.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 5.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| "Both metformin and orlistat show a similar effect on weight loss, ovulation rates and androgen concentrations." | 5.14 | An RCT of metformin versus orlistat for the management of obese anovulatory women. ( Amer, S; Ledger, WL; Li, TC; Metwally, M, 2009) |
| " Obesity increased circulating fibrinogen levels, prothrombin activity and platelet counts, and reduced prothrombin and activated partial thromboplastin times." | 5.14 | Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. ( del Rey Sánchez, JM; Escobar-Morreale, HF; Luque-Ramírez, M; Matíes, M; Mendieta-Azcona, C, 2009) |
| "This study assessed the efficacy of adding metformin to a structured lifestyle intervention in reducing BMI in obese adolescents with insulin resistance." | 5.14 | Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. ( Baker, JE; Clark, HE; Clarson, CL; Hill, DJ; Mahmud, FH; McKay, WM; Schauteet, VD, 2009) |
| " We evaluated whether changes in body weight were associated with changes in health utilities in the Diabetes Prevention Program (DPP) and whether associations differed by treatment assignment (lifestyle intervention, metformin, placebo) or baseline obesity severity." | 5.14 | Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. ( Ackermann, RT; Edelstein, SL; Engelgau, MM; Herman, WH; Marrero, DG; Narayan, KM; Zhang, P, 2009) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 5.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "We studied the effect of metformin or placebo in a lifestyle modification program combined with oral contraceptives (OC) on quality-of-life parameters measured by the polycystic ovary syndrome (PCOS) questionnaire in obese adolescent women with validated PCOS." | 5.14 | Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. ( Davidson, K; Guzick, D; Harris-Glocker, M; Hoeger, K; Kochman, L, 2010) |
| "Sibutramine and metformin are drugs commonly used to obtain weight loss." | 5.14 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. ( Akbas, H; Coban, E; Eray, E; Ozdem, S; Sari, R, 2010) |
| "The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction." | 5.14 | The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. ( Beckmann, MW; Cupisti, S; Dittrich, R; Jentsch, K; Kronawitter, D; Mueller, A; Oppelt, PG; Reissmann, C, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 5.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported." | 5.14 | Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. ( Abrams, SH; Aye, T; Feldman, HA; Lee, PD; Lenders, C; Lustig, RH; Osganian, SV; Wilson, DM, 2010) |
| "In our 6-month prospective study, both low-dose metformin and dietary treatment alone ameliorated liver steatosis and metabolic derangements in patients with NAFLD." | 5.14 | Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. ( Abenavoli, L; Abenavoli, S; Belfiore, A; De Siena, M; Fruci, B; Garinis, GA; Greco, M; Gulletta, E; Mazza, A; Ventura, V, 2010) |
| "Obese European adolescents' insulin sensitivity improved without weight change during placebo or metformin intervention in addition to lifestyle intervention." | 5.14 | Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. ( Bürmann, M; Grüters, A; Holl, RW; Hübel, H; Krude, H; l'Allemand, D; Martus, P; Wiegand, S, 2010) |
| "To measure the vascularization and ovarian volume with three-dimensional sonography in patients diagnosed of polycystic ovary syndrome with stimulated ovulation treatment, and to analyse the differences between the patients treated with clomiphen citrate versus clomiphen citrate and metformin." | 5.14 | [Sonographic ovarian vascularization and volume in women with polycystic ovary syndrome treated with clomiphene citrate and metformin]. ( Alvarez-Alvarez, P; Bajo-Arenas, JM; de la Fuente-Valero, J; Engels-Calvo, V; Orensanz-Fernández, I; Zapardiel-Gutiérrez, I, 2010) |
| "To determine whether metformin treatment for 6 months is effective in reducing body weight and hyperinsulinemia and also ameliorating insulin sensitivity indices in obese adolescents with hyperinsulinemia." | 5.13 | Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. ( Atabek, ME; Pirgon, O, 2008) |
| "Although metformin (MET) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus, few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance (NGT)." | 5.13 | Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. ( Burgert, TS; Caprio, S; Duran, EJ; Dziura, J; Goldberg-Gell, R; Katz, S; Tamborlane, WV; Yeckel, CW, 2008) |
| "Our study shows that in severely obese, non-diabetic, hyperinsulinaemic patients undergoing a nutritional programme, rosiglitazone is more effective than metformin in producing favourable changes in fasting-based indexes of glucose metabolism, with a reduction of both insulin resistance and hyperinsulinaemia." | 5.13 | Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. ( Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G, 2008) |
| "Forty patients with schizophrenia were randomly assigned to treatment for 12 weeks with olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or olanzapine, 15 mg/day, plus placebo (N=20)." | 5.13 | Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. ( Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Six hundred and ninety-four consecutive overweight and obese type 2 diabetic patients were evaluated and 56 patients were intolerant to metformin at maximum dosage." | 5.13 | Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA, 2008) |
| "Serum uric acid levels were measured in 40 polycystic ovary syndrome (PCOS) patients and 40 non-hyperandrogenic women matched for BMI and grade of obesity, and were followed-up in 34 PCOS patients who were randomized to an oral contraceptive containing 35 mg ethinyl-estradiol plus 2 mg cyproterone acetate (Diane(35) Diario) or metformin (850 mg twice daily) for 24 weeks." | 5.13 | Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. ( Alvarez-Blasco, F; Escobar-Morreale, HF; Luque-Ramírez, M; Uriol Rivera, MG, 2008) |
| "Due to the very high prevalences of excess weight and probably many associated disorders with the excess weight, including IGT or DM, WCH or HT, and dyslipidemia, above the age of 50 years, and the detected significant benefits of metformin on all of the above parameters, metformin treatment should be initiated in patients with excess weight in their fifties." | 5.13 | Metformin and parameters of physical health. ( Borazan, A; Helvaci, MR; Kaya, H; Ozer, C; Seyhanli, M; Yalcin, A, 2008) |
| "An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate." | 5.13 | Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? ( Bossuyt, PM; Korevaar, JC; Moll, E; van der Veen, F, 2008) |
| "In a randomized double-blind placebo controlled trial, 85 adolescents with insulin resistance were randomized to receive metformin (70%) or placebo (30%), along with monthly goal setting for diet and exercise modification." | 5.13 | Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. ( Love-Osborne, K; Sheeder, J; Zeitler, P, 2008) |
| " Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes." | 5.12 | Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 5.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "To assess the use of oral glucose tolerance testing (OGTT) to predict efficacy of insulin sensitization (metformin) or suppression (octreotide) because insulin resistance and insulin hypersecretion may impact pharmacotherapeutic efficacy in obese children." | 5.12 | Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. ( Bacchetti, P; Christensen, ML; Lazar, AA; Lustig, RH; Mietus-Snyder, ML; Velasquez-Mieyer, PA, 2006) |
| "To determine if short courses of metformin (MET) administration in patients with polycystic ovary syndrome (PCOS) would reduce fasting insulin and improve the efficacy of clomiphene citrate (CC) to induce ovulation." | 5.12 | Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. ( Bonpane, CM; Helliwell, JP; Jaramillo, L; Katz, S; Khorram, O, 2006) |
| "We assessed the effect of metformin on body composition and insulin sensitivity in pediatric subjects with exogenous obesity." | 5.12 | Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. ( Ambler, GR; Baur, LA; Cowell, CT; Garnett, SP; Srinivasan, S; Tepsa, M; Ward, GM; Yap, F, 2006) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 5.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "Topiramate was effective for weight reduction and improvement in glycemic control in obese subjects with type 2 diabetes treated with metformin monotherapy." | 5.12 | Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. ( Fitchet, M; Gorska, M; Hamann, A; Masson, E; Moore, R; Sun, X; Toplak, H; Vercruysse, F, 2007) |
| "To evaluate the therapeutic effect of metformin on the clinical features, hormonal and metabolic profile in obese women with a hyperinsulinemic polycystic ovary syndrome (PCOS)." | 5.12 | Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. ( Ahmeti, I; Dimitrovski, Ch; Dimova, Z; Krstevska, B; Misevska, S; Pemovska, G; Simeonova, S, 2006) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 5.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 5.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "Height, weight, waist circumference, hip circumference, and skinfolds were measured at baseline in 3234 participants enrolled in a randomized clinical trial to treat individuals with impaired glucose tolerance with placebo, metformin, or a lifestyle modification program." | 5.12 | Relationship of body size and shape to the development of diabetes in the diabetes prevention program. ( , 2006) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 5.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "Despite the fact that treatment with Diane(35) Diario restored regular menstrual cycles in all the patients, whereas metformin only did so in 50% of them, serum ferritin levels decreased at 12 and 24 weeks of treatment only with metformin, in association with a marked increase in insulin sensitivity." | 5.12 | Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. ( Alvarez-Blasco, F; Botella-Carretero, JI; Escobar-Morreale, HF; Luque-Ramírez, M; San Millán, JL; Sanchón, R, 2007) |
| "Our findings suggest that metformin might reduce the rates or severity of liver dysfunction in selected high-risk adolescents." | 5.12 | Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. ( Freemark, M, 2007) |
| "Our aim was to assess the effects of metformin on menstrual frequency, fasting plasma glucose (FPG), insulin resistance assessed as HOMA-index, weight, waist/hip ratio, blood pressure (BP), serum lipids, and testosterone levels in women with polycystic ovary syndrome (PCOS) METHODS: In a randomized, controlled, double-blinded setup, 56 women aged 18-45 with PCOS were treated with either metformin 850 mg or placebo twice daily for 6 months." | 5.12 | Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. ( Flyvbjerg, A; Kesmodel, U; Lauszus, FF; Trolle, B, 2007) |
| "We tested the effect-modifying role of Pro12Ala on the 1 year change in obesity-related traits in a randomised clinical trial of treatment with metformin (n = 989), troglitazone (n = 363) or lifestyle modification (n = 1,004) vs placebo (n = 1,000) for diabetes prevention in high-risk individuals." | 5.12 | The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. ( Altshuler, D; Delahanty, L; Florez, JC; Franks, PW; Hanson, RL; Jablonski, KA; Kahn, SE; Knowler, WC, 2007) |
| "To compare the clinical results and reproductive outcome in obese women with polycystic ovary syndrome (PCOS) following dietary intervention or treatment with metformin." | 5.12 | Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. ( Al-Qudah, MA; El-Uri, FI; Qublan, HS; Yannakoula, EK, 2007) |
| " Objective To prospectively evaluate if administration of metformin to obese, diabetic patients with primary hypothyroidism on stable thyroxine replacement doses modifies TSH levels." | 5.12 | Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. ( Cordido, F; Isidro, ML; Nemiña, R; Penín, MA, 2007) |
| " Through its effect on RBP4 expression in adipocytes, metformin may improve total insulin sensitivity in obese individuals including those with MS and delay the onset of manifest DM." | 5.12 | [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin]. ( Donicová, V; Ivancová, G; Petrovicová, J; Semanová, Z; Tajtáková, M; Zemberová, E, 2007) |
| "Based on the known effect of metformin (MET) in improving insulin sensitivity in type 2 diabetes, with the scope to focus the effects on glycaemic and free fatty acids (FFA) levels, we studied the effects of a short-term treatment with this drug in obese subjects and obese patients with diabetes or family history of diabetes (FHD)." | 5.11 | Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. ( Belfiore, F; Bellomia, D; Camuto, M; Cavaleri, A; Iannello, S; Milazzo, P; Pisano, MG, 2004) |
| "To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS)." | 5.11 | Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. ( Abi Haidar, M; Alves da Motta, EL; Baracat, EC; de Lima, GR; Maciel, GA; Soares Júnior, JM, 2004) |
| "Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study." | 5.11 | Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. ( Balci, MK; Coban, E; Sari, R; Yazicioglu, G, 2004) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 5.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| " Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention." | 5.11 | A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. ( Craig, K; Guzick, DS; Hoeger, KM; Kochman, L; Miller, RK; Wixom, N, 2004) |
| "Metformin improves insulin sensitivity, which is correlated to phospholipid fatty acid composition in obese type 2 diabetics." | 5.11 | Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals. ( Christophe, AB; Feyen, E; Giri, M; Rodríguez, Y, 2004) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| "Orlistat, in combination with a reduced calorie diet and a weight management programme, promotes weight loss and clinically relevant improvements in glycaemic control and other cardiovascular risk factors in obese patients with Type 2 diabetes." | 5.11 | A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. ( Berne, C, 2005) |
| " The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance." | 5.11 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. ( Barrett-Connor, E; Crandall, J; Fowler, S; Goldberg, R; Haffner, S; Horton, E; Marcovina, S; Mather, K; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 5.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia." | 5.11 | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. ( James, AP; Mamo, JC; Watts, GF, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 5.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS)." | 5.10 | Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. ( Capp, E; Chou, KH; Spritzer, PM; von Eye Corleta, H, 2003) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 5.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "The purpose of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on body weight, glycemic control, and cardiovascular risk factors in metformin-treated type 2 diabetic patients." | 5.10 | Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. ( Anderson, JW; Aronne, L; Doyle, M; Foreyt, J; Hollander, P; Klein, S; Leiter, L; Miles, JM; Wadden, T, 2002) |
| "In 43 amenorrheic women with polycystic ovary syndrome (PCOS), 31 (74%) with fasting hyperinsulinemia (> or =20 microU/mL), our aim was to determine whether Metformin (Bristol-Myers Squibb, Princeton, NJ), which reduces hyperinsulinemia, would reverse the endocrinopathy of PCOS, allowing resumption of regular normal menses." | 5.09 | Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 1999) |
| "Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study." | 5.09 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. ( Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L, 1999) |
| "Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial." | 5.09 | Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2000) |
| "To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus." | 5.09 | Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). ( Adler, A; Clarke, P; Cull, C; Gray, A; Holman, R; Raikou, M; Stevens, R; Stratton, I, 2001) |
| "To determine the clinical, hormonal and biochemical effect of 4-5 months of insulin-sensitizing therapy (hypocaloric diet+metformin) in obese patients with polycystic ovary syndrome (PCOS)." | 5.09 | Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. ( Kinalska, I; Kinalski, M; Kowalska, I; Straczkowski, M; Wolczyski, S, 2001) |
| "To describe our clinical experience in using Metformin combined with a high protein-low carbohydrate diet to restore normal menstrual cycles in teenaged females with polycystic ovary syndrome (PCOS)." | 5.09 | Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 2001) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| "We measured fasting serum steroid concentrations and the response of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotrophin-releasing hormone agonist, and performed oral glucose-tolerance tests before and after oral administration of either metformin (500 mg three times daily) or placebo for four to eight weeks in 24 obese women with the polycystic ovary syndrome." | 5.08 | Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. ( Jakubowicz, DJ; Nestler, JE, 1996) |
| "The BIGuanides and Prevention of Risks in Obesity (BIGPRO1) results suggest that metformin would be a suitable candidate for long-term intervention for the prevention of diabetes but that its use in a trial of primary prevention of cardiovascular diseases requires either a reevaluation of its properties toward the most potentially atherogenic anomalies of the IRS or a better definition of the target population." | 5.08 | The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. ( André, P; Bard, JM; Charles, MA; Cohen, JM; Eschwège, E; Fontbonne, A; Grandmottet, P; Isnard, F; Juhan-Vague, I; Safar, ME; Vague, P, 1996) |
| "Metformin often promotes weight loss in patients with obesity with non-insulin-dependent diabetes mellitus (NIDDM)." | 5.08 | Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. ( Lee, A; Morley, JE, 1998) |
| "To determine the clinical, hormonal, and biochemical effects of 4-6 months of metformin therapy in obese patients with polycystic ovary syndrome (PCOS)." | 5.08 | Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A, 1998) |
| "We performed oral glucose-tolerance tests before and after the administration of 500 mg of metformin or placebo three times daily for 35 days in 61 obese women with the polycystic ovary syndrome." | 5.08 | Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. ( Evans, WS; Jakubowicz, DJ; Nestler, JE; Pasquali, R, 1998) |
| "Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS)." | 5.08 | Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tomás, C, 1998) |
| "To evaluate the effect of metformin on insulin sensitivity and to further examine the relationship between insulin resistance, sympathetic nerve activity and blood pressure, 6 obese insulin resistant, normoglycemic hypertensive men were investigated (age 49 +/- 2 years, BMI 27." | 5.07 | The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. ( Attvall, S; Elam, M; Friberg, P; Gudbjörnsdottir, S; Lönnroth, P; Wallin, BG, 1994) |
| "To establish the antihyperglycemic mechanisms of metformin in non-insulin-dependent diabetes mellitus (NIDDM) independently of the long-term, aspecific effects of removal of glucotoxicity, 21 NIDDM subjects (14 obese, 7 nonobese) were studied on two separate occasions, with an isoglycemic (plasma glucose approximately 9 mM) hyperinsulinemic (two-step insulin infusion, 2 h each, at the rate of 4 and 40 mU." | 5.07 | Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. ( Bolli, GB; Brunetti, P; Ferrannini, E; Misericordia, P; Perriello, G; Santeusanio, F; Santucci, A; Santucci, C; Ventura, MM; Volpi, E, 1994) |
| "The aim of this study was to review TZD and metformin as pharmacological treatments for insulin resistance associated with obesity and cancer." | 5.05 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. ( Biondo, LA; de O S Ferreira, KC; Neto, JCR; Teixeira, AAS, 2020) |
| " Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis." | 5.05 | COVID-19 in diabetic patients: Related risks and specifics of management. ( Hermans, MP; Maiter, D; Orioli, L; Thissen, JP; Vandeleene, B; Yombi, JC, 2020) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 5.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| "The present study firstly provided quantitative information for metformin effects on weight in different disease states, including patients with type 2 diabetes mellitus, patients with antipsychotic induced weight gain, patients with obesity." | 5.05 | Time course and dose effect of metformin on weight in patients with different disease states. ( Chen, X; Li, ZP; Wang, DD, 2020) |
| "Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults." | 5.01 | Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. ( Hui, F; Li, X; Ren, T; Zhang, Y; Zhao, M; Zhao, Q, 2019) |
| "Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance." | 5.01 | Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. ( He, X; Hu, C; Liu, C; Liu, Y; Tang, W; Wu, D; Xu, B; Xu, T, 2019) |
| " Metformin is an effective oral antihyperglycaemic agent that is considered to be effective during pregnancy." | 5.01 | Metformin reduces maternal weight gain in obese pregnant women: A systematic review and meta-analysis of two randomized controlled trials. ( Benedetti Panici, P; Boccherini, C; Brunelli, R; D'Ambrosio, V; Di Mascio, D; Giancotti, A; Marchetti, C; Piccioni, MG; Vena, F, 2019) |
| "Oral antidiabetic medication of metformin is increasingly used in pregnant women with gestational diabetes mellitus (GDM), polycystic ovary syndrome (PCOS) and obesity." | 5.01 | Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis. ( Xie, Q; Xu, Q, 2019) |
| "There is a recent growing evidence that abnormalities in the microbiota composition can have a major role in the development of obesity and diabetes and that some actions of metformin may be mediated by gut bacteria." | 5.01 | The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. ( Coppola, A; Gazzaruso, C; Govoni, S; Marchesi, N; Pascale, A, 2019) |
| "This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide 1 (GLP-1) receptor agonists for women with polycystic ovary syndrome (PCOS) by comparing their effect with that of metformin." | 5.01 | GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. ( Han, Y; He, B; Li, Y, 2019) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "Metformin has been reported to reduce the risk of pre-eclampsia." | 4.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy." | 4.98 | Metformin in Pregnancy: Mechanisms and Clinical Applications. ( Balani, J; Hyer, S; Shehata, H, 2018) |
| "Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9)." | 4.98 | Review of Metformin Use for Type 2 Diabetes Prevention. ( Flory, JH; Herman, WH; Karter, AJ; Kruge, LE; Mangione, CM; Moin, T; Schillinger, D; Schmittdiel, JA; Walker, EA; Yeh, J, 2018) |
| "To evaluate the efficacy of metformin versus a placebo in the treatment of patients with simple obesity without obesity related diseases." | 4.98 | The effects of metformin on simple obesity: a meta-analysis. ( Deng, B; Gao, PX; Le, J; Ning, HH; Qin, SL; Wang, Q; Young, CA; Zhang, HQ, 2018) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 4.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| "The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial." | 4.95 | Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. ( Chen, L; Chen, Y; Deng, H; Li, M; Li, N; Wang, Q; Wang, S; Xu, D, 2017) |
| "This meta-analysis suggested that metformin could effectively lower SBP in nondiabetic patients, especially in those with impaired glucose tolerance or obesity." | 4.95 | Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. ( Liu, H; Peng, Y; Tian, Y; Wen, X; Zhao, L; Zhou, L, 2017) |
| "Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment." | 4.93 | Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. ( Apovian, CM; Aronne, LJ; Igel, LI; Saunders, KH; Sinha, A; Vojta, D, 2016) |
| " Interestingly, several potential antiobesity and/or antidiabetic agents, some of which are currently in clinical use such as metformin and liraglutide, exert some of their actions by acting on AMPK." | 4.93 | Hypothalamic AMPK: a canonical regulator of whole-body energy balance. ( Diéguez, C; López, M; Nogueiras, R; Tena-Sempere, M, 2016) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 4.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "Metformin is a biguanide used in the treatment of type 2 diabetes mellitus and obesity." | 4.93 | Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2. ( Arenas, M; Cabre, N; Camps, J; Garcia-Heredia, A; Hernandez-Aguilera, A; Joven, J; Luciano-Mateo, F, 2016) |
| "Orlistat should be considered as an addition to lifestyle interventions in the treatment of obesity." | 4.90 | The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. ( Carter, P; Chilton, M; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K, 2014) |
| " Treatment with metformin has been shown to improve insulin sensitivity, lowering blood glucose and androgen levels." | 4.90 | Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. ( Spritzer, PM, 2014) |
| "Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug." | 4.90 | Effects of metformin on weight loss: potential mechanisms. ( Kashyap, SR; Malin, SK, 2014) |
| " These options are mostly new and have the advantage a neutral or favourable (for GLP-1) effect on body weight in obese type 2 DM patient and the absence of any hypoglycaemic risk in both classes of incretins." | 4.89 | [Management of type 2 diabetes: new or previous agents, how to choose?]. ( Halimi, S, 2013) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 4.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 4.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries." | 4.88 | Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 4.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| " Insulin resistance drives islet cell upregulation, manifested by elevated glucagon and c-peptide levels, early in the transition to IGT." | 4.88 | Insulin resistance in type 2 diabetic youth. ( Cree-Green, M; Mizokami-Stout, K; Nadeau, KJ, 2012) |
| " The Pregnancy in PCOS trial II will determine the safety and efficacy of clomiphene citrate compared to letrozole, in achieving live birth in infertile women with PCOS." | 4.88 | Reproductive impact of polycystic ovary syndrome. ( Legro, RS; Usadi, RS, 2012) |
| "There are differences in opinion as to whether metformin should play a role in the primary treatment of anovulatory infertility for women with polycystic ovary syndrome (PCOS)." | 4.87 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. ( Johnson, N, 2011) |
| "Substantial evidence confirms the weight benefits of metformin and shows that, of the newer available agents, glucagon-like peptide-1 (GLP-1) agonists and amylin analogs promote weight loss." | 4.87 | Weight beneficial treatments for type 2 diabetes. ( Caputo, S; Damçi, T; Khunti, K; Liebl, A; Meneghini, LF; Orozco-Beltran, D; Ross, SA, 2011) |
| "Articles were identified by searching the MEDLINE database (from 1949 through January 2010) using the key words metformin, topiramate, antipsychotic, weight, weight gain, and obesity." | 4.86 | Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. ( Ellinger, LK; Ipema, HJ; Stachnik, JM, 2010) |
| " Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus." | 4.86 | The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. ( Ali, F; Dahmen, MM; Girrens, K; Khan, AY; Macaluso, M; McHale, RJ, 2010) |
| "Metformin is widely used for treating patients with type 2 diabetes mellitus." | 4.86 | [New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010) |
| " Metformin is currently the preferred insulin-sensitizing drug for chronic treatment of PCOS and has been shown to improve the metabolic profile, menstrual cyclicity and fertility in women with PCOS, and is associated with weight loss." | 4.85 | Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Palermo, V; Petraglia, F, 2009) |
| " Key words included adolescents, overweight, obesity, anti-obesity agents, drug therapy, orlistat, sibutramine, and metformin." | 4.84 | Pharmacotherapeutic options for overweight adolescents. ( Desilets, AR; Dunican, KC; Montalbano, JK, 2007) |
| "To evaluate the efficacy and safety of metformin for weight management in overweight and obese patients without type 2 diabetes." | 4.84 | Role of metformin for weight management in patients without type 2 diabetes. ( Desilets, AR; Dhakal-Karki, S; Dunican, KC, 2008) |
| " This review provides information regarding diagnosis of type 2 diabetes in children, as well as prevention strategies, such as lifestyle modification and pharmacologic options for weight loss, including metformin, orlistat, and sibutramine." | 4.83 | The treatment of type 2 diabetes mellitus in youth : which therapies? ( Miller, JL; Silverstein, JH, 2006) |
| "The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-gamma, and decreases metabolic and vascular insulin resistance." | 4.83 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. ( Forst, T; Pfützner, A; Schneider, CA, 2006) |
| "Metformin has been used as a treatment in many studies of the infertility associated with polycystic ovary syndrome (PCOS)." | 4.82 | Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. ( Attia, GR; Carr, BR; Haas, DA, 2003) |
| "In obese type 2 diabetic patients inadequately controlled on MET alone, addition of rosiglitazone improves glycaemic control, insulin sensitivity and beta-cell function to a clinically important extent." | 4.82 | Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. ( Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF, 2003) |
| " In at least two randomized controlled studies, metformin proved to be clinically effective in increasing insulin sensitivity in hyperinsulinemic, nondiabetic adolescents." | 4.82 | Insulin resistance syndrome in children : pathophysiology and potential management strategies. ( Decsi, T; Molnár, D, 2003) |
| "Both metformin and thiazolidinedione derivatives(TZDs) improve insulin resistance, a major pathogenesis of type 2 diabetes, and decrease blood glucose levels without stimulating insulin secretion." | 4.82 | [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives]. ( Satoh, J, 2003) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "The drugs orlistat and sibutramine appear beneficial for the treatment of adults with obesity, and metformin for obese patients with type 2 diabetes." | 4.82 | Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. ( Aucott, L; Avenell, A; Broom, J; Brown, TJ; Campbell, MK; Grant, AM; Jung, RT; Poobalan, A; Smith, WC; Stearns, SC, 2004) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Metformin-associated lactic acidosis is not necessarily due to metformin accumulation." | 4.80 | [Current role of metformin in treatment of diabetes mellitus type 2]. ( Janssen, JA, 2000) |
| " On the other hand, treatment of obese patients with metformin significantly reduced the incidence of myocardial infarction and of mortality diabetes related." | 4.80 | [Should the occurrence of a first coronary event change the management of diabetes?]. ( Dubois-Laforgue, D; Timsit, J, 2000) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " The present study aimed to determine whether metformin exerts beneficial effects on metabolic and neurobehavioral outcomes in the streptozotocin (STZ)-induced T1D model and western diet (WD)-induced obesity model in male Swiss mice." | 4.31 | Metformin improves neurobehavioral impairments of streptozotocin-treated and western diet-fed mice: Beyond glucose-lowering effects. ( Barbosa, LADS; Barros, WM; Braga, SP; Bullich, S; Delanogare, E; Dos Santos, GJ; Guiard, BP; Kasprowicz, JN; Kraus, SI; Moreira, ELG, 2023) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 4.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 4.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "The keywords of PCOS research focused on PCOS, insulin resistance (IR), obesity and metformin." | 4.31 | Past and present: a bibliometric study on polycystic ovary syndrome. ( Cai, M; Ni, Z; Yao, R; Yu, C; Yu, J; Yuan, Z; Zhang, D; Zhou, L, 2023) |
| "The anti-diabetic drug metformin might reduce prevalence of chronic low back pain in people who are older, overweight, or less active." | 4.31 | The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank. ( Carvalho-E-Silva, AP; Ferreira, ML; Ferreira, PH; Harmer, AR; Hartvigsen, J, 2023) |
| "Our findings showed that Dapagliflozin and Metformin may inhibit bulimia induced obesity with different mechanisms." | 4.31 | Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity. ( Gu, R; Hao, H; Jia, J; Kang, L; Li, Z; Qi, Y; Qiao, S; Sun, X; Wang, K; Xu, B; Zhang, Q; Zhang, X, 2023) |
| "The high-fat diet-induced mouse model of obesity and insulin resistance of both sexes was developed in a randomized block experiment and bulk RNA-Seq of the ileum tissue was the method of choice for comparative transcriptional profiling after metformin intervention for ten weeks." | 4.31 | Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance. ( Ansone, L; Birzniece, L; Brīvība, M; Elbere, I; Jagare, L; Kalniņa, I; Kloviņš, J; Silamiķele, L; Silamiķelis, I, 2023) |
| "We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic." | 4.12 | Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. ( Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D, 2022) |
| "To evaluate and compare the effects of the combined intervention of metformin and exercise on the degeneration of cartilage and subchondral bone in a mouse model of osteoarthritis (OA) induced by estrogen deficiency and obesity." | 4.12 | Combination of metformin and exercise alleviates osteoarthritis in ovariectomized mice fed a high-fat diet. ( Gou, Y; Hu, Y; Li, H; Lian, Q; Tian, F; Zhang, L; Zhang, Y, 2022) |
| "Elevated RIF1 in oocytes caused by maternal obesity may mediate abnormal embryonic epigenetic remodeling and increase metabolic risk in offspring by regulating histone modifications on MuERV-L, which can be partially rescued by metformin treatment." | 4.12 | Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice. ( Huang, J; Li, Z; Ru, G; Sun, J; Sun, L, 2022) |
| " Questionnaire and linked administrative health data from the Centre for Health Record Linkage and Services Australia were used to identify incident PC, healthcare utilisations, Prostate Specific Antigen (PSA) testing reimbursements and dispensing of metformin and benign prostatic hyperplasia (BPH) prescriptions." | 4.12 | Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study. ( Armstrong, BK; Bang, A; Banks, E; Chiam, K; Egger, S; Nair-Shalliker, V; O'Connell, DL; Patel, MI; Smith, DP; Steinberg, J; Yu, XQ, 2022) |
| " While atypical antipsychotics such as aripiprazole are not associated with obesity and diabetes, olanzapine is still widely used based on the anticipation that it is more effective in treating severe schizophrenia than aripiprazole, despite its metabolic side effects." | 4.12 | Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance. ( Choi, SY; Jang, S; Kim, DG; Kim, J; Kim, S; Lee, CH; Lee, KW; Lee, N; Park, JK; Suh, SB, 2022) |
| " To assess the relationship between PDIA4, adiponectin, and metformin, we used the palmitate-induced inflammation in hypertrophic adipocytes and the high-fat diet-induced obesity mouse model." | 4.12 | PDIA4, a novel ER stress chaperone, modulates adiponectin expression and inflammation in adipose tissue. ( Chen, YC; Chiang, CF; Chien, CY; Ho, LJ; Hsieh, CH; Huang, CL; Hung, YJ; Kuo, FC; Lee, CH; Li, PF; Lin, FH; Liu, JS; Lu, CH; Shieh, YS; Su, SC, 2022) |
| "Metformin is still being investigated due to its potential use as a therapeutic agent for managing overweight or obesity." | 4.12 | Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells. ( Cheng, Y; Deng, W; Du, B; Fang, D; Gao, Y; Jia, X; Lu, T; Wang, L; Yang, C; Yang, L; Zhai, Z, 2022) |
| "Of those prescribed metformin, 83% were overweight or obese and 72% had elevated HOMA2-IR scores." | 4.12 | Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting. ( Carpenter, J; Hickie, IB; McHugh, C; Park, S; Scott, EM; Wilson, C, 2022) |
| " The aim of this study is the comparison of 3 mg liraglutide and metformin combination, metformin monotherapy on the blood glucose regulation, weight loss and lipid panel in the patients with Type 2 diabetes mellitus whose BMI is ≥ 30 kg/m2." | 4.12 | Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. ( Keskin, L; Yaprak, B, 2022) |
| "The US FDA required a Risk Evaluation and Mitigation Strategy (REMS) for phentermine/topiramate, an anti-obesity medication, to prevent congenital malformations." | 4.12 | Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2022) |
| "Metformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i." | 4.12 | Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. ( Afonso, J; Azócar-Gallardo, J; García-García, JM; González-Rojas, L; Granacher, U; Ojeda-Aravena, A; Ramirez-Campillo, R; Sá, M, 2022) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 4.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| " The effect of HFD on maternal rats was alleviated by prenatal metformin, which also ameliorated inflammation and apoptosis in the fetal liver and intestines." | 4.02 | Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis. ( Hou, CY; Huang, LT; Huang, SW; Lin, IC; Ou, YC; Sheen, JM; Tain, YL; Tang, KS; Tiao, MM; Tsai, CC; Yu, HR, 2021) |
| "Metformin (MET), the most common medicine for type 2 diabetes (T2DM), improves insulin sensitivity by targeting the liver, intestine and other organs." | 4.02 | Restoration of mRNA Expression of Solute Carrier Proteins in Liver of Diet-Induced Obese Mice by Metformin. ( Chen, Y; Fu, Y; Han, Q; Ji, H; Le, J; Li, J; Lin, X; Pi, P; Wang, Q; Wei, X; Ye, J; Zhang, X; Zhang, Y, 2021) |
| " Metformin is shown to lower body weight and adiposity, but the underlying mechanism is unclear." | 4.02 | Metformin effectively restores the HPA axis function in diet-induced obese rats. ( Balasubramanian, P; Herdt, TH; MohanKumar, PS; MohanKumar, SMJ; Shin, AC; Suryadevara, P; Zyskowski, J, 2021) |
| " Gas6 levels were found to be in proportion to the expression of adiponectin, which has been regarded as closely relevant to improved insulin sensitivity after metformin treatment." | 4.02 | Growth arrest-specific 6 modulates adiponectin expression and insulin resistance in adipose tissue. ( Chiang, CF; Hsieh, CH; Hung, YJ; Lee, CH; Liu, JS; Lu, GH; Shieh, YS; Su, SC, 2021) |
| " Metformin has potential effects on improving asthma airway inflammation." | 4.02 | Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. ( Chen, M; Guo, Y; Hong, L; Jiang, S; Liu, S; Shi, J; Wang, Q; Yuan, X, 2021) |
| "Metformin was significantly associated with reduced mortality in women with obesity or type 2 diabetes who were admitted to hospital for COVID-19." | 4.02 | Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. ( Abdelwahab, N; Benson, B; Bramante, CT; Feng, R; Gronski, J; Guzman, G; Hovertsen, S; Ingraham, NE; King, S; Marmor, S; McNeil, C; Meehan, T; Murray, TA; Pendleton, KM; Tamariz, L; Tignanelli, CJ; Vojta, D, 2021) |
| " Its circulating levels are acutely increased by the type 2 diabetes medication metformin, resulting in reduced appetite and weight loss." | 4.02 | Genetically proxied growth-differentiation factor 15 levels and body mass index. ( Gill, D; Karhunen, V; Larsson, SC, 2021) |
| "Sixty-two obese patients in treatment with metformin-with prediabetes (n = 41) or newly diagnosed T2DM (n = 21), were studied." | 4.02 | Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. ( Ciotti, S; Cipollone, F; Consoli, A; Desideri, G; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tartaro, A; Tripaldi, R; Vadini, F, 2021) |
| " We have recently demonstrated that the combined treatment between moderate exercise and metformin slows sarcopenia's onset by a mechanism that includes adipose reduction and REDOX regulation." | 4.02 | Metformin and tBHQ Treatment Combined with an Exercise Regime Prevents Osteosarcopenic Obesity in Middle-Aged Wistar Female Rats. ( Hernández-Álvarez, D; Königsberg, M; Lopéz-Cervantes, SP; López-Diazguerrero, NE; Luna-López, A; Mena-Montes, B; Pedraza-Vázquez, G; Sánchez-Garibay, C; Toledo-Pérez, R, 2021) |
| "Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis." | 3.96 | Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. ( Aedo, S; Arriola-Montenegro, J; Arteaga, E; Belardo, A; Blümel, JE; Chedraui, P; Fighera, TM; López, M; Martino, M; Miranda, C; Miranda, O; Mostajo, D; Ñañez, M; Ojeda, E; Pilnik, S; Rojas, J; Salinas, C; Sosa, L; Spritzer, PM; Tserotas, K; Vallejo, MS, 2020) |
| " Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials." | 3.96 | Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020) |
| "Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease." | 3.96 | Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. ( Avolio, T; Bachman, TN; Bai, Y; Baust, JJ; Bonetto, A; Considine, RV; Cook, T; Fisher, A; Gladwin, MT; Goncharov, DA; Goncharova, EA; Halliday, G; Hu, J; Huot, JR; Lai, YC; Machado, RF; McTiernan, CF; Mora, AL; Satoh, T; Sebastiani, A; Tan, J; Vanderpool, RR; Wang, L, 2020) |
| " Metformin is used for the treatment of type 2 diabetes and was reported to exert therapeutic effects against rheumatoid arthritis and obesity by improving mitochondrial dysfunction via the activation of fibroblast growth factor 21." | 3.96 | Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome. ( Cho, ML; Choi, JW; Jung, KA; Kim, DS; Kim, EK; Lee, SY; Min, HK; Na, HS; Park, SH; Ryu, JG, 2020) |
| "The aim of this study was to investigate the effects of metformin supplementation on metabolic dysfunction, testicular antioxidant capacity, apoptosis, inflammation and spermatogenesis in male mice with high-fat and high-cholesterol diet-induced obesity." | 3.96 | Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity. ( Cha, TL; Chang, TC; Lin, SH; Liu, CY; Tsao, CW; Wu, ST, 2020) |
| "This study aims to demonstrate the effects of metformin on epicardial adipose tissue and electromechanical delay in patients using metformin for insulin resistance." | 3.96 | Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance. ( Çelik, E; Güneş, H; Özmen, Ş; Temiz, F, 2020) |
| " As changes in T-cell mitochondrial oxidation were observed in obesity, obese mice were treated with metformin for 6 weeks and compared to lean control mice or obese mice undergoing weight loss through diet switch; immunity was measured by survival to influenza infection." | 3.96 | Targeting T-cell oxidative metabolism to improve influenza survival in a mouse model of obesity. ( Alwarawrah, Y; Beck, MA; Eisner, W; Green, WD; Hale, LP; Kiernan, K; MacIver, NJ; Nichols, AG; Warren, J, 2020) |
| "What is the central question of this study? Studies reported the efficacy of metformin as a promising drug for preventing or treating of metabolic diseases." | 3.96 | Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood. ( Alves, VS; de Moraes, AMP; de Oliveira, JC; Francisco, FA; Franco, CCDS; Malta, A; Martins, IP; Mathias, PCF; Matiusso, CCI; Miranda, RA; Moreira, VM; Pavanello, A; Prates, KV; Previate, C, 2020) |
| " The aims of this study were to evaluate the potential effect of metformin in GWG in overweight or obese women with GDM, to report our experience and to assess metformin's safety in this population." | 3.91 | Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. ( Belo, S; Bettencourt-Silva, R; Carvalho, D; Ferreira, MJ; Montenegro, N; Namora, G; Neves, JS; Oliveira, AI; Queirós, J; Souteiro, P, 2019) |
| "Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 3.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
| " We examined the effects of SGLT2 inhibitor-dapagliflozin on insulin resistance, hepatic gluconeogenesis, hepatic injury and pancreatic ER stress in high-fat diet-induced obese rats." | 3.91 | Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. ( Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L, 2019) |
| "In diet-induced obesity, metformin (MF) has weight-lowering effect and improves glucose homeostasis and insulin sensitivity." | 3.91 | The evidence of metabolic-improving effect of metformin in Ay/a mice with genetically-induced melanocortin obesity and the contribution of hypothalamic mechanisms to this effect. ( Bakhtyukov, A; Bayunova, L; Derkach, K; Romanova, I; Shpakov, A; Zakharova, I; Zorina, I, 2019) |
| "These data suggest that metformin use may have a beneficial effect on long-term knee joint outcomes in those with knee osteoarthritis and obesity." | 3.91 | Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative-a prospective cohort study. ( Abram, F; Cicuttini, FM; Hussain, SM; Lim, YZ; Martel-Pelletier, J; Pelletier, JP; Wang, Y; Wluka, AE, 2019) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 3.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 3.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " Metformin has been reported to have a therapeutic effect on RA and obesity." | 3.88 | Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. ( Cho, ML; Choi, JY; Jhun, JY; Kim, EK; Kim, JK; Kim, SY; Lee, SH; Lee, SY; Na, HS; Park, SH; Yang, CW, 2018) |
| "Objective The study's objective was to evaluate the thyroid parameters in obese insulin-resistant patients with euthyroid diffuse or nodular goiter, following Metformin treatment." | 3.88 | The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter. ( Bolboacă, SD; Ghervan, C; Mârza, S; Moga, D; Răcătăianu, N; Sitar-Tăut, AV; Valea, A, 2018) |
| " Using metformin during pregnancy and nursing to improve the metabolic status of obese mothers could prevent the sequence of events that lead to an increase in postnatal serum estradiol levels in female offspring and, hence, reproductive dysfunction." | 3.88 | Prenatal metformin treatment improves ovarian function in offspring of obese rats. ( Álvarez, D; Ceballo, K; Cruz, G; Fernandois, D; Maliqueo, M; Martinez-Pinto, J; Olguín, S; Sotomayor-Zárate, R, 2018) |
| "The present study aimed to investigate the effect of metformin on the induction of autophagy in the liver and adipose tissues of a mouse model of obesity." | 3.85 | Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice. ( Li, M; Sharma, A; Tan, X; Xiao, Y; Yin, C, 2017) |
| "There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication." | 3.85 | Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. ( Galletly, C; Myles, H; Smith, C, 2017) |
| "Sitagliptin can reduce BMI and the occurrence of hypoglycemia in obese patients with insulin treatment-induced diabetes mellitus, and the effect may be related to decreased HOMA-IR, decreased leptin and visfatin levels, and increased adiponectin levels." | 3.85 | The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus. ( Li, H; Li, S; Wang, R; Zhang, JP, 2017) |
| "The metabolic parameters and functional state of hypothalamic systems in mice with the Yellow mutation in the Agouti locus and with obesity of the melanocortin type and the effect of metformin (MF) treatment (9 days, 200 mg/kg/day) were studied." | 3.85 | Metabolic parameters and functional state of hypothalamic signaling systems in A ( Derkach, KV; Mikhrina, AL; Romanova, IV; Shpakov, AO; Zakharova, IO; Zorina, II, 2017) |
| "To investigate the role of apolipoprotein A5 (apoA5) in the pathogenesis of obesity-related hypertriglyceridemia and the related therapeutic effects of metformin." | 3.85 | [Metformin reduces plasma triglycerides in ob/ob obese mice via inhibiting the hepatic apoA5 expression]. ( Chen, L; Dai, W; Huang, X; Li, R, 2017) |
| "To compare the therapeutic potential of TP-113, a unique molecular entity linking DHA with metformin, for alleviating insulin resistance in obese diabetic mice through the PDX/IL-6 pathway." | 3.85 | Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice. ( Barbier, O; Lachance, D; Marette, A; Mitchell, PL; Nachbar, R; St-Pierre, P; Trottier, J, 2017) |
| "The purpose of this study was to determine the effects of metformin on dysfunctional retinas in obesity-induced type 2 diabetic mice." | 3.85 | The Effects of Metformin on Obesity-Induced Dysfunctional Retinas. ( Chang, JY; Chang, RC; Kim, AJ; Ko, GY; Ko, ML; Shi, L, 2017) |
| " Thus, in patients with diabetes-associated chronic kidney disease, the glucose lowering therapy has to account for renal function to avoid hypoglycemic episodes and other side effects such as lactic acidosis due to metformin." | 3.83 | [New aspects in prevention and therapy of diabetic nephropathy]. ( Böger, CA; Büttner, R; Rheinberger, M, 2016) |
| "To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM)." | 3.83 | Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. ( Chen, J; Liao, L; Sun, W; Wang, Y; Zeng, C, 2016) |
| "A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily)." | 3.83 | Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. ( Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D, 2016) |
| " Here we show that treatment with the antidiabetic drug metformin inhibits excessive ECM deposition in WAT of ob/ob mice and mice with diet-induced obesity, as evidenced by decreased collagen deposition surrounding adipocytes and expression of fibrotic genes including the collagen cross-linking regulator LOX Inhibition of interstitial fibrosis by metformin is likely attributable to the activation of AMPK and the suppression of transforming growth factor-β1 (TGF-β1)/Smad3 signaling, leading to enhanced systemic insulin sensitivity." | 3.83 | AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. ( Fry, J; Han, J; Jiang, B; Li, Q; Luo, T; Nocon, A; Rui, X; Sherban, A; Xu, XJ; Yan, Y; Yang, Q; Zang, M, 2016) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| " This study is to investigate the role of apoA5 in obesity-associated hypertriglyceridemia and metformin-related hypotriglyceridemic actions." | 3.83 | Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. ( Chen, LZ; Huang, XS; Li, R; Zhao, SP; Zhao, W, 2016) |
| "Our data allow us to suggest that metformin, reducing the stimulatory effect of obesity on tumor development, has a potential role in the management of cancers." | 3.81 | Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a. ( Akamine, EH; de Carvalho, MH; de Queiroz, EA; Fortes, ZB; Sampaio, SC, 2015) |
| " Metformin is a first-line treatment of type 2 diabetes, with minimal weight loss in humans." | 3.81 | Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice. ( Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A, 2015) |
| " Leucine (Leu) activates Sirt1 by lowering its Km for NAD(+) and potentiates other sirtuin/AMPK-activators, resulting in improvement of insulin sensitivity." | 3.81 | Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice. ( Bruckbauer, A; Cao, Q; Cui, X; Fu, L; Li, F; Shi, H; Wu, R; Xue, B; Zemel, MB, 2015) |
| " Metformin, which is widely used in the treatment of diabetes, ameliorates insulin sensitivity." | 3.81 | Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice. ( Baba, A; Kochi, T; Kubota, M; Moriwaki, H; Ohno, T; Shimizu, M; Shirakami, Y; Tanaka, T; Tsurumi, H, 2015) |
| "Percentage of health plan enrollees with prediabetes who were prescribed metformin." | 3.81 | Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. ( Duru, OK; Ettner, S; Ho, S; Keckhafer, A; Li, J; Mangione, CM; Moin, T; Turk, N, 2015) |
| "To evaluate the effects of treatment with metformin on a murine model of obesity-associated erectile dysfunction." | 3.81 | Treatment With Metformin Improves Erectile Dysfunction in a Murine Model of Obesity Associated With Insulin Resistance. ( Alexandre, EC; Antunes, E; Calixto, MC; Calmasini, FB; Silva, FH, 2015) |
| "To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients." | 3.81 | IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. ( Gong, WJ; Han, XY; Ji, LN; Li, X; Lin, X; Liu, RR; Liu, ZQ; Tang, Q; Xiao, D; Xu, XJ; Yin, JY; Zhang, SM; Zhang, W; Zheng, Y; Zhou, HH, 2015) |
| "The aim of this retrospective observational study was to evaluate whether adding liraglutide to lifestyle changes, metformin (Met) and testosterone replacement therapy (TRT), by means of improving weight and glycaemic control, could boost erectile function in type 2 diabetic obese men with overt hypogonadism and erectile dysfunction (ED) in a 'real-life setting'." | 3.81 | Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. ( Carbone, MD; De Pergola, G; Giagulli, VA; Guastamacchia, E; Licchelli, B; Ramunni, MI; Sabbà, C; Triggiani, V, 2015) |
| "Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study." | 3.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| "Metformin and phosphatidylcholine attenuated lipopolysaccharide induced toll-like receptor 4 overexpression and overproduction of pro-inflammatory cytokines; however, their efficacy depended on combined presence of non-alcoholic fatty liver disease, metabolic syndrome and obesity." | 3.81 | Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate. ( Daniluk, J; Kandefer-Szerszeń, M; Szuster-Ciesielska, A; Słabczyńska, O; Zwolak, A, 2015) |
| "To authenticate the effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome (PCOS) using 3-dimensional (3D) power Doppler." | 3.80 | Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome. ( El Sherbiny, M; Elkabarity, R; Makled, AK, 2014) |
| "In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet." | 3.80 | Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014) |
| " Whether the vascular benefits of antidiabetic drug metformin (AMPK activator) in diabetes mellitus and obesity is mediated by PPARδ remains unknown." | 3.80 | Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. ( Cheang, WS; Chen, ZY; Huang, Y; Lau, CW; Lee, SS; Tian, XY; Wang, N; Wong, WT; Yao, X, 2014) |
| "Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations (P < 0·05) in women with polycystic ovary syndrome (PCOS), a pro-inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis." | 3.80 | Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. ( Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2014) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 3.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "Metformin and swimming exercise improved lipid profile, and increased insulin sensitivity and body weight reduction were observed." | 3.80 | Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. ( Gao, Y; Luo, L; Pan, T; Wang, C, 2014) |
| "The combination of dimethylbiguanide and pioglitazone was more effective for the treatment of PCOS complicated with IR than simple pioglitazone; chronic inflammation occurrence was possibly one of reasons for insulin sensitivity reduction of patients with PCOS." | 3.80 | Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. ( Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF, 2014) |
| "Metformin could retard body weight gain, improve insulin sensitivity and reduce intramyocellular lipid accumulation in ob/ob mice." | 3.80 | Metformin suppresses lipid accumulation in skeletal muscle by promoting fatty acid oxidation. ( Hu, P; Li, Q; Li, Z; Liu, F; Wang, C; Wang, H; Wu, J; Ye, J; Yuan, Y; Zhang, L, 2014) |
| "Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate." | 3.80 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S, 2014) |
| "Metformin is commonly used as the first line of medication for the treatment of metabolic syndromes, such as obesity and type 2 diabetes (T2D)." | 3.80 | Effect of metformin on metabolic improvement and gut microbiota. ( Ko, G; Lee, H, 2014) |
| "To study the effect of Mudan Granule (MD) on the glucose metabolism and beta cell function in monosodium glutamate (MSG) induced obese mice with insulin resistance (IR)." | 3.80 | [Effect of Mudan Granule on islets beta cell function in monosodium glutamate induced obese mice with insulin resistance: an experimental study]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ, 2014) |
| "In an experimental model of obesity and hyperglycemia in Drosophila melanogaster we studied the effect of diet modification and administration of metformin on systemic infection with Rhizopus, a common cause of mucormycosis in diabetic patients." | 3.80 | Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. ( Albert, N; Do, KA; Farmakiotis, D; Kim-Anh, D; Kontoyiannis, DP; Shirazi, F; Yan, Y, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 3.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "Obesity is becoming a health concern worldwide and metformin, a first line anti-diabetic drug, was associated with weight loss under different backgrounds." | 3.79 | Effect of metformin on the urinary metabolites of diet-induced-obese mice studied by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-TOF/MS). ( Cong, W; Feng, Y; Ruan, K; Shen, L; Wang, B; Xu, D; Zhu, Y, 2013) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 3.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| " The AMP-activated protein kinase (AMPK) activator metformin reverses obesity-associated insulin resistance (IR) and inhibits different types of inflammatory responses." | 3.79 | Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. ( André, DM; Anhê, GF; Antunes, E; Bordin, S; Calixto, MC; Ferreira, D; Landgraf, RG; Leiria, LO; Lellis-Santos, C; Lintomen, L, 2013) |
| " As a result of the proposed method of treatment had improved the clinical course of CCH due to lower body weight, body mass index (BMI) and abdominal obesity indexes (AOI), which were characterized by decreasing the duration and frequency of angina attacks, reducing the number of nitroglycerin tablets taken, and also increased exercise tolerance (ET)." | 3.79 | [Оptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity]. ( Teslenko, IuV, 2013) |
| "Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate." | 3.79 | Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography. ( Elkattan, E; Khattab, S; Mohsen, IA; Nabil, H, 2013) |
| "The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results." | 3.79 | Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. ( Schehler, B; Schneider, HJ; Seifarth, C, 2013) |
| "Metformin is widely used to treat obese diabetics because of its beneficial effects on body weight, energy intake, and glucose regulation." | 3.79 | Metformin decreases meal size and number and increases c-Fos expression in the nucleus tractus solitarius of obese mice. ( Choi, SH; Chun, BG; Kim, DH; Kim, HJ; Park, EY; Shin, KH; Zhang, XH, 2013) |
| "The pharmacological action of metformin goes beyond mere glycemic control, decreasing markers of inflammation and contributing to the reduction of oxidative stress." | 3.78 | [Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients]. ( Andrews, M; Arredondo, M; Soto, N, 2012) |
| "The pharmacokinetics of metformin was influenced by lean body weight on an allometric basis and was related to markers of renal function, age, and serum creatinine in this population of 105 patients." | 3.78 | Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. ( Bardin, C; Chast, F; Larger, E; Nobecourt, E; Treluyer, JM; Urien, S, 2012) |
| "To observe the effects of metformin on epididymal sperm quality and antioxidant function of the testis in diet-induced obesity rats." | 3.78 | [Metformin improves epididymal sperm quality and antioxidant function of the testis in diet-induced obesity rats]. ( Fang, X; Jia, C; Peng, YF; Xu, QY, 2012) |
| "The objective was to explore the effects of metformin on the expression of endometrial glucose transporter 4 (GLUT4) and analyze the related factors of GLUT4 in patients with polycystic ovary syndrome (PCOS)." | 3.78 | Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. ( Jiang, QH; Liu, CX; Sun, YP; Tian, ZR; Zhai, J, 2012) |
| " Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
| "Hyperuricemia may underlie obesity and related disorders, but the impact of weight reduction and metformin on serum uric acid (sUA) in Caucasian children/adolescents is unknown." | 3.77 | The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. ( Chrzanowska, J; Gamian, A; Krzystek-Korpacka, M; Kustrzeba-Wojcicka, I; Noczynska, A; Patryn, E, 2011) |
| " We studied the metabolic effects of treatment with mildronate, metformin and a combination of the two in the Zucker rat model of obesity and impaired glucose tolerance." | 3.77 | Anti-diabetic effects of mildronate alone or in combination with metformin in obese Zucker rats. ( Cirule, H; Dambrova, M; Liepinsh, E; Makrecka, M; Skapare, E; Svalbe, B, 2011) |
| "Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills." | 3.77 | [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011) |
| " Metformin mediates a phenotypic shift away from lipid accretion through AMPK-NAMPT-SIRT1 mediated changes in clock components, supporting chronotherapeutic treatment approaches for obesity." | 3.77 | Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. ( Caton, PW; Holness, MJ; Kieswich, J; Sugden, MC; Yaqoob, MM, 2011) |
| " Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study." | 3.77 | Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011) |
| "Circulating galectin-3 was similarly elevated in T2D and obesity compared with normal-weight individuals and revealed a body mass index-dependent positive correlation with leptin, resistin, IL-6, and age." | 3.76 | Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. ( Aslanidis, C; Bauer, S; Buechler, C; Farkas, S; Neumeier, M; Schäffler, A; Scherer, MN; Schnitzbauer, A; Schölmerich, J; Wanninger, J; Weigert, J, 2010) |
| "To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD)." | 3.76 | Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. ( Bachyrycz, AM; Cone, CJ; Murata, GH, 2010) |
| " The variables evaluated were first-line methods of weight reduction used, proportion of women with PCOS seen that were obese, whether the patients had tried other weight reduction methods before seeking help, the optimal dietary advice and optimal composition, the optimal duration and frequency of exercise suggested, BMI used for suggesting weight loss, percentage of women in whom weight loss worked, length of time allowed prior to suggesting another method, methods considered most effective by patients, use of metformin for weight loss, criteria used for prescribing metformin, first-line anti-obesity drugs preferred if any, second- and third-line methods used, referral to other specialists and criteria for referral for bariatric surgery." | 3.76 | National survey on management of weight reduction in PCOS women in the United Kingdom. ( Atiomo, W; Sharma, A; Walker, DM, 2010) |
| "Impaired glucose tolerance in obese youth is a reversible abnormality by lifestyle modification with or without metformin." | 3.76 | Successful strategy to improve glucose tolerance in Thai obese youth. ( Kiattisakthavee, P; Likitmaskul, S; Nakavachara, P; Numbenjapon, N; Santiprabhob, J; Wongarn, R, 2010) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 3.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS)." | 3.74 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. ( Bednarek-Tupikowska, G; Bohdanowicz-Pawlak, A; Demissie, M; Jakubowska, J; Milewicz, A; Szymczak, J, 2008) |
| " These mice also have enhanced inflammatory responses to ozone, a common air pollutant that exacerbates asthma." | 3.74 | No effect of metformin on the innate airway hyperresponsiveness and increased responses to ozone observed in obese mice. ( Shore, SA; Williams, ES; Zhu, M, 2008) |
| "7%) stopped metformin therapy due to excessive anorexia." | 3.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up." | 3.74 | Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. ( Fu, JF; Hong, F; Liang, L; Wang, CL; Wang, XM; Zhao, ZY; Zou, CC, 2007) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| " We evaluated serum CRP level, before and after metformin therapy in obese women with polycystic ovarian syndrome (PCOS)." | 3.74 | C-reactive protein in obese PCOS women and the effect of metformin therapy. ( Velija-Asimi, Z, 2007) |
| " At the beginning of the therapy, among the biochemical measurements, insulin resistance was defined and metformin treatment was begun." | 3.74 | Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report. ( Balci, H; Eker, E; Ozenoglu, A; Ugurlu, S, 2007) |
| "The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin." | 3.74 | Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. ( Cowan, PA; Harden, KA; Patton, SB; Velasquez-Mieyer, P, 2007) |
| "Before and 3 months after low-dose metformin therapy, eight overweight/obese Japanese subjects [body mass index (BMI) >25 kg/m2] were studied with blood sampling, measurement of IHL and IMCL by 1H magnetic resonance spectroscopy and glucose infusion rate (GIR) during euglycaemic-hyperinsulinaemic clamp as an index of peripheral insulin sensitivity." | 3.74 | Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. ( Hirose, T; Kawamori, R; Kumashiro, N; Sakurai, Y; Sato, F; Tamura, Y; Tanaka, Y; Watada, H, 2008) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 3.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| "A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)." | 3.74 | Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007) |
| " She would like to know whether she can continue using metformin during the pregnancy and also is concerned about the effect of the gastric bypass surgery." | 3.74 | A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery. ( Coustan, DR, 2008) |
| "A MEDLINE literature search was conducted (1950-January 2008) using the search terms acanthosis nigricans (AN), metformin, rosiglitazone, octreotide, retinoic acid, acitretin, etretinate, and isotretinoin." | 3.74 | Treatment options in insulin resistance obesity-related acanthosis nigricans. ( Benavides, S; Romo, A, 2008) |
| "This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)." | 3.73 | Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005) |
| " Obesity is the most important risk factor to develop this disease and metformin is considered as a first line drug in overweighted diabetic patients." | 3.73 | [Metformin in the treatment of type 2 diabetes in overweighted or obese patients]. ( Costa Zamora, P; Díaz, JM; González Alvaro, A; Martín Muñoz, MC; Muros Bayo, JM, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 3.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| " However, obese mares exhibited a significantly longer duration of the oestrous cycle, significant increases in circulating concentrations of leptin and insulin, and decreased insulin sensitivity and concentrations of thyroxine compared with feed-restricted mares throughout the experiment." | 3.73 | Obesity is associated with altered metabolic and reproductive activity in the mare: effects of metformin on insulin sensitivity and reproductive cyclicity. ( Fitzgerald, BP; Kennedy, EL; Murphy, BA; Reedy, SE; Sessions, DR; Vick, MM, 2006) |
| "We report 4 cases of lactic acidosis in diabetic patients usually treated with metformin." | 3.72 | [Metformin-associated lactic acidosis remains a serious complication of metformin therapy]. ( Giunti, C; Grimaud, D; Ichai, C; Levraut, J; Orban, JC, 2003) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 3.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| "The objective of the study was to determine whether plasma migration inhibitor factor (MIF) concentration and mononuclear cell (MNC) mRNA are elevated in obesity and whether treatment with metformin reduces plasma MIF concentration." | 3.72 | Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. ( Aljada, A; Chaudhuri, A; Dandona, P; Ghanim, H; Hofmeyer, D; Mohanty, P; Tripathy, C, 2004) |
| "The aim of the present study was to evaluate the effect of metformin on body weight, body fat mass, waist circumference, lipid parameters, insulin secretion and insulin resistance in obese subjects with normal glucose tolerance." | 3.72 | Metformin in the treatment of obesity in subjects with normal glucose tolerance. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2003) |
| "The aim of the present study was to evaluate the effect of metformin in very obese subjects with acanthosis nigricans." | 3.71 | Therapeutic approach in insulin resistance with acanthosis nigricans. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2002) |
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 3.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "55 g/d for 28 weeks) would ameliorate morbid obesity and reduce centripetal obesity; lipid and lipoprotein cholesterol, insulin, and leptin levels; and plasminogen activator inhibitor activity (PAI-Fx), risk factors for coronary heart disease (CHD)." | 3.71 | Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. ( Fontaine, RN; Glueck, CJ; Illig, E; Lang, JE; McCullough, P; Sieve-Smith, L; Streicher, P; Subbiah, MT; Tracy, TM; Wang, P; Weber, K, 2001) |
| "The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it." | 3.71 | Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS, 2001) |
| "The aim of the study was to evaluate the effects of insulin-metformin combination therapy compared to insulin monotherapyin obese, insulin-requiring patients with type 2 diabetes mellitus." | 3.71 | Insulin-metformin combination therapy in obese patients with type 2 diabetes. ( Jaber, LA; Nowak, SN; Slaughter, RR, 2002) |
| "To evaluate the long-term effects of metformin on biochemical variables and body weight in polycystic ovary syndrome (PCOS)." | 3.71 | Biochemical and body weight changes with metformin in polycystic ovary syndrome. ( Batukan, C; Batukan, M; Baysal, B, 2001) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 3.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "HCl and metformin on diabetes and obesity were investigated in Wistar fatty rats, which are hyperglycaemic and hypertriglyceridaemic and have higher plasma levels of total ketone bodies than lean rats." | 3.71 | Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats. ( Ikeda, H; Odaka, H; Sugiyama, Y; Suzuki, M; Suzuki, N, 2002) |
| " Since the clinical utility of metformin in diabetes is probably traceable to inhibition of gluconeogenesis, its use as an adjunct to HCA/carnitine treatment of obesity in diabetics deserves evaluation, particularly as metformin therapy itself tends to reduce body weight." | 3.70 | Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics. ( McCarty, MF, 1998) |
| " Principal study measures were the proportions of patients started on metformin who met prescribing guidelines (previously on sulfonylureas, HbA1c, obesity, creatinine), the change in HbA1c at 6 months after starting metformin, and hospitalization rates for lactic acidosis." | 3.70 | First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. ( Brown, JB; Ettinger, B; Selby, JV; Swain, BE, 1999) |
| "The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years." | 3.69 | Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. ( Dailey, G; Gerich, JE; Nurjhan, N; Perriello, G; Stumvoll, M, 1995) |
| "The hypothalamic neuropeptide Y content and preproneuropeptide Y mRNA expression were studied in metformin-treated (300 mg/kg orally for 12 days), in pair-fed and in ad libitum-fed obese Zucker rats in order to elucidate possible mechanisms involved in the anorectic and body weight reducing effect of chronic metformin treatment in genetically obese Zucker rats." | 3.69 | Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y. ( Huupponen, R; Jhanwar-Uniyal, M; Koulu, M; Pesonen, U; Rouru, J; Rouvari, T; Santti, E; Virtanen, K, 1995) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 3.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 3.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "To assess the effects of metformin on tissue insulin sensitivity in obese and hyperandrogenic women." | 3.69 | [Effects of metformin on insulin resistance in obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; López, G; Muñoz, S; Sir, T, 1997) |
| "To examine the cellular mechanism of the antihyperglycemic action of in vivo metformin (M) we used an animal model of severe insulin resistance, the genetically obese (fa/fa) Zucker rat." | 3.68 | In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. ( Benecke, H; Greten, H; Hamann, A; Häring, HU; Klein, HH; Matthaei, S; Reibold, JP, 1993) |
| "The effect of metformin on glucose metabolism was examined in eight obese (percent ideal body weight, 151 +/- 9%) and six lean (percent ideal body weight, 104 +/- 4%) noninsulin-dependent diabetic (NIDD) subjects before and after 3 months of metformin treatment (2." | 3.68 | Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. ( Barzilai, N; DeFronzo, RA; Simonson, DC, 1991) |
| "This study investigated the relative effect of obesity alone and in combination with non-insulin-dependent diabetes mellitus (NIDDM) on the intracellular processing of insulin and evaluated the effect of metformin therapy on this process." | 3.68 | Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients. ( Benzi, L; Brunetti, A; Cecchetti, P; Ciccarone, A; Marchetti, P; Navalesi, R; Squatrito, S; Trischitta, V; Vigneri, R, 1990) |
| " In Austria, the association of lactic acidosis with biguanide therapy has led to a cancellation of the registration of buformin and phenformin." | 3.66 | [Biguanides: reasons for withdrawal of drugs and remaining indications]. ( Bolzano, K, 1978) |
| "Seventy drug-naïve patients with type 2 diabetes (mean age, 52." | 3.30 | Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. ( Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M, 2023) |
| "Bicalutamide 50 mg/day was added after 8 weeks to both arms." | 3.11 | A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). ( Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M, 2022) |
| "Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic." | 3.11 | Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. ( Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A, 2022) |
| "A total of 40 obese patients with type 2 diabetes mellitus in our hospital from July 2019 to June 2020 were randomly divided into a control group and a study group." | 3.11 | Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity. ( Chen, FW; Chen, JX; Hou, DC; Hou, KJ; Li, CP; Li, XY; Wu, ZZ; Zhang, CY; Zhang, S; Zheng, CY; Zhu, D, 2022) |
| "Treatment with dapagliflozin and interval-based exercise lead to similar but small improvements in glycaemic variability compared with control and metformin therapy." | 3.01 | The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D, 2021) |
| "Metformin treatment was analyzed as a potential modulator of the response." | 2.94 | Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial. ( Amadieu, C; Azzi, AS; Bindelle, J; Bindels, LB; Cani, PD; Cnop, M; Delzenne, NM; Gianfrancesco, MA; Gomes da Silveira Cauduro, C; Hiel, S; Kalala, G; Klein, O; Lanthier, N; Leyrolle, Q; Loumaye, A; Luminet, O; Mulders, MDGH; Neyrinck, AM; Pachikian, BD; Paquot, N; Portheault, D; Rodriguez, J; Thissen, JP; Trefois, P; Zamariola, G, 2020) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | 2.94 | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| "Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes." | 2.90 | Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. ( Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T, 2019) |
| "In the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study, metformin plus rosiglitazone (M + R) maintained glycemic control better than metformin alone (M) or metformin plus lifestyle (M + L) in youth with type 2 diabetes (T2D)." | 2.90 | Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study. ( Copeland, KC; Dhaliwal, R; El Ghormli, L; Geffner, ME; Higgins, J; Levitsky, LL; Nadeau, KJ; Shepherd, JA; Weinstock, RS; White, NH, 2019) |
| "Large numbers of people with type 2 diabetes are obese." | 2.90 | Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. ( Bi, Y; Qing, Z; Wang, X; Yang, QX; Zhang, B; Zhang, W; Zhang, X; Zhang, Z; Zhu, D, 2019) |
| " Metformin was not effective in reducing BMI and preventing GDM in obese pregnant women." | 2.87 | Effectiveness of Metformin in the Prevention of Gestational Diabetes Mellitus in Obese Pregnant Women. ( Dienstmann, G; Nascimento, IBD; Sales, WB; Silva, GDD; Silva, JC; Souza, MLR, 2018) |
| "Obesity increases risk of endometrial cancer through dysregulation of estrogen and insulin signaling." | 2.87 | Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. ( Basen-Engquist, K; Broaddus, RR; Coletta, AM; Fellman, B; Levy, E; Lu, K; Medepalli, M; Milbourne, A; Nebgen, D; Schmandt, RE; Soletsky, B; Urbauer, D; Yates, MS; Yuan, Y; Zhang, Q, 2018) |
| "Metformin was administered for at least 6 months in 74 patients, while 40 patients did not receive metformin." | 2.87 | Metformin added to intensive insulin therapy improves metabolic control in patients with type 1 diabetes and excess body fat. ( Burchardt, P; Grzymisławski, M; Naskręt, D; Niedźwiecki, P; Piłaciński, S; Wierusz-Wysocka, B; Zawada, A; Zozulińska-Ziółkiewicz, D, 2018) |
| "Overweight and obesity are major health concerns worldwide, and are major predisposing factors for type 2 diabetes." | 2.87 | Effect of a nonsystemic, orally administered hydrogel, GS100, on metformin pharmacokinetics. ( Audet, D; Demitri, C; Heshmati, HM; Panteca, E; Ron, ES; Sannino, A; Surano, I; Urban, LE; Zohar, Y, 2018) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 2.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| "Obesity is a systemic disease and represents one of the leading causes of death worldwide by constituting the main risk factor for a series of non-communicable diseases such as type 2 diabetes mellitus (T2DM), cardiovascular diseases and dyslipidemia." | 2.82 | Enhancing Metformin Effects by Adding Gut Microbiota Modulators to Ameliorate the Metabolic Status of Obese, Insulin-Resistant Hosts. ( Cătinean, A; Crăciun, AM; Ghervan, C; Popa Ilie, IR; Seicaru, EM, 2022) |
| "Individuals with obesity are known to have increased inflammation, increased risk to select autoimmune diseases, impaired response to several infections, and impaired vaccine response." | 2.82 | Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity. ( Greene, E; MacIver, NJ, 2022) |
| " Owing to the high pharmacokinetic (PK) variability, several population pharmacokinetic (PPK) models have been developed for metformin to explore potential covariates that affect its pharmacokinetic variation." | 2.82 | Research Progress of Population Pharmacokinetic of Metformin. ( Hu, H; Shen, C; Tang, J; Wang, X; Xie, H, 2022) |
| "Metformin is an old drug with multiple beneficial metabolic health effects beyond glycemic control." | 2.82 | Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review. ( Alfaraidi, H; Samaan, MC, 2022) |
| "Identifying novel biomarkers of type 2 diabetes risk may improve prediction and prevention among individuals at high risk of the disease and elucidate new biological pathways relevant to diabetes development." | 2.82 | Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program. ( Clish, C; Florez, JC; Gerszten, RE; Ma, Y; Walford, GA; Wang, TJ, 2016) |
| " From October 2013 to July 2014, a total of 166 T2DM outpatients who attended the Shanghai Changhai Hospital and the Yijishan Hospital of Wannan Medical College were randomly assigned into an experimental sitagliptin/metformin combined with low caloric diet group (n = 115) and an insulin glargine combined with metformin control group (n = 51)." | 2.82 | Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes. ( Cao, J; Ji, M; Xia, L; Zou, D, 2016) |
| " The mean terminal half-life (t1/2 ) was 2-3 h." | 2.82 | Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. ( Abribat, T; Allas, S; Delale, T; Julien, M; Ngo, N; Ritter, J; Sahakian, P; van der Lely, AJ, 2016) |
| "Among overweight adolescents with type 1 diabetes, the addition of metformin to insulin did not improve glycemic control after 6 months." | 2.80 | Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. ( Beck, RW; Bethin, KE; Coffey, JK; DiMeglio, LA; Haller, MJ; Katz, ML; Libman, IM; Miller, KM; Nadeau, KJ; Raman, S; Saenz, AM; Shah, A; Simmons, JH; Tamborlane, WV, 2015) |
| "These observations indicate that in type 2 diabetes, 1) the capacity of endogenous GIP to lower blood glucose is impaired; 2) the effect of DPP-4 inhibition on glycemia is likely to depend on adequate endogenous GLP-1 release, requiring gastric emptying >2 kcal/min; and 3) the action of metformin to lower blood glucose is not predominantly by way of the incretin axis." | 2.79 | Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. ( Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T, 2014) |
| "Type 2 diabetes mellitus is increasingly diagnosed in obese children and adolescents." | 2.79 | Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. ( Narasimhan, S; Weinstock, RS, 2014) |
| "Approximately 2000 people with Type 2 diabetes mellitus who were drug-naive or who were treated with metformin for less than 1 month, and who have HbA1c of 48-58 mmol/mol (6." | 2.79 | Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. ( Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M, 2014) |
| "The METFORMIN study is a multi-centre prospective study that consists of two 18-month phases: a double-blind randomized placebo-controlled trial (part 1) and an open-label follow-up study (part 2)." | 2.79 | METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. ( Elst, MA; Knibbe, CA; van der Aa, MP; van der Vorst, MM; van Mil, EG, 2014) |
| "Metformin was administered in the dose of 50 mg daily to the overweight and obese participants." | 2.78 | Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention. ( Erzen, DJ; Hozo, I; Radman, M; Tesanović, D; Tesanović, S, 2013) |
| "Metformin therapy has a beneficial treatment effect over placebo for BMI-SDS, fasting glucose, ALT, and ALR ratio at 3 months, with changes in BMI-SDS sustained at 6 months." | 2.78 | Metformin in obese children and adolescents: the MOCA trial. ( Amin, R; Barrett, T; Clayton, P; Dimitri, P; Hall, C; Ivison, F; Kendall, D; Kibirige, M; Mathew, V; Matyka, K; McGovern, A; Stirling, H; Tetlow, L; Vail, A; Wales, J; Wright, N, 2013) |
| "Although weight loss is frequently initiated successfully, most patients regain substantial amounts of weight within the first year after completing a weight loss programme." | 2.77 | Weight loss/maintenance as an effective tool for controlling type 2 diabetes: novel methodology to sustain weight reduction. ( Gage, D, 2012) |
| " Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks." | 2.76 | Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011) |
| "Treatment with cetilistat 80 or 120 mg t." | 2.75 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). ( Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010) |
| "Obesity is epidemic among adolescents in the United States." | 2.75 | Intraperitoneal fat and insulin resistance in obese adolescents. ( , 2010) |
| "The objective of this study was to assess the efficacy and safety of metformin at the dosage of 2,500 mg/day in the treatment of obese women with PCOS and also to evaluate its effect on weight, hormones, and lipid profile." | 2.75 | Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. ( Aghahosseini, M; Aleyaseen, A; Kashani, L; Moddaress-Hashemi, S; Mofid, B; Safdarian, L, 2010) |
| "Metformin did not inhibit plasma DPP-4 activity either in vitro or in vivo." | 2.75 | Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. ( Amatruda, J; Bergeron, R; Deacon, C; Gutierrez, M; Herman, G; Hilliard, D; Holst, JJ; Jiang, G; Larson, P; Liu, F; Migoya, EM; Miller, JL; Pryor, KA; SinhaRoy, R; Snyder, RN; Tanen, M; Thornberry, N; Wagner, JA; Weiss, B; Williams-Herman, D; Yao, J; Zhu, L, 2010) |
| "Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)." | 2.74 | The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009) |
| "In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin." | 2.74 | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. ( Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M, 2009) |
| "Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)." | 2.74 | Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009) |
| "Metformin treatment increases serum TSP-1 in these women." | 2.74 | Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. ( Adya, R; Chen, J; Farhatullah, S; Heutling, D; Lehnert, H; Mitchell, D; Randeva, HS; Tan, BK, 2009) |
| "Childhood obesity is a serious health concern affecting over 155 million children in developed countries worldwide." | 2.74 | Lifestyle modification and metformin as long-term treatment options for obese adolescents: study protocol. ( Clarson, CL; Cramp, AG; Jung, ME; Lenhardt, L; Prapavessis, H; Robinson, T; Shoemaker, JK; Vascotto, J; Watson, M; Wilson, AJ, 2009) |
| "Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin." | 2.73 | A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. ( Gadde, KM; Hollander, P; Leung, A; Rosenstock, J; Strauss, R; Sun, X, 2007) |
| "We investigated whether treatment of obesity and its associated metabolic abnormalities corrects salt sensitivity and restores impaired nitric oxide (NO) metabolism characteristic of salt sensitivity." | 2.73 | Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics. ( Alfieri, AB; Cubeddu, LX; Hoffmann, IS, 2007) |
| "Metformin treatment induced a significant decrease in insulin levels (P < 0." | 2.73 | Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. ( Campagna, G; De Marinis, L; Guido, M; Lanzone, A; Proto, C; Romualdi, D, 2008) |
| " In the following 12 weeks, metformin (mean daily dosage of 1381+/-85 mg) was added." | 2.73 | The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. ( Budak, F; Duran, C; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Oral, B; Selimoglu, H; Tuncel, E, 2008) |
| "Management of hyperinsulinemia by pharmacological approaches, including metformin, sodium-glucose cotransporter 2 inhibitor, or β3-adrenergic receptor agonist, decreased GRP78 gene expression in adipose tissue." | 2.72 | Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. ( Fukuhara, A; Kita, S; Nishitani, S; Otsuki, M; Shimomura, I; Shin, J; Toyoda, S, 2021) |
| "Obesity is the most significant risk factor for the development of diabetes." | 2.72 | Obesity and Diabetes. ( Aras, M; Pape, J; Tchang, BG, 2021) |
| "Obesity has health consequences going beyond glucose elevation." | 2.72 | Pharmacotherapeutic options for prediabetes. ( Rendell, M, 2021) |
| "Metformin is a widely used glucose-lowering drug, although its impact on adipose tissue function remains elusive." | 2.72 | Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials. ( Cirilli, I; Dludla, PV; Louw, J; Marcheggiani, F; Mazibuko-Mbeje, SE; Mokgalaboni, K; Mxinwa, V; Nkambule, BB; Nyambuya, TM; Tiano, L; Ziqubu, K, 2021) |
| "Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles." | 2.72 | Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. ( Driver, C; Gcwensa, SK; Mbara, KC; Mcobothi, EN; Mkhombo, NT; Mofo Mato, PE; Nzuza, S; Owira, PM, 2021) |
| "Semaglutide is an advantageous choice for the treatment of T2D since it has greater efficacy in reducing glycated hemoglobin and body weight compared with other GLP-1RAs, has demonstrated benefits in reducing major adverse cardiovascular events, and has a favorable profile in special populations (e." | 2.72 | Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. ( Gallwitz, B; Giorgino, F, 2021) |
| "Metformin treatment had no significant impact on GSK-3 protein expression in either adipocytes or skeletal muscle." | 2.72 | Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. ( Baxi, S; Christiansen, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, S; Nikoulina, SE; Oh, DK, 2006) |
| "Obesity is often accompanied by insulin resistance and/or hyperinsulinemia." | 2.72 | Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. ( Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J, 2006) |
| "Sibutramine treatment raised sitting diastolic blood pressure by > or = 5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs." | 2.71 | A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. ( McNulty, SJ; Ur, E; Williams, G, 2003) |
| "Troglitazone treatment increased serum adiponectin levels nearly threefold." | 2.71 | Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. ( Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA, 2003) |
| "Type 2 diabetes is caused by reduced insulin secretion and insulin resistance in skeletal muscle and liver." | 2.71 | The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. ( Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK, 2003) |
| "Metformin treatment, but not placebo treatment, was associated with a decrease in fasting plasma glucose (P <." | 2.71 | Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. ( Barbagallo, M; Esposito, K; Giugliano, D; Grella, R; Manzella, D; Paolisso, G, 2004) |
| "Metformin treatment significantly reduced their body weights (p < 0." | 2.71 | Metformin ameliorates treatment of obese type 2 diabetic patients with mental retardation; its effects on eating behavior and serum leptin levels. ( Iguchi, A; Komori, T; Miura, H; Miyazaki, S; Nakamura, J; Yoshida, F, 2004) |
| "Glyburide treatment of diabetes decreased CRP and did so even though body weight increased." | 2.71 | Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. ( Bar, RS; Goldner, WS; Haynes, WG; Putz, DM; Sivitz, WI, 2004) |
| "Metformin was tolerated well by the majority of patients." | 2.70 | The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. ( Bursey, D; Freemark, M, 2001) |
| "Obese and overweight type 2 diabetes patients treated with insulin for at least 1 year, and with poor glycaemic control (HbA1c > upper reference level + 2%), were included in a randomised, double-blind, placebo-controlled study." | 2.70 | Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. ( Hermann, LS; Kalén, J; Katzman, P; Lager, I; Nilsson, A; Norrhamn, O; Sartor, G; Ugander, L, 2001) |
| "458 patients with newly diagnosed type 2 diabetes that could not be controlled with diet and had hyperglycemic symptoms or fasting plasma glucose levels greater than 15 mmol/L during the initial 3 months of diet therapy (primary diet failure group) and 1620 patients in whom disease was controlled by diet therapy and who had fasting plasma glucose levels of 6 to 15 mmol/L and no hyperglycemic symptoms while receiving diet therapy alone." | 2.69 | United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Pro ( , 1998) |
| "Metformin was well tolerated except for one case of flatulence." | 2.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Defective GS activity in obese NIDDM patients is not secondary to hyperglycemia." | 2.69 | Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. ( Beck-Nielsen, H; Damsbo, P; Hermann, LS; Hother-Nielsen, O; Vaag, A, 1998) |
| "In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks." | 2.69 | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. ( , 1998) |
| "Metformin has been shown to improve insulin sensitivity and fibrinolysis." | 2.69 | Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. ( André, P; Charles, MA; Eschwège, E; Juhan-Vague, I; Morange, P; Vague, P, 1998) |
| "Metformin is an effective adjunct to insulin therapy in patients with type 2 diabetes." | 2.69 | Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. ( Avilés-Santa, L; Raskin, P; Sinding, J, 1999) |
| "Metformin was added progressively over a year in total doses of 1." | 2.69 | [The combination of insulin and metformin in obese patients with type-2 diabetes mellitus]. ( Ibarra Rueda, JM; Ruiz de Adana Pérez, R; Sánchez-Barba Izquierdo, MI, 1999) |
| " In all, 60% of patients in the acarbose group and 33% in the placebo group had an adverse event considered to be possibly or probably related to drug therapy, leading to withdrawal by 15 and 3%, respectively." | 2.69 | Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. ( Grangé, V; Halimi, S; Le Berre, MA, 2000) |
| "Metformin is an effective, safe, and well-tolerated treatment that improves metabolic control and favorably modifies secondary clinical alterations due to insulin resistance, such as arterial hypertension, overweight, and hyperlipidemia, in obese patients with NIDDM suffering from secondary failure to sulfonylureas." | 2.68 | Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. ( Espinosa-Campos, J; Fanghänel, G; Sánchez-Reyes, L; Sotres, D; Trujillo, C, 1996) |
| "Metformin was shown to be beneficial in the clearance of postprandial lipoproteins in nondiabetic individuals who were mildly overweight and glucose intolerant." | 2.68 | Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. ( Charach, G; Grosskopf, I; Iaina, A; Maharshak, N; Mor, R; Ringel, Y; Weintraub, M, 1997) |
| "Metformin therapy was associated with a significant decrease in fasting blood glucose (6." | 2.67 | The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. ( Argyraki, M; Cooper, BG; Heseltine, L; Johnson, AB; Sum, CF; Taylor, R; Webster, JM, 1993) |
| "Metformin was well tolerated by all diabetics." | 2.67 | Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. ( Ceriello, A; Consoli, G; D'Onofrio, F; De Rosa, N; Giugliano, D; Minei, A; Quatraro, A, 1993) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm" or less-is-more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.66 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III. ( Moyad, MA, 2020) |
| "Obesity is responsible for an increased risk of sub-fecundity and infertility." | 2.66 | Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. ( Cena, H; Chiovato, L; Nappi, RE, 2020) |
| "The pooled HR of prostate cancer for metformin therapy was 0." | 2.66 | Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies. ( Bi, Y; Chen, T; Liu, X; Sun, Y; Tang, J; Wang, Y; Yan, P; Zhang, ZJ; Zhou, W, 2020) |
| "Metformin therapy was associated with a significant fall in serum fructosamine levels (3." | 2.66 | The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. ( Bak, J; Beck-Nielsen, H; Nielsen, O; Pedersen, O; Richelsen, B; Sørensen, N, 1989) |
| "Metformin treatment significantly reduced mean day-time plasma glucose levels (10." | 2.66 | Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. ( Andersen, PH; Beck-Nielsen, H; Hother-Nielsen, O; Pedersen, O; Schmitz, O, 1989) |
| " The daily dosage of phenformin and metformin was increased at weekly intervals up to 300 mg." | 2.63 | Weight-reducing effect of diguanides in obese non-diabetic women. ( Duncan, LJ; MacCuish, AC; Marshall, A; Munro, JF; Wilson, EM, 1969) |
| "Obesity and its comorbidities, such as type 2 diabetes mellitus and cardiovascular disease, constitute growing challenges for public health and economies globally." | 2.61 | Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. ( Clemmensen, C; DiMarchi, RD; Finan, B; Hofmann, SM; Müller, TD; Tschöp, MH, 2019) |
| "Obesity is one of the main risk factors for type 2 diabetes (T2D), representing a major worldwide health crisis." | 2.61 | Body Weight Considerations in the Management of Type 2 Diabetes. ( Apovian, CM; O'Neil, PM; Okemah, J, 2019) |
| "Metformin is a first-line therapy for type 2 diabetes." | 2.61 | Metformin: Mechanisms in Human Obesity and Weight Loss. ( Soukas, AA; Yerevanian, A, 2019) |
| "Obesity is a prominent risk factor for type 2 diabetes." | 2.58 | Treatment of 'Diabesity': Beyond Pharmacotherapy. ( Singh, H; Venkatesan, V, 2018) |
| "Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years." | 2.58 | Metformin: An Old Drug with New Applications. ( Li, L; Massey, S; Story, D; Zhou, J, 2018) |
| "The prevalence of type 2 diabetes mellitus in children and adolescents has increased worldwide over the past three decades." | 2.58 | Type 2 Diabetes Mellitus in Children. ( Verre, MC; Xu, H, 2018) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm", or less is more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.58 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I. ( Moyad, MA, 2018) |
| " Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks." | 2.55 | Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017) |
| "The increased risk of type 2 diabetes and cardiovascular disease in PCOS is closely associated with BMI." | 2.55 | Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. ( Andersen, M; Glintborg, D, 2017) |
| "Hirsutism affects 5-25% women, and the condition is most often caused by polycystic ovary syndrome (PCOS)." | 2.53 | Endocrine and metabolic characteristics in polycystic ovary syndrome. ( Glintborg, D, 2016) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Maternal obesity is associated with adverse perinatal outcome." | 2.52 | Placental dysfunction in obese women and antenatal surveillance strategies. ( Doshani, A; Jeve, YB; Konje, JC, 2015) |
| "Obesity is a known risk factor for infertility in women." | 2.52 | Medical and surgical interventions to improve outcomes in obese women planning for pregnancy. ( Bahadursingh, S; Ramsewak, S; Sharma, A; Teelucksingh, S, 2015) |
| "Insulin resistance is prevalent in women with polycystic ovary syndrome (PCOS), and plays a critical pathophysiologic role in both the metabolic and reproductive complications of PCOS." | 2.52 | Polycystic ovary syndrome and insulin: our understanding in the past, present and future. ( Evans, WS; Mayer, SB; Nestler, JE, 2015) |
| "Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC)." | 2.52 | Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. ( Noureddin, M; Rinella, ME, 2015) |
| "Chemoprevention in Barrett's esophagus is currently applied only in research settings." | 2.52 | Chemoprevention in Barrett's Esophagus: Current Status. ( Baruah, A; Buttar, NS; Kossak, SK; Zeb, MH, 2015) |
| "Metabolic syndrome is a cluster of conditions that synergistically increase the risk of cardiovascular disease, type 2 diabetes, and premature mortality." | 2.52 | Metabolic Syndrome: Insulin Resistance and Prediabetes. ( Mayans, L, 2015) |
| "The different types of cancer, heterogeneity of populations and presence of comorbidity make it difficult to determine the benefits of metformin in cancer prevention and treatment." | 2.52 | Metformin: risk-benefit profile with a focus on cancer. ( Cazzaniga, M; DeCensi, A; Dunn, BK; Gorlero, F; Lazzeroni, M; Provinciali, N, 2015) |
| "Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer." | 2.52 | Obesity and cancer: mechanistic insights from transdisciplinary studies. ( Allott, EH; Hursting, SD, 2015) |
| "As the incidence of obesity is increasing worldwide, there is an urgent need for adequate preclinical models and preclinical and clinical studies designed to investigate how to inhibit the tumor-promoting activity of the adipose tissue." | 2.52 | Mechanisms of obesity in the development of breast cancer. ( Bertolini, F; Orecchioni, S; Reggiani, F; Talarico, G, 2015) |
| "Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015) |
| "Polycystic ovary syndrome is the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management]. ( Csenteri, OK; Gődény, S, 2015) |
| "In particular, when obesity is present, lifestyle intervention should be always considered, and if necessary combined with pharmacotherapy." | 2.50 | Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. ( Gambineri, A; Pasquali, R, 2014) |
| "Given that diabetes and cancer each account for 8% and 13% of global deaths and there is a substantial financial burden incurred by both disorders, developing diabetes therapies that are safe, efficacious and cost-effective has never been more desirable." | 2.50 | Cancer risks from diabetes therapies: evaluating the evidence. ( Kong, D; Li, C, 2014) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.50 | The therapy of insulin resistance in other diseases besides type 2 diabetes. ( Barbaro, V; Dicembrini, I; Pala, L; Rotella, CM, 2014) |
| "Metformin is a biguanide drug, typically used for diabetes treatment, currently being studied to evaluate its role in the treatment and prevention of gynecologic cancers." | 2.50 | Metformin and gynecologic cancers. ( Bae-Jump, V; Stine, JE, 2014) |
| "Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well." | 2.49 | Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013) |
| "Overweight and obesity are risk factors for type 2 diabetes, and they also influence the overall prognosis." | 2.49 | [Diabetes drugs and body weight]. ( Eriksson, J; Laine, M, 2013) |
| "Obesity is a known risk factor for many types of cancers and a number of endocrine factors, including adipokines and steroid hormones, are regulated by and regulate AMPK." | 2.49 | Endocrine-related cancers and the role of AMPK. ( Brown, KA; Samarajeewa, NU; Simpson, ER, 2013) |
| "The objective was to review type 2 diabetes as a risk factor for breast cancer, its influence on tumor aggressiveness and prognosis, and the interactions with obesity." | 2.48 | Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. ( Rose, DP; Vona-Davis, L, 2012) |
| "Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing." | 2.48 | Endometrial carcinoma tumorigenesis and pharmacotherapy research. ( Fang, S; Huang, H; Shu, J; Teichman, PG; Xing, L, 2012) |
| "The metabolic syndrome affects 30% of the US population with increasing prevalence." | 2.48 | The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. ( Hutcheson, R; Rocic, P, 2012) |
| "Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities." | 2.48 | Polycystic ovarian syndrome management options. ( Bates, GW; Propst, AM, 2012) |
| "Polycystic ovarian syndrome is the major cause of anovulation and is generally associated with obesity." | 2.48 | Evaluation and treatment of anovulatory and unexplained infertility. ( Bates, GW; Propst, AM, 2012) |
| "Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients." | 2.48 | Diabetes and pancreatic cancer. ( Chari, ST; Muniraj, T, 2012) |
| "Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk." | 2.47 | [Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011) |
| "In obese patients, especially with type 2 diabetes mellitus (DM2), only the PI 3-K, but not the MAP-K, is resistant to insulin stimulation: hence insulin resistance is better defined as metabolic insulin resistance." | 2.47 | Insulin resistance: pathophysiology and rationale for treatment. ( Muntoni, S, 2011) |
| "Colorectal carcinoma is a tumour with higher incidence in patients with type 2 diabetes and obesity." | 2.47 | [Colorectal cancer and diabetes]. ( Svacina, S, 2011) |
| "In the pathophysiology of type 2 diabetes there are several biological processes, which may explain the higher cancer risk in type 2 diabetes." | 2.47 | [Diabetes and cancer risk: oncologic considerations]. ( Rosta, A, 2011) |
| "Obesity and insulin resistance have been associated with breast cancer risk, and breast cancer outcomes." | 2.47 | Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. ( Goodwin, PJ; Stambolic, V, 2011) |
| "Weight loss is the best treatment option, which can be a challenging task for patients to achieve and maintain." | 2.46 | Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. ( Brown, A; Desai, M; Taneja, D; Tannock, LR, 2010) |
| "Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poorer prognosis than patients with cancer without diabetes." | 2.46 | Insulin, insulin resistance, obesity, and cancer. ( Gallagher, EJ; LeRoith, D, 2010) |
| "Metformin has been shown to inhibit proliferation, invasion and angiogenesis of neoplastic cells and to overcome resistance of breast cancer to chemotherapy, hormonal therapy and HER2 inhibition." | 2.46 | Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. ( Wierusz-Wysocka, B; Wysocki, PJ, 2010) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 2.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Metformin is an insulin-sensitizing agent that may lower androgen levels." | 2.45 | The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. ( Akl, EA; Barba, M; Guyatt, G; Musicco, F; Muti, P; Schünemann, HJ; Sperati, F, 2009) |
| "Metformin is an antidiabetic drug that has been shown to cause weight loss in patients with diabetes mellitus, as well as in some individuals without diabetes." | 2.45 | Management of atypical antipsychotic drug-induced weight gain: focus on metformin. ( Miller, LJ, 2009) |
| "Childhood obesity is emerging as a major public health threat, with adverse implications on the health of individuals and long-term costs to society." | 2.45 | Pharmacotherapy in pediatric obesity: current agents and future directions. ( Uli, NK; Wald, AB, 2009) |
| "This inflammation is characterized by infiltration with macrophages, alterations of adipokine secretion, development of insulin resistance." | 2.45 | [Adipose tissue inflammation and atherosclerosis]. ( Shwarts, V, 2009) |
| "Obesity increases the risk of type 2 diabetes." | 2.44 | Pharmacotherapy for obesity in menopausal women. ( Barnett, A; Rahim, A; Samat, A, 2008) |
| "Polycystic ovary syndrome is estimated to affect 5-10% of premenopausal women." | 2.44 | Polycystic ovary syndrome update in adolescence. ( Gordon, CM; Hassan, A, 2007) |
| "However, many antidiabetic treatments increase body weight." | 2.44 | Metformin and body weight. ( Golay, A, 2008) |
| "Weight loss has been shown to improve sensitivity to insulin as a result of either altered diet or exercise." | 2.44 | Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications. ( Cokkinos, D; Stefanadis, C; Tousoulis, D; Tsarpalis, K, 2008) |
| "Obesity is a chronic metabolic disorder that affects one third of American adults." | 2.44 | Pharmacotherapy for obesity. ( Aronne, LJ; Neff, LM, 2007) |
| "Children with psychiatric illness are at greater risk for obesity than those in the general population." | 2.44 | An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. ( Bregman, H; Frazier, J; Noyes, N; Shin, L, 2008) |
| "Rates of pediatric obesity have increased dramatically over the past decade." | 2.44 | Pediatric obesity: parallels with addiction and treatment recommendations. ( Acosta, MC; Levin, FR; Manubay, J, 2008) |
| "Polycystic ovary syndrome is a diagnosis of exclusion of other causes of hyperandrogenism." | 2.43 | Polycystic ovary syndrome--a management update. ( Costello, MF, 2005) |
| "Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highly-active antiretroviral therapy) - associated lipodystrophy." | 2.43 | The fatty liver and insulin resistance. ( Westerbacka, J; Yki-Järvinen, H, 2005) |
| "Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy." | 2.43 | [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. ( Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF, 2005) |
| "Type 2 diabetes and obesity are common metabolic disorders characterized by resistance to the actions of insulin to stimulate skeletal muscle glucose disposal." | 2.43 | Insulin resistance and improvements in signal transduction. ( Goodyear, LJ; Musi, N, 2006) |
| "Treatment with rosiglitazone in combination with metformin provides better glycaemic control over the remaining lifetime of patients than metformin and sulfonylurea combination therapy." | 2.43 | Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. ( Bagust, A; Beale, S; Hulme, L; Martin, A; Shearer, AT, 2006) |
| "To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and obese patients failing to maintain glycaemic control with metformin monotherapy compared with conventional care of metformin in combination with either sulfonylureas or bedtime insulin." | 2.43 | Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. ( Ampudia-Blasco, FJ; Bagust, A; Martínez-Lage Alvarez, B; París, G; Pérez Escolano, I; Shearer, AT, 2006) |
| "Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus." | 2.43 | Metformin beyond diabetes: new life for an old drug. ( Mannucci, E; Monami, M; Rotella, CM, 2006) |
| "Metformin has been shown to reduce ovarian production, enhance ovulatory cycles and in some cases increase fertility." | 2.42 | [Insulin resistance and polycystic ovary syndrome]. ( Basille, C; Bernard, L; Chabbert-Buffet, N; Christin-Maître, S, 2003) |
| "In the United States, the incidence of type 2 diabetes mellitus (DM) in children and adolescents has been increasing at an alarming rate." | 2.42 | Type 2 diabetes mellitus in youth. ( Evans, BJ; Kerrigan, JR; Quarry-Horn, JL, 2003) |
| "Metformin is a hypoglycaemic agent widely used in the management of type 2 diabetes." | 2.42 | Antiatherogenic properties of metformin: the experimental evidence. ( Mamputu, JC; Renier, G; Wiernsperger, NF, 2003) |
| "Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder." | 2.42 | Insulin-lowering agents in the management of polycystic ovary syndrome. ( De Leo, V; la Marca, A; Petraglia, F, 2003) |
| "Only metformin has clearly proved that it can reduce mortality in obese patients with type 2 diabetes." | 2.42 | [Drug treatment of type 2 diabetes]. ( Bock, GM; Plank, J, 2003) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.42 | Current indications for metformin therapy. ( Tankova, T, 2003) |
| "The prevalence of type 2 diabetes continues to show a clear upward trend in Germany." | 2.42 | [Oral diabetes treatment. Which substance is indicated at which time?]. ( Hamann, A; Morcos, M; Nawroth, P, 2004) |
| "Obesity is an increasingly prevalent problem with many associated health risks." | 2.42 | Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. ( Ghali, P; Lindor, KD, 2004) |
| "Obesity is associated with considerable morbidity and decreased life expectancy." | 2.41 | Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002) |
| "For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population." | 2.41 | A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. ( Hoogwerf, BJ; Nambi, V; Sprecher, DL, 2002) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 2.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| "In these populations, NIDDM may be present in 10% to as much as 50% of the adult population." | 2.40 | [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. ( Flórez, H, 1997) |
| " They also suggest that long term administration of metformin might be helpful in treating insulin resistance, thus reducing risks of type 2 (non-insulin-dependent) diabetes and cardiovascular disease in these patients." | 2.40 | Insulin resistance, polycystic ovary syndrome and metformin. ( Ducluzeau, PH; Pugeat, M, 1999) |
| "Obesity is a chronic disease and requires ongoing treatment." | 2.40 | Obesity medications and the treatment of type 2 diabetes. ( Greenway, F, 1999) |
| "Metformin or exenatide treatment could prevent the degradation of insulin receptor substrate-1 protein by reducing the effect of suppressors of cytokine signaling-1 and suppressors of cytokine signaling-3 proteins, especially in the liver tissue." | 1.91 | Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity. ( Akarsu, E; Balcı, SO; Bozdag, Z; Demirel, C; Korkmaz, M; Sayiner, ZA; Yılmaz, I, 2023) |
| "Diabetes mellitus is a disease with no cure that can cause complications and even death." | 1.91 | Using Artificial Intelligence to Develop a Multivariate Model with a Machine Learning Model to Predict Complications in Mexican Diabetic Patients without Arterial Hypertension (National Nested Case-Control Study): Metformin and Elevated Normal Blood Press ( Canseco-Avila, LM; Ceja-Espiritu, G; Delgado-Enciso, I; Delgado-Enciso, J; Espinoza-Gomez, F; Garcia-Nevares, A; Guzman-Esquivel, J; Hernández-Suarez, CM; Lara-Esqueda, A; Martinez-Fierro, ML; Ochoa-Díaz-Lopez, H; Rodriguez-Sanchez, IP; Sanchez-Diaz, I; Zaizar-Fregoso, SA, 2023) |
| "Metformin was started and increased to 1,000 mg twice daily." | 1.91 | Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity. ( Alkhatib, EH; Dauber, A; Estrada, DE; Majidi, S, 2023) |
| "Obesity has been linked to a higher risk of pancreatic cancer." | 1.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
| " However, as the two agents have very different chemical structure and bioavailability in oral route, the goal of this study is to learn their characteristics in treating metabolic disorders." | 1.91 | Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. ( Gao, TL; Guo, HH; Han, YX; Jiang, JD; Luo, ZG; Shen, HR; Wang, LL; Zhang, HJ; Zhang, JL, 2023) |
| "Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on liver steatosis is unclear." | 1.91 | Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. ( Bahramzadeh, A; Goodarzi, G; Meshkani, R; Panahi, G; Tehrani, SS, 2023) |
| "Obesity was significantly associated with the cAMP signal pathway, and HHIP was a secreted protein related to cAMP signalling, as determined by KEGG analysis." | 1.91 | Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies. ( Dai, H; Hu, W; Li, K; Li, L; Liang, Z; Qiu, S; Wang, H; Wang, Y; Yang, G; Yang, M; Zhang, H; Zhang, L, 2023) |
| "Common comorbidities were type 2 diabetes (56%), hyperlipidemia (44%), hypertension (46%), and obesity (42%)." | 1.91 | Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. ( Articolo, A; Charlton, M; Luthra, R; Shelley, K, 2023) |
| "Metformin treatment decreased hepatic SGK1 expression levels in db/db mice." | 1.91 | Role of serum- and glucocorticoid-inducible kinase 1 in the regulation of hepatic gluconeogenesis. ( Chen, J; Liu, Q; Shao, L; Sheng, C; Tan, J; Wang, S; Wang, X; Wang, Y; Xu, Z; Zhou, L, 2023) |
| "Metformin, a frontline therapy for type 2 diabetes and related metabolic diseases, results in variable outcomes." | 1.91 | Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice. ( Bernier, A; de Lartigue, G; Rourk, K; Singh, A, 2023) |
| "Obesity, type 2 diabetes mellitus and cancers are equally endemic in our country." | 1.91 | [Investigation of glycaemic and nutritional status of patients suffering from cancer.] ( Bánhegyi, RJ; Beke, S; Mátrai, ÁA; Rácz, B; Veréb, B, 2023) |
| "It has been used for the treatment of obesity, gestational diabetes, and polycystic ovary syndrome." | 1.91 | Role of metformin in the management of type 2 diabetes: recent advances. ( Gonzalez-Lopez, C; Wojeck, BS, 2023) |
| "Hypothalamic insulin resistance is known to precede that in the periphery, thus a critical unanswered question is whether central insulin resistance creates a specific hypothalamic miRNA signature that can be identified and targeted." | 1.72 | Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin. ( Belsham, DD; Chalmers, JA; Dalvi, PS; Dash, S; Eversley, JA; Loganathan, N; McIlwraith, EK; Mohan, H; Nazarians-Armavil, A; Stahel, P; Wellhauser, L; Wheeler, MB, 2022) |
| " These include (i) marked glucose lowering shortly after dosing, which fades rapidly with the decrease in metformin concentrations in plasma and liver, but could, at least to a major extent, rely on the mechanism also accounting for metformin's therapeutic action in humans; (ii) indirect action via reduced weight gain, which might be responsible for glucose lowering observed in many previous rodent studies; and (iii) deterioration of glucose homeostasis by prolonged treatment that can be unmasked by avoidance of dosing shortly before measuring blood glucose in combination with exclusion of weight-related actions via restricted feeding of the control mice." | 1.72 | Deciphering metformin action in obese mice: A critical re-evaluation of established protocols. ( Beghini, M; Eid, SA; Fürnsinn, C; Hackl, MT; Kaplanian, M; Kautzky-Willer, A; Luca, AC; Metz, M; Philippe, C; Scherer, T, 2022) |
| "Recent research has demonstrated that Type 2 Diabetes (T2D) risk is influenced by a number of common polymorphisms, including MC4R rs17782313, PPARG rs1801282, and TCF7L2 rs7903146." | 1.72 | Association of gene polymorphisms with body weight changes in prediabetic patients. ( Ahmetov, II; Egorova, ES; Khasanova, KB; Kiseleva, TA; Medvedeva, MS; Pickering, C; Valeeva, EV; Valeeva, FV, 2022) |
| "Metformin (MTF) treatment improves insulin signaling in endometrial tissues, but its mechanism is not fully understood." | 1.72 | Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. ( Astorga, I; Carvajal, R; García, V; Oróstica, ML; Plaza-Parrochia, F; Poblete, C; Romero, C; Vega, M, 2022) |
| "Obesity is associated with an increased incidence and aggressiveness of breast cancer and is estimated to increment the development of this tumor by 50 to 86%." | 1.72 | Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model. ( Cabrera-Quintero, AJ; Flores-García, LC; García-García, E; Hernández-Juárez, AJ; Méndez, JP; Meraz-Cruz, N; Naranjo-Meneses, MA; Pedraza-Sánchez, S; Ramírez-Ruíz, A; Romero-Córdoba, SL; Vadillo-Ortega, F; Ventura-Gallegos, JL; Zentella-Dehesa, A, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common cause of clinical liver dysfunction and an important prepathological change of liver cirrhosis." | 1.72 | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022) |
| "Metformin may reduce colorectal cancer but the mechanisms mediating this effect remain unclear." | 1.72 | Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. ( Bezverbnaya, K; Blandino, G; Blouin, MJ; Bramson, JL; Broadfield, LA; Collins, SM; Di Pastena, F; Gautam, J; Hammill, JA; Lally, JSV; McArthur, AG; McNicol, J; Muti, P; Pollak, M; Raphenya, AR; Sacconi, A; Saigal, A; Schertzer, JD; Steinberg, GR; Surette, MG; Syed, S; Szamosi, JC; Tsakiridis, EE; Tsakiridis, T; Wang, D; Wu, J, 2022) |
| "Obesity has become a health threat and hard enough to deal with." | 1.72 | Metformin combats obesity by targeting FTO in an m ( Chen, W; Chen, Y; Guo, G; Huang, C; Liao, X; Liu, J; Liu, Y; Luo, Y; Wang, X; Wang, Y; Zeng, B, 2022) |
| "Metformin was more often used in patients with obesity who also required higher daily doses." | 1.72 | Impact Of Prepregnancy Overweight And Obesity On Treatment Modality And Pregnancy Outcome In Women With Gestational Diabetes Mellitus. ( Eder, A; Eppel, D; Geissler, F; Göbl, CS; Hösli, I; Huhn, EA; Linder, T; Monod, C; Redling, K; Rosicky, I, 2022) |
| "Metformin treatment reduced weight gain and visceral fat accumulation." | 1.72 | Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice. ( Appel, S; Bae-Gartz, I; Dötsch, J; Gellhaus, A; Gründemann, D; Handwerk, M; Hucklenbruch-Rother, E; Janoschek, R; Kammerer, MD; Köninger, A; Kretschmer, T; Schmitz, K; Turnwald, EM; Voßbrecher, K; Wohlfarth, M, 2022) |
| "Metformin is a blood-glucose-lowering medication with physiological effects that extend beyond its anti-diabetic indication." | 1.72 | The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. ( Blond, MB; Clemmensen, C; Fritzen, AM; Færch, K; Gil, C; Johann, K; Karstoft, K; Klein, AB; Kleinert, M; Lund, J; Mathiesen, CV; Nicolaisen, TS; Pilmark, NS; Quist, JS; Seeley, RJ, 2022) |
| "Metformin may offer benefits to certain cancer populations experiencing metabolic abnormalities." | 1.72 | Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice. ( Chang, CY; Chen, CJ; Chen, WY; Li, JR; Liao, SL; Ou, YC; Wang, JD; Wu, CC, 2022) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 1.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| " In the present study, pancreatic and ileal tissues were excised from male Zucker-Diabetic Sprague Dawley (ZDSD) rats 8-weeks after RYGB, BMT (daily oral dosing with metformin 300mg/kg, fenofibrate 100mg/kg, ramipril 1mg/kg, rosuvastatin 10mg/kg and subcutaneous liraglutide 0." | 1.72 | Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats. ( Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A, 2022) |
| "Metformin was used in a median of 30% of the patients (Interquartile range: 10-50) and liraglutide in 10% of the cases (IQR 0-30), while orlistat (median 0%; IQR 0-10) and naltrexone/bupropion (median 0%; IQR 0-5) were seldom prescribed." | 1.72 | Obesity management: Attitudes and practice of Italian endocrinologists. ( Attanasio, R; Borretta, G; Busetto, L; Chianelli, M; Disoteo, OE; Grimaldi, F; Nicolucci, A; Paoletta, A; Papini, E; Persichetti, A; Samperi, I; Scoppola, A, 2022) |
| "To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity, we conducted a cohort study with 28,095 anonymized COVID-19 patients using data from the COVID-19 Research Database from January 1, 2020 to November 30, 2020." | 1.62 | Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. ( Ando, W; Atsuda, K; Hanaki, H; Horii, T; Otori, K; Uematsu, T, 2021) |
| "Obesity is considered an important factor for many chronic diseases, including diabetes, cardiovascular disease and cancer." | 1.62 | Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce. ( Alexandersson, I; Aouadi, M; Arifen, N; Boucher, J; Chen, P; Hagberg, CE; Harms, MJ; Hyvönen, MT; Knibbe, C; Krämer, N; Kutschke, M; Lang, S; Li, Q; Salehzadeh, F; Silva Cascales, H; Spalding, KL; Terezaki, E; Thorell, A, 2021) |
| "Obesity is a significant global health and socio-economic challenge, and considered an important risk factor for poor health outcomes including male reproductive dysfunction and infertility." | 1.62 | The effect of Nigella sativa oil and metformin on male seminal parameters and testosterone in Wistar rats exposed to an obesogenic diet. ( Almaghrawi, W; Henkel, R; Leisegang, K, 2021) |
| "Metformin treatment of the diabetic/obese mice effectively normalized glucose levels, reconfigured the mammary tumor milieu, and decreased metastatic seeding." | 1.62 | Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. ( Alsheikh, HAM; Ha, CM; Hinshaw, DC; Kammerud, SC; Lama-Sherpa, T; Metge, BJ; Mota, MSV; Samant, RS; Sharafeldin, N; Shevde, LA; Wende, AR, 2021) |
| "Metformin treatment normalized the cholinergic response, which involved mostly the M3 muscarinic acetylcholine receptor (M3 mAChR) in pancreatic beta-cells." | 1.62 | Metformin Improves Autonomic Nervous System Imbalance and Metabolic Dysfunction in Monosodium L-Glutamate-Treated Rats. ( Alves, VS; Barella, LF; de Castro Prado, MAA; de Freitas Mathias, PC; de Moraes, AMP; de Oliveira, JC; de Sant Anna, JR; Francisco, FA; Franco, CCDS; Gomes, RM; Malta, A; Martins, IP; Matiusso, CCI; Miranda, RA; Moreira, VM; Pavanello, A; Prates, KV; Previate, C; Ribeiro, TA; Saavedra, LPJ; Tófolo, LP; Trombini, AB; Vieira, E, 2021) |
| "Treatment with metformin reduced peripheral metabolic impairment and cardiac dysfunction via decreased cardiac mitochondrial dysfunction, mitochondrial dynamic imbalance, and apoptosis." | 1.62 | Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jinawong, K; Kerdphoo, S; Singhanat, K, 2021) |
| "Metformin is an antidiabetic drug commonly used in obesity treatment." | 1.56 | Effect of high-fat diet-induced obesity on thyroid gland structure in female rats and the possible ameliorating effect of metformin therapy. ( El-Sayed, SM; Ibrahim, HM, 2020) |
| " This study sought to identify a predictive and/or pharmacodynamic proteomic signature of metformin response to tailor its pharmacologic use." | 1.56 | Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. ( Ao, W; Bae-Jump, V; Bateman, NW; Casablanca, Y; Conrads, KA; Conrads, TP; Darcy, KM; Hamilton, CA; Hood, BL; Hope, E; Litzy, T; Maxwell, GL; Oliver, J; Teng, PN; Tommarello, D; Wang, G; Wilson, K; Zhou, M, 2020) |
| "Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear." | 1.56 | The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. ( Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 1.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM)." | 1.56 | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study. ( Begum, S; Lawlor, DL; Nelson, SM; Pasupathy, D; Poston, L; Sattar, N; Seed, P; Vieira, MC; Welsh, P; White, SL, 2020) |
| "Obesity is a major health problem threatening humanity in medical, social and psychological dimensions." | 1.56 | Histological, immunohistochemical and biochemical effects of bee bread on stomach tissue of obese rats. ( Doganyigit, Z; Kaymak, E; Okan, A; Silici, S; Soylu, M; Yakan, B, 2020) |
| "Metformin was used as a positive control." | 1.51 | Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation. ( Bhonde, RR; Datta, I; Shree, N; Venkategowda, S; Venkatranganna, MV, 2019) |
| "Metformin (Met) was reported to possess positive effects on preventing muscle damage and promoting muscle mass maintenance." | 1.51 | Beneficial effects of metformin on muscle atrophy induced by obesity in rats. ( Abdelghany, EMA; El-Gendy, J; Hasan, MM; Shalaby, SM, 2019) |
| "Severe hypertriglyceridemia was considered to have been a consequence of impaired insulin action and his apolipoprotein E4/2 phenotype." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
| "Metformin treatment increased the levels of butyrylcarnitine and acylcarnitine C18:1 concentrations and decreased the levels of isoleucine concentrations compared to untreated HFD mice." | 1.51 | Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination. ( Bugáňová, M; Haluzík, M; Holubová, M; Kuneš, J; Kuzma, M; Maletínská, L; Pelantová, H; Šedivá, B; Tomášová, P; Železná, B, 2019) |
| "To examine the incidence of type 2 diabetes in people with newly diagnosed prediabetes and the factors that protect against this progression." | 1.51 | What protects against pre-diabetes progressing to diabetes? Observational study of integrated health and social data. ( Blakely, T; Jansen, R; Krebs, J; Masters-Awatere, B; Oetzel, J; Scott, N; Teng, A, 2019) |
| "Bariatric surgery leads to type 2 diabetes mellitus (T2DM) remission, but recurrence can ensue afterwards." | 1.51 | Long-term diabetes outcomes after bariatric surgery-managing medication withdrawl. ( Belo, S; Carvalho, D; Freitas, P; Magalhães, D; Neves, JS; Oliveira, SC; Pedro, J; Souteiro, P; Varela, A, 2019) |
| "15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide)." | 1.51 | Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. ( Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE, 2019) |
| "The simulation of type 2 diabetes on the background of obesity in the animals has led to the development of signs of insulin's inhibition of insulin producing apparatus - some different expressions of dystrophy and degeneration of the β-cells." | 1.51 | MODERN ASPECTS OF SUGAR-REDUCING EFFECT OF THICK BEAN EXTRACT BASED ON A TYPE II DIABETES MODEL ON THE BACKGROUND OF OBESITY. ( Derkach, N; Korol, V; Rybak, V, 2019) |
| "Metformin was administered for 7 weeks to high fat-fed C57/6J male mice in vivo." | 1.48 | Metformin improves obesity-associated inflammation by altering macrophages polarization. ( Jing, Y; Li, D; Li, Q; Li, R; Wu, F; Yang, L, 2018) |
| "Metformin treatment decreased the expression of IL-1β and IL-6 in epididymal fat, which was correlated with the abundance of various bacterial genera." | 1.48 | Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice. ( An, J; Kim, J; Kim, K; Kong, H; Lee, CK; Lee, H; Lee, S; Lee, Y; Song, Y, 2018) |
| "Obesity is associated with hypoxic adipose tissues, including those in the breast, resulting in increased production of some of the aforementioned factors." | 1.48 | Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. ( Ancukiewicz, M; Babykutty, S; Boucher, Y; Chin, SM; Duda, DG; Fukumura, D; Gomes-Santos, IL; Hoffmman, U; Huang, Y; Incio, J; Jain, RK; Jung, K; Kawaguchi, K; Krop, IE; Ligibel, JA; McManus, DT; Pinter, M; Puchner, SB; Rahbari, NN; Roberge, S; Schlett, CL; Suboj, P; Tolaney, SM; Vardam, TD; Wang, D, 2018) |
| "Dapagliflozin or metformin treatment decreased insulin resistance, hypercholesterolemia, creatinine clearance and renal oxidative stress leading to improved renal function." | 1.48 | Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model. ( Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, L; Wanchai, K, 2018) |
| "Obesity-driven Type 2 diabetes (T2D) is a systemic inflammatory condition associated with cardiovascular disease." | 1.48 | Inflammatory signatures distinguish metabolic health in African American women with obesity. ( Andrieu, G; Bertrand, KA; Denis, GV; Medina, ND; Palmer, JR; Sebastiani, P; Slama, J; Strissel, KJ; Tran, AH, 2018) |
| "Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)." | 1.48 | Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018) |
| "Metformin is a first-line drug for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear." | 1.48 | Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. ( Hughey, CC; Hunter, RW; Jessen, N; Lantier, L; Peggie, M; Sakamoto, K; Sicheri, F; Sundelin, EI; Wasserman, DH; Zeqiraj, E, 2018) |
| "Insulin resistance was assessed by 3-h oral glucose tolerance test (OGTT)." | 1.46 | Metabolic and androgen profile in underweight women with polycystic ovary syndrome. ( Anastasiou, OE; Canbay, A; Fuhrer, D; Reger-Tan, S, 2017) |
| "Metformin treatment led to maintained good glycemic control and improved neuropathy and pancreatic lesions in female SDT fatty rats." | 1.46 | Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model. ( Fatchiyah, F; Miyajima, K; Murai, Y; Ohta, T; Shinohara, M; Tadaki, H; Yamada, T, 2017) |
| "Metformin-treated rats exhibited a reduction in body weight, adiposity, and HbA1c ( P < 0." | 1.46 | Transcriptomic effects of metformin in skeletal muscle arteries of obese insulin-resistant rats. ( Akter, S; Davis, JW; Jenkins, NT; Laughlin, MH; Martin, JS; Padilla, J; Rector, RS; Thorne, PK, 2017) |
| " Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily." | 1.43 | Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. ( Balladares, N; Contreras, M; D'Marco, L; Iacobellis, G; Lima-Martínez, MM; Paoli, M; Rodney, M, 2016) |
| "However, for those patients with type I endometrial cancer, only 1 patient (1." | 1.43 | Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. ( Burnett, AF; Gehlot, A; Hall, C; Stone, RL; Zorn, KK, 2016) |
| "Metformin is a treatment of choice for patients with type 2 diabetes." | 1.43 | HL271, a novel chemical compound derived from metformin, differs from metformin in its effects on the circadian clock and metabolism. ( Cho, S; Jeong, J; Kim, K; Kim, S; Row, H, 2016) |
| "BE subjects developing esophageal cancer (EC) 12 months after their index BE diagnosis were defined as progressors." | 1.43 | Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. ( Borah, B; Chak, A; Das, A; Heien, H; Iyer, PG; Krishnamoorthi, R, 2016) |
| "Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of PlGF in obesity-induced tumor progression is not known." | 1.43 | PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. ( Ancukiewicz, M; Babykutty, S; Batista, A; Carmeliet, P; Chin, SM; Duda, DG; Fukumura, D; Hato, T; Hoffmman, U; Incio, J; Jain, RK; Jung, K; Khachatryan, A; Krop, IE; Ligibel, JA; McManus, DT; Puchner, SB; Rahbari, NN; Schlett, CL; Shibuya, M; Soares, R; Suboj, P; Tam, J; Vardam, TD, 2016) |
| "Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored." | 1.43 | Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016) |
| "Finally, when compared to untreated type 2 diabetes patients, the metformin-treated diabetic patients showed increased IGFBP-2 levels with diminished serum IGF-1 levels." | 1.43 | Metformin stimulates IGFBP-2 gene expression through PPARalpha in diabetic states. ( Cho, HC; Choi, HS; Im, SS; Kang, HS; Koo, SH; Lee, IK; Lee, JH; Oh, GT; Park, BH; Song, DK, 2016) |
| "Metformin was treated daily for 14 weeks in a high-fat dieting C57BL/6J mice." | 1.43 | Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. ( Byun, JK; Cho, ML; Choi, JY; Jeong, JH; Jhun, JY; Kim, EK; Kim, JK; Lee, SH; Lee, SY, 2016) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 1.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "In patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin monotherapy, the addition of alogliptin contributed to clinically significant increases in pulmonary function through regulating glycemia and improving the imbalance of the oxidative-related substances in the serum, without increasing the incidence of hypoglycemia, dyslipidemia, dysarteriotony, and any notable increase in body weight." | 1.43 | The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. ( Dong, QY; Kuang, JS; Li, LB; Liu, XG; Tai, H; Wang, MY; Zhao, YP, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 1.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "A significant decrement of hyperinsulinemia, triglyceridemia, serum IL6 and oxidised LDL were observed at the end of the study." | 1.43 | Metformin preconditioned adipose derived mesenchymal stem cells is a better option for the reversal of diabetes upon transplantation. ( Bhonde, RR; Shree, N, 2016) |
| "Obesity is known to be associated with many diseases in the long and short terms." | 1.42 | The effect of lifestyle change and metformin therapy on serum arylesterase and paraoxonase activity in obese children. ( Çayır, A; Gurbuz, F; Kurt, N; Turan, Mİ; Yildirim, A, 2015) |
| "Bariatric surgery rapidly improves Type 2 diabetes mellitus (T2DM)." | 1.42 | Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats. ( Abegg, K; Boza, C; Corteville, C; Docherty, NG; le Roux, CW; Lutz, TA; Muñoz, R, 2015) |
| "Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6." | 1.42 | [Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015) |
| "Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear." | 1.42 | Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. ( Côté, CD; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Rutter, GA; Zadeh-Tahmasebi, M, 2015) |
| "Maternal obesity and gestational diabetes mellitus (GDM) are two increasingly common and important obstetric complications that are associated with severe long-term health risks to mothers and babies." | 1.42 | Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes. ( Lappas, M; Liong, S, 2015) |
| "Metformin treatment protected against the HFD-induced decrease in the number of spermatogonia, Sertoli cells, and Leydig cells (P < 0." | 1.42 | Protective effects of metformin on reproductive function in obese male rats induced by high-fat diet. ( Cheng, D; Mu, Y; Pang, XL; Yan, WJ; Yang, J; Yi, TL; Yu, N; Zhang, Y, 2015) |
| "The metformin treatment of Wistar rats with obesity induced by high-fat diet was carried out for 2 months (daily dose of 200 mg/kg)." | 1.42 | [THE EFFECTS OF LONG-TERM METFORMIN TREATMENT ON THE ACTIVITY OF ADENYLYL CYCLASE SYSTEM AND NO-SYNTHASES IN THE BRAIN AND THE MYOCARDIUM OF RATS WITH OBESITY]. ( Bondareva, VM; Derkach, KV; Ignatieva, PA; Kuznetsova, LA; Sharova, TS; Shpakov, AO, 2015) |
| " The differences in the reductions achieved in FPG and HbA1c with the two dosing regimens were significant." | 1.40 | Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study. ( Chatterjee, S, 2014) |
| "Metformin is a first-line, anti-diabetic agent prescribed to over 150 million people worldwide." | 1.40 | Potential biomarker of metformin action. ( Germain-Lee, EL; He, L; Meng, S; Radovick, S; Wondisford, FE, 2014) |
| "Metformin is a widely prescribed drug for the treatment of type 2 diabetes." | 1.40 | Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner. ( Ciapaite, J; Nicolay, K; Prompers, JJ; van den Broek, NM; Wessels, B, 2014) |
| "Metformin suppress adipocyte-induced cell proliferation and adipocyte-secreted adipokines in vitro." | 1.40 | Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. ( Carlock, C; Chen, J; Chen, JS; Choi, HH; Chou, PC; Ensor, J; Esteva, FJ; Fraser Symmans, W; Fuentes-Mattei, E; Gully, C; Hortobagyi, GN; Lee, MH; Luo, Y; McKeehan, WL; Phan, L; Pusztai, L; Qi, Y; Shin, JH; Velazquez-Torres, G; Wu, Y; Yeung, SC; Zhang, F; Zhang, Y; Zhao, R, 2014) |
| "Metformin treatments would have positive effects on growth patterns, adiposity and metabolic features of young females from ethnicities with thrifty genotype or developing leptin resistance, but a negative effect by advancing the attainment of puberty." | 1.40 | Advanced onset of puberty after metformin therapy in swine with thrifty genotype. ( Astiz, I; Astiz, S; Barbero, A; Garcia-Real, I; Gonzalez-Bulnes, A; Perez-Solana, ML, 2014) |
| "This association is less clear in epithelial ovarian cancer (EOC)." | 1.40 | Diabetes mellitus and ovarian cancer: more complex than just increasing risk. ( Daily, LB; Erickson, BK; Fauci, JM; Haygood, CW; Leath, CA; Martin, JY; Matin, T; McGwin, G; Pasko, D; Shah, MM, 2014) |
| "There was a significant lowering of HbA1c, fasting blood glucose levels, postprandial glucose levels and better blood pressure control by which we have proved that GLP1 analogues in combination with basal insulin and metformin provide a good glycaemic control with a cardio protective effect, and reduce the risk of late complications." | 1.40 | Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. ( Buturovic, BA; Narancic, AM; Ristic, LB, 2014) |
| "Obesity is a significant contributing factor to endometrial cancer risk." | 1.39 | Chemopreventive effects of metformin on obesity-associated endometrial proliferation. ( Broaddus, RR; Burzawa, JK; Celestino, J; Huang, M; Iglesias, D; Lu, KH; McCampbell, AS; Meyer, LA; Schmandt, R; Urbauer, DL; Yates, MS; Zhang, Q, 2013) |
| "Metformin has recently drawn attention because of its potential antitumor effect." | 1.39 | Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. ( Aoki, K; Atsumi, T; Inoue, H; Ito, Y; Kaji, M; Nagashima, Y; Nakamura, A; Orime, K; Sakamoto, E; Sato, K; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y, 2013) |
| " The majority of the patients with type 2 diabetes of short duration did not meet any of the treatment goals as recommended in the current practice guidelines." | 1.39 | Management and treatment goals in Polish patients with type 2 diabetes of short duration: results of the ARETAEUS2-Grupa study. ( Bała, MM; Czupryniak, L; Jankowski, M; Leśniak, W; Michałejko, M; Płaczkiewicz-Jankowska, E; Sieradzki, J; Strzeszyński, L; Topór-Mądry, R, 2013) |
| "Obesity was induced in rats by high-fat diet feeding for 8 weeks, and then the rats were given exenatide, avandamet and diet change to normal chow, respectively, for additional 8 weeks." | 1.39 | Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats. ( Bi, Y; Dai, YY; Feng, WH; Hu, J; Hu, Y; Li, P; Liu, YQ; Shao, LL; Shen, SM; Tong, GY; Wang, WM; Xiang, SK; Yang, DH; Yuan, XW; Zhu, DL, 2013) |
| "Metformin treatment was able to reduce insulin resistance and attenuated this adverse cardiac and vascular remodeling." | 1.39 | Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. ( Burlá, AK; Fortes, ZB; Lobato, NS; Neves, MF; Oigman, W, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues." | 1.38 | Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease. ( Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C, 2012) |
| "Obesity and insulin resistance are associated with chronic, low grade inflammation." | 1.38 | Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. ( Aatsinki, SM; Buler, M; Georgiadi, A; Hakkola, J; Kerkelä, R; Kersten, S; Komka, Z; Skoumal, R; Tóth, M, 2012) |
| "Metformin treatment improved these alterations." | 1.38 | Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats. ( Akamine, EH; Carvalho, MH; Filgueira, FP; Fortes, ZB; Hagihara, GN; Lobato, NS; Pariz, JR; Tostes, RC, 2012) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 1.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Obesity is a common problem and its health consequences depend on the phenotype of obesity." | 1.38 | Menopausal obesity and metabolic syndrome - PolSenior study. ( Milewicz, A, 2012) |
| "Metformin has been well characterized in vitro as a substrate of liver-expressed organic cation transporters (OCTs)." | 1.37 | OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. ( Fernández-Real, JM; Moreno-Navarrete, JM; Ortega, FJ; Pardo, G; Ricart, W; Rodríguez-Hermosa, JI; Sabater, M, 2011) |
| "Insulin resistance in type 2 diabetes (T2D) is associated with intramuscular lipid (IMCL) accumulation." | 1.37 | Abnormal metabolism flexibility in response to high palmitate concentrations in myotubes derived from obese type 2 diabetic patients. ( Aguer, C; Foretz, M; Hébrard, S; Kitzmann, M; Lantier, L; Mercier, J, 2011) |
| "Type 2 diabetes mellitus is one of the significant comorbidities of obesity." | 1.37 | Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment. ( Eid, WE, 2011) |
| " Our previous work demonstrated that dihydroberberine (dhBBR) has enhanced bioavailability and in vivo efficacy compared with berberine." | 1.36 | 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. ( Chen, AF; Cheng, Z; Gu, M; Hu, LH; Li, J; Li, JY; Li, YY; Sheng, L; Wu, F; Zhang, HK; Zhang, LN, 2010) |
| "This article describes a patient with type 2 diabetes mellitus achieving glycemic control after transitioning from premixed to basal-prandial insulin." | 1.36 | Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes. ( Lavernia, F, 2010) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 1.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "Insulin resistance is a characteristic of type 2 diabetes and is a major independent risk factor for progression to the disease." | 1.36 | Generation, validation and humanisation of a novel insulin resistant cell model. ( Brady, JD; Crowther, D; Feuerstein, GZ; Grierson, CE; Hansen, MK; Hundal, HS; Logie, L; Morris, AD; Pearson, E; Ruiz-Alcaraz, AJ; Schofield, CJ; Shepherd, B; Sutherland, C; Tommasi, AM, 2010) |
| "Metformin is a widely prescribed drug for treatment of type 2 diabetes, although no cellular mechanism of action has been established." | 1.36 | Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. ( Anderson, EJ; Bikman, BT; Cortright, RN; Kane, DA; Lin, CT; Neufer, PD; Price, JW; Woodlief, TL, 2010) |
| "GVHD had little effect." | 1.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| "Obese patients with type 2 diabetes and impaired glucose tolerance are at increased risk of development of cardiovascular diseases." | 1.35 | Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction. ( Ascić-Buturović, B; Kacila, M, 2008) |
| "Type 2 diabetes is associated with elevated inflammatory systemic cytokines but activin A serum levels were similar in slim probands, overweight controls and type 2 diabetic patients." | 1.35 | Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. ( Aslanidis, C; Buechler, C; Filarsky, M; Neumeier, M; Schäffler, A; Schober, F; Schölmerich, J; Schramm, A; Sporrer, D; Stögbauer, F; Wanninger, J; Weber, M; Weigert, J; Wurm, S, 2009) |
| "In Yucatán, 52% of patients with type 2 diabetes (DT2) present secondary failure to treatment associated with sulphonylurea and metformin." | 1.35 | [Effect of the Gly972Arg, SNP43 and Prol2Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatán, México]. ( García-Escalante, MG; Laviada-Molina, H; López-Avila, MT; Pinto-Escalante, Ddel C; Suárez-Solís, VM, 2009) |
| "Obesity is associated with chronic inflammation and low adiponectin, an anti-inflammatory adipokine." | 1.35 | Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity. ( Bala, M; Buechler, C; Kopp, A; Lieberer, E; Neumeier, M; Schäffler, A; Sporrer, D; Stögbauer, F; Wanninger, J; Weber, M; Weigert, J, 2009) |
| "For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction." | 1.34 | Ovulation induction management of PCOS. ( Guzick, DS, 2007) |
| "Over half of these German patients with type 2 diabetes failed to attain the HbA(1c) target for glycemic control." | 1.34 | Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. ( Lage, MJ; Secnik, K; Yurgin, N, 2007) |
| "Metformin treatment of the hepatocytes resulted in activation of the AMP-activated kinase, attenuation of the mTOR/S6K1 pathway, reduction of IRS-1 phosphorylation, and a leftward shift in the insulin dose-response curve for PKB activation." | 1.34 | Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. ( Iynedjian, PB; Mordier, S, 2007) |
| " Biphasic insulin aspart 30 in combination with metformin administered twice a day may be recommended as a starting insulin treatment in obese diabetic persons whose glycaemic control remained poor while on oral metformin therapy alone." | 1.34 | Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes. ( Ascić-Buturović, B, 2007) |
| "Micro vascular morphology and hemodynamics were evaluated non-invasively by means of nailfold videocapillaroscopy." | 1.34 | [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions]. ( Bahia, LR; Bottino, DA; Bouskela, E; Kraemer de Aguiar, LG; Nivoit, P; Villela, NR, 2007) |
| "A 57-year-old Caucasian woman with Type 2 diabetes treated for seven years with diet and oral combination hypoglycaemic therapy was referred because of the progressive deterioration of glycaemic control." | 1.33 | Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change. ( Atkin, SL; González, S; Kilpatrick, ES, 2005) |
| "Obesity is associated with altered glucocorticoid metabolism, which may impact on hypothalamic-pituitary-adrenal axis activity." | 1.33 | Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization. ( Andrew, R; Livingstone, DE; McInnes, KJ; Walker, BR, 2005) |
| "Metformin was more effective in lowering glucose in those with a lower BMI (r = -0." | 1.33 | The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. ( Doney, AS; Donnelly, LA; Hattersley, AT; Morris, AD; Pearson, ER, 2006) |
| "There were eight (14%) patients with vitamin B12 deficiency and three among them had hyperhomocysteinaemia." | 1.33 | [Factors influencing homocysteineamia in type 2 diabetic patients]. ( Bouzid, C; Essais, O; Ibrahim, H; Machghoul, S; Ouertani, H; Ouni, Z; Zidi, B, 2006) |
| "Metformin treatment significantly improved hyperandrogenism, menstrual cyclicity, body weight, and insulin resistance independent of GNAS1 genotype." | 1.33 | The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. ( Frey, UH; Hahn, S; Janssen, OE; Mann, K; Siffert, W; Tan, S, 2006) |
| "Patients with type 2 diabetes and complete HbA(1c) (A1C) data and treated with metformin or sulfonylurea monotherapy for at least three visits before receiving dual oral therapy were included (n = 644)." | 1.33 | Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. ( Constantino, MI; Molyneaux, LM; Ong, CR; Twigg, SM; Yue, DK, 2006) |
| "For the treatment of type 2 diabetes we now have available a wide spectrum of oral antidiabetic agents and insulins that make it possible to offer the patient an individualized, pathophysiologically oriented therapy." | 1.32 | [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. ( Fischer, S; Hanefeld, M, 2003) |
| "Type 2 diabetes can present as diabetic ketoacidosis in obese adolescent subjects." | 1.32 | Type 2 diabetes presenting as diabetic ketoacidosis in adolescence. ( Cox, J; Elkeles, RS; Elwig, C; Poulter, C; Valabhji, J; Watson, M, 2003) |
| "Insulin resistance is a key feature of type 2 diabetes mellitus." | 1.32 | Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide. ( Antić, S; Bogicević, M; Milojković, M; Mitić-Zlatković, M; Stefanović, V; Stojiljković, S; Vlahović, P, 2003) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "The increasing incidence of type 2 diabetes constitutes a considerable individual and socio-economic risk, therefore preventive concepts are urgently needed." | 1.32 | [Primary prevention of diabetes mellitus type 2]. ( Gallwitz, B, 2004) |
| "Metformin has been shown to increase glucagon-like peptide-1 (GLP-1) levels after an oral glucose load in obese non-diabetic subjects." | 1.32 | Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. ( Bardini, G; Brogi, M; Ciani, S; Cremasco, F; Dicembrini, I; Mannucci, E; Messeri, G; Ognibene, A; Petracca, MG; Pezzatini, A; Rotella, CM; Tesi, F, 2004) |
| "Metformin was then administered." | 1.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
"Metformin treatment was accompanied by a drop in fasting insulin and serum androgens and by a less atherogenic lipid profile (all P | 1.31 | Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. ( De Zegher, F; Ferrer, A; Ibáñez, L; Marcos, MV; Potau, N; Rodriguez-Hierro, F, 2002) | |
| "There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease." | 1.31 | Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000) |
| "Obesity has been associated with alterations in glucocorticoid metabolism in both man and rodents, but the underlying mechanisms remain undefined." | 1.31 | Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. ( Kenyon, CJ; Livingstone, DE; Walker, BR, 2000) |
| "But metformin has fibrinolytic features by means of diminished plasminogen activator inhibitor 1 activity." | 1.31 | Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection? ( Andreu-Garcia, M; Burrull-Madero, MA; Del-Villar-Ruiz, A; Goday-Arno, A; Grau-Cerrato, S, 2001) |
| "Twenty obese men with type 2 diabetes (mean body mass index [BMI]: 35." | 1.31 | The effects of metformin and diet on plasma testosterone and leptin levels in obese men. ( Bingol, N; Oktenli, C; Ozata, M; Ozdemir, IC, 2001) |
| "Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate." | 1.31 | Metformin for weight loss in pediatric patients taking psychotropic drugs. ( Barton, BA; Cottingham, EM; Morrison, JA, 2002) |
| "Metformin plays a particularly important role in the treatment of diabetes mellitus type 2 by decreasing insulin resistance." | 1.30 | [Renaissance of metformin]. ( Sieradzki, J, 1999) |
| "Glycerol release was lowered by metformin during the 3-h experiment (P<0." | 1.30 | Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study. ( Adler, G; Alt, A; Ditschuneit, HH; Flechtner-Mors, M; Jenkinson, CP, 1999) |
| "Metformin treatment significantly elevated GLUT 1 in control rats (p < 0." | 1.29 | Elevated GLUT 1 level in crude muscle membranes from diabetic Zucker rats despite a normal GLUT 1 level in perineurial sheaths. ( Handberg, A; Høyer, PE; Kayser, L; Micheelsen, J; Vinten, J, 1994) |
| "The weight gains were identically reduced in the metformin- and pair-fed control group compared to the ad libitum--fed rats." | 1.29 | Metformin and brown adipose tissue thermogenetic activity in genetically obese Zucker rats. ( Huupponen, R; Isaksson, K; Koulu, M; Rouru, J; Santti, E, 1993) |
| "Patients affected by NIDDM (n = 11) and normal subjects (n = 6) were studied." | 1.29 | The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes. ( Barone, R; Chianelli, M; Fiore, V; Negri, M; Pozzilli, P; Procaccini, E; Ronga, G; Signore, A, 1996) |
| "A total of 40 NIDDM patients were examined (24 females and 16 males) with a mean age of 55." | 1.29 | [Comparison of two treatment models in type-II diabetic patients with poor metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months]. ( Cavallo, P; D'Argenzio, R; Merante, D; Morelli, A, 1996) |
| "Metformin markedly reduced also the hyperinsulinemia of the obese animals without altering their plasma glucose or pancreatic insulin content which may reflect an improved insulin sensitivity after metformin treatment." | 1.28 | Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. ( Huupponen, R; Koulu, M; Pesonen, U; Rouru, J, 1992) |
| " Metformin, administered at 200 mg/kg per os, ineffective dosage in normal mice, showed a strong hypoglycemic effect in younger mice (11--18 weeks) with a plasma IRI decrease and no blood lactate and liver glycogen alteration." | 1.26 | DBM mice as a pharmacological model of maturity onset diabetes. Studies with metformin. ( Brohon, J; Guillaume, M; Junien, JL; Sterne, J, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (4.28) | 18.7374 |
| 1990's | 86 (6.95) | 18.2507 |
| 2000's | 327 (26.41) | 29.6817 |
| 2010's | 549 (44.35) | 24.3611 |
| 2020's | 223 (18.01) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z | 1 |
| Chen, AF | 1 |
| Wu, F | 3 |
| Sheng, L | 1 |
| Zhang, HK | 1 |
| Gu, M | 3 |
| Li, YY | 1 |
| Zhang, LN | 1 |
| Hu, LH | 1 |
| Li, JY | 2 |
| Li, J | 6 |
| Ma, L | 2 |
| Xie, C | 2 |
| Ran, Y | 1 |
| Liang, X | 1 |
| Huang, L | 2 |
| Pei, H | 1 |
| Chen, J | 10 |
| Liu, J | 5 |
| Sang, Y | 1 |
| Lai, H | 1 |
| Peng, A | 1 |
| Xiang, M | 1 |
| Wei, Y | 1 |
| Chen, L | 6 |
| Li, X | 7 |
| Xu, Q | 2 |
| Li, C | 4 |
| Luo, J | 1 |
| Wang, L | 6 |
| Jiang, B | 2 |
| Shi, D | 1 |
| Rao, Y | 1 |
| Xu, Z | 3 |
| Hu, YT | 1 |
| Xu, YH | 1 |
| Song, QQ | 1 |
| Yu, H | 2 |
| Song, BB | 1 |
| Chen, SB | 1 |
| Li, QJ | 1 |
| Huang, SL | 1 |
| Tan, JH | 1 |
| Ou, TM | 1 |
| Wang, HG | 1 |
| Zhong, GP | 1 |
| Ye, JM | 1 |
| Huang, ZS | 1 |
| Xie, Y | 5 |
| Xiao, L | 1 |
| Li, S | 3 |
| Cai, X | 1 |
| Liu, Z | 5 |
| Dong, X | 1 |
| Wang, Y | 9 |
| Zhu, L | 2 |
| Li, M | 6 |
| Xu, Y | 3 |
| Huang, SW | 1 |
| Ou, YC | 2 |
| Tang, KS | 1 |
| Yu, HR | 1 |
| Huang, LT | 1 |
| Tain, YL | 1 |
| Lin, IC | 1 |
| Sheen, JM | 1 |
| Hou, CY | 1 |
| Tsai, CC | 1 |
| Tiao, MM | 1 |
| Ando, W | 1 |
| Horii, T | 1 |
| Uematsu, T | 1 |
| Hanaki, H | 1 |
| Atsuda, K | 1 |
| Otori, K | 1 |
| Cobb, LP | 1 |
| Siamakpour-Reihani, S | 1 |
| Zhang, D | 3 |
| Qin, X | 1 |
| Owzar, K | 1 |
| Zhou, C | 1 |
| Conrads, TP | 2 |
| Maxwell, GL | 2 |
| Darcy, KM | 2 |
| Bateman, NW | 2 |
| Litzi, T | 1 |
| Bae-Jump, V | 3 |
| Secord, AA | 1 |
| Li, Q | 6 |
| Hagberg, CE | 1 |
| Silva Cascales, H | 1 |
| Lang, S | 1 |
| Hyvönen, MT | 1 |
| Salehzadeh, F | 1 |
| Chen, P | 1 |
| Alexandersson, I | 1 |
| Terezaki, E | 1 |
| Harms, MJ | 1 |
| Kutschke, M | 1 |
| Arifen, N | 1 |
| Krämer, N | 1 |
| Aouadi, M | 1 |
| Knibbe, C | 1 |
| Boucher, J | 1 |
| Thorell, A | 1 |
| Spalding, KL | 1 |
| Shin, J | 1 |
| Toyoda, S | 1 |
| Nishitani, S | 1 |
| Fukuhara, A | 1 |
| Kita, S | 1 |
| Otsuki, M | 1 |
| Shimomura, I | 1 |
| Le, J | 2 |
| Fu, Y | 2 |
| Han, Q | 1 |
| Wei, X | 1 |
| Ji, H | 1 |
| Chen, Y | 6 |
| Wang, Q | 5 |
| Pi, P | 1 |
| Lin, X | 2 |
| Zhang, X | 10 |
| Zhang, Y | 13 |
| Ye, J | 4 |
| Soldat-Stanković, V | 1 |
| Popović-Pejičić, S | 1 |
| Stanković, S | 1 |
| Prtina, A | 1 |
| Malešević, G | 1 |
| Bjekić-Macut, J | 1 |
| Livadas, S | 1 |
| Ognjanović, S | 1 |
| Mastorakos, G | 1 |
| Micić, D | 1 |
| Macut, D | 1 |
| Abdulmalek, S | 1 |
| Eldala, A | 1 |
| Awad, D | 1 |
| Balbaa, M | 1 |
| Calco, GN | 1 |
| Proskocil, BJ | 1 |
| Jacoby, DB | 1 |
| Fryer, AD | 1 |
| Nie, Z | 1 |
| Ma, RL | 2 |
| Deng, Y | 3 |
| Wang, YF | 1 |
| Zhu, SY | 2 |
| Ding, XS | 2 |
| Sun, AJ | 2 |
| Aras, M | 1 |
| Tchang, BG | 1 |
| Pape, J | 1 |
| Ali Kazem, T | 1 |
| Zeylabi, F | 1 |
| Filayih Hassan, A | 1 |
| Paridar, P | 1 |
| Pezeshki, SP | 1 |
| Pezeshki, SMS | 1 |
| Tracer, H | 2 |
| West, R | 1 |
| Gao, L | 2 |
| Huang, H | 2 |
| Zhang, L | 4 |
| Zhang, N | 2 |
| Zhu, D | 5 |
| Bi, Y | 4 |
| Feng, W | 1 |
| Zhao, YX | 1 |
| Wang, LJ | 1 |
| Gong, FY | 1 |
| Pan, H | 1 |
| Miao, H | 1 |
| Duan, L | 1 |
| Yang, HB | 1 |
| Zhu, HJ | 1 |
| Chalmers, JA | 1 |
| Dalvi, PS | 1 |
| Loganathan, N | 1 |
| McIlwraith, EK | 1 |
| Wellhauser, L | 1 |
| Nazarians-Armavil, A | 1 |
| Eversley, JA | 1 |
| Mohan, H | 1 |
| Stahel, P | 1 |
| Dash, S | 1 |
| Wheeler, MB | 1 |
| Belsham, DD | 1 |
| Seikrit, C | 1 |
| Lausberg, E | 1 |
| Buhl, EM | 1 |
| Gaspar, R | 2 |
| Tabi, T | 1 |
| Heffer, M | 2 |
| Ducza, E | 2 |
| Sztojkov-Ivanov, A | 1 |
| Seres, AB | 1 |
| Szucs, K | 1 |
| Ivic, V | 2 |
| Floege, J | 1 |
| Vari, SG | 2 |
| Boor, P | 1 |
| Klinkhammer, BM | 1 |
| Kaplanian, M | 1 |
| Philippe, C | 1 |
| Eid, SA | 1 |
| Hackl, MT | 1 |
| Metz, M | 1 |
| Beghini, M | 1 |
| Luca, AC | 1 |
| Kautzky-Willer, A | 2 |
| Scherer, T | 1 |
| Fürnsinn, C | 1 |
| Bakhtiari, M | 1 |
| Asadipooya, K | 1 |
| Tilves, C | 1 |
| Yeh, HC | 3 |
| Maruthur, N | 1 |
| Juraschek, SP | 3 |
| Miller, ER | 3 |
| Appel, LJ | 3 |
| Mueller, NT | 3 |
| Li, H | 7 |
| Gou, Y | 1 |
| Tian, F | 1 |
| Lian, Q | 1 |
| Hu, Y | 3 |
| Mohnot, S | 1 |
| Lule, KO | 1 |
| Akarsu, E | 2 |
| Sayiner, ZA | 2 |
| Lule, NO | 1 |
| Balci, SO | 2 |
| Demirel, C | 2 |
| Bozdag, Z | 2 |
| Korkmaz, M | 2 |
| Yilmaz, I | 2 |
| Bilusic, M | 1 |
| Toney, NJ | 1 |
| Donahue, RN | 1 |
| Wroblewski, S | 1 |
| Zibelman, M | 1 |
| Ghatalia, P | 1 |
| Ross, EA | 1 |
| Karzai, F | 1 |
| Madan, RA | 1 |
| Dahut, WL | 1 |
| Gulley, JL | 1 |
| Schlom, J | 1 |
| Plimack, ER | 1 |
| Geynisman, DM | 1 |
| Huang, J | 1 |
| Ru, G | 1 |
| Sun, J | 1 |
| Sun, L | 2 |
| Li, Z | 4 |
| Aylor, KW | 1 |
| Chai, W | 1 |
| Barrett, EJ | 1 |
| Shams, HA | 1 |
| Al-Kuraishy, HM | 4 |
| Al-Gareeb, AI | 4 |
| Herman, R | 1 |
| Kravos, NA | 3 |
| Jensterle, M | 6 |
| Janež, A | 7 |
| Dolžan, V | 1 |
| Valeeva, FV | 1 |
| Medvedeva, MS | 1 |
| Khasanova, KB | 1 |
| Valeeva, EV | 1 |
| Kiseleva, TA | 1 |
| Egorova, ES | 1 |
| Pickering, C | 1 |
| Ahmetov, II | 1 |
| Oróstica, ML | 1 |
| Astorga, I | 1 |
| Plaza-Parrochia, F | 2 |
| Poblete, C | 1 |
| Carvajal, R | 1 |
| García, V | 1 |
| Romero, C | 2 |
| Vega, M | 2 |
| Flores-García, LC | 1 |
| Ventura-Gallegos, JL | 1 |
| Romero-Córdoba, SL | 1 |
| Hernández-Juárez, AJ | 1 |
| Naranjo-Meneses, MA | 1 |
| García-García, E | 1 |
| Méndez, JP | 1 |
| Cabrera-Quintero, AJ | 1 |
| Ramírez-Ruíz, A | 1 |
| Pedraza-Sánchez, S | 1 |
| Meraz-Cruz, N | 1 |
| Vadillo-Ortega, F | 1 |
| Zentella-Dehesa, A | 1 |
| Kudabayeva, K | 2 |
| Kosmuratova, R | 2 |
| Bazargaliyev, Y | 2 |
| Shagatayeva, B | 1 |
| Zhou, ST | 1 |
| Cui, W | 1 |
| Kong, L | 2 |
| Yang, X | 1 |
| Broadfield, LA | 1 |
| Saigal, A | 1 |
| Szamosi, JC | 1 |
| Hammill, JA | 1 |
| Bezverbnaya, K | 1 |
| Wang, D | 3 |
| Gautam, J | 1 |
| Tsakiridis, EE | 1 |
| Di Pastena, F | 1 |
| McNicol, J | 1 |
| Wu, J | 5 |
| Syed, S | 1 |
| Lally, JSV | 1 |
| Raphenya, AR | 1 |
| Blouin, MJ | 1 |
| Pollak, M | 2 |
| Sacconi, A | 1 |
| Blandino, G | 1 |
| McArthur, AG | 1 |
| Schertzer, JD | 1 |
| Surette, MG | 1 |
| Collins, SM | 1 |
| Bramson, JL | 1 |
| Muti, P | 2 |
| Tsakiridis, T | 1 |
| Steinberg, GR | 2 |
| Liao, X | 1 |
| Liu, Y | 8 |
| Chen, W | 1 |
| Zeng, B | 1 |
| Luo, Y | 2 |
| Huang, C | 2 |
| Guo, G | 1 |
| Wang, X | 8 |
| Hu, L | 3 |
| Xia, X | 2 |
| Ying, T | 1 |
| Zhou, M | 2 |
| Zou, S | 1 |
| Yin, J | 2 |
| Nair-Shalliker, V | 1 |
| Bang, A | 1 |
| Egger, S | 1 |
| Yu, XQ | 1 |
| Chiam, K | 1 |
| Steinberg, J | 1 |
| Patel, MI | 1 |
| Banks, E | 1 |
| O'Connell, DL | 1 |
| Armstrong, BK | 1 |
| Smith, DP | 1 |
| Kim, J | 2 |
| Lee, N | 1 |
| Suh, SB | 1 |
| Jang, S | 1 |
| Kim, S | 2 |
| Kim, DG | 1 |
| Park, JK | 1 |
| Lee, KW | 1 |
| Choi, SY | 1 |
| Lee, CH | 3 |
| Linder, T | 1 |
| Eder, A | 1 |
| Monod, C | 1 |
| Rosicky, I | 1 |
| Eppel, D | 1 |
| Redling, K | 1 |
| Geissler, F | 1 |
| Huhn, EA | 1 |
| Hösli, I | 1 |
| Göbl, CS | 1 |
| Su, SC | 2 |
| Chien, CY | 1 |
| Chen, YC | 1 |
| Chiang, CF | 2 |
| Lin, FH | 1 |
| Kuo, FC | 1 |
| Huang, CL | 1 |
| Li, PF | 1 |
| Liu, JS | 2 |
| Lu, CH | 2 |
| Ho, LJ | 1 |
| Hsieh, CH | 2 |
| Hung, YJ | 3 |
| Shieh, YS | 2 |
| Yang, L | 3 |
| Jia, X | 1 |
| Fang, D | 1 |
| Cheng, Y | 1 |
| Zhai, Z | 1 |
| Deng, W | 1 |
| Du, B | 1 |
| Lu, T | 2 |
| Yang, C | 1 |
| Gao, Y | 5 |
| Schmitz, K | 1 |
| Turnwald, EM | 1 |
| Kretschmer, T | 1 |
| Janoschek, R | 1 |
| Bae-Gartz, I | 1 |
| Voßbrecher, K | 1 |
| Kammerer, MD | 1 |
| Köninger, A | 1 |
| Gellhaus, A | 1 |
| Handwerk, M | 1 |
| Wohlfarth, M | 1 |
| Gründemann, D | 1 |
| Hucklenbruch-Rother, E | 1 |
| Dötsch, J | 1 |
| Appel, S | 1 |
| Merce, AP | 1 |
| Ionică, LN | 2 |
| Bînă, AM | 2 |
| Popescu, S | 1 |
| Lighezan, R | 2 |
| Petrescu, L | 1 |
| Borza, C | 1 |
| Sturza, A | 2 |
| Muntean, DM | 2 |
| Creţu, OM | 2 |
| Arguelles-Tello, FA | 1 |
| Kammar-García, A | 1 |
| Trejo-Jasso, CA | 1 |
| Huerta-Cruz, JC | 1 |
| Barranco-Garduño, LM | 1 |
| Rocha-González, HI | 1 |
| Reyes-García, JG | 2 |
| Li, R | 4 |
| Mai, T | 2 |
| Zheng, S | 2 |
| Wilson, C | 1 |
| Carpenter, J | 1 |
| Park, S | 2 |
| McHugh, C | 1 |
| Scott, EM | 1 |
| Hickie, IB | 1 |
| Sartayeva, A | 1 |
| Kereyeva, N | 1 |
| Lyu, Q | 1 |
| Wen, Y | 1 |
| He, B | 4 |
| Sun, Y | 3 |
| Zhao, Y | 5 |
| Xu, L | 1 |
| Xiao, Q | 1 |
| Deng, H | 2 |
| Joham, AE | 1 |
| Norman, RJ | 6 |
| Stener-Victorin, E | 2 |
| Legro, RS | 6 |
| Franks, S | 2 |
| Moran, LJ | 1 |
| Boyle, J | 2 |
| Teede, HJ | 4 |
| Fernández-García, JC | 1 |
| Barrios-Rodríguez, R | 1 |
| Asenjo-Plaza, M | 1 |
| Ramos-Molina, B | 1 |
| Molina-Vega, M | 1 |
| Guzmán-Guzmán, A | 1 |
| Moreno-León, L | 1 |
| Yubero-Serrano, EM | 1 |
| Rius-Díaz, F | 1 |
| Valdés, S | 1 |
| Martínez-González, MÁ | 1 |
| Jiménez-Moleón, JJ | 1 |
| Tinahones, FJ | 2 |
| Delanogare, E | 1 |
| Bullich, S | 1 |
| Barbosa, LADS | 1 |
| Barros, WM | 1 |
| Braga, SP | 1 |
| Kraus, SI | 1 |
| Kasprowicz, JN | 1 |
| Dos Santos, GJ | 1 |
| Guiard, BP | 1 |
| Moreira, ELG | 1 |
| Klein, AB | 1 |
| Nicolaisen, TS | 1 |
| Johann, K | 1 |
| Fritzen, AM | 1 |
| Mathiesen, CV | 1 |
| Gil, C | 1 |
| Pilmark, NS | 1 |
| Karstoft, K | 3 |
| Blond, MB | 2 |
| Quist, JS | 1 |
| Seeley, RJ | 1 |
| Færch, K | 3 |
| Lund, J | 1 |
| Kleinert, M | 1 |
| Clemmensen, C | 2 |
| Chen, CJ | 2 |
| Wu, CC | 1 |
| Chang, CY | 1 |
| Li, JR | 1 |
| Chen, WY | 1 |
| Liao, SL | 1 |
| Wang, JD | 1 |
| Zhao, G | 1 |
| Zhang, Q | 5 |
| Yin, S | 1 |
| Liu, H | 4 |
| Manzoor, F | 1 |
| Nisa, MU | 1 |
| Shakoor, A | 1 |
| Hussain, L | 1 |
| Mahmood, A | 1 |
| Younas, A | 1 |
| Xing, C | 2 |
| Zhao, H | 1 |
| Zhang, J | 4 |
| Bramante, CT | 3 |
| Huling, JD | 1 |
| Tignanelli, CJ | 3 |
| Buse, JB | 2 |
| Liebovitz, DM | 1 |
| Nicklas, JM | 1 |
| Cohen, K | 2 |
| Puskarich, MA | 1 |
| Belani, HK | 1 |
| Proper, JL | 1 |
| Siegel, LK | 1 |
| Klatt, NR | 1 |
| Odde, DJ | 1 |
| Luke, DG | 1 |
| Anderson, B | 1 |
| Karger, AB | 1 |
| Ingraham, NE | 2 |
| Hartman, KM | 1 |
| Rao, V | 1 |
| Hagen, AA | 1 |
| Patel, B | 1 |
| Fenno, SL | 1 |
| Avula, N | 1 |
| Reddy, NV | 1 |
| Erickson, SM | 1 |
| Lindberg, S | 1 |
| Fricton, R | 1 |
| Lee, S | 2 |
| Zaman, A | 1 |
| Saveraid, HG | 1 |
| Tordsen, WJ | 1 |
| Pullen, MF | 1 |
| Biros, M | 1 |
| Sherwood, NE | 1 |
| Thompson, JL | 1 |
| Boulware, DR | 1 |
| Murray, TA | 2 |
| Jonas, DE | 1 |
| Vander Schaaf, EB | 1 |
| Riley, S | 1 |
| Allison, BA | 1 |
| Middleton, JC | 1 |
| Baker, C | 1 |
| Ali, R | 1 |
| Voisin, CE | 1 |
| LeBlanc, ES | 1 |
| Schoonejans, JM | 1 |
| Blackmore, HL | 1 |
| Ashmore, TJ | 1 |
| Pantaleão, LC | 1 |
| Pellegrini Pisani, L | 1 |
| Dearden, L | 1 |
| Tadross, JA | 1 |
| Aiken, CE | 1 |
| Fernandez-Twinn, DS | 1 |
| Ozanne, SE | 1 |
| Seicaru, EM | 1 |
| Popa Ilie, IR | 1 |
| Cătinean, A | 1 |
| Crăciun, AM | 1 |
| Ghervan, C | 2 |
| Sridhar, A | 1 |
| Khan, D | 1 |
| Abdelaal, M | 1 |
| Elliott, JA | 1 |
| Naughton, V | 1 |
| Flatt, PR | 2 |
| Le Roux, CW | 3 |
| Docherty, NG | 2 |
| Moffett, CR | 1 |
| Cheng, X | 2 |
| Hassan, S | 1 |
| Shah, M | 1 |
| Malik, MO | 1 |
| Ehtesham, E | 1 |
| Habib, SH | 1 |
| Rauf, B | 1 |
| Popp, CJ | 1 |
| Kharmats, AY | 1 |
| Curran, M | 1 |
| Berube, L | 1 |
| Wang, C | 4 |
| Pompeii, ML | 1 |
| Illiano, P | 1 |
| St-Jules, DE | 1 |
| Mottern, M | 1 |
| Williams, N | 1 |
| Schoenthaler, A | 1 |
| Segal, E | 1 |
| Godneva, A | 1 |
| Thomas, D | 1 |
| Bergman, M | 1 |
| Schmidt, AM | 1 |
| Sevick, MA | 1 |
| Stephan, D | 1 |
| Taege, N | 1 |
| Dore, R | 1 |
| Folberth, J | 1 |
| Jöhren, O | 1 |
| Schwaninger, M | 1 |
| Lehnert, H | 3 |
| Schulz, C | 1 |
| Keskin, L | 1 |
| Yaprak, B | 1 |
| Tsai, PC | 1 |
| Kuo, HT | 1 |
| Hung, CH | 1 |
| Tseng, KC | 1 |
| Lai, HC | 1 |
| Peng, CY | 1 |
| Wang, JH | 1 |
| Chen, JJ | 1 |
| Lee, PL | 1 |
| Chien, RN | 1 |
| Yang, CC | 1 |
| Lo, GH | 1 |
| Kao, JH | 1 |
| Liu, CJ | 1 |
| Liu, CH | 1 |
| Yan, SL | 1 |
| Bair, MJ | 1 |
| Lin, CY | 1 |
| Su, WW | 1 |
| Chu, CH | 1 |
| Tung, SY | 1 |
| Tai, CM | 1 |
| Lin, CW | 1 |
| Lo, CC | 1 |
| Cheng, PN | 1 |
| Chiu, YC | 1 |
| Wang, CC | 1 |
| Cheng, JS | 1 |
| Tsai, WL | 1 |
| Lin, HC | 1 |
| Huang, YH | 1 |
| Yeh, ML | 1 |
| Huang, CF | 1 |
| Hsieh, MH | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chung, WL | 1 |
| Chen, CY | 1 |
| Yu, ML | 1 |
| Greene, E | 1 |
| MacIver, NJ | 2 |
| Gao, S | 1 |
| Yang, Q | 2 |
| Kong, W | 1 |
| Peng, Y | 2 |
| Bao, M | 1 |
| Bian, X | 1 |
| Jiang, Q | 1 |
| Yan, F | 1 |
| Sarayani, A | 1 |
| Hampp, C | 1 |
| Brown, JD | 1 |
| Donahoo, WT | 1 |
| Winterstein, AG | 1 |
| Zhao, X | 2 |
| Niu, J | 1 |
| Shi, C | 1 |
| Azócar-Gallardo, J | 1 |
| Ramirez-Campillo, R | 1 |
| Afonso, J | 1 |
| Sá, M | 1 |
| Granacher, U | 1 |
| González-Rojas, L | 1 |
| Ojeda-Aravena, A | 1 |
| García-García, JM | 1 |
| Madievsky, R | 3 |
| Vu, A | 3 |
| Cheng, F | 4 |
| Chon, J | 3 |
| Turk, N | 5 |
| Krueger, A | 3 |
| Krong, J | 3 |
| Maranon, R | 3 |
| Liu, S | 5 |
| Han, CS | 3 |
| Norris, KC | 3 |
| Mangione, C | 3 |
| Page, J | 3 |
| Thomas, S | 3 |
| Duru, OK | 5 |
| Moin, T | 6 |
| Li, XY | 3 |
| Li, CP | 3 |
| Zhang, CY | 3 |
| Zhang, S | 4 |
| Chen, JX | 3 |
| Chen, FW | 3 |
| Wu, ZZ | 3 |
| Hou, DC | 3 |
| Zheng, CY | 3 |
| Hou, KJ | 3 |
| Alexiou, A | 3 |
| Papadakis, M | 3 |
| Nadwa, EH | 3 |
| Albogami, SM | 3 |
| Alorabi, M | 3 |
| Saad, HM | 3 |
| Batiha, GE | 3 |
| Bianzano, S | 2 |
| Nordaby, M | 2 |
| Plum-Mörschel, L | 2 |
| Peil, B | 2 |
| Heise, T | 2 |
| Fakhoury, HMA | 1 |
| Elahi, MA | 1 |
| Al Sarheed, S | 1 |
| Al Dubayee, M | 2 |
| Alshahrani, A | 2 |
| Zhra, M | 1 |
| Almassri, A | 1 |
| Aljada, A | 4 |
| El-Attar, AA | 1 |
| Ibrahim, OM | 1 |
| Alhassanin, SA | 1 |
| Essa, ES | 1 |
| Mostafa, TM | 2 |
| Tang, J | 2 |
| Shen, C | 1 |
| Hu, H | 2 |
| Xie, H | 1 |
| Bellerba, F | 1 |
| Chatziioannou, AC | 1 |
| Jasbi, P | 1 |
| Robinot, N | 1 |
| Keski-Rahkonen, P | 1 |
| Trolat, A | 1 |
| Vozar, B | 1 |
| Hartman, SJ | 3 |
| Scalbert, A | 1 |
| Bonanni, B | 1 |
| Johansson, H | 1 |
| Sears, DD | 1 |
| Gandini, S | 1 |
| Lim, S | 1 |
| Sohn, M | 1 |
| Florez, JC | 6 |
| Nauck, MA | 1 |
| Ahn, J | 1 |
| Rabah, HM | 1 |
| Mohamed, DA | 1 |
| Mariah, RA | 1 |
| Abd El-Khalik, SR | 1 |
| Khattab, HA | 1 |
| AbuoHashish, NA | 1 |
| Abdelsattar, AM | 1 |
| Raslan, MA | 1 |
| Farghal, EE | 1 |
| Eltokhy, AK | 1 |
| Hong, MK | 1 |
| Han, Y | 2 |
| Park, HJ | 1 |
| Shin, MR | 1 |
| Roh, SS | 1 |
| Kwon, EY | 1 |
| Chianelli, M | 2 |
| Busetto, L | 1 |
| Attanasio, R | 1 |
| Disoteo, OE | 1 |
| Borretta, G | 1 |
| Persichetti, A | 1 |
| Samperi, I | 1 |
| Scoppola, A | 1 |
| Paoletta, A | 1 |
| Grimaldi, F | 1 |
| Papini, E | 1 |
| Nicolucci, A | 1 |
| Ziqubu, K | 3 |
| Mazibuko-Mbeje, SE | 3 |
| Mthembu, SXH | 2 |
| Mabhida, SE | 1 |
| Jack, BU | 1 |
| Nyambuya, TM | 2 |
| Nkambule, BB | 2 |
| Basson, AK | 1 |
| Tiano, L | 3 |
| Dludla, PV | 3 |
| Cai, H | 1 |
| Chen, Q | 3 |
| Duan, Y | 1 |
| Cai, M | 1 |
| Ni, Z | 1 |
| Yuan, Z | 1 |
| Yu, J | 1 |
| Yao, R | 1 |
| Zhou, L | 3 |
| Yu, C | 2 |
| Alfaraidi, H | 1 |
| Samaan, MC | 1 |
| Zaizar-Fregoso, SA | 1 |
| Lara-Esqueda, A | 1 |
| Hernández-Suarez, CM | 1 |
| Delgado-Enciso, J | 1 |
| Garcia-Nevares, A | 1 |
| Canseco-Avila, LM | 1 |
| Guzman-Esquivel, J | 1 |
| Rodriguez-Sanchez, IP | 1 |
| Martinez-Fierro, ML | 1 |
| Ceja-Espiritu, G | 1 |
| Ochoa-Díaz-Lopez, H | 1 |
| Espinoza-Gomez, F | 1 |
| Sanchez-Diaz, I | 1 |
| Delgado-Enciso, I | 1 |
| Carvalho-E-Silva, AP | 1 |
| Ferreira, PH | 1 |
| Harmer, AR | 1 |
| Hartvigsen, J | 1 |
| Ferreira, ML | 1 |
| Peng, G | 1 |
| Yan, Z | 2 |
| Ma, J | 2 |
| Tong, N | 1 |
| Thongnak, L | 4 |
| Pengrattanachot, N | 1 |
| Promsan, S | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Jaikumkao, K | 4 |
| Lungkaphin, A | 4 |
| Alkhatib, EH | 1 |
| Dauber, A | 1 |
| Estrada, DE | 1 |
| Majidi, S | 1 |
| Wang, G | 3 |
| Gao, H | 1 |
| Dai, S | 1 |
| Yin, L | 1 |
| Zhang, K | 2 |
| Jiang, K | 1 |
| Miao, Y | 1 |
| Lu, Z | 2 |
| Long, Y | 1 |
| Subramaniam, S | 1 |
| Ong, KC | 1 |
| Sabaratnam, V | 1 |
| Chua, KH | 1 |
| Kuppusamy, UR | 1 |
| Wang, F | 2 |
| Zhou, Y | 1 |
| Wang, M | 1 |
| Zhou, S | 1 |
| Zhou, B | 1 |
| Fang, C | 1 |
| Huang, Y | 3 |
| Sang, G | 1 |
| Tao, S | 1 |
| He, C | 1 |
| Guo, HH | 1 |
| Shen, HR | 1 |
| Wang, LL | 1 |
| Luo, ZG | 1 |
| Zhang, JL | 2 |
| Zhang, HJ | 2 |
| Gao, TL | 1 |
| Han, YX | 1 |
| Jiang, JD | 1 |
| Goodarzi, G | 1 |
| Tehrani, SS | 1 |
| Panahi, G | 1 |
| Bahramzadeh, A | 1 |
| Meshkani, R | 1 |
| Zhong, X | 1 |
| Li, Y | 7 |
| Liang, W | 1 |
| Hu, Q | 1 |
| Zeng, A | 1 |
| Ding, M | 1 |
| Chen, D | 1 |
| Xie, M | 1 |
| Meng, XM | 1 |
| Hao, YP | 1 |
| Yu, S | 1 |
| Ren, RZ | 1 |
| Yu, X | 1 |
| Tang, YX | 1 |
| Poh Shean, W | 1 |
| Chin Voon, T | 1 |
| Long Bidin, MBB | 1 |
| Adam, NLB | 1 |
| Wang, H | 4 |
| Zhang, H | 2 |
| Liang, Z | 1 |
| Hu, W | 2 |
| Qiu, S | 1 |
| Li, K | 1 |
| Dai, H | 1 |
| Yang, M | 2 |
| Yang, G | 3 |
| Li, L | 5 |
| Shelley, K | 1 |
| Articolo, A | 1 |
| Luthra, R | 1 |
| Charlton, M | 1 |
| Chen, H | 2 |
| Lyu, N | 1 |
| Chan, W | 1 |
| De La Cruz, A | 1 |
| Calarge, C | 1 |
| Jia, J | 1 |
| Hao, H | 1 |
| Qiao, S | 1 |
| Qi, Y | 2 |
| Sun, X | 3 |
| Wang, K | 1 |
| Gu, R | 1 |
| Kang, L | 1 |
| Xu, B | 2 |
| Liu, Q | 3 |
| Wang, S | 3 |
| Sheng, C | 1 |
| Tan, J | 3 |
| Shao, L | 1 |
| Gan, J | 1 |
| Singh, A | 1 |
| Rourk, K | 1 |
| Bernier, A | 1 |
| de Lartigue, G | 1 |
| Bánhegyi, RJ | 1 |
| Veréb, B | 1 |
| Mátrai, ÁA | 1 |
| Rácz, B | 1 |
| Beke, S | 1 |
| Gonzalez-Lopez, C | 1 |
| Wojeck, BS | 1 |
| Paavilainen, E | 1 |
| Niinikoski, H | 1 |
| Parkkola, R | 1 |
| Koskensalo, K | 1 |
| Nikkinen, H | 1 |
| Veijola, R | 1 |
| Vääräsmäki, M | 2 |
| Loo, BM | 1 |
| Tossavainen, P | 1 |
| Rönnemaa, T | 1 |
| Tertti, K | 1 |
| Wen, Q | 1 |
| Fang, S | 2 |
| Liang, Y | 1 |
| Tian, Y | 2 |
| Yuan, J | 1 |
| de Andrade Mesquita, L | 1 |
| Wayerbacher, LF | 1 |
| Schwartsmann, G | 1 |
| Gerchman, F | 1 |
| Sciacca, L | 1 |
| Bianchi, C | 1 |
| Burlina, S | 1 |
| Formoso, G | 1 |
| Manicardi, E | 1 |
| Sculli, MA | 1 |
| Resi, V | 1 |
| Tosti, G | 1 |
| Barberio, A | 1 |
| Tartaglione, L | 1 |
| Rizzi, A | 1 |
| Di Leo, M | 1 |
| Viti, L | 1 |
| Sirico, A | 1 |
| De Carolis, S | 1 |
| Pontecorvi, A | 1 |
| Lanzone, A | 7 |
| Pitocco, D | 1 |
| Bahat, G | 1 |
| Ozkok, S | 1 |
| Petrovic, M | 1 |
| Tapia-Rivera, JC | 1 |
| Mendoza-Jaramillo, HE | 1 |
| González-Villaseñor, CO | 1 |
| Ramirez-Flores, M | 1 |
| Aguilar-Velazquez, JA | 1 |
| López-Quintero, A | 1 |
| Pérez-Guerrero, EE | 1 |
| Vargas-Rodriguez, MLÁ | 1 |
| Gutiérrez-Hurtado, IA | 1 |
| Martínez-López, E | 1 |
| Pei, J | 1 |
| Niu, W | 1 |
| Sun, H | 1 |
| Melnyk, S | 1 |
| Hakkak, R | 1 |
| Gkiourtzis, N | 1 |
| Michou, P | 1 |
| Moutafi, M | 1 |
| Glava, A | 1 |
| Cheirakis, K | 1 |
| Christakopoulos, A | 1 |
| Vouksinou, E | 1 |
| Fotoulaki, M | 1 |
| Brīvība, M | 1 |
| Silamiķele, L | 1 |
| Kalniņa, I | 1 |
| Silamiķelis, I | 1 |
| Birzniece, L | 1 |
| Ansone, L | 1 |
| Jagare, L | 1 |
| Elbere, I | 1 |
| Kloviņš, J | 1 |
| Watanabe, K | 1 |
| Yamaguchi, S | 1 |
| Kosakai, Y | 1 |
| Ioji, T | 1 |
| Ishihara, H | 1 |
| Bettencourt-Silva, R | 1 |
| Neves, JS | 2 |
| Ferreira, MJ | 1 |
| Souteiro, P | 2 |
| Belo, S | 2 |
| Oliveira, AI | 1 |
| Carvalho, D | 2 |
| Namora, G | 1 |
| Montenegro, N | 1 |
| Queirós, J | 1 |
| Barnett, R | 1 |
| Yang, AJT | 1 |
| Frendo-Cumbo, S | 1 |
| MacPherson, REK | 1 |
| Shree, N | 2 |
| Venkategowda, S | 1 |
| Venkatranganna, MV | 1 |
| Datta, I | 1 |
| Bhonde, RR | 2 |
| Chon, JS | 1 |
| Frosch, DL | 1 |
| Martin, JM | 1 |
| Jeffers, KS | 1 |
| Castellon-Lopez, Y | 1 |
| Tseng, CH | 1 |
| Norris, K | 1 |
| Mangione, CM | 3 |
| El-Sayed, SM | 1 |
| Ibrahim, HM | 1 |
| Derkach, KV | 3 |
| Romanova, IV | 2 |
| Zorina, II | 2 |
| Bakhtyukov, AA | 1 |
| Perminova, AA | 1 |
| Ivantsov, AO | 1 |
| Shpakov, AO | 3 |
| Zúñiga Curz, CA | 1 |
| Calzada Mendoza, CC | 1 |
| Miranda Mondragón, ID | 1 |
| Bustamante Bacame, A | 1 |
| Portilla Robertson, J | 1 |
| Ocharán Hernández, E | 1 |
| Zhang, W | 3 |
| Xu, JH | 1 |
| Yu, T | 1 |
| Chen, QK | 1 |
| Adeshirlarijaney, A | 1 |
| Zou, J | 1 |
| Tran, HQ | 1 |
| Chassaing, B | 1 |
| Gewirtz, AT | 1 |
| Luo, D | 1 |
| Xu, X | 2 |
| Sun, M | 1 |
| Su, X | 2 |
| Tian, Z | 1 |
| Zhang, M | 4 |
| Guan, Q | 1 |
| Pelusi, C | 3 |
| Fanelli, F | 2 |
| Baccini, M | 2 |
| Triggiani, V | 2 |
| Bartolomeo, N | 1 |
| Carbone, MD | 3 |
| De Pergola, G | 3 |
| Di Dalmazi, G | 1 |
| Pagotto, U | 4 |
| Pasquali, R | 8 |
| Giagulli, VA | 3 |
| Carris, NW | 1 |
| Nwabuobi, CK | 1 |
| He, W | 1 |
| Bullers, K | 1 |
| Wilson, RE | 1 |
| Louis, JM | 1 |
| Magness, RR | 1 |
| Duan, C | 1 |
| Huang, W | 2 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Swe, MT | 2 |
| Pongchaidecha, A | 3 |
| Chatsudthipong, V | 3 |
| Teng, PN | 1 |
| Hope, E | 1 |
| Hood, BL | 1 |
| Oliver, J | 1 |
| Ao, W | 1 |
| Tommarello, D | 1 |
| Wilson, K | 1 |
| Litzy, T | 1 |
| Conrads, KA | 1 |
| Hamilton, CA | 1 |
| Casablanca, Y | 1 |
| Jura-Półtorak, A | 2 |
| Olczyk, P | 2 |
| Chałas-Lipka, A | 1 |
| Komosińska-Vassev, K | 2 |
| Kuźnik-Trocha, K | 1 |
| Winsz-Szczotka, K | 1 |
| Ivanova, D | 1 |
| Kiselova-Kaneva, Y | 1 |
| Krysik, K | 1 |
| Telega, A | 1 |
| Olczyk, K | 2 |
| Bassols, J | 1 |
| Martínez-Calcerrada, JM | 1 |
| Osiniri, I | 1 |
| Díaz-Roldán, F | 1 |
| Xargay-Torrent, S | 1 |
| Mas-Parés, B | 1 |
| Dorado-Ceballos, E | 1 |
| Prats-Puig, A | 1 |
| Carreras-Badosa, G | 1 |
| de Zegher, F | 5 |
| Ibáñez, L | 4 |
| López-Bermejo, A | 2 |
| Cabrera-Cruz, H | 1 |
| Oróstica, L | 1 |
| Torres-Pinto, I | 1 |
| Salvatore, T | 1 |
| Pafundi, PC | 1 |
| Morgillo, F | 1 |
| Di Liello, R | 1 |
| Galiero, R | 1 |
| Nevola, R | 1 |
| Marfella, R | 3 |
| Monaco, L | 1 |
| Rinaldi, L | 1 |
| Adinolfi, LE | 1 |
| Sasso, FC | 1 |
| Vadini, F | 2 |
| Simeone, PG | 3 |
| Boccatonda, A | 1 |
| Guagnano, MT | 3 |
| Liani, R | 2 |
| Tripaldi, R | 2 |
| Di Castelnuovo, A | 3 |
| Cipollone, F | 2 |
| Consoli, A | 3 |
| Santilli, F | 3 |
| Biondo, LA | 1 |
| Teixeira, AAS | 1 |
| de O S Ferreira, KC | 1 |
| Neto, JCR | 1 |
| Blümel, JE | 1 |
| Arteaga, E | 1 |
| Aedo, S | 1 |
| Arriola-Montenegro, J | 1 |
| López, M | 3 |
| Martino, M | 1 |
| Miranda, C | 1 |
| Miranda, O | 1 |
| Mostajo, D | 1 |
| Ñañez, M | 1 |
| Ojeda, E | 1 |
| Pilnik, S | 1 |
| Rojas, J | 1 |
| Salinas, C | 1 |
| Sosa, L | 1 |
| Spritzer, PM | 6 |
| Tserotas, K | 1 |
| Vallejo, MS | 1 |
| Belardo, A | 1 |
| Fighera, TM | 1 |
| Chedraui, P | 1 |
| Arya, S | 1 |
| Hansen, KR | 1 |
| Wild, RA | 1 |
| Elkind-Hirsch, KE | 2 |
| Shaler, D | 1 |
| Harris, R | 1 |
| Singh, R | 2 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Singh, DP | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Ahmadi, S | 1 |
| Razazan, A | 1 |
| Nagpal, R | 1 |
| Jain, S | 1 |
| Wang, B | 2 |
| Mishra, SP | 1 |
| Justice, J | 1 |
| Ding, J | 1 |
| McClain, DA | 1 |
| Kritchevsky, SB | 1 |
| Kitzman, D | 1 |
| Yadav, H | 1 |
| White, SL | 1 |
| Begum, S | 1 |
| Vieira, MC | 1 |
| Seed, P | 1 |
| Lawlor, DL | 1 |
| Sattar, N | 3 |
| Nelson, SM | 1 |
| Welsh, P | 1 |
| Pasupathy, D | 1 |
| Poston, L | 1 |
| Halliday, G | 1 |
| Huot, JR | 1 |
| Satoh, T | 1 |
| Baust, JJ | 1 |
| Fisher, A | 1 |
| Cook, T | 1 |
| Hu, J | 3 |
| Avolio, T | 1 |
| Goncharov, DA | 1 |
| Bai, Y | 1 |
| Vanderpool, RR | 1 |
| Considine, RV | 1 |
| Bonetto, A | 1 |
| Bachman, TN | 1 |
| Sebastiani, A | 1 |
| McTiernan, CF | 1 |
| Mora, AL | 1 |
| Machado, RF | 1 |
| Goncharova, EA | 1 |
| Gladwin, MT | 1 |
| Lai, YC | 1 |
| Kim, EK | 3 |
| Min, HK | 1 |
| Lee, SY | 3 |
| Kim, DS | 1 |
| Ryu, JG | 1 |
| Na, HS | 2 |
| Jung, KA | 1 |
| Choi, JW | 1 |
| Park, SH | 2 |
| Cho, ML | 3 |
| Muller, CJF | 1 |
| Obonye, N | 1 |
| Louw, J | 2 |
| Kappo, AP | 1 |
| Silvestri, S | 1 |
| Orlando, P | 1 |
| Ouyang, J | 1 |
| Lin, J | 1 |
| Isnard, S | 1 |
| Fombuena, B | 1 |
| Peng, X | 1 |
| Marette, A | 3 |
| Routy, B | 1 |
| Messaoudene, M | 1 |
| Routy, JP | 1 |
| Hiel, S | 1 |
| Gianfrancesco, MA | 1 |
| Rodriguez, J | 1 |
| Portheault, D | 1 |
| Leyrolle, Q | 1 |
| Bindels, LB | 1 |
| Gomes da Silveira Cauduro, C | 1 |
| Mulders, MDGH | 1 |
| Zamariola, G | 1 |
| Azzi, AS | 1 |
| Kalala, G | 1 |
| Pachikian, BD | 1 |
| Amadieu, C | 1 |
| Neyrinck, AM | 1 |
| Loumaye, A | 1 |
| Cani, PD | 1 |
| Lanthier, N | 1 |
| Trefois, P | 1 |
| Klein, O | 1 |
| Luminet, O | 1 |
| Bindelle, J | 1 |
| Paquot, N | 1 |
| Cnop, M | 1 |
| Thissen, JP | 2 |
| Delzenne, NM | 1 |
| Moyad, MA | 2 |
| Orioli, L | 1 |
| Hermans, MP | 1 |
| Maiter, D | 1 |
| Vandeleene, B | 1 |
| Yombi, JC | 1 |
| Bahlouli, W | 1 |
| Breton, J | 1 |
| Lelouard, M | 1 |
| L'Huillier, C | 1 |
| Tirelle, P | 1 |
| Salameh, E | 1 |
| Amamou, A | 1 |
| Atmani, K | 1 |
| Goichon, A | 1 |
| Bôle-Feysot, C | 1 |
| Ducrotté, P | 1 |
| Ribet, D | 1 |
| Déchelotte, P | 1 |
| Coëffier, M | 1 |
| Cena, H | 1 |
| Chiovato, L | 1 |
| Nappi, RE | 1 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Papaetis, GS | 1 |
| Filippou, PK | 1 |
| Constantinidou, KG | 1 |
| Stylianou, CS | 1 |
| Luo, C | 2 |
| Liang, J | 1 |
| Sharabi, K | 1 |
| Hatting, M | 1 |
| Perry, EA | 1 |
| Tavares, CDJ | 1 |
| Goyal, L | 1 |
| Srivastava, A | 1 |
| Bilodeau, M | 1 |
| Zhu, AX | 1 |
| Sicinski, P | 1 |
| Puigserver, P | 1 |
| Liu, CY | 1 |
| Chang, TC | 1 |
| Lin, SH | 1 |
| Wu, ST | 1 |
| Cha, TL | 1 |
| Tsao, CW | 1 |
| Güneş, H | 2 |
| Özmen, Ş | 1 |
| Çelik, E | 1 |
| Temiz, F | 1 |
| Jiang, G | 2 |
| Luk, AO | 1 |
| Tam, CHT | 1 |
| Lau, ES | 1 |
| Ozaki, R | 1 |
| Chow, EYK | 1 |
| Kong, APS | 1 |
| Lim, CKP | 1 |
| Lee, KF | 1 |
| Siu, SC | 1 |
| Hui, G | 1 |
| Tsang, CC | 1 |
| Lau, KP | 1 |
| Leung, JYY | 1 |
| Tsang, MW | 1 |
| Kam, G | 1 |
| Lau, IT | 1 |
| Li, JK | 1 |
| Yeung, VT | 1 |
| Lau, E | 1 |
| Lo, S | 1 |
| Fung, SKS | 1 |
| Cheng, YL | 1 |
| Chow, CC | 1 |
| Pearson, ER | 2 |
| So, WY | 1 |
| Chan, JCN | 1 |
| Ma, RCW | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Qian, SN | 1 |
| Peng, SQ | 1 |
| Zhang, XY | 1 |
| Ye, JP | 1 |
| Kyo, S | 1 |
| Nakayama, K | 1 |
| de Oliveira, AM | 1 |
| de Freitas, AFS | 1 |
| Costa, MDS | 1 |
| Torres, MKDS | 1 |
| Castro, YAA | 1 |
| Almeida, AMR | 1 |
| Paiva, PMG | 1 |
| Carvalho, BM | 1 |
| Napoleão, TH | 1 |
| Rendell, M | 1 |
| Mahey, R | 1 |
| Gupta, M | 2 |
| Bansiwal, R | 1 |
| Sethi, A | 1 |
| Gala, O | 1 |
| Chen, X | 1 |
| Wang, DD | 1 |
| Li, ZP | 1 |
| Shin, AC | 1 |
| Balasubramanian, P | 1 |
| Suryadevara, P | 1 |
| Zyskowski, J | 1 |
| Herdt, TH | 1 |
| MohanKumar, SMJ | 1 |
| MohanKumar, PS | 1 |
| Lu, GH | 1 |
| Doganyigit, Z | 1 |
| Yakan, B | 1 |
| Soylu, M | 1 |
| Kaymak, E | 1 |
| Okan, A | 1 |
| Silici, S | 1 |
| Tao, T | 1 |
| Zhu, YC | 1 |
| Fu, JR | 1 |
| Wang, YY | 1 |
| Cai, J | 2 |
| Ma, JY | 1 |
| Gao, YN | 1 |
| Fan, W | 1 |
| Liu, W | 1 |
| Aludwan, M | 1 |
| Kobyliak, N | 1 |
| Abenavoli, L | 2 |
| Kyriienko, D | 1 |
| Fagoonee, S | 1 |
| Pellicano, R | 1 |
| Komisarenko, I | 1 |
| Mxinwa, V | 1 |
| Mokgalaboni, K | 1 |
| Cirilli, I | 1 |
| Marcheggiani, F | 1 |
| Guo, W | 1 |
| Tian, W | 1 |
| Lin, L | 1 |
| Alwarawrah, Y | 1 |
| Nichols, AG | 1 |
| Green, WD | 1 |
| Eisner, W | 1 |
| Kiernan, K | 1 |
| Warren, J | 1 |
| Hale, LP | 1 |
| Beck, MA | 1 |
| Bruhn, L | 1 |
| Amadid, H | 2 |
| Vistisen, D | 1 |
| Clemmensen, KKB | 1 |
| Vainø, CTR | 1 |
| Pedersen, C | 1 |
| Tvermosegaard, M | 1 |
| Dejgaard, TF | 1 |
| Ried-Larsen, M | 2 |
| Persson, F | 2 |
| Jørgensen, ME | 2 |
| Previate, C | 2 |
| Malta, A | 2 |
| Miranda, RA | 2 |
| Martins, IP | 2 |
| Pavanello, A | 2 |
| de Oliveira, JC | 2 |
| Prates, KV | 2 |
| Alves, VS | 2 |
| Francisco, FA | 2 |
| Moreira, VM | 2 |
| Matiusso, CCI | 2 |
| de Moraes, AMP | 2 |
| Mathias, PCF | 1 |
| Franco, CCDS | 2 |
| Pratchayasakul, W | 2 |
| Jinawong, K | 2 |
| Pongkan, W | 2 |
| Jaiwongkam, T | 2 |
| Arunsak, B | 1 |
| Chunchai, T | 1 |
| Tokuda, M | 1 |
| Chattipakorn, N | 5 |
| Chattipakorn, SC | 3 |
| Almalk, M | 1 |
| Hakami, A | 1 |
| Homoud, B | 1 |
| Alzneidi, N | 1 |
| Aldhalaan, J | 1 |
| Aljbli, G | 1 |
| Nasr, A | 1 |
| Farahat, AI | 1 |
| Couselo-Seijas, M | 1 |
| Almengló, C | 1 |
| M Agra-Bermejo, R | 1 |
| Luis Fernandez, Á | 1 |
| Alvarez, E | 1 |
| R González-Juanatey, J | 1 |
| Eiras, S | 1 |
| Shankar, A | 1 |
| Leisegang, K | 1 |
| Almaghrawi, W | 1 |
| Henkel, R | 1 |
| Damiano, S | 1 |
| Sozio, C | 1 |
| La Rosa, G | 1 |
| Santillo, M | 1 |
| Ferrer, MJ | 1 |
| Silva, AF | 1 |
| Abruzzese, GA | 1 |
| Velázquez, ME | 1 |
| Motta, AB | 3 |
| Guo, Y | 1 |
| Shi, J | 3 |
| Hong, L | 1 |
| Chen, M | 1 |
| Yuan, X | 1 |
| Jiang, S | 2 |
| Tanner, JE | 1 |
| Alfieri, C | 1 |
| Jurczak, MJ | 1 |
| Lear, TB | 1 |
| Lin, B | 1 |
| Larsen, MB | 1 |
| Kennerdell, JR | 1 |
| Huckestein, BR | 1 |
| Nguyen, MK | 1 |
| Tuncer, F | 1 |
| Jiang, Y | 2 |
| Monga, SP | 1 |
| O'Donnell, CP | 1 |
| Finkel, T | 1 |
| Chen, BB | 1 |
| Mallampalli, RK | 1 |
| Marmor, S | 1 |
| Hovertsen, S | 1 |
| Gronski, J | 1 |
| McNeil, C | 1 |
| Feng, R | 1 |
| Guzman, G | 1 |
| Abdelwahab, N | 1 |
| King, S | 1 |
| Tamariz, L | 1 |
| Meehan, T | 1 |
| Pendleton, KM | 1 |
| Benson, B | 1 |
| Vojta, D | 3 |
| Olivier, S | 1 |
| Pochard, C | 1 |
| Diounou, H | 1 |
| Castillo, V | 1 |
| Divoux, J | 1 |
| Alcantara, J | 1 |
| Leclerc, J | 1 |
| Guilmeau, S | 1 |
| Huet, C | 1 |
| Charifi, W | 1 |
| Varin, TV | 1 |
| Daniel, N | 1 |
| Foretz, M | 3 |
| Neunlist, M | 1 |
| Salomon, BL | 1 |
| Ghosh, P | 1 |
| Rolli-Derkinderen, M | 1 |
| Viollet, B | 2 |
| Singh, Y | 1 |
| Gupta, G | 1 |
| Anand, K | 1 |
| Kumar Jha, N | 1 |
| Thangavelu, L | 1 |
| Kumar Chellappan, D | 1 |
| Dua, K | 1 |
| Buse, J | 1 |
| Tamaritz, L | 1 |
| Palacio, A | 1 |
| Liebovitz, D | 1 |
| Mitchell, N | 1 |
| Nicklas, J | 1 |
| Lingvay, I | 2 |
| Clark, JM | 2 |
| Aronne, LJ | 3 |
| Anderson, E | 1 |
| Usher, M | 1 |
| Demmer, R | 1 |
| Melton, GB | 1 |
| Ingraham, N | 1 |
| Huan, Y | 1 |
| Lei, L | 1 |
| Cao, H | 1 |
| Gao, A | 1 |
| Shen, Z | 1 |
| Mbara, KC | 1 |
| Mofo Mato, PE | 1 |
| Driver, C | 1 |
| Nzuza, S | 1 |
| Mkhombo, NT | 1 |
| Gcwensa, SK | 1 |
| Mcobothi, EN | 1 |
| Owira, PM | 1 |
| Ma, X | 1 |
| Xiao, W | 1 |
| Pang, P | 1 |
| Xue, F | 1 |
| Wan, L | 1 |
| Pei, L | 1 |
| Yan, H | 1 |
| Karhunen, V | 1 |
| Larsson, SC | 1 |
| Gill, D | 1 |
| Celotto, S | 1 |
| Pizzol, D | 1 |
| Gasevic, D | 1 |
| Ji, MM | 1 |
| Barnini, T | 1 |
| Solmi, M | 1 |
| Stubbs, B | 1 |
| Smith, L | 1 |
| López Sánchez, GF | 1 |
| Pesolillo, G | 1 |
| Yu, Z | 1 |
| Tzoulaki, I | 1 |
| Theodoratou, E | 1 |
| Ioannidis, JPA | 1 |
| Veronese, N | 1 |
| Demurtas, J | 1 |
| Taghavi, SA | 1 |
| van Wely, M | 1 |
| Jahanfar, S | 1 |
| Bazarganipour, F | 1 |
| Castan-Laurell, I | 1 |
| Dray, C | 1 |
| Valet, P | 1 |
| Maruthur, NM | 2 |
| Wang, NY | 1 |
| Jerome, GJ | 1 |
| Dalcin, AT | 1 |
| Tseng, E | 1 |
| White, K | 1 |
| Charleston, J | 1 |
| Durkin, N | 1 |
| Hassoon, A | 1 |
| Lansey, DG | 1 |
| Kanarek, NF | 1 |
| Carducci, MA | 1 |
| Hegazy, SK | 1 |
| Elnaidany, SS | 1 |
| Shehabeldin, WA | 1 |
| Sawan, ES | 1 |
| Differding, MK | 1 |
| Sardu, C | 1 |
| Trotta, MC | 1 |
| Pieretti, G | 1 |
| Gatta, G | 1 |
| Ferraro, G | 1 |
| Nicoletti, GF | 1 |
| D' Onofrio, N | 1 |
| Balestrieri, ML | 1 |
| D' Amico, M | 1 |
| Abbatecola, A | 1 |
| Ferraraccio, F | 1 |
| Panarese, I | 1 |
| Paolisso, G | 3 |
| Li, W | 2 |
| Zou, G | 1 |
| Ma, Z | 1 |
| Li, F | 3 |
| Alsheikh, HAM | 1 |
| Metge, BJ | 1 |
| Ha, CM | 1 |
| Hinshaw, DC | 1 |
| Mota, MSV | 1 |
| Kammerud, SC | 1 |
| Lama-Sherpa, T | 1 |
| Sharafeldin, N | 1 |
| Wende, AR | 1 |
| Samant, RS | 1 |
| Shevde, LA | 1 |
| Chappell, N | 1 |
| Seidemann, E | 1 |
| Storment, J | 1 |
| Bellanger, D | 1 |
| Saxena, AR | 1 |
| Gorman, DN | 1 |
| Esquejo, RM | 1 |
| Bergman, A | 1 |
| Chidsey, K | 1 |
| Buckeridge, C | 1 |
| Griffith, DA | 1 |
| Kim, AM | 1 |
| Lacey, L | 1 |
| Whyte, S | 1 |
| Quenby, S | 2 |
| Denison, FC | 2 |
| Dhaun, N | 1 |
| Norman, JE | 3 |
| Drake, AJ | 2 |
| Reynolds, RM | 2 |
| Trombini, AB | 1 |
| Barella, LF | 1 |
| Saavedra, LPJ | 1 |
| Tófolo, LP | 1 |
| Ribeiro, TA | 1 |
| de Sant Anna, JR | 1 |
| de Castro Prado, MAA | 1 |
| Gomes, RM | 1 |
| Vieira, E | 1 |
| de Freitas Mathias, PC | 1 |
| Matić, A | 1 |
| Vuković, R | 1 |
| Balog, M | 1 |
| Szucs, KF | 1 |
| Seres, A | 1 |
| Drenjančević, I | 1 |
| Gaiță, L | 1 |
| Soșdean, R | 1 |
| Sima, A | 1 |
| Malița, D | 1 |
| Burlacu, O | 1 |
| Desideri, G | 1 |
| Ciotti, S | 1 |
| Tartaro, A | 2 |
| Apaijai, N | 2 |
| Singhanat, K | 1 |
| Kerdphoo, S | 1 |
| Gallwitz, B | 2 |
| Giorgino, F | 1 |
| Mika, K | 1 |
| Szafarz, M | 1 |
| Bednarski, M | 1 |
| Kuder, K | 1 |
| Szczepańska, K | 1 |
| Pociecha, K | 1 |
| Pomierny, B | 1 |
| Kieć-Kononowicz, K | 1 |
| Sapa, J | 1 |
| Kotańska, M | 1 |
| Fu, CN | 1 |
| Wei, H | 1 |
| Gao, WS | 1 |
| Song, SS | 1 |
| Yue, SW | 1 |
| Qu, YJ | 1 |
| Day, EA | 1 |
| Townsend, LK | 1 |
| Djordjevic, D | 1 |
| Jørgensen, SB | 1 |
| Tapia, E | 1 |
| Villa-Guillen, DE | 2 |
| Chalasani, P | 2 |
| Centuori, S | 1 |
| Roe, DJ | 1 |
| Guillen-Rodriguez, J | 1 |
| Galons, JP | 2 |
| Thomson, CA | 2 |
| Altbach, M | 2 |
| Trujillo, J | 1 |
| Pinto, L | 1 |
| Martinez, JA | 2 |
| Algotar, AM | 1 |
| Chow, HS | 1 |
| Janani, L | 1 |
| Bamehr, H | 1 |
| Tanha, K | 1 |
| Mirzabeigi, P | 1 |
| Montazeri, H | 1 |
| Tarighi, P | 1 |
| Toledo-Pérez, R | 1 |
| Lopéz-Cervantes, SP | 1 |
| Hernández-Álvarez, D | 1 |
| Mena-Montes, B | 1 |
| Pedraza-Vázquez, G | 1 |
| Sánchez-Garibay, C | 1 |
| López-Diazguerrero, NE | 1 |
| Königsberg, M | 1 |
| Luna-López, A | 1 |
| Ge, JJ | 1 |
| Wang, DJ | 1 |
| Song, W | 1 |
| Shen, SM | 2 |
| Ge, WH | 1 |
| Goricar, K | 2 |
| Jaganjac, M | 1 |
| Almuraikhy, S | 1 |
| Al-Khelaifi, F | 1 |
| Al-Jaber, M | 1 |
| Bashah, M | 1 |
| Mazloum, NA | 1 |
| Zarkovic, K | 1 |
| Zarkovic, N | 1 |
| Waeg, G | 1 |
| Kafienah, W | 1 |
| Elrayess, MA | 1 |
| Folsom, LJ | 1 |
| Hannon, TS | 1 |
| Sharma, Y | 1 |
| Bashir, S | 1 |
| Faraz Khan, M | 1 |
| Ahmad, A | 2 |
| Khan, F | 1 |
| Diaz, A | 1 |
| Romero, M | 1 |
| Vazquez, T | 1 |
| Lechner, S | 1 |
| Blomberg, BB | 1 |
| Frasca, D | 1 |
| van Haare, J | 1 |
| Kooi, ME | 1 |
| van Teeffelen, JW | 1 |
| Vink, H | 1 |
| Slenter, J | 1 |
| Cobelens, H | 1 |
| Strijkers, GJ | 1 |
| Koehn, D | 1 |
| Post, MJ | 1 |
| van Bilsen, M | 1 |
| Li, N | 1 |
| Xu, D | 3 |
| Dy, ABC | 1 |
| Tassone, F | 1 |
| Eldeeb, M | 1 |
| Salcedo-Arellano, MJ | 1 |
| Tartaglia, N | 1 |
| Hagerman, R | 1 |
| Nie, L | 1 |
| Shuai, L | 1 |
| Zhu, M | 2 |
| Liu, P | 1 |
| Xie, ZF | 1 |
| Jiang, HW | 1 |
| Tan, M | 1 |
| Stagi, S | 1 |
| Ricci, F | 1 |
| Bianconi, M | 1 |
| Sammarco, MA | 1 |
| Municchi, G | 1 |
| Toni, S | 1 |
| Lenzi, L | 1 |
| Verrotti, A | 1 |
| de Martino, M | 1 |
| Sharma, A | 3 |
| Yin, C | 1 |
| Tan, X | 1 |
| Xiao, Y | 1 |
| Wang, Z | 1 |
| Zhang, T | 1 |
| Wang, J | 2 |
| Zhou, X | 3 |
| Nielsen, LB | 1 |
| Anastasiou, OE | 1 |
| Canbay, A | 1 |
| Fuhrer, D | 1 |
| Reger-Tan, S | 1 |
| Riediger, ND | 1 |
| Lukianchuk, V | 1 |
| Roulette, J | 1 |
| Lix, LM | 1 |
| Elliott, L | 2 |
| Bruce, SG | 1 |
| Harris, S | 1 |
| Jaeckel, E | 1 |
| Chandarana, K | 1 |
| Ranthe, MF | 1 |
| Jódar, E | 1 |
| Kim, C | 2 |
| Dabelea, D | 2 |
| Kalyani, RR | 1 |
| Christophi, CA | 3 |
| Bray, GA | 7 |
| Pi-Sunyer, X | 2 |
| Darwin, CH | 1 |
| Yalamanchi, S | 1 |
| Barrett-Connor, E | 9 |
| Golden, SH | 2 |
| Boyko, EJ | 1 |
| Maniar, K | 1 |
| Moideen, A | 1 |
| Bhattacharyya, R | 1 |
| Banerjee, D | 1 |
| Out, M | 1 |
| Miedema, I | 1 |
| Jager-Wittenaar, H | 1 |
| van der Schans, C | 1 |
| Krijnen, W | 1 |
| Lehert, P | 1 |
| Stehouwer, C | 1 |
| Kooy, A | 1 |
| Dawson, AJ | 2 |
| Kilpatrick, ES | 7 |
| Coady, AM | 4 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 2 |
| Ahmed, L | 2 |
| Atkin, SL | 7 |
| Sathyapalan, T | 6 |
| Esquivel, MA | 1 |
| Lansang, MC | 1 |
| Smith, C | 1 |
| Myles, H | 1 |
| Galletly, C | 1 |
| Kaplowitz, P | 1 |
| Chatterjee, S | 3 |
| Davies, M | 1 |
| Khunti, K | 3 |
| Morris, A | 1 |
| Wang, R | 1 |
| Zhang, JP | 1 |
| Gonzalez, FJ | 2 |
| Jiang, C | 2 |
| Perreault, L | 3 |
| Pan, Q | 5 |
| Aroda, VR | 1 |
| Dagogo-Jack, S | 1 |
| Hamman, RF | 2 |
| Kahn, SE | 4 |
| Mather, KJ | 5 |
| Knowler, WC | 7 |
| Nielsen, SM | 1 |
| Bartels, EM | 1 |
| Henriksen, M | 1 |
| Wæhrens, EE | 1 |
| Gudbergsen, H | 1 |
| Bliddal, H | 1 |
| Astrup, A | 1 |
| Knop, FK | 1 |
| Carmona, L | 1 |
| Taylor, WJ | 1 |
| Singh, JA | 1 |
| Perez-Ruiz, F | 1 |
| Kristensen, LE | 1 |
| Christensen, R | 1 |
| Mezzullo, M | 1 |
| Fazzini, A | 1 |
| Bianchi, N | 1 |
| Mastroroberto, M | 1 |
| Morselli Labate, AM | 1 |
| Glintborg, D | 2 |
| Andersen, M | 1 |
| Leo, M | 1 |
| Maccarone, MT | 1 |
| Sborgia, C | 1 |
| Bonadonna, RC | 1 |
| Angelucci, E | 1 |
| Federico, V | 1 |
| Cianfarani, S | 1 |
| Manzoli, L | 1 |
| Davì, G | 1 |
| Jing, Y | 1 |
| Li, D | 3 |
| García-Calzón, S | 1 |
| Perfilyev, A | 1 |
| Männistö, V | 1 |
| de Mello, VD | 1 |
| Nilsson, E | 1 |
| Pihlajamäki, J | 1 |
| Ling, C | 1 |
| Dias, MD | 1 |
| Goulart, M | 1 |
| Dalécio, C | 1 |
| Enes-Marques, S | 1 |
| Salles, ÉDSL | 1 |
| Venâncio, M | 1 |
| Pereira, EM | 1 |
| Paffaro, VA | 1 |
| Incerpi, EK | 1 |
| Soncini, R | 1 |
| Bornstein, S | 1 |
| Moschetta, M | 1 |
| Kawano, Y | 1 |
| Sacco, A | 1 |
| Huynh, D | 1 |
| Brooks, D | 1 |
| Manier, S | 1 |
| Fairfield, H | 1 |
| Falank, C | 1 |
| Roccaro, AM | 1 |
| Nagano, K | 1 |
| Baron, R | 1 |
| Bouxein, M | 1 |
| Vary, C | 1 |
| Ghobrial, IM | 1 |
| Rosen, CJ | 1 |
| Reagan, MR | 1 |
| Herman, WH | 3 |
| Edelstein, SL | 4 |
| Dabelea, DM | 1 |
| Horton, E | 3 |
| Lorenzo, C | 1 |
| Venditti, E | 1 |
| Ye, W | 1 |
| Lee, H | 2 |
| Lee, Y | 1 |
| An, J | 1 |
| Kong, H | 1 |
| Song, Y | 1 |
| Lee, CK | 1 |
| Kim, K | 2 |
| Ali, A | 2 |
| Shastry, S | 1 |
| Nithiyananthan, R | 1 |
| Ganapathy, R | 1 |
| Song, J | 2 |
| Ruan, X | 2 |
| Mueck, AO | 2 |
| Allison, DB | 1 |
| Pastor-Villaescusa, B | 1 |
| Plaza-Díaz, J | 1 |
| Aguilera, CM | 1 |
| Dos Santos, IK | 1 |
| de Lima Nunes, R | 1 |
| Soares, GM | 1 |
| de Oliveira Maranhão, TM | 1 |
| Dantas, PMS | 1 |
| Zakharova, IO | 1 |
| Mikhrina, AL | 1 |
| Huang, X | 1 |
| Dai, W | 1 |
| Raz, I | 2 |
| Mosenzon, O | 1 |
| Bonaca, MP | 1 |
| Cahn, A | 1 |
| Kato, ET | 1 |
| Silverman, MG | 1 |
| Bhatt, DL | 1 |
| Leiter, LA | 1 |
| McGuire, DK | 2 |
| Wilding, JPH | 1 |
| Gause-Nilsson, IAM | 1 |
| Langkilde, AM | 1 |
| Johansson, PA | 1 |
| Sabatine, MS | 1 |
| Wiviott, SD | 1 |
| Lee, SH | 2 |
| Kim, JK | 2 |
| Jhun, JY | 2 |
| Kim, SY | 1 |
| Choi, JY | 2 |
| Yang, CW | 1 |
| Anagnostou, E | 1 |
| McKillop, AM | 1 |
| Stevenson, CL | 1 |
| Moran, BM | 1 |
| Abdel-Wahab, YHA | 1 |
| Murai, Y | 1 |
| Ohta, T | 1 |
| Tadaki, H | 1 |
| Miyajima, K | 1 |
| Shinohara, M | 1 |
| Fatchiyah, F | 1 |
| Yamada, T | 1 |
| Răcătăianu, N | 1 |
| Bolboacă, SD | 1 |
| Sitar-Tăut, AV | 1 |
| Mârza, S | 1 |
| Moga, D | 1 |
| Valea, A | 1 |
| Siskind, D | 1 |
| Friend, N | 1 |
| Russell, A | 1 |
| McGrath, JJ | 1 |
| Lim, C | 1 |
| Patterson, S | 1 |
| Flaws, D | 1 |
| Stedman, T | 1 |
| Moudgil, V | 1 |
| Sardinha, S | 1 |
| Suetani, S | 1 |
| Kisely, S | 2 |
| Winckel, K | 1 |
| Baker, A | 1 |
| El-Arabey, AA | 1 |
| Incio, J | 3 |
| Ligibel, JA | 3 |
| McManus, DT | 2 |
| Suboj, P | 2 |
| Jung, K | 2 |
| Kawaguchi, K | 1 |
| Pinter, M | 1 |
| Babykutty, S | 2 |
| Chin, SM | 2 |
| Vardam, TD | 2 |
| Rahbari, NN | 2 |
| Roberge, S | 1 |
| Gomes-Santos, IL | 1 |
| Puchner, SB | 2 |
| Schlett, CL | 2 |
| Hoffmman, U | 2 |
| Ancukiewicz, M | 2 |
| Tolaney, SM | 1 |
| Krop, IE | 2 |
| Duda, DG | 2 |
| Boucher, Y | 1 |
| Fukumura, D | 3 |
| Jain, RK | 3 |
| Chueakula, N | 1 |
| Wanchai, K | 1 |
| Abdalmageed, OS | 1 |
| Farghaly, TA | 1 |
| Abdelaleem, AA | 1 |
| Abdelmagied, AE | 1 |
| Ali, MK | 2 |
| Abbas, AM | 1 |
| Mormile, R | 1 |
| Landim, BC | 1 |
| de Jesus, MM | 1 |
| Bosque, BP | 1 |
| Zanon, RG | 1 |
| da Silva, CV | 1 |
| Góes, RM | 1 |
| Ribeiro, DL | 1 |
| Chang, HH | 1 |
| Moro, A | 1 |
| Chou, CEN | 1 |
| Dawson, DW | 1 |
| French, S | 1 |
| Schmidt, AI | 1 |
| Sinnett-Smith, J | 1 |
| Hao, F | 1 |
| Hines, OJ | 1 |
| Eibl, G | 1 |
| Rozengurt, E | 1 |
| Zheng, J | 2 |
| Jiang, M | 1 |
| Sales, WB | 1 |
| Nascimento, IBD | 1 |
| Dienstmann, G | 1 |
| Souza, MLR | 1 |
| Silva, GDD | 1 |
| Silva, JC | 1 |
| Salamun, V | 2 |
| Vrtacnik Bokal, E | 2 |
| Yates, MS | 3 |
| Coletta, AM | 1 |
| Schmandt, RE | 1 |
| Medepalli, M | 1 |
| Nebgen, D | 1 |
| Soletsky, B | 1 |
| Milbourne, A | 1 |
| Levy, E | 1 |
| Fellman, B | 1 |
| Urbauer, D | 1 |
| Yuan, Y | 2 |
| Broaddus, RR | 3 |
| Basen-Engquist, K | 1 |
| Lu, K | 1 |
| Denis, GV | 1 |
| Sebastiani, P | 1 |
| Bertrand, KA | 1 |
| Strissel, KJ | 1 |
| Tran, AH | 1 |
| Slama, J | 1 |
| Medina, ND | 1 |
| Andrieu, G | 1 |
| Palmer, JR | 1 |
| Zabielski, P | 1 |
| Hady, HR | 1 |
| Chacinska, M | 1 |
| Roszczyc, K | 1 |
| Gorski, J | 1 |
| Blachnio-Zabielska, AU | 1 |
| Shao, N | 1 |
| Yu, XY | 1 |
| Yu, YM | 1 |
| Li, BW | 1 |
| Pan, J | 1 |
| Wu, WH | 1 |
| Ma, XF | 1 |
| Hao, M | 1 |
| Kuang, HY | 1 |
| Kalafat, E | 1 |
| Sukur, YE | 1 |
| Abdi, A | 1 |
| Thilaganathan, B | 1 |
| Khalil, A | 1 |
| Mediani, A | 1 |
| Abas, F | 1 |
| Maulidiani, M | 1 |
| Abu Bakar Sajak, A | 1 |
| Khatib, A | 1 |
| Tan, CP | 1 |
| Ismail, IS | 1 |
| Shaari, K | 1 |
| Ismail, A | 1 |
| Lajis, NH | 1 |
| Lohmann, AE | 1 |
| Pimentel, I | 1 |
| Goodwin, PJ | 2 |
| Hilado, MA | 1 |
| Randhawa, RS | 1 |
| Zawada, A | 3 |
| Naskręt, D | 3 |
| Burchardt, P | 3 |
| Niedźwiecki, P | 1 |
| Piłaciński, S | 1 |
| Wierusz-Wysocka, B | 4 |
| Grzymisławski, M | 2 |
| Zozulińska-Ziółkiewicz, D | 2 |
| Puscheck, EE | 1 |
| Bolnick, A | 1 |
| Awonuga, A | 1 |
| Yang, Y | 1 |
| Abdulhasan, M | 1 |
| Secor, E | 1 |
| Louden, E | 1 |
| Hüttemann, M | 1 |
| Rappolee, DA | 1 |
| Willingham, MC | 1 |
| Qi, J | 1 |
| Cheng, SY | 2 |
| Singh, H | 1 |
| Venkatesan, V | 1 |
| Hyer, S | 3 |
| Balani, J | 3 |
| Shehata, H | 3 |
| Marciniak, A | 1 |
| Lejman-Larysz, K | 1 |
| Nawrocka-Rutkowska, J | 1 |
| Brodowska, A | 1 |
| Songin, D | 1 |
| Urban, LE | 1 |
| Audet, D | 1 |
| Ron, ES | 1 |
| Sannino, A | 1 |
| Zohar, Y | 1 |
| Demitri, C | 1 |
| Panteca, E | 1 |
| Surano, I | 1 |
| Heshmati, HM | 1 |
| Yang, P | 1 |
| Liu, X | 3 |
| Gao, J | 1 |
| Qu, S | 1 |
| Schmittdiel, JA | 1 |
| Flory, JH | 1 |
| Yeh, J | 1 |
| Karter, AJ | 1 |
| Kruge, LE | 1 |
| Schillinger, D | 1 |
| Walker, EA | 1 |
| Rubio Osornio, MDC | 1 |
| Custodio Ramírez, V | 1 |
| Calderón Gámez, D | 1 |
| Paz Tres, C | 1 |
| Carvajal Aguilera, KG | 1 |
| Phillips Farfán, BV | 1 |
| Hunter, RW | 1 |
| Hughey, CC | 1 |
| Lantier, L | 2 |
| Sundelin, EI | 1 |
| Peggie, M | 1 |
| Zeqiraj, E | 1 |
| Sicheri, F | 1 |
| Jessen, N | 1 |
| Wasserman, DH | 1 |
| Sakamoto, K | 1 |
| Ning, HH | 1 |
| Young, CA | 1 |
| Deng, B | 1 |
| Gao, PX | 1 |
| Zhang, HQ | 1 |
| Qin, SL | 1 |
| Loves, S | 1 |
| van Groningen, L | 1 |
| Filius, M | 1 |
| Mekking, M | 1 |
| Brandon, T | 1 |
| Tack, CJ | 1 |
| Hermus, A | 1 |
| de Boer, H | 1 |
| Zhou, J | 1 |
| Massey, S | 1 |
| Story, D | 1 |
| Xiang, AH | 1 |
| Trigo, E | 1 |
| Martinez, M | 2 |
| Katkhouda, N | 1 |
| Beale, E | 1 |
| Chow, T | 1 |
| Montgomery, C | 1 |
| Nayak, KS | 1 |
| Hendee, F | 1 |
| Buchanan, TA | 1 |
| Hasan, MM | 1 |
| Shalaby, SM | 1 |
| El-Gendy, J | 1 |
| Abdelghany, EMA | 1 |
| Xu, H | 2 |
| Verre, MC | 1 |
| Álvarez, D | 1 |
| Ceballo, K | 1 |
| Olguín, S | 1 |
| Martinez-Pinto, J | 1 |
| Maliqueo, M | 1 |
| Fernandois, D | 1 |
| Sotomayor-Zárate, R | 1 |
| Cruz, G | 1 |
| Tsuchiya, S | 1 |
| Sawada, S | 1 |
| Takeda, K | 1 |
| Takahashi, K | 1 |
| Nakajima, T | 1 |
| Kohata, M | 1 |
| Kurosawa, S | 1 |
| Satake, C | 1 |
| Imai, J | 1 |
| Kikuchi, K | 1 |
| Aiba, S | 1 |
| Katagiri, H | 1 |
| Tomášová, P | 1 |
| Bugáňová, M | 2 |
| Pelantová, H | 2 |
| Holubová, M | 2 |
| Šedivá, B | 2 |
| Železná, B | 2 |
| Haluzík, M | 2 |
| Maletínská, L | 2 |
| Kuneš, J | 2 |
| Kuzma, M | 2 |
| Wu, Y | 4 |
| Wu, Q | 1 |
| Xia, J | 1 |
| Chen, B | 1 |
| Yun, C | 1 |
| Lian, G | 1 |
| Bisson, WH | 1 |
| Gao, X | 1 |
| Ge, P | 1 |
| Liu, C | 2 |
| Krausz, KW | 1 |
| Nichols, RG | 1 |
| Rimal, B | 1 |
| Patterson, AD | 1 |
| Claßen, M | 1 |
| Finan, B | 1 |
| Müller, TD | 1 |
| DiMarchi, RD | 1 |
| Tschöp, MH | 1 |
| Hofmann, SM | 1 |
| Apovian, CM | 2 |
| Okemah, J | 1 |
| O'Neil, PM | 1 |
| Lentferink, YE | 1 |
| Knibbe, CAJ | 1 |
| van der Vorst, MMJ | 1 |
| Hui, F | 1 |
| Ren, T | 1 |
| Zhao, M | 1 |
| Zhao, Q | 1 |
| Catalano, PM | 1 |
| Zemel, MB | 3 |
| Kolterman, O | 1 |
| Rinella, M | 1 |
| Vuppalanchi, R | 2 |
| Flores, O | 1 |
| Barritt, AS | 1 |
| Siddiqui, M | 1 |
| Chalasani, N | 3 |
| Bashir, M | 1 |
| Dabbous, Z | 1 |
| Baagar, K | 1 |
| Elkhatib, F | 1 |
| Ibrahim, A | 1 |
| Brich, SA | 1 |
| Abdel-Rahman, ME | 1 |
| Konje, JC | 2 |
| Abou-Samra, AB | 1 |
| He, X | 1 |
| Wu, D | 1 |
| Hu, C | 1 |
| Xu, T | 1 |
| Tang, W | 1 |
| Yam, C | 1 |
| Esteva, FJ | 3 |
| Patel, MM | 1 |
| Raghavendra, AS | 1 |
| Ueno, NT | 1 |
| Moulder, SL | 2 |
| Hess, KR | 1 |
| Shroff, GS | 1 |
| Hodge, S | 1 |
| Koenig, KH | 1 |
| Chavez Mac Gregor, M | 1 |
| Griner, RL | 1 |
| Yeung, SJ | 1 |
| Hortobagyi, GN | 3 |
| Valero, V | 1 |
| Teng, A | 1 |
| Blakely, T | 1 |
| Scott, N | 1 |
| Jansen, R | 1 |
| Masters-Awatere, B | 1 |
| Krebs, J | 1 |
| Oetzel, J | 1 |
| Kujawska-Luczak, M | 1 |
| Szulinska, M | 2 |
| Skrypnik, D | 1 |
| Musialik, K | 2 |
| Swora-Cwynar, E | 2 |
| Kregielska-Narozna, M | 2 |
| Markuszewski, L | 1 |
| Grzymislawska, M | 1 |
| Bogdanski, P | 2 |
| Tian, S | 1 |
| Magalhães, D | 1 |
| Pedro, J | 1 |
| Oliveira, SC | 1 |
| Freitas, P | 1 |
| Varela, A | 1 |
| Abbott, DH | 1 |
| El Sharkwy, I | 1 |
| Sharaf El-Din, M | 1 |
| Jainchill, AL | 1 |
| Gawrys, BL | 1 |
| Arnold, JJ | 1 |
| Krüger, HJ | 1 |
| De Wet, R | 1 |
| Blumberg, LH | 1 |
| Weyer, J | 1 |
| Lemke, FG | 1 |
| Xourgia, E | 1 |
| Papazafiropoulou, A | 1 |
| Papanas, N | 1 |
| Melidonis, A | 1 |
| Javed, Z | 2 |
| Papageorgiou, M | 1 |
| Deshmukh, H | 1 |
| Rigby, AS | 1 |
| Qamar, U | 1 |
| Abbas, J | 1 |
| Khan, AY | 2 |
| Derkach, K | 1 |
| Zakharova, I | 1 |
| Zorina, I | 1 |
| Bakhtyukov, A | 1 |
| Romanova, I | 1 |
| Bayunova, L | 1 |
| Shpakov, A | 1 |
| Yerevanian, A | 1 |
| Soukas, AA | 1 |
| Jia, D | 1 |
| Li, ZW | 1 |
| Feng, Y | 2 |
| Ma, M | 1 |
| Wu, Z | 1 |
| Savchenko, LG | 1 |
| Digtiar, NI | 1 |
| Selikhova, LG | 1 |
| Kaidasheva, EI | 1 |
| Shlykova, OA | 1 |
| Vesnina, LE | 1 |
| Kaidashev, IP | 1 |
| Liu, E | 1 |
| Long, T | 1 |
| Gong, Y | 1 |
| Shen, H | 2 |
| Lin, R | 1 |
| Zheng, Y | 2 |
| D'Ambrosio, V | 1 |
| Brunelli, R | 1 |
| Vena, F | 1 |
| Di Mascio, D | 1 |
| Marchetti, C | 1 |
| Boccherini, C | 1 |
| Piccioni, MG | 1 |
| Benedetti Panici, P | 1 |
| Giancotti, A | 1 |
| Yan, P | 1 |
| Chen, T | 1 |
| Zhou, W | 1 |
| Zhang, ZJ | 1 |
| Xie, Q | 1 |
| Katzel, LI | 1 |
| Sorkin, JD | 1 |
| Pascale, A | 1 |
| Marchesi, N | 1 |
| Govoni, S | 1 |
| Coppola, A | 1 |
| Gazzaruso, C | 1 |
| Anholm, C | 2 |
| Kumarathurai, P | 2 |
| Samkani, A | 2 |
| Pedersen, LR | 2 |
| Boston, RC | 1 |
| Nielsen, OW | 2 |
| Kristiansen, OP | 2 |
| Fenger, M | 2 |
| Madsbad, S | 5 |
| Sajadieh, A | 2 |
| Haugaard, SB | 2 |
| Hussain, SM | 1 |
| Wluka, AE | 1 |
| Lim, YZ | 1 |
| Abram, F | 1 |
| Pelletier, JP | 1 |
| Martel-Pelletier, J | 1 |
| Cicuttini, FM | 1 |
| Nelson, SH | 1 |
| Marinac, CR | 2 |
| Natarajan, L | 2 |
| Parker, BA | 1 |
| Patterson, RE | 2 |
| Dhaliwal, R | 1 |
| Shepherd, JA | 1 |
| El Ghormli, L | 1 |
| Copeland, KC | 1 |
| Geffner, ME | 1 |
| Higgins, J | 1 |
| Levitsky, LL | 1 |
| Nadeau, KJ | 3 |
| Weinstock, RS | 2 |
| White, NH | 1 |
| Hong-Hong, N | 1 |
| Jiong, L | 1 |
| Shu-Lan, Q | 1 |
| Zhang, Z | 2 |
| Zhang, B | 1 |
| Yang, QX | 1 |
| Qing, Z | 1 |
| Sena, CM | 1 |
| Rybak, V | 1 |
| Derkach, N | 1 |
| Korol, V | 1 |
| Walzem, RL | 1 |
| Zubkiewicz-Kucharska, A | 1 |
| Chrzanowska, J | 2 |
| Noczyńska, A | 2 |
| Hollander, P | 4 |
| Lasko, B | 1 |
| Barnett, AH | 1 |
| Bengus, M | 1 |
| Kanitra, L | 1 |
| Pi-Sunyer, FX | 2 |
| Balena, R | 1 |
| Andersen, DK | 2 |
| Derosa, G | 3 |
| Cicero, AF | 3 |
| Franzetti, IG | 1 |
| Querci, F | 1 |
| Carbone, A | 1 |
| Piccinni, MN | 3 |
| D'Angelo, A | 3 |
| Fogari, E | 2 |
| Maffioli, P | 3 |
| Eriksson, J | 1 |
| Laine, M | 1 |
| Juárez-López, C | 1 |
| Klünder-Klünder, M | 1 |
| Madrigal-Azcárate, A | 1 |
| Flores-Huerta, S | 1 |
| Hopkins, ND | 1 |
| Cuthbertson, DJ | 2 |
| Kemp, GJ | 1 |
| Pugh, C | 1 |
| Green, DJ | 1 |
| Cable, NT | 1 |
| Jones, H | 1 |
| Celestino, J | 2 |
| Schmandt, R | 2 |
| McCampbell, AS | 1 |
| Urbauer, DL | 2 |
| Meyer, LA | 1 |
| Burzawa, JK | 1 |
| Huang, M | 1 |
| Iglesias, D | 1 |
| Lu, KH | 2 |
| Malin, SK | 2 |
| Nightingale, J | 1 |
| Choi, SE | 1 |
| Chipkin, SR | 1 |
| Braun, B | 1 |
| Delahanty, LM | 3 |
| Jablonski, KA | 4 |
| Franks, PW | 3 |
| Zhu, Y | 2 |
| Shen, L | 2 |
| Ruan, K | 1 |
| Cong, W | 1 |
| Ortúzar, N | 1 |
| Garnett, SP | 5 |
| Gow, M | 3 |
| Ho, M | 3 |
| Baur, LA | 4 |
| Noakes, M | 2 |
| Woodhead, HJ | 1 |
| Broderick, CR | 1 |
| Burrell, S | 1 |
| Chisholm, K | 1 |
| Halim, J | 2 |
| De, S | 1 |
| Steinbeck, K | 1 |
| Srinivasan, S | 2 |
| Ambler, GR | 2 |
| Kohn, MR | 1 |
| Cowell, CT | 5 |
| Schlechte, JA | 1 |
| Bozdag, G | 1 |
| Yildiz, BO | 1 |
| Halimi, S | 2 |
| Desai, N | 2 |
| Roman, A | 1 |
| Rochelson, B | 1 |
| Xue, X | 1 |
| Chatterjee, PK | 2 |
| Tam Tam, H | 1 |
| Metz, CN | 2 |
| Gray, L | 1 |
| Lee, JH | 2 |
| Nashelsky, J | 1 |
| Zheng, YH | 1 |
| Wang, XH | 1 |
| Lai, MH | 1 |
| Yao, H | 1 |
| Ma, HX | 1 |
| Andrews, M | 2 |
| Soto, N | 2 |
| Arredondo, M | 1 |
| Erlich, DR | 1 |
| Slawson, DC | 2 |
| Shaughnessy, A | 1 |
| Strickler, HD | 1 |
| Auble, B | 1 |
| Elder, D | 1 |
| Gross, A | 1 |
| Hillman, JB | 1 |
| Chen, CH | 2 |
| Huang, MC | 2 |
| Kao, CF | 2 |
| Lin, SK | 2 |
| Kuo, PH | 2 |
| Chiu, CC | 2 |
| Lu, ML | 2 |
| Randolph, JF | 1 |
| Kong, S | 1 |
| Nan, B | 1 |
| Jarskog, LF | 2 |
| Hamer, RM | 1 |
| Catellier, DJ | 1 |
| Stewart, DD | 1 |
| Lavange, L | 1 |
| Ray, N | 1 |
| Golden, LH | 1 |
| Lieberman, JA | 1 |
| Stroup, TS | 2 |
| Lautatzis, ME | 1 |
| Goulis, DG | 1 |
| Vrontakis, M | 1 |
| Tabaczewski, P | 1 |
| Kaczmarek, J | 2 |
| Marcinkaniec, J | 2 |
| Wysocki, H | 2 |
| Tesanović, S | 1 |
| Radman, M | 1 |
| Tesanović, D | 1 |
| Erzen, DJ | 1 |
| Hozo, I | 1 |
| Tajima, K | 1 |
| Nakamura, A | 1 |
| Shirakawa, J | 1 |
| Togashi, Y | 1 |
| Orime, K | 1 |
| Sato, K | 1 |
| Inoue, H | 1 |
| Kaji, M | 1 |
| Sakamoto, E | 1 |
| Ito, Y | 1 |
| Aoki, K | 1 |
| Nagashima, Y | 1 |
| Atsumi, T | 1 |
| Terauchi, Y | 1 |
| Chilton, M | 1 |
| Dunkley, A | 1 |
| Carter, P | 1 |
| Davies, MJ | 1 |
| Gray, LJ | 1 |
| Gallagher, EJ | 2 |
| LeRoith, D | 2 |
| Ortega, FJ | 2 |
| Moreno-Navarrete, JM | 3 |
| Mayas, D | 1 |
| Serino, M | 1 |
| Rodriguez-Hermosa, JI | 2 |
| Ricart, W | 3 |
| Luche, E | 1 |
| Burcelin, R | 1 |
| Frühbeck, G | 2 |
| Mingrone, G | 1 |
| Fernández-Real, JM | 4 |
| Bajuk Studen, K | 1 |
| Jensterle Sever, M | 2 |
| Pfeifer, M | 2 |
| Scheinfeld, N | 1 |
| Correll, CU | 1 |
| Sikich, L | 1 |
| Reeves, G | 1 |
| Riddle, M | 1 |
| Cappelli, V | 1 |
| Di Sabatino, A | 2 |
| Musacchio, MC | 3 |
| De Leo, V | 4 |
| Karatas, A | 1 |
| Özlü, T | 1 |
| Erdem, A | 1 |
| Ghotbi, AA | 1 |
| Køber, L | 1 |
| Finer, N | 1 |
| James, WP | 1 |
| Sharma, AM | 2 |
| Caterson, I | 1 |
| Coutinho, W | 1 |
| Van Gaal, LF | 2 |
| Torp-Pedersen, C | 1 |
| Andersson, C | 1 |
| Makled, AK | 1 |
| El Sherbiny, M | 1 |
| Elkabarity, R | 1 |
| Checkley, LA | 1 |
| Rho, O | 1 |
| Angel, JM | 1 |
| Cho, J | 1 |
| Blando, J | 1 |
| Beltran, L | 1 |
| Hursting, SD | 2 |
| DiGiovanni, J | 1 |
| Calixto, MC | 3 |
| Lintomen, L | 2 |
| André, DM | 1 |
| Leiria, LO | 2 |
| Ferreira, D | 1 |
| Lellis-Santos, C | 1 |
| Anhê, GF | 2 |
| Bordin, S | 1 |
| Landgraf, RG | 1 |
| Antunes, E | 3 |
| Bała, MM | 1 |
| Płaczkiewicz-Jankowska, E | 1 |
| Leśniak, W | 1 |
| Topór-Mądry, R | 1 |
| Michałejko, M | 1 |
| Jankowski, M | 1 |
| Strzeszyński, L | 1 |
| Sieradzki, J | 2 |
| Czupryniak, L | 1 |
| Gambineri, A | 5 |
| Billings, LK | 1 |
| Horton, ES | 1 |
| Teslenko, IuV | 1 |
| Kocjan, T | 3 |
| Fiorentino, TV | 1 |
| Sesti, G | 1 |
| Barthelmess, EK | 1 |
| Naz, RK | 1 |
| Rosenfeld, JE | 1 |
| Cheang, WS | 1 |
| Tian, XY | 1 |
| Wong, WT | 1 |
| Lau, CW | 1 |
| Lee, SS | 1 |
| Chen, ZY | 1 |
| Yao, X | 1 |
| Wang, N | 2 |
| Feng, WH | 1 |
| Yuan, XW | 1 |
| Tong, GY | 1 |
| Wang, WM | 1 |
| Li, P | 1 |
| Shao, LL | 1 |
| Dai, YY | 1 |
| Liu, YQ | 1 |
| Xiang, SK | 1 |
| Yang, DH | 1 |
| Zhu, DL | 1 |
| Ke, RW | 1 |
| Joslowski, G | 1 |
| Goletzke, J | 1 |
| Louie, JC | 1 |
| Buyken, AE | 1 |
| Kruszyńska, A | 1 |
| Słowińska-Srzednicka, J | 1 |
| Jeske, W | 1 |
| Zgliczyński, W | 1 |
| Walford, GA | 2 |
| Ma, Y | 4 |
| Goldberg, RB | 3 |
| Jarolim, P | 1 |
| Davis, J | 1 |
| Wang, TJ | 2 |
| Grigoryan, O | 1 |
| Absatarova, J | 1 |
| Andreeva, E | 1 |
| Melnichenko, G | 1 |
| Dedov, I | 1 |
| Velija-Asimi, Z | 2 |
| Izetbegovic, S | 1 |
| Karamehic, J | 1 |
| Coric, J | 1 |
| Panjeta, M | 1 |
| Macic-Dzankovic, A | 1 |
| Djelilovic-Vranic, J | 1 |
| Dizdarevic-Bostandzic, A | 1 |
| Kalinsky, K | 1 |
| Crew, KD | 1 |
| Refice, S | 1 |
| Xiao, T | 1 |
| Wang, A | 1 |
| Feldman, SM | 1 |
| Taback, B | 1 |
| Cremers, S | 1 |
| Hibshoosh, H | 1 |
| Maurer, M | 1 |
| Hershman, DL | 1 |
| Pau, CT | 1 |
| Keefe, C | 1 |
| Duran, J | 1 |
| Welt, CK | 1 |
| Tan, BK | 3 |
| Amar, O | 1 |
| Mattu, HS | 1 |
| Ramanjaneya, M | 1 |
| Patel, V | 1 |
| Randeva, HS | 3 |
| Woo, SL | 1 |
| Hu, X | 1 |
| Zhao, J | 1 |
| Guo, X | 1 |
| Guo, T | 1 |
| Botchlett, R | 1 |
| Qi, T | 1 |
| Pei, Y | 1 |
| An, X | 1 |
| Xiao, X | 1 |
| Huo, Y | 1 |
| Wu, C | 2 |
| He, L | 1 |
| Meng, S | 1 |
| Germain-Lee, EL | 1 |
| Radovick, S | 1 |
| Wondisford, FE | 1 |
| Wu, T | 1 |
| Bound, MJ | 1 |
| Checklin, H | 1 |
| Deacon, CF | 1 |
| Jones, KL | 1 |
| Horowitz, M | 1 |
| Rayner, CK | 1 |
| McCampbell, A | 1 |
| Loose, DS | 1 |
| Shipley, GL | 1 |
| Tek, C | 1 |
| Chwastiak, L | 1 |
| Narasimhan, S | 1 |
| Pan, T | 1 |
| Luo, L | 1 |
| Ong, KK | 1 |
| Dunger, DB | 1 |
| Tilg, H | 1 |
| Moschen, AR | 1 |
| Kong, D | 1 |
| Del Prato, S | 1 |
| Foley, JE | 1 |
| Kothny, W | 1 |
| Kozlovski, P | 1 |
| Stumvoll, M | 3 |
| Paldánius, PM | 1 |
| Matthews, DR | 2 |
| van der Aa, MP | 2 |
| Elst, MA | 2 |
| van Mil, EG | 2 |
| Knibbe, CA | 2 |
| van der Vorst, MM | 2 |
| Beiroa, D | 1 |
| Imbernon, M | 1 |
| Gallego, R | 1 |
| Senra, A | 1 |
| Herranz, D | 1 |
| Villarroya, F | 1 |
| Serrano, M | 1 |
| Fernø, J | 1 |
| Salvador, J | 1 |
| Escalada, J | 1 |
| Dieguez, C | 2 |
| Nogueiras, R | 2 |
| Rosenstock, J | 2 |
| Jelaska, A | 1 |
| Frappin, G | 1 |
| Salsali, A | 1 |
| Kim, G | 1 |
| Woerle, HJ | 2 |
| Broedl, UC | 2 |
| Stiefelhagen, P | 1 |
| Wessels, B | 1 |
| Ciapaite, J | 1 |
| van den Broek, NM | 1 |
| Nicolay, K | 1 |
| Prompers, JJ | 1 |
| Benitez-Aguirre, PZ | 1 |
| Tam, CS | 1 |
| Donaghue, KC | 1 |
| Craig, ME | 1 |
| Fuentes-Mattei, E | 1 |
| Velazquez-Torres, G | 1 |
| Phan, L | 1 |
| Zhang, F | 1 |
| Chou, PC | 1 |
| Shin, JH | 1 |
| Choi, HH | 1 |
| Chen, JS | 1 |
| Zhao, R | 1 |
| Gully, C | 1 |
| Carlock, C | 1 |
| McKeehan, WL | 1 |
| Ensor, J | 2 |
| Pusztai, L | 1 |
| Fraser Symmans, W | 1 |
| Lee, MH | 2 |
| Yeung, SC | 2 |
| Wu, QF | 1 |
| Tian, L | 1 |
| Hu, MH | 1 |
| Hawkes, AL | 1 |
| Quinn, M | 1 |
| Gebski, V | 1 |
| Armes, J | 1 |
| Brennan, D | 1 |
| Janda, M | 1 |
| Obermair, A | 1 |
| Liu, F | 3 |
| Hu, P | 1 |
| Chinda, K | 1 |
| Palee, S | 1 |
| Chattipakorn, S | 1 |
| Ko, G | 1 |
| Pala, L | 1 |
| Barbaro, V | 1 |
| Dicembrini, I | 2 |
| Rotella, CM | 4 |
| Neschen, S | 1 |
| Scheerer, M | 1 |
| Seelig, A | 1 |
| Huypens, P | 1 |
| Schultheiss, J | 1 |
| Wu, M | 1 |
| Wurst, W | 1 |
| Rathkolb, B | 1 |
| Suhre, K | 1 |
| Wolf, E | 1 |
| Beckers, J | 1 |
| Hrabé de Angelis, M | 1 |
| Urbinati, S | 1 |
| Bordoni, B | 1 |
| Astiz, S | 1 |
| Gonzalez-Bulnes, A | 1 |
| Astiz, I | 1 |
| Barbero, A | 1 |
| Perez-Solana, ML | 1 |
| Garcia-Real, I | 1 |
| Kashyap, SR | 1 |
| Liu, SN | 1 |
| Sun, SJ | 1 |
| Hou, SC | 1 |
| Shen, ZF | 1 |
| Stokes, VJ | 1 |
| Anderson, RA | 1 |
| George, JT | 1 |
| Stine, JE | 1 |
| Shah, MM | 1 |
| Erickson, BK | 1 |
| Matin, T | 1 |
| McGwin, G | 1 |
| Martin, JY | 1 |
| Daily, LB | 1 |
| Pasko, D | 1 |
| Haygood, CW | 1 |
| Fauci, JM | 1 |
| Leath, CA | 1 |
| Çayır, A | 1 |
| Turan, Mİ | 1 |
| Gurbuz, F | 1 |
| Kurt, N | 1 |
| Yildirim, A | 1 |
| Jenkins, Y | 1 |
| Sun, TQ | 1 |
| Markovtsov, V | 1 |
| Uy, G | 1 |
| Gross, L | 1 |
| Goff, DA | 1 |
| Shaw, SJ | 1 |
| Boralsky, L | 1 |
| Payan, DG | 1 |
| Hitoshi, Y | 1 |
| Shirazi, F | 1 |
| Farmakiotis, D | 1 |
| Yan, Y | 2 |
| Albert, N | 1 |
| Do, KA | 1 |
| Kim-Anh, D | 1 |
| Kontoyiannis, DP | 1 |
| Linderholm, AL | 1 |
| Bratt, JM | 1 |
| Schuster, GU | 1 |
| Zeki, AA | 1 |
| Kenyon, NJ | 1 |
| Agrawal, A | 1 |
| Worsley, R | 1 |
| Jane, F | 1 |
| Robinson, PJ | 1 |
| Bell, RJ | 1 |
| Davis, SR | 1 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| Joham, A | 1 |
| De Courten, B | 1 |
| Schuler, KM | 1 |
| Rambally, BS | 1 |
| DiFurio, MJ | 1 |
| Sampey, BP | 1 |
| Gehrig, PA | 1 |
| Makowski, L | 1 |
| Bae-Jump, VL | 1 |
| Arredondo-Olguín, M | 1 |
| Jeve, YB | 1 |
| Doshani, A | 1 |
| Louden, ED | 1 |
| Luzzo, KM | 1 |
| Jimenez, PT | 1 |
| Chi, T | 1 |
| Chi, M | 1 |
| Moley, KH | 1 |
| Messinis, IE | 1 |
| Messini, CI | 1 |
| Anifandis, G | 1 |
| Dafopoulos, K | 1 |
| de Queiroz, EA | 1 |
| Akamine, EH | 3 |
| de Carvalho, MH | 2 |
| Sampaio, SC | 1 |
| Fortes, ZB | 4 |
| Abegg, K | 1 |
| Corteville, C | 1 |
| Boza, C | 1 |
| Lutz, TA | 1 |
| Muñoz, R | 1 |
| Mohan, M | 1 |
| McSwiggan, S | 1 |
| Baig, F | 1 |
| Rutherford, L | 1 |
| Lang, CC | 1 |
| Hou, W | 1 |
| Lu, W | 1 |
| Zheng, T | 1 |
| Lu, F | 1 |
| Bao, Y | 1 |
| Jia, W | 1 |
| Buturovic, BA | 1 |
| Ristic, LB | 1 |
| Narancic, AM | 1 |
| Chiswick, CA | 1 |
| Whyte, SA | 1 |
| Newby, DE | 1 |
| Walker, BR | 4 |
| Forbes, S | 1 |
| Murray, GD | 1 |
| Wray, S | 1 |
| Rees, J | 1 |
| Brima, W | 1 |
| Eden, DJ | 1 |
| Mehdi, SF | 1 |
| Bravo, M | 1 |
| Wiese, MM | 1 |
| Stein, J | 1 |
| Almonte, V | 1 |
| Zhao, D | 1 |
| Kurland, I | 1 |
| Pessin, JE | 1 |
| Zima, T | 1 |
| Tanowitz, HB | 1 |
| Weiss, LM | 1 |
| Roth, J | 1 |
| Nagajyothi, F | 1 |
| Guo, J | 1 |
| Xie, J | 1 |
| Bahadursingh, S | 1 |
| Ramsewak, S | 1 |
| Teelucksingh, S | 1 |
| Ortega, F | 1 |
| Moreno, M | 1 |
| Xifra, G | 1 |
| Fang, X | 2 |
| Zhu, W | 1 |
| Liu, D | 3 |
| Irving, BA | 1 |
| Carter, RE | 1 |
| Soop, M | 1 |
| Weymiller, A | 1 |
| Syed, H | 1 |
| Karakelides, H | 1 |
| Bhagra, S | 1 |
| Short, KR | 1 |
| Tatpati, L | 1 |
| Barazzoni, R | 1 |
| Nair, KS | 1 |
| Madsen, HN | 1 |
| Lauszus, FF | 2 |
| Trolle, B | 2 |
| Ingerslev, HJ | 1 |
| Tørring, N | 1 |
| Tanaka, K | 2 |
| Saisho, Y | 2 |
| Kawai, T | 2 |
| Tanaka, M | 2 |
| Meguro, S | 2 |
| Irie, J | 2 |
| Imai, T | 1 |
| Shigihara, T | 1 |
| Morimoto, J | 1 |
| Yajima, K | 1 |
| Atsumi, Y | 1 |
| Takei, I | 1 |
| Itoh, H | 2 |
| Al-Barazanji, K | 1 |
| McNulty, J | 1 |
| Binz, J | 1 |
| Generaux, C | 1 |
| Benson, W | 1 |
| Young, A | 1 |
| Mayer, SB | 1 |
| Evans, WS | 2 |
| Nestler, JE | 8 |
| Sir-Petermann, T | 1 |
| Diamanti-Kandarakis, E | 3 |
| Łukasiewicz, D | 1 |
| Chodorowska, M | 1 |
| Jakubowska, I | 1 |
| Duca, FA | 1 |
| Côté, CD | 1 |
| Rasmussen, BA | 1 |
| Zadeh-Tahmasebi, M | 1 |
| Rutter, GA | 1 |
| Filippi, BM | 1 |
| Lam, TK | 1 |
| Liong, S | 1 |
| Lappas, M | 1 |
| Fu, L | 2 |
| Bruckbauer, A | 2 |
| Cao, Q | 2 |
| Cui, X | 2 |
| Wu, R | 2 |
| Shi, H | 2 |
| Xue, B | 2 |
| Ciaraldi, TP | 3 |
| Samad, F | 1 |
| Ohno, T | 1 |
| Shimizu, M | 1 |
| Shirakami, Y | 1 |
| Baba, A | 1 |
| Kochi, T | 1 |
| Kubota, M | 1 |
| Tsurumi, H | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Ettner, S | 1 |
| Keckhafer, A | 1 |
| Ho, S | 1 |
| Noureddin, M | 1 |
| Rinella, ME | 1 |
| Kuate, D | 1 |
| Kengne, AP | 1 |
| Biapa, CP | 1 |
| Azantsa, BG | 1 |
| Abdul Manan Bin Wan Muda, W | 1 |
| Zeb, MH | 1 |
| Baruah, A | 1 |
| Kossak, SK | 1 |
| Buttar, NS | 1 |
| Zhang, C | 1 |
| Gao, F | 1 |
| Luo, H | 1 |
| Zhang, CT | 1 |
| Zhang, R | 1 |
| Yan, WJ | 1 |
| Mu, Y | 1 |
| Yu, N | 1 |
| Yi, TL | 1 |
| Pang, XL | 1 |
| Cheng, D | 1 |
| Yang, J | 1 |
| Kharroubi, AT | 1 |
| Darwish, HM | 1 |
| Akkawi, MA | 1 |
| Ashareef, AA | 1 |
| Almasri, ZA | 1 |
| Bader, KA | 1 |
| Khammash, UM | 1 |
| Lin, XF | 1 |
| Wu, RR | 3 |
| Du, J | 1 |
| Liao, YC | 1 |
| Du, Y | 1 |
| Ye, Y | 1 |
| Zhang, XB | 1 |
| Chen, A | 1 |
| Silva, FH | 1 |
| Alexandre, EC | 1 |
| Calmasini, FB | 1 |
| Sanduloviciu, M | 1 |
| Jornayvaz, FR | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Lima-Martínez, MM | 1 |
| Paoli, M | 1 |
| Rodney, M | 1 |
| Balladares, N | 1 |
| Contreras, M | 1 |
| D'Marco, L | 1 |
| Iacobellis, G | 1 |
| Tokmak, M | 1 |
| Altiok, IB | 1 |
| Guven, M | 1 |
| Aras, AB | 1 |
| Cosar, M | 1 |
| Chen, PY | 1 |
| Okanović, A | 1 |
| Prnjavorac, B | 1 |
| Jusufović, E | 1 |
| Sejdinović, R | 1 |
| Mayans, L | 1 |
| Kuznetsova, LA | 1 |
| Sharova, TS | 1 |
| Ignatieva, PA | 1 |
| Bondareva, VM | 1 |
| Ko, KP | 1 |
| Ma, SH | 1 |
| Yang, JJ | 1 |
| Hwang, Y | 1 |
| Ahn, C | 1 |
| Cho, YM | 1 |
| Noh, DY | 1 |
| Park, BJ | 1 |
| Han, W | 1 |
| Park, SK | 1 |
| Funahashi, T | 1 |
| Arakaki, R | 1 |
| Falkner, B | 1 |
| Sharma, K | 1 |
| Goldstein, BJ | 1 |
| Provinciali, N | 1 |
| Lazzeroni, M | 1 |
| Cazzaniga, M | 1 |
| Gorlero, F | 1 |
| Dunn, BK | 1 |
| DeCensi, A | 1 |
| Nwosu, BU | 1 |
| Maranda, L | 1 |
| Cullen, K | 1 |
| Greenman, L | 1 |
| Fleshman, J | 1 |
| McShea, N | 1 |
| Barton, BA | 3 |
| Lee, MM | 1 |
| Manesso, E | 1 |
| Sugiura, H | 1 |
| Jinzaki, M | 1 |
| Cobelli, C | 1 |
| Allott, EH | 1 |
| Zhao, L | 4 |
| Huang, T | 1 |
| Jia, F | 1 |
| Chen, C | 2 |
| Linden, MA | 1 |
| Lopez, KT | 1 |
| Fletcher, JA | 1 |
| Morris, EM | 1 |
| Meers, GM | 1 |
| Siddique, S | 1 |
| Laughlin, MH | 2 |
| Sowers, JR | 1 |
| Thyfault, JP | 1 |
| Ibdah, JA | 1 |
| Rector, RS | 2 |
| Xu, J | 1 |
| Xue, Z | 1 |
| Pang, X | 1 |
| Xiao, D | 1 |
| Zhang, SM | 1 |
| Yin, JY | 1 |
| Gong, WJ | 1 |
| Xu, XJ | 2 |
| Ji, LN | 1 |
| Liu, RR | 1 |
| Tang, Q | 1 |
| Zhou, HH | 1 |
| Han, XY | 1 |
| Liu, ZQ | 1 |
| Ramunni, MI | 1 |
| Licchelli, B | 1 |
| Sabbà, C | 1 |
| Guastamacchia, E | 1 |
| Orecchioni, S | 1 |
| Reggiani, F | 1 |
| Talarico, G | 1 |
| Bertolini, F | 1 |
| de Silva, VA | 1 |
| Dayabandara, M | 1 |
| Wijesundara, H | 1 |
| Henegama, T | 1 |
| Gunewardena, H | 1 |
| Suraweera, C | 1 |
| Hanwella, R | 1 |
| Gődény, S | 2 |
| Csenteri, OK | 2 |
| Hall, C | 2 |
| Stone, RL | 1 |
| Gehlot, A | 1 |
| Zorn, KK | 1 |
| Burnett, AF | 1 |
| Libman, IM | 1 |
| Miller, KM | 1 |
| DiMeglio, LA | 1 |
| Bethin, KE | 1 |
| Katz, ML | 1 |
| Shah, A | 1 |
| Simmons, JH | 1 |
| Haller, MJ | 1 |
| Raman, S | 1 |
| Tamborlane, WV | 3 |
| Coffey, JK | 1 |
| Saenz, AM | 1 |
| Beck, RW | 1 |
| Zwolak, A | 1 |
| Szuster-Ciesielska, A | 1 |
| Daniluk, J | 1 |
| Słabczyńska, O | 1 |
| Kandefer-Szerszeń, M | 1 |
| Wise, J | 1 |
| Cadmus-Bertram, L | 1 |
| Flatt, SW | 1 |
| Parker, B | 1 |
| Oratowski-Coleman, J | 1 |
| Villaseñor, A | 1 |
| Godbole, S | 1 |
| Kerr, J | 1 |
| Row, H | 1 |
| Jeong, J | 1 |
| Cho, S | 1 |
| Krishnamoorthi, R | 1 |
| Borah, B | 1 |
| Heien, H | 1 |
| Das, A | 1 |
| Chak, A | 1 |
| Iyer, PG | 1 |
| Mogul, H | 1 |
| Freeman, R | 1 |
| Nguyen, K | 1 |
| Shankaraiah, RC | 1 |
| Zhang, FY | 1 |
| Gao, KM | 1 |
| Ou, JJ | 1 |
| Shao, P | 1 |
| Jin, H | 1 |
| Guo, WB | 2 |
| Chan, PK | 1 |
| Zhao, JP | 2 |
| Weinrauch, LA | 1 |
| D'Elia, JA | 1 |
| Finn, P | 1 |
| Lewis, EF | 1 |
| Desai, AS | 1 |
| Claggett, BL | 1 |
| Cooper, ME | 1 |
| McGill, JB | 1 |
| Syngelaki, A | 1 |
| Nicolaides, KH | 1 |
| Akolekar, R | 1 |
| Kotecha, R | 1 |
| Pastides, A | 1 |
| Rheinberger, M | 1 |
| Büttner, R | 1 |
| Böger, CA | 1 |
| Tam, J | 1 |
| Batista, A | 1 |
| Khachatryan, A | 1 |
| Hato, T | 1 |
| Shibuya, M | 1 |
| Carmeliet, P | 1 |
| Soares, R | 1 |
| Clish, C | 1 |
| Gerszten, RE | 1 |
| Neeland, IJ | 1 |
| Chilton, R | 1 |
| Crowe, S | 1 |
| Lund, SS | 1 |
| Johansen, OE | 1 |
| Igel, LI | 1 |
| Sinha, A | 1 |
| Saunders, KH | 1 |
| McKie, EA | 1 |
| Reid, JL | 1 |
| Mistry, PC | 1 |
| DeWall, SL | 1 |
| Abberley, L | 1 |
| Ambery, PD | 1 |
| Gil-Extremera, B | 1 |
| Negrotto, L | 1 |
| Farez, MF | 1 |
| Correale, J | 1 |
| Boursi, B | 1 |
| Weiss, BM | 1 |
| Haynes, K | 1 |
| Mamtani, R | 1 |
| Yang, YX | 1 |
| De Sousa, SM | 1 |
| Amouyal, C | 1 |
| Andreelli, F | 2 |
| Ji, M | 1 |
| Xia, L | 1 |
| Cao, J | 1 |
| Zou, D | 1 |
| Topyildiz, F | 1 |
| Kiyici, S | 2 |
| Gul, Z | 1 |
| Sigirli, D | 1 |
| Guclu, M | 2 |
| Kisakol, G | 1 |
| Cavun, S | 1 |
| Kang, HS | 1 |
| Cho, HC | 1 |
| Oh, GT | 1 |
| Koo, SH | 1 |
| Park, BH | 1 |
| Lee, IK | 1 |
| Choi, HS | 1 |
| Song, DK | 1 |
| Im, SS | 1 |
| Sun, W | 1 |
| Zeng, C | 1 |
| Liao, L | 1 |
| Byun, JK | 1 |
| Jeong, JH | 1 |
| Allas, S | 1 |
| Delale, T | 1 |
| Ngo, N | 1 |
| Julien, M | 1 |
| Sahakian, P | 1 |
| Ritter, J | 1 |
| Abribat, T | 1 |
| van der Lely, AJ | 1 |
| Chen, MJ | 1 |
| Ho, HN | 1 |
| Kalra, S | 1 |
| Gupta, Y | 1 |
| Kishor, K | 1 |
| Hao, Z | 1 |
| Liao, H | 1 |
| Zheng, D | 1 |
| Xiao, C | 1 |
| Li, G | 1 |
| Seow, KM | 1 |
| Lee, WL | 1 |
| Wang, PH | 1 |
| Firouzjaei, A | 1 |
| Li, GC | 1 |
| Liu, WX | 1 |
| Zhu, BM | 1 |
| Park, J | 1 |
| Kim, WG | 1 |
| Enomoto, K | 1 |
| Willingham, M | 1 |
| Zemenová, J | 1 |
| Sýkora, D | 1 |
| Kaválková, P | 1 |
| Tena-Sempere, M | 1 |
| Luo, T | 1 |
| Nocon, A | 1 |
| Fry, J | 1 |
| Sherban, A | 1 |
| Rui, X | 1 |
| Han, J | 1 |
| Zang, M | 1 |
| Anyanwagu, U | 1 |
| Mamza, J | 1 |
| Mehta, R | 1 |
| Donnelly, R | 2 |
| Idris, I | 1 |
| Elshewehy, AM | 1 |
| Siskind, DJ | 1 |
| Leung, J | 1 |
| Russell, AW | 1 |
| Wysoczanski, D | 1 |
| Sivasinprasasn, S | 1 |
| Sa-Nguanmoo, P | 1 |
| Sahin, M | 1 |
| Corapcioglu, D | 1 |
| Stanford, FC | 1 |
| Alfaris, N | 1 |
| Misra, M | 1 |
| Hsieh, PS | 1 |
| Gai, Z | 1 |
| Visentin, M | 1 |
| Hiller, C | 1 |
| Krajnc, E | 1 |
| Li, T | 1 |
| Zhen, J | 1 |
| Kullak-Ublick, GA | 1 |
| Sam, WJ | 1 |
| Roza, O | 1 |
| Hon, YY | 1 |
| Alfaro, RM | 1 |
| Calis, KA | 2 |
| Reynolds, JC | 2 |
| Yanovski, JA | 3 |
| Dravecká, I | 3 |
| Figurová, J | 2 |
| Javorský, M | 2 |
| Petríková, J | 2 |
| Vaľková, M | 1 |
| Lazúrová, I | 3 |
| Roe, D | 1 |
| Stopeck, A | 1 |
| Thompson, PA | 1 |
| Chow, HH | 1 |
| Lapik, IA | 1 |
| Gapparova, KM | 1 |
| Sharafetdinov, KhKh | 1 |
| Sorokina, EY | 1 |
| Sentsova, TB | 1 |
| Plotnikova, OA | 1 |
| Chekhonina, YG | 1 |
| Anderson, AJ | 1 |
| Andrew, R | 2 |
| Homer, NZ | 1 |
| Jones, GC | 1 |
| Smith, K | 1 |
| Livingstone, DE | 3 |
| Stimson, RH | 1 |
| Weber, MB | 1 |
| Ranjani, H | 1 |
| Staimez, LR | 1 |
| Anjana, RM | 1 |
| Narayan, KM | 2 |
| Mohan, V | 1 |
| Balen, AH | 4 |
| Morley, LC | 1 |
| Misso, M | 1 |
| Wijeyaratne, CN | 1 |
| Fauser, BC | 1 |
| Teede, H | 1 |
| Tai, H | 1 |
| Wang, MY | 1 |
| Zhao, YP | 1 |
| Li, LB | 1 |
| Dong, QY | 1 |
| Liu, XG | 1 |
| Kuang, JS | 1 |
| Chen, LZ | 1 |
| Zhao, W | 1 |
| Zhao, SP | 1 |
| Huang, XS | 1 |
| van de Garde, EM | 1 |
| Vellanki, P | 1 |
| Smiley, DD | 1 |
| Stefanovski, D | 1 |
| Anzola, I | 1 |
| Duan, W | 1 |
| Hudson, M | 1 |
| Peng, L | 1 |
| Pasquel, FJ | 1 |
| Umpierrez, GE | 1 |
| Rzeźniczak, J | 1 |
| Wen, X | 1 |
| Camps, J | 1 |
| Hernandez-Aguilera, A | 1 |
| Garcia-Heredia, A | 1 |
| Cabre, N | 1 |
| Luciano-Mateo, F | 1 |
| Arenas, M | 1 |
| Joven, J | 1 |
| Thomas, AP | 1 |
| Hoang, J | 1 |
| Vongbunyong, K | 1 |
| Nguyen, A | 1 |
| Rakshit, K | 1 |
| Matveyenko, AV | 1 |
| Kargulewicz, A | 1 |
| Kujawska-Łuczak, M | 1 |
| Grzymisławska, M | 1 |
| Kępczyńska-Nyk, A | 1 |
| Muszel, M | 1 |
| Radziszewski, M | 1 |
| Wocial, K | 1 |
| Garibay-Nieto, N | 1 |
| Queipo-García, G | 1 |
| Alvarez, F | 1 |
| Bustos, M | 1 |
| Villanueva, E | 1 |
| Ramírez, F | 1 |
| León, M | 1 |
| Laresgoiti-Servitje, E | 1 |
| Duggirala, R | 1 |
| Macías, T | 1 |
| Cuevas, S | 1 |
| Jalife, A | 1 |
| Fonseca-Sánchez, M | 1 |
| Serratos, F | 1 |
| López-Alvarenga, JC | 1 |
| Mitchell, PL | 1 |
| Nachbar, R | 1 |
| Lachance, D | 1 |
| St-Pierre, P | 1 |
| Trottier, J | 1 |
| Barbier, O | 1 |
| de Oliveira Santana, KN | 1 |
| Lelis, DF | 1 |
| Mendes, KL | 1 |
| Lula, JF | 1 |
| Paraíso, AF | 1 |
| Andrade, JM | 1 |
| Feltenberger, JD | 1 |
| Cota, J | 1 |
| da Costa, DV | 1 |
| de Paula, AM | 1 |
| Guimarães, AL | 1 |
| Santos, SH | 1 |
| Rohde, U | 1 |
| Tabatabaei-Malazy, O | 1 |
| Nikfar, S | 1 |
| Larijani, B | 1 |
| Abdollahi, M | 1 |
| Gow, ML | 1 |
| Johnson, NA | 1 |
| Kim, T | 1 |
| Holleman, CL | 1 |
| Ptacek, T | 1 |
| Morrow, CD | 1 |
| Habegger, KM | 1 |
| Lucas-Herald, AK | 1 |
| Robertson, KJ | 1 |
| Tagliaferri, V | 2 |
| Romualdi, D | 6 |
| Immediata, V | 1 |
| De Cicco, S | 2 |
| Di Florio, C | 1 |
| Guido, M | 6 |
| Kim, AJ | 1 |
| Chang, JY | 1 |
| Shi, L | 1 |
| Chang, RC | 1 |
| Ko, ML | 1 |
| Ko, GY | 1 |
| Padilla, J | 1 |
| Thorne, PK | 1 |
| Martin, JS | 1 |
| Akter, S | 1 |
| Davis, JW | 1 |
| Jenkins, NT | 1 |
| Chen, CZ | 1 |
| Hsu, CH | 1 |
| Li, CY | 1 |
| Hsiue, TR | 1 |
| Heden, TD | 1 |
| Kanaley, JA | 1 |
| Shaw, E | 1 |
| Samat, A | 1 |
| Rahim, A | 1 |
| Barnett, A | 1 |
| Atabek, ME | 2 |
| Pirgon, O | 2 |
| Preiss, D | 1 |
| Harborne, L | 1 |
| Norman, J | 1 |
| Fleming, R | 3 |
| Cao, Y | 1 |
| Cocksedge, KA | 1 |
| Li, TC | 2 |
| Saravelos, SH | 1 |
| Metwally, M | 2 |
| Jakubowska, J | 1 |
| Bohdanowicz-Pawlak, A | 1 |
| Milewicz, A | 2 |
| Szymczak, J | 1 |
| Bednarek-Tupikowska, G | 1 |
| Demissie, M | 1 |
| Kapoor, S | 1 |
| Yao-Borengasser, A | 5 |
| Rassouli, N | 1 |
| Varma, V | 5 |
| Bodles, AM | 3 |
| Rasouli, N | 5 |
| Unal, R | 1 |
| Phanavanh, B | 3 |
| Ranganathan, G | 2 |
| McGehee, RE | 5 |
| Kern, PA | 5 |
| Shore, SA | 1 |
| Williams, ES | 1 |
| Venditti, EM | 1 |
| Carrion-Petersen, ML | 1 |
| Hoskin, MA | 1 |
| Hoeger, K | 2 |
| Davidson, K | 2 |
| Kochman, L | 3 |
| Cherry, T | 1 |
| Kopin, L | 1 |
| Guzick, DS | 3 |
| Burgert, TS | 1 |
| Duran, EJ | 1 |
| Goldberg-Gell, R | 1 |
| Dziura, J | 1 |
| Yeckel, CW | 1 |
| Katz, S | 2 |
| Caprio, S | 2 |
| Alamiri, B | 1 |
| Balf, G | 1 |
| Nar, A | 1 |
| Gedik, O | 1 |
| Drown, DJ | 1 |
| Nauck, M | 1 |
| Frid, A | 1 |
| Hermansen, K | 1 |
| Shah, NS | 1 |
| Tankova, T | 4 |
| Mitha, IH | 1 |
| Zdravkovic, M | 1 |
| Düring, M | 1 |
| Kashi, MR | 1 |
| Torres, DM | 1 |
| Harrison, SA | 1 |
| Luque-Ramírez, M | 5 |
| Alvarez-Blasco, F | 3 |
| Escobar-Morreale, HF | 5 |
| Cohen, P | 1 |
| Andreadis, EA | 1 |
| Katsanou, PM | 1 |
| Georgiopoulos, DX | 1 |
| Tsourous, GI | 1 |
| Yfanti, GK | 1 |
| Gouveri, ET | 1 |
| Diamantopoulos, EJ | 1 |
| Harvey, SB | 1 |
| Wilson-Grady, J | 1 |
| Monkkonen, T | 1 |
| Nelsestuen, GL | 1 |
| Kasthuri, RS | 1 |
| Verneris, MR | 1 |
| Lund, TC | 1 |
| Ely, EW | 1 |
| Bernard, GR | 1 |
| Zeisler, H | 1 |
| Homoncik, M | 1 |
| Jilma, B | 1 |
| Swan, T | 1 |
| Kellogg, TA | 1 |
| Palomba, S | 2 |
| Falbo, A | 1 |
| Zullo, F | 2 |
| Orio, F | 2 |
| Helvaci, MR | 2 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Yalcin, A | 2 |
| Amer, S | 1 |
| Ledger, WL | 1 |
| Ascić-Buturović, B | 3 |
| Kacila, M | 1 |
| Weigert, J | 3 |
| Neumeier, M | 3 |
| Wanninger, J | 3 |
| Schober, F | 1 |
| Sporrer, D | 2 |
| Weber, M | 2 |
| Schramm, A | 1 |
| Wurm, S | 1 |
| Stögbauer, F | 2 |
| Filarsky, M | 1 |
| Schäffler, A | 3 |
| Aslanidis, C | 2 |
| Schölmerich, J | 2 |
| Buechler, C | 3 |
| Mendieta-Azcona, C | 1 |
| del Rey Sánchez, JM | 1 |
| Matíes, M | 1 |
| Fischer, R | 1 |
| Shneider, B | 1 |
| Barba, M | 1 |
| Schünemann, HJ | 1 |
| Sperati, F | 1 |
| Akl, EA | 1 |
| Musicco, F | 1 |
| Guyatt, G | 1 |
| Mereu, R | 1 |
| Salvadeo, SA | 2 |
| Ciccarelli, L | 2 |
| Ferrari, I | 2 |
| Gravina, A | 2 |
| Svendsen, PF | 2 |
| Nilas, L | 2 |
| Holst, JJ | 2 |
| Clarson, CL | 2 |
| Mahmud, FH | 1 |
| Baker, JE | 1 |
| Clark, HE | 1 |
| McKay, WM | 1 |
| Schauteet, VD | 1 |
| Hill, DJ | 1 |
| Ackermann, RT | 2 |
| Zhang, P | 1 |
| Engelgau, MM | 1 |
| Marrero, DG | 2 |
| Adya, R | 1 |
| Farhatullah, S | 1 |
| Heutling, D | 1 |
| Mitchell, D | 1 |
| García-Escalante, MG | 1 |
| Suárez-Solís, VM | 1 |
| López-Avila, MT | 1 |
| Pinto-Escalante, Ddel C | 1 |
| Laviada-Molina, H | 1 |
| Kopelman, P | 1 |
| Groot, Gde H | 1 |
| Rissanen, A | 1 |
| Rossner, S | 1 |
| Toubro, S | 1 |
| Palmer, R | 1 |
| Hallam, R | 1 |
| Bryson, A | 1 |
| Hickling, RI | 1 |
| Miller, LJ | 1 |
| Cho, L | 1 |
| Lieberer, E | 1 |
| Bala, M | 1 |
| Kopp, A | 1 |
| Casteels, K | 1 |
| Fieuws, S | 1 |
| van Helvoirt, M | 1 |
| Verpoorten, C | 1 |
| Goemans, N | 1 |
| Coudyzer, W | 1 |
| Loeckx, D | 1 |
| Park, MH | 1 |
| Kinra, S | 2 |
| Ward, KJ | 1 |
| White, B | 1 |
| Viner, RM | 2 |
| Mitri, J | 1 |
| Hamdy, O | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Crandall, JP | 1 |
| Polsky, S | 1 |
| Howard, AA | 1 |
| Brown-Friday, J | 1 |
| Whittington, T | 1 |
| Foo, S | 1 |
| Spencer, HJ | 3 |
| Peterson, CA | 2 |
| Mehta, JL | 1 |
| Wald, AB | 1 |
| Uli, NK | 1 |
| Harris-Glocker, M | 1 |
| Guzick, D | 1 |
| Forcheron, F | 1 |
| Basset, A | 1 |
| Del Carmine, P | 1 |
| Beylot, M | 1 |
| Sari, R | 2 |
| Eray, E | 1 |
| Ozdem, S | 1 |
| Akbas, H | 1 |
| Coban, E | 2 |
| Wilson, AJ | 2 |
| Prapavessis, H | 2 |
| Jung, ME | 2 |
| Cramp, AG | 1 |
| Vascotto, J | 1 |
| Lenhardt, L | 1 |
| Shoemaker, JK | 1 |
| Watson, M | 2 |
| Robinson, T | 1 |
| Oppelt, PG | 1 |
| Mueller, A | 1 |
| Jentsch, K | 1 |
| Kronawitter, D | 1 |
| Reissmann, C | 1 |
| Dittrich, R | 1 |
| Beckmann, MW | 1 |
| Cupisti, S | 1 |
| Nawaz, FH | 1 |
| Rizvi, J | 1 |
| Shwarts, V | 1 |
| Palermo, V | 1 |
| Morgante, G | 2 |
| Petraglia, F | 3 |
| Bauer, S | 1 |
| Farkas, S | 1 |
| Scherer, MN | 1 |
| Schnitzbauer, A | 1 |
| Nader, S | 1 |
| Brown, A | 1 |
| Desai, M | 1 |
| Taneja, D | 1 |
| Tannock, LR | 1 |
| Wilson, DM | 1 |
| Abrams, SH | 2 |
| Aye, T | 1 |
| Lee, PD | 1 |
| Lenders, C | 1 |
| Lustig, RH | 2 |
| Osganian, SV | 1 |
| Feldman, HA | 1 |
| Lim, SS | 1 |
| Clifton, PM | 1 |
| Garinis, GA | 1 |
| Fruci, B | 1 |
| Mazza, A | 1 |
| De Siena, M | 1 |
| Abenavoli, S | 1 |
| Gulletta, E | 1 |
| Ventura, V | 1 |
| Greco, M | 1 |
| Belfiore, A | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Ellinger, LK | 1 |
| Ipema, HJ | 1 |
| Stachnik, JM | 1 |
| Aubert, G | 1 |
| Mansuy, V | 1 |
| Voirol, MJ | 1 |
| Pellerin, L | 1 |
| Pralong, FP | 1 |
| Souza-Mello, V | 1 |
| Gregório, BM | 1 |
| Cardoso-de-Lemos, FS | 1 |
| de Carvalho, L | 1 |
| Aguila, MB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Lavernia, F | 1 |
| Wysocki, PJ | 1 |
| Matsui, Y | 1 |
| Hirasawa, Y | 1 |
| Sugiura, T | 1 |
| Toyoshi, T | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Bestermann, WH | 1 |
| Hou, M | 1 |
| Venier, N | 1 |
| Sugar, L | 1 |
| Musquera, M | 1 |
| Kiss, A | 1 |
| Fleshner, N | 1 |
| Klotz, L | 1 |
| Venkateswaran, V | 1 |
| Aghahosseini, M | 1 |
| Aleyaseen, A | 1 |
| Safdarian, L | 1 |
| Moddaress-Hashemi, S | 1 |
| Mofid, B | 1 |
| Kashani, L | 2 |
| Logie, L | 1 |
| Ruiz-Alcaraz, AJ | 1 |
| Schofield, CJ | 1 |
| Hundal, HS | 1 |
| Feuerstein, GZ | 1 |
| Brady, JD | 1 |
| Crowther, D | 1 |
| Tommasi, AM | 1 |
| Grierson, CE | 1 |
| Shepherd, B | 1 |
| Morris, AD | 3 |
| Hansen, MK | 1 |
| Pearson, E | 1 |
| Sutherland, C | 1 |
| Tharayil, V | 1 |
| Roberts, LR | 2 |
| Kane, DA | 1 |
| Anderson, EJ | 1 |
| Price, JW | 1 |
| Woodlief, TL | 1 |
| Lin, CT | 1 |
| Bikman, BT | 1 |
| Cortright, RN | 1 |
| Neufer, PD | 1 |
| Sukkari, SR | 1 |
| Sasich, LD | 1 |
| Humaidan, AS | 1 |
| Burikan, O | 1 |
| Wiegand, S | 1 |
| l'Allemand, D | 1 |
| Hübel, H | 1 |
| Krude, H | 1 |
| Bürmann, M | 1 |
| Martus, P | 1 |
| Grüters, A | 1 |
| Holl, RW | 1 |
| Cone, CJ | 1 |
| Bachyrycz, AM | 1 |
| Murata, GH | 1 |
| Abbruzzese, JL | 1 |
| Walker, DM | 1 |
| Atiomo, W | 1 |
| Pramyothin, P | 1 |
| Khaodhiar, L | 1 |
| Brouwers, MC | 1 |
| de Graaf, J | 1 |
| van Greevenbroek, MM | 1 |
| Schaper, N | 1 |
| Stehouwer, CD | 1 |
| Stalenhoef, AF | 1 |
| Jang, EH | 1 |
| Kim, HK | 1 |
| Park, CS | 1 |
| Kang, JH | 1 |
| Lee, HH | 1 |
| Yeh, CH | 1 |
| Chen, YT | 1 |
| Chi, TC | 1 |
| Cheng, JT | 1 |
| Lo, SH | 1 |
| Macaluso, M | 1 |
| McHale, RJ | 1 |
| Dahmen, MM | 1 |
| Girrens, K | 1 |
| Ali, F | 1 |
| de la Fuente-Valero, J | 1 |
| Zapardiel-Gutiérrez, I | 1 |
| Orensanz-Fernández, I | 1 |
| Alvarez-Alvarez, P | 1 |
| Engels-Calvo, V | 1 |
| Bajo-Arenas, JM | 1 |
| Sabater, M | 1 |
| Pardo, G | 1 |
| Al-Jebawi, AF | 1 |
| Migoya, EM | 1 |
| Bergeron, R | 1 |
| Miller, JL | 2 |
| Snyder, RN | 1 |
| Tanen, M | 1 |
| Hilliard, D | 1 |
| Weiss, B | 1 |
| Larson, P | 1 |
| Gutierrez, M | 1 |
| Pryor, KA | 1 |
| Yao, J | 2 |
| Deacon, C | 1 |
| Herman, G | 1 |
| Thornberry, N | 1 |
| Amatruda, J | 1 |
| Williams-Herman, D | 1 |
| Wagner, JA | 1 |
| SinhaRoy, R | 1 |
| Rezvanian, H | 1 |
| Hashemipour, M | 1 |
| Kelishadi, R | 1 |
| Tavakoli, N | 1 |
| Poursafa, P | 1 |
| Ijäs, H | 1 |
| Morin-Papunen, L | 2 |
| Keravuo, R | 1 |
| Ebeling, T | 1 |
| Saarela, T | 1 |
| Raudaskoski, T | 1 |
| Kilic, S | 1 |
| Yilmaz, N | 1 |
| Zulfikaroglu, E | 1 |
| Erdogan, G | 1 |
| Aydin, M | 1 |
| Batioglu, S | 1 |
| Jermendy, G | 1 |
| Mellor, DD | 1 |
| Hasnain, M | 1 |
| Fredrickson, SK | 1 |
| Vieweg, WV | 1 |
| Kitzmann, M | 1 |
| Hébrard, S | 1 |
| Mercier, J | 1 |
| Aguer, C | 1 |
| González Jiménez, E | 1 |
| Schmidt Río-Valle, J | 1 |
| Álvarez Ferre, J | 1 |
| Krakoff, J | 1 |
| Salaita, CG | 1 |
| McDuffie, JR | 1 |
| Kozlosky, M | 1 |
| Sebring, NG | 1 |
| Brady, SM | 1 |
| Yasmin, E | 1 |
| Glanville, J | 2 |
| Barth, J | 1 |
| Numbenjapon, N | 1 |
| Nakavachara, P | 1 |
| Santiprabhob, J | 1 |
| Kiattisakthavee, P | 1 |
| Wongarn, R | 1 |
| Likitmaskul, S | 2 |
| Greydanus, DE | 1 |
| Bricker, LA | 1 |
| Feucht, C | 1 |
| Krzystek-Korpacka, M | 1 |
| Patryn, E | 1 |
| Kustrzeba-Wojcicka, I | 1 |
| Gamian, A | 1 |
| Muntoni, S | 2 |
| Proto, C | 3 |
| Duan, Ym | 1 |
| Yuan, Zf | 1 |
| Zhang, Tt | 1 |
| Guo, Xh | 2 |
| Brufani, C | 1 |
| Fintini, D | 1 |
| Nobili, V | 1 |
| Patera, PI | 1 |
| Cappa, M | 1 |
| Brufani, M | 1 |
| Liepinsh, E | 1 |
| Skapare, E | 1 |
| Svalbe, B | 1 |
| Makrecka, M | 1 |
| Cirule, H | 1 |
| Dambrova, M | 1 |
| Zulian, A | 1 |
| Cancello, R | 1 |
| Girola, A | 1 |
| Gilardini, L | 1 |
| Alberti, L | 1 |
| Croci, M | 1 |
| Micheletto, G | 1 |
| Danelli, P | 1 |
| Invitti, C | 1 |
| Fonseca, EA | 1 |
| de Oliveira, MA | 1 |
| Lobato, Nde S | 1 |
| Colquhoun, A | 1 |
| Zyngier, SB | 1 |
| Petrányi, G | 1 |
| Zaoura-Petrányi, M | 1 |
| Johnson, N | 1 |
| Ghandi, S | 1 |
| Aflatoonian, A | 1 |
| Tabibnejad, N | 1 |
| Moghaddam, MH | 1 |
| Lavine, JE | 3 |
| Schwimmer, JB | 3 |
| Van Natta, ML | 1 |
| Molleston, JP | 1 |
| Murray, KF | 1 |
| Rosenthal, P | 1 |
| Scheimann, AO | 1 |
| Sanyal, AJ | 1 |
| Tonascia, J | 1 |
| Ünalp, A | 1 |
| Brunt, EM | 1 |
| Kleiner, DE | 1 |
| Hoofnagle, JH | 1 |
| Robuck, PR | 1 |
| Sharif, A | 1 |
| Pacifico, L | 1 |
| Anania, C | 1 |
| Martino, F | 1 |
| Poggiogalle, E | 1 |
| Chiarelli, F | 1 |
| Arca, M | 1 |
| Chiesa, C | 1 |
| Svacina, S | 1 |
| Hopkins, KF | 1 |
| Decristofaro, C | 1 |
| Sathyanarayana, P | 2 |
| Jogi, M | 2 |
| Muthupillai, R | 2 |
| Krishnamurthy, R | 2 |
| Samson, SL | 2 |
| Bajaj, M | 2 |
| Shi, Y | 1 |
| Ming, J | 1 |
| Rosta, A | 1 |
| Yeager, CA | 1 |
| Winsberg, B | 1 |
| Hobbs, B | 1 |
| Eid, WE | 1 |
| Caton, PW | 1 |
| Kieswich, J | 1 |
| Yaqoob, MM | 1 |
| Holness, MJ | 1 |
| Sugden, MC | 1 |
| Essah, PA | 1 |
| Arrowood, JA | 1 |
| Cheang, KI | 1 |
| Adawadkar, SS | 1 |
| Stovall, DW | 1 |
| Koiou, E | 1 |
| Tziomalos, K | 1 |
| Katsikis, I | 1 |
| Kandaraki, EA | 1 |
| Kalaitzakis, E | 1 |
| Delkos, D | 1 |
| Vosnakis, C | 1 |
| Panidis, D | 1 |
| Hsia, Y | 1 |
| Dawoud, D | 1 |
| Sutcliffe, AG | 1 |
| Wong, IC | 1 |
| Meneghini, LF | 1 |
| Orozco-Beltran, D | 1 |
| Caputo, S | 1 |
| Damçi, T | 1 |
| Liebl, A | 2 |
| Ross, SA | 1 |
| Aberle, J | 1 |
| Reining, F | 1 |
| Dannheim, V | 1 |
| Flitsch, J | 1 |
| Klinge, A | 1 |
| Mann, O | 1 |
| Burlá, AK | 1 |
| Lobato, NS | 2 |
| Oigman, W | 1 |
| Neves, MF | 1 |
| Gonzalez, EV | 1 |
| Gutierrez, A | 1 |
| Chan, L | 1 |
| Stambolic, V | 1 |
| Rynders, C | 1 |
| Weltman, A | 2 |
| Delgiorno, C | 2 |
| Balagopal, P | 2 |
| Damaso, L | 2 |
| Killen, K | 2 |
| Mauras, N | 2 |
| Kostev, K | 1 |
| Richter, H | 1 |
| Sullivan, SD | 1 |
| Umans, JG | 1 |
| Ratner, R | 2 |
| Ryan, DH | 1 |
| Buler, M | 1 |
| Aatsinki, SM | 1 |
| Skoumal, R | 1 |
| Komka, Z | 1 |
| Tóth, M | 1 |
| Kerkelä, R | 1 |
| Georgiadi, A | 1 |
| Kersten, S | 1 |
| Hakkola, J | 1 |
| Li, XM | 1 |
| Zhang, NN | 1 |
| Xie, YH | 1 |
| Shi, YQ | 1 |
| Filgueira, FP | 1 |
| Hagihara, GN | 1 |
| Pariz, JR | 1 |
| Tostes, RC | 1 |
| Carvalho, MH | 1 |
| Pujante Alarcón, P | 1 |
| Hellín Gil, MD | 1 |
| Román, LM | 1 |
| Ferrer Gómez, M | 1 |
| García Zafra, MV | 1 |
| Tébar Massó, J | 1 |
| Gage, D | 1 |
| Pyra, KA | 1 |
| Saha, DC | 1 |
| Reimer, RA | 1 |
| Cramp, A | 1 |
| Simatovic, J | 1 |
| Clarson, C | 1 |
| Vona-Davis, L | 1 |
| Rose, DP | 1 |
| Bardin, C | 1 |
| Nobecourt, E | 1 |
| Larger, E | 1 |
| Chast, F | 1 |
| Treluyer, JM | 1 |
| Urien, S | 1 |
| Deji, N | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Chin-Kanasaki, M | 1 |
| Tanaka, Y | 2 |
| Nishiyama, A | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Le Donne, M | 1 |
| Alibrandi, A | 1 |
| Giarrusso, R | 1 |
| Lo Monaco, I | 1 |
| Muraca, U | 1 |
| Ghazeeri, GS | 1 |
| Nassar, AH | 1 |
| Younes, Z | 1 |
| Awwad, JT | 1 |
| Weickert, MO | 1 |
| Hodges, P | 1 |
| Kuller, LH | 1 |
| Thondam, SK | 1 |
| Cross, A | 1 |
| Wilding, JP | 1 |
| Daousi, C | 1 |
| Janczyk, W | 1 |
| Socha, P | 1 |
| He, H | 1 |
| Zhao, Z | 1 |
| Ni, Y | 1 |
| Zhong, J | 1 |
| Pletcher, MJ | 1 |
| Zhu, Z | 1 |
| Xu, QY | 1 |
| Jia, C | 1 |
| Peng, YF | 1 |
| Zadik, Z | 1 |
| Evia-Viscarra, ML | 1 |
| Rodea-Montero, ER | 1 |
| Apolinar-Jiménez, E | 1 |
| Muñoz-Noriega, N | 1 |
| García-Morales, LM | 1 |
| Leaños-Pérez, C | 1 |
| Figueroa-Barrón, M | 1 |
| Sánchez-Fierros, D | 1 |
| Hossain, J | 1 |
| Bird, K | 1 |
| Merinbaum, D | 1 |
| Zhai, J | 1 |
| Liu, CX | 1 |
| Tian, ZR | 1 |
| Jiang, QH | 1 |
| Sun, YP | 1 |
| Berstein, LM | 1 |
| Costello, MF | 2 |
| Misso, ML | 1 |
| Wong, J | 1 |
| Hart, R | 1 |
| Rombauts, L | 1 |
| Melder, A | 1 |
| Akcam, M | 1 |
| Boyaci, A | 1 |
| Kaya, S | 1 |
| Uysal, S | 1 |
| Dundar, BN | 1 |
| Shu, J | 1 |
| Teichman, PG | 1 |
| Xing, L | 1 |
| Florez, H | 2 |
| Delahanty, L | 2 |
| Kriska, A | 2 |
| Saudek, CD | 1 |
| Rubin, RR | 1 |
| Mizokami-Stout, K | 1 |
| Cree-Green, M | 1 |
| Brower, V | 1 |
| Brown, KA | 1 |
| Samarajeewa, NU | 1 |
| Simpson, ER | 1 |
| Curtis, J | 1 |
| Newall, H | 1 |
| Myles, N | 1 |
| Shiers, D | 1 |
| Samaras, K | 1 |
| Hutcheson, R | 1 |
| Rocic, P | 1 |
| Cui, Y | 1 |
| Lansdown, A | 1 |
| Rees, DA | 1 |
| Yuan, GH | 1 |
| Song, WL | 1 |
| Huang, YY | 1 |
| Omidvar, T | 1 |
| Farazmand, B | 1 |
| Modabbernia, A | 1 |
| Ramzanzadeh, F | 1 |
| Tehraninejad, ES | 1 |
| Ashrafi, M | 1 |
| Tabrizi, M | 1 |
| Akhondzadeh, S | 1 |
| Fradkin, JE | 1 |
| Roberts, BT | 1 |
| Rodgers, GP | 1 |
| de Oliveira Baraldi, C | 1 |
| Moisés, EC | 1 |
| de Jesus Ponte Carvalho, TM | 1 |
| de Jesus Antunes, N | 1 |
| Lanchote, VL | 1 |
| Duarte, G | 1 |
| Cavalli, RC | 1 |
| Lemmens-Gruber, R | 1 |
| Gi, YJ | 1 |
| Chakravarti, D | 1 |
| Chan, IL | 1 |
| Zhang, A | 1 |
| Tsai, KY | 1 |
| Flores, ER | 1 |
| Gonzalez-Angulo, AM | 1 |
| Murray, JL | 1 |
| Green, MC | 1 |
| Koenig, KB | 1 |
| Chaiteerakij, R | 1 |
| Yang, JD | 1 |
| Harmsen, WS | 1 |
| Slettedahl, SW | 1 |
| Mettler, TA | 1 |
| Fredericksen, ZS | 1 |
| Kim, WR | 1 |
| Gores, GJ | 1 |
| Roberts, RO | 1 |
| Olson, JE | 1 |
| Therneau, TM | 1 |
| Falk, B | 1 |
| Dotan, R | 1 |
| Geier, LM | 1 |
| Bekx, MT | 1 |
| Connor, EL | 1 |
| Usadi, RS | 1 |
| Bouza, C | 1 |
| López-Cuadrado, T | 1 |
| Gutierrez-Torres, LF | 1 |
| Amate, J | 1 |
| Mohsen, IA | 1 |
| Elkattan, E | 1 |
| Nabil, H | 1 |
| Khattab, S | 1 |
| Sollon, C | 1 |
| Mónica, FZ | 1 |
| De Nucci, G | 1 |
| Zanesco, A | 1 |
| Grant, AD | 1 |
| Seifarth, C | 1 |
| Schehler, B | 1 |
| Schneider, HJ | 1 |
| Kendall, D | 1 |
| Vail, A | 1 |
| Amin, R | 1 |
| Barrett, T | 1 |
| Dimitri, P | 1 |
| Ivison, F | 1 |
| Kibirige, M | 1 |
| Mathew, V | 1 |
| Matyka, K | 1 |
| McGovern, A | 1 |
| Stirling, H | 1 |
| Tetlow, L | 1 |
| Wales, J | 1 |
| Wright, N | 1 |
| Clayton, P | 1 |
| Mahmood, K | 1 |
| Naeem, M | 1 |
| Rahimnajjad, NA | 1 |
| Bates, GW | 2 |
| Propst, AM | 2 |
| Haq, S | 1 |
| Ali, S | 1 |
| Mohammad, R | 1 |
| Sarkar, FH | 1 |
| Muniraj, T | 1 |
| Chari, ST | 1 |
| Esfahanian, F | 1 |
| Zamani, MM | 1 |
| Heshmat, R | 1 |
| Moini nia, F | 1 |
| Kim, HJ | 1 |
| Zhang, XH | 1 |
| Park, EY | 1 |
| Shin, KH | 1 |
| Choi, SH | 1 |
| Chun, BG | 1 |
| Kim, DH | 1 |
| Brännmark, C | 1 |
| Nyman, E | 1 |
| Fagerholm, S | 1 |
| Bergenholm, L | 1 |
| Ekstrand, EM | 1 |
| Cedersund, G | 1 |
| Strålfors, P | 1 |
| Werneke, U | 1 |
| Taylor, D | 1 |
| Sanders, TA | 1 |
| Dove, A | 1 |
| Serrano Rios, M | 1 |
| Ascaso Gimilio, JF | 1 |
| Blázquez Fernández, E | 1 |
| Cabezas Cerraro, J | 1 |
| Carmena Rodríguez, R | 1 |
| Escobar Jiménez, F | 1 |
| Gabriel Sánchez, R | 1 |
| Gomis de Barberá, R | 1 |
| Grande Aragón, C | 1 |
| Herrera Pomba, JL | 1 |
| Pallardo Sánchez, LF | 1 |
| Potau Vilalta, N | 1 |
| Ricart Engel, W | 1 |
| Rovira Loscos, A | 1 |
| Zorzano Olarte, A | 1 |
| Koev, D | 2 |
| Dakovska, L | 2 |
| Kirilov, G | 2 |
| Vicennati, V | 2 |
| Heiman, ML | 1 |
| Tschöp, M | 1 |
| Potau, N | 1 |
| Ferrer, A | 1 |
| Rodriguez-Hierro, F | 1 |
| Marcos, MV | 1 |
| Solignac, M | 1 |
| McNulty, SJ | 1 |
| Ur, E | 1 |
| Williams, G | 1 |
| Nambi, V | 1 |
| Hoogwerf, BJ | 1 |
| Sprecher, DL | 1 |
| Phillips, P | 1 |
| Karrasch, J | 1 |
| Scott, R | 1 |
| Wilson, D | 1 |
| Moses, R | 1 |
| Kiattisathavee, P | 1 |
| Chaichanwatanakul, K | 1 |
| Punnakanta, L | 1 |
| Angsusingha, K | 1 |
| Tuchinda, C | 1 |
| Phillips, SA | 1 |
| Kong, AP | 2 |
| Bandukwala, R | 1 |
| Aroda, V | 1 |
| Carter, L | 1 |
| Baxi, S | 2 |
| Mudaliar, SR | 1 |
| Henry, RR | 2 |
| Haas, DA | 1 |
| Carr, BR | 1 |
| Attia, GR | 1 |
| Hanefeld, M | 1 |
| Fischer, S | 1 |
| Das, S | 1 |
| Jones, TA | 1 |
| Sautter, M | 1 |
| Jones, NP | 1 |
| Decsi, T | 1 |
| Molnár, D | 1 |
| Yoshioka, K | 1 |
| Yoshida, T | 1 |
| Yoshikawa, T | 1 |
| Bernard, L | 1 |
| Christin-Maître, S | 1 |
| Basille, C | 1 |
| Chabbert-Buffet, N | 1 |
| Chou, KH | 2 |
| von Eye Corleta, H | 2 |
| Capp, E | 2 |
| Binnert, C | 1 |
| Seematter, G | 1 |
| Tappy, L | 1 |
| Giusti, V | 1 |
| Valabhji, J | 1 |
| Cox, J | 1 |
| Poulter, C | 1 |
| Elwig, C | 1 |
| Elkeles, RS | 1 |
| Gunton, JE | 1 |
| Twigg, SM | 2 |
| Stefanović, V | 1 |
| Antić, S | 1 |
| Mitić-Zlatković, M | 1 |
| Stojiljković, S | 1 |
| Milojković, M | 1 |
| Bogicević, M | 1 |
| Vlahović, P | 1 |
| Orban, JC | 1 |
| Giunti, C | 1 |
| Levraut, J | 1 |
| Grimaud, D | 1 |
| Ichai, C | 1 |
| Glueck, CJ | 5 |
| Moreira, A | 1 |
| Goldenberg, N | 1 |
| Sieve, L | 1 |
| Wang, P | 4 |
| Satoh, J | 1 |
| Quarry-Horn, JL | 1 |
| Evans, BJ | 1 |
| Kerrigan, JR | 1 |
| Grinstein, G | 1 |
| Muzumdar, R | 1 |
| Aponte, L | 1 |
| Vuguin, P | 1 |
| Saenger, P | 1 |
| DiMartino-Nardi, J | 1 |
| Peter, P | 1 |
| Kumar, S | 1 |
| Siraj, ES | 1 |
| TEITELBAUM, M | 1 |
| LEMARCHANT, JM | 1 |
| PEDERSEN, J | 2 |
| Després, JP | 1 |
| Mamputu, JC | 1 |
| Wiernsperger, NF | 1 |
| Renier, G | 1 |
| Rautio, K | 2 |
| Ruokonen, A | 6 |
| Hedberg, P | 1 |
| Puukka, M | 1 |
| Tapanainen, JS | 4 |
| la Marca, A | 1 |
| Eagleson, CA | 1 |
| Bellows, AB | 1 |
| Hu, K | 1 |
| Gingrich, MB | 1 |
| Marshall, JC | 1 |
| Poulsen, MK | 1 |
| Henriksen, JE | 1 |
| Hother-Nielsen, O | 3 |
| Beck-Nielsen, H | 5 |
| Ibrahim, TM | 1 |
| Plank, J | 1 |
| Bock, GM | 1 |
| Magill, SB | 1 |
| Weiss, D | 1 |
| Iannello, S | 1 |
| Camuto, M | 1 |
| Cavaleri, A | 1 |
| Milazzo, P | 1 |
| Pisano, MG | 1 |
| Bellomia, D | 1 |
| Belfiore, F | 1 |
| Lawrence, JM | 1 |
| Reid, J | 1 |
| Taylor, GJ | 1 |
| Stirling, C | 1 |
| Reckless, JP | 1 |
| Genazzani, AD | 1 |
| Battaglia, C | 1 |
| Malavasi, B | 1 |
| Strucchi, C | 1 |
| Tortolani, F | 1 |
| Gamba, O | 1 |
| Baillargeon, JP | 1 |
| Iuorno, MJ | 2 |
| Jakubowicz, DJ | 4 |
| Apridonidze, T | 1 |
| He, N | 1 |
| Genghini, S | 1 |
| Morselli-Labate, AM | 3 |
| Cacciari, M | 2 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Bin-Abbas, BS | 1 |
| Al-Ashwal, AA | 1 |
| Maciel, GA | 1 |
| Soares Júnior, JM | 1 |
| Alves da Motta, EL | 1 |
| Abi Haidar, M | 1 |
| de Lima, GR | 1 |
| Baracat, EC | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Barbieri, RL | 2 |
| Gargiulo, AR | 1 |
| Kellerer, M | 1 |
| Jakob, S | 1 |
| Linn, T | 1 |
| Haslbeck, M | 1 |
| Herrmann, BL | 2 |
| Berg, C | 2 |
| Vogel, E | 1 |
| Nowak, T | 1 |
| Renzing-Koehler, K | 1 |
| Mann, K | 4 |
| Saller, B | 2 |
| Manzella, D | 1 |
| Grella, R | 1 |
| Esposito, K | 2 |
| Giugliano, D | 5 |
| Barbagallo, M | 1 |
| Homburg, R | 2 |
| Lambalk, CB | 1 |
| Belosi, C | 1 |
| Selvaggi, L | 2 |
| Cariou, B | 1 |
| Capitaine, N | 1 |
| Le Marcis, V | 1 |
| Vega, N | 1 |
| Béréziat, V | 1 |
| Kergoat, M | 1 |
| Laville, M | 1 |
| Girard, J | 1 |
| Vidal, H | 1 |
| Burnol, AF | 1 |
| Maggs, DG | 2 |
| Ruggles, JA | 1 |
| Fineman, M | 1 |
| Kolterman, OG | 1 |
| Weyer, C | 1 |
| Avenell, A | 1 |
| Broom, J | 1 |
| Brown, TJ | 1 |
| Poobalan, A | 1 |
| Aucott, L | 1 |
| Stearns, SC | 1 |
| Smith, WC | 1 |
| Jung, RT | 1 |
| Campbell, MK | 1 |
| Grant, AM | 1 |
| Weill, J | 1 |
| Vanderbecken, S | 1 |
| Froguel, P | 1 |
| Dandona, P | 2 |
| Chaudhuri, A | 2 |
| Mohanty, P | 2 |
| Balci, MK | 1 |
| Yazicioglu, G | 1 |
| Saleh, AM | 1 |
| Khalil, HS | 1 |
| Enriquez, YR | 1 |
| Giri, M | 2 |
| Rottiers, R | 2 |
| Christophe, A | 1 |
| Hoeger, KM | 1 |
| Wixom, N | 1 |
| Craig, K | 1 |
| Miller, RK | 1 |
| Komori, T | 1 |
| Yoshida, F | 1 |
| Nakamura, J | 1 |
| Miyazaki, S | 1 |
| Miura, H | 1 |
| Iguchi, A | 1 |
| Ghanim, H | 1 |
| Tripathy, C | 1 |
| Hofmeyer, D | 1 |
| Zhang, YW | 1 |
| Schuster, D | 1 |
| Gaillard, T | 1 |
| Rhinesmith, S | 1 |
| Habash, D | 1 |
| Osei, K | 1 |
| Rodríguez, Y | 1 |
| Feyen, E | 1 |
| Christophe, AB | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 2 |
| Hamann, A | 4 |
| Morcos, M | 1 |
| Nawroth, P | 1 |
| Putz, DM | 1 |
| Goldner, WS | 1 |
| Bar, RS | 1 |
| Haynes, WG | 1 |
| Sivitz, WI | 1 |
| Doggrell, SA | 1 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 3 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Ghali, P | 1 |
| Lindor, KD | 1 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| Stratmann, M | 1 |
| Janssen, OE | 3 |
| Kumari, AS | 1 |
| Haq, A | 1 |
| Jayasundaram, R | 1 |
| Abdel-Wareth, LO | 1 |
| Al Haija, SA | 1 |
| Alvares, M | 1 |
| González, S | 1 |
| Morin-Papunen, LC | 5 |
| McCarty, MF | 2 |
| Berne, C | 1 |
| Haffner, S | 2 |
| Temprosa, M | 1 |
| Crandall, J | 1 |
| Fowler, S | 1 |
| Goldberg, R | 1 |
| Marcovina, S | 1 |
| Mather, K | 1 |
| Orchard, T | 1 |
| Harborne, LR | 1 |
| Mannucci, E | 3 |
| Tesi, F | 1 |
| Bardini, G | 2 |
| Ognibene, A | 2 |
| Petracca, MG | 1 |
| Ciani, S | 2 |
| Pezzatini, A | 1 |
| Brogi, M | 1 |
| Cremasco, F | 2 |
| Messeri, G | 2 |
| Yki-Järvinen, H | 1 |
| Westerbacka, J | 1 |
| James, AP | 1 |
| Watts, GF | 1 |
| Mamo, JC | 1 |
| Moreno Sánchez, D | 1 |
| Wainstein, J | 1 |
| Metzger, M | 1 |
| Boaz, M | 1 |
| Minuchin, O | 1 |
| Cohen, Y | 1 |
| Yaffe, A | 1 |
| Yerushalmy, Y | 1 |
| Harman-Boehm, I | 1 |
| Di Gregorio, GB | 1 |
| Miles, LM | 1 |
| Carter, AM | 1 |
| Bennett, CE | 1 |
| Bostock, JA | 1 |
| Grant, PJ | 1 |
| Nørgaard, K | 1 |
| Fujita, H | 1 |
| Fujishima, H | 1 |
| Koshimura, J | 1 |
| Hosoba, M | 1 |
| Yoshioka, N | 1 |
| Shimotomai, T | 1 |
| Morii, T | 1 |
| Narita, T | 1 |
| Kakei, M | 1 |
| Ito, S | 1 |
| Qublan, HS | 2 |
| Malkawi, HY | 1 |
| Fernández Fernández, I | 1 |
| Tang, T | 1 |
| Hayden, CJ | 1 |
| White, D | 1 |
| Barth, JH | 1 |
| Allen, HF | 1 |
| Mazzoni, C | 1 |
| Heptulla, RA | 1 |
| Murray, MA | 1 |
| Miller, N | 1 |
| Koenigs, L | 1 |
| Reiter, EO | 1 |
| McInnes, KJ | 1 |
| Meyer, C | 1 |
| Giuliani, M | 1 |
| Suriano, R | 1 |
| Tienforti, D | 1 |
| Costantini, B | 1 |
| Onalan, G | 1 |
| Goktolga, U | 1 |
| Ceyhan, T | 1 |
| Bagis, T | 1 |
| Onalan, R | 1 |
| Pabuçcu, R | 1 |
| Bekker, D | 1 |
| Mietus-Snyder, ML | 1 |
| Bacchetti, P | 1 |
| Lazar, AA | 1 |
| Velasquez-Mieyer, PA | 1 |
| Christensen, ML | 1 |
| Donnelly, LA | 1 |
| Doney, AS | 1 |
| Hattersley, AT | 1 |
| Martín Muñoz, MC | 1 |
| Díaz, JM | 1 |
| Muros Bayo, JM | 1 |
| González Alvaro, A | 1 |
| Costa Zamora, P | 1 |
| Yilmaz, M | 1 |
| Biri, A | 1 |
| Karakoç, A | 1 |
| Törüner, F | 1 |
| Bingöl, B | 1 |
| Cakir, N | 1 |
| Tiras, B | 1 |
| Ayvaz, G | 1 |
| Arslan, M | 1 |
| Kim, YW | 1 |
| Kim, JY | 1 |
| Park, YH | 1 |
| Park, SY | 1 |
| Won, KC | 1 |
| Choi, KH | 1 |
| Huh, JY | 1 |
| Moon, KH | 1 |
| Khorram, O | 1 |
| Helliwell, JP | 1 |
| Bonpane, CM | 1 |
| Jaramillo, L | 1 |
| Tepsa, M | 1 |
| Yap, F | 1 |
| Ward, GM | 1 |
| Taleux, N | 1 |
| Guigas, B | 1 |
| Horman, S | 1 |
| Beauloye, C | 1 |
| Bertrand, L | 1 |
| Baptista, T | 3 |
| Martínez, J | 1 |
| Lacruz, A | 1 |
| Rangel, N | 2 |
| Beaulieu, S | 2 |
| Serrano, A | 1 |
| Arapé, Y | 1 |
| de Mendoza, S | 2 |
| Teneud, L | 1 |
| Musi, N | 1 |
| Goodyear, LJ | 1 |
| Liang, L | 2 |
| Fu, JF | 2 |
| Zou, CC | 2 |
| Hong, F | 2 |
| Wang, CL | 2 |
| Wang, XM | 2 |
| Toplak, H | 1 |
| Moore, R | 1 |
| Masson, E | 1 |
| Gorska, M | 1 |
| Vercruysse, F | 1 |
| Fitchet, M | 1 |
| Oh, DK | 1 |
| Christiansen, L | 1 |
| Nikoulina, SE | 1 |
| Mudaliar, S | 1 |
| Piomboni, P | 1 |
| Beale, S | 1 |
| Bagust, A | 3 |
| Shearer, AT | 3 |
| Martin, A | 1 |
| Hulme, L | 1 |
| Schoeffski, O | 1 |
| Goertz, A | 1 |
| Ampudia-Blasco, FJ | 1 |
| Martínez-Lage Alvarez, B | 1 |
| Pérez Escolano, I | 1 |
| París, G | 1 |
| Krstevska, B | 1 |
| Dimitrovski, Ch | 1 |
| Pemovska, G | 1 |
| Misevska, S | 1 |
| Dimova, Z | 1 |
| Simeonova, S | 1 |
| Ahmeti, I | 1 |
| Patton, L | 1 |
| Vaccina, A | 1 |
| Cavazza, C | 1 |
| Silverstein, JH | 1 |
| Essais, O | 1 |
| Bouzid, C | 1 |
| Ouni, Z | 1 |
| Ibrahim, H | 1 |
| Ouertani, H | 1 |
| Machghoul, S | 1 |
| Zidi, B | 1 |
| Pfützner, A | 1 |
| Schneider, CA | 1 |
| Forst, T | 1 |
| Webb, E | 1 |
| Viner, R | 1 |
| Vick, MM | 1 |
| Sessions, DR | 1 |
| Murphy, BA | 1 |
| Kennedy, EL | 1 |
| Reedy, SE | 1 |
| Fitzgerald, BP | 1 |
| Zhao, ZY | 1 |
| Dastjerdi, MS | 1 |
| Kazemi, F | 1 |
| Najafian, A | 1 |
| Mohammady, M | 1 |
| Aminorroaya, A | 1 |
| Amini, M | 1 |
| Schmidt-Trucksäss, A | 1 |
| Bellot-Rojas, P | 1 |
| Posadas-Sanchez, R | 1 |
| Caracas-Portilla, N | 1 |
| Zamora-Gonzalez, J | 1 |
| Cardoso-Saldaña, G | 1 |
| Jurado-Santacruz, F | 1 |
| Posadas-Romero, C | 1 |
| Hahn, S | 2 |
| Frey, UH | 1 |
| Siffert, W | 1 |
| Tan, S | 2 |
| Ong, CR | 1 |
| Molyneaux, LM | 1 |
| Constantino, MI | 1 |
| Yue, DK | 1 |
| Lee, MJ | 2 |
| Starks, T | 2 |
| Kern, LM | 2 |
| Fried, SK | 2 |
| Bouma, M | 1 |
| Rutten, GE | 1 |
| Wiersma, T | 1 |
| Towbin, KE | 1 |
| Klein, DJ | 1 |
| Cottingham, EM | 2 |
| Sorter, M | 1 |
| Morrison, JA | 2 |
| Guimarães, C | 1 |
| Pereira, LR | 1 |
| Iucif Júnior, N | 1 |
| Cesarino, EJ | 1 |
| de Almeida, CA | 1 |
| de Carvalho, D | 1 |
| Queiroz, RH | 1 |
| Inagaki, K | 1 |
| Suzuki, A | 1 |
| Nagata, M | 1 |
| Sekiguchi, S | 1 |
| Itoi, T | 1 |
| Asano, S | 1 |
| Hiroaki, K | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Itoh, M | 1 |
| Towler, MC | 1 |
| Hardie, DG | 1 |
| Seibel, SA | 1 |
| Gadde, KM | 1 |
| Strauss, R | 1 |
| Leung, A | 1 |
| Klonoff, DC | 1 |
| Nielsen, LL | 1 |
| Guan, X | 1 |
| Bowlus, CL | 1 |
| Holcombe, JH | 1 |
| Wintle, ME | 1 |
| Schroeder-Gloeckler, JM | 1 |
| Rahman, SM | 1 |
| Janssen, RC | 1 |
| Qiao, L | 1 |
| Shao, J | 1 |
| Roper, M | 1 |
| Fischer, SJ | 1 |
| Lowe, E | 1 |
| Orlicky, DJ | 1 |
| McManaman, JL | 1 |
| Palmer, C | 1 |
| Gitomer, WL | 1 |
| O'Doherty, RM | 1 |
| Becker, TC | 1 |
| Klemm, DJ | 1 |
| Jensen, DR | 1 |
| Pulawa, LK | 1 |
| Eckel, RH | 1 |
| Friedman, JE | 1 |
| Brunani, A | 1 |
| Caumo, A | 1 |
| Graci, S | 1 |
| Castagna, G | 1 |
| Viberti, G | 1 |
| Liuzzi, A | 1 |
| Hoffmann, IS | 2 |
| Alfieri, AB | 2 |
| Cubeddu, LX | 2 |
| Yurgin, N | 1 |
| Secnik, K | 1 |
| Lage, MJ | 1 |
| Botella-Carretero, JI | 1 |
| Sanchón, R | 1 |
| San Millán, JL | 1 |
| Rashidi, AA | 1 |
| Hassan, A | 1 |
| Gordon, CM | 1 |
| Dunican, KC | 2 |
| Desilets, AR | 2 |
| Montalbano, JK | 1 |
| Golay, A | 2 |
| Campagna, G | 2 |
| Cento, R | 1 |
| Ozenoglu, A | 1 |
| Ugurlu, S | 1 |
| Balci, H | 1 |
| Eker, E | 1 |
| Harden, KA | 1 |
| Cowan, PA | 1 |
| Velasquez-Mieyer, P | 1 |
| Patton, SB | 1 |
| Nagai, T | 1 |
| Imamura, M | 1 |
| Mori, M | 1 |
| Mordier, S | 1 |
| Iynedjian, PB | 1 |
| Freemark, M | 2 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Cylkowska, B | 1 |
| Hajduk, A | 1 |
| Kujawska-Danecka, H | 1 |
| Flyvbjerg, A | 1 |
| Kesmodel, U | 1 |
| Hanson, RL | 2 |
| Altshuler, D | 1 |
| Rutherford, AJ | 1 |
| Martínez-Bermejo, E | 1 |
| Haffner, SM | 1 |
| Tamura, Y | 1 |
| Watada, H | 1 |
| Sato, F | 1 |
| Kumashiro, N | 1 |
| Sakurai, Y | 1 |
| Hirose, T | 1 |
| Kawamori, R | 1 |
| Yannakoula, EK | 1 |
| Al-Qudah, MA | 1 |
| El-Uri, FI | 1 |
| Benson, S | 1 |
| Dietz, T | 1 |
| Lahner, H | 1 |
| Moeller, LC | 1 |
| Schmidt, M | 1 |
| Elsenbruch, S | 1 |
| Kimmig, R | 1 |
| Isidro, ML | 1 |
| Penín, MA | 1 |
| Nemiña, R | 1 |
| Cordido, F | 1 |
| Sucharda, P | 1 |
| Tajtáková, M | 1 |
| Semanová, Z | 1 |
| Ivancová, G | 1 |
| Donicová, V | 1 |
| Zemberová, E | 1 |
| Rodríguez, JE | 1 |
| Shearer, B | 1 |
| Tousoulis, D | 1 |
| Tsarpalis, K | 1 |
| Cokkinos, D | 1 |
| Stefanadis, C | 1 |
| Sinha, SK | 1 |
| Bhangoo, A | 1 |
| Anhalt, H | 1 |
| Maclaren, N | 1 |
| Marshall, JD | 1 |
| Collin, GB | 1 |
| Naggert, JK | 1 |
| Ten, S | 1 |
| Bouskela, E | 1 |
| Kraemer de Aguiar, LG | 1 |
| Nivoit, P | 1 |
| Bahia, LR | 1 |
| Villela, NR | 1 |
| Bottino, DA | 1 |
| Garcia-Puig, J | 1 |
| Paul, G | 1 |
| Donaldson, J | 1 |
| Stewart, M | 1 |
| Krentz, AJ | 1 |
| Holman, R | 2 |
| Drucker, DJ | 1 |
| Monami, M | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Guo, XF | 1 |
| He, YQ | 1 |
| Fang, MS | 1 |
| Chen, JD | 1 |
| Li, LH | 1 |
| De Marinis, L | 1 |
| Pollack, MN | 1 |
| Ersoy, C | 1 |
| Budak, F | 1 |
| Oral, B | 1 |
| Duran, C | 1 |
| Selimoglu, H | 1 |
| Erturk, E | 1 |
| Tuncel, E | 1 |
| Imamoglu, S | 1 |
| Uzcátegui, E | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| de Baptista, EA | 1 |
| Ragonesi, PD | 1 |
| Uriol Rivera, MG | 1 |
| Neff, LM | 1 |
| Shin, L | 1 |
| Bregman, H | 1 |
| Frazier, J | 1 |
| Noyes, N | 1 |
| Acosta, MC | 1 |
| Manubay, J | 1 |
| Levin, FR | 1 |
| Kaya, H | 1 |
| Borazan, A | 1 |
| Ozer, C | 1 |
| Seyhanli, M | 1 |
| Scheen, AJ | 3 |
| Kircher, C | 1 |
| Smith, KP | 1 |
| Coustan, DR | 1 |
| Fujimoto, WY | 1 |
| Hill, JO | 1 |
| Hubbard, V | 1 |
| Stamm, E | 1 |
| Dhakal-Karki, S | 1 |
| Moll, E | 1 |
| Korevaar, JC | 1 |
| Bossuyt, PM | 1 |
| van der Veen, F | 1 |
| Kasa-Vubu, JZ | 1 |
| Love-Osborne, K | 1 |
| Sheeder, J | 1 |
| Zeitler, P | 2 |
| Romo, A | 1 |
| Benavides, S | 1 |
| Selvini, A | 1 |
| Brugi, A | 1 |
| Emanueli, A | 1 |
| Mehrotra, TN | 1 |
| Young, BA | 1 |
| Trischitta, V | 3 |
| Gullo, D | 1 |
| Pezzino, V | 1 |
| Vigneri, R | 3 |
| Lean, ME | 1 |
| Borthwick, LJ | 1 |
| Joffroy-Lavieuville, M | 1 |
| Noël, M | 1 |
| Lord, JM | 1 |
| White, SI | 1 |
| Bailey, CJ | 2 |
| Atkins, TW | 1 |
| Fletcher, RF | 1 |
| Taylor, KG | 1 |
| Curtis-Prior, PB | 1 |
| Crave, JC | 1 |
| Fimbel, S | 1 |
| Lejeune, H | 1 |
| Cugnardey, N | 1 |
| Déchaud, H | 1 |
| Pugeat, M | 2 |
| DeFronzo, RA | 2 |
| Goodman, AM | 1 |
| Nurjhan, N | 1 |
| Perriello, G | 2 |
| Dailey, G | 1 |
| Gerich, JE | 1 |
| Crofford, OB | 1 |
| Gudbjörnsdottir, S | 1 |
| Friberg, P | 1 |
| Elam, M | 1 |
| Attvall, S | 1 |
| Lönnroth, P | 1 |
| Wallin, BG | 1 |
| Rouru, J | 5 |
| Pesonen, U | 2 |
| Koulu, M | 5 |
| Huupponen, R | 5 |
| Santti, E | 2 |
| Virtanen, K | 1 |
| Rouvari, T | 1 |
| Jhanwar-Uniyal, M | 1 |
| Valensi, P | 1 |
| Behar, A | 1 |
| Andre, P | 6 |
| Wiernsperger, N | 1 |
| Attali, JR | 1 |
| Michalak, J | 1 |
| Bloomgarden, ZT | 2 |
| Misericordia, P | 1 |
| Volpi, E | 1 |
| Santucci, A | 1 |
| Santucci, C | 1 |
| Ferrannini, E | 1 |
| Ventura, MM | 1 |
| Santeusanio, F | 1 |
| Brunetti, P | 1 |
| Bolli, GB | 1 |
| Handberg, A | 3 |
| Kayser, L | 2 |
| Høyer, PE | 2 |
| Micheelsen, J | 1 |
| Vinten, J | 3 |
| Beer, NA | 1 |
| Beer, RM | 1 |
| Velazquez, EM | 1 |
| Mendoza, S | 1 |
| Hamer, T | 1 |
| Sosa, F | 1 |
| De Rosa, N | 2 |
| Di Maro, G | 1 |
| Acampora, R | 1 |
| Buoninconti, R | 1 |
| D'Onofrio, F | 3 |
| Voldstedlund, M | 1 |
| Hansen, HP | 1 |
| Isaksson, K | 1 |
| Matthaei, S | 1 |
| Reibold, JP | 1 |
| Benecke, H | 1 |
| Häring, HU | 2 |
| Greten, H | 1 |
| Klein, HH | 1 |
| Johnson, AB | 1 |
| Webster, JM | 1 |
| Sum, CF | 1 |
| Heseltine, L | 1 |
| Argyraki, M | 1 |
| Cooper, BG | 1 |
| Taylor, R | 1 |
| Pyykkö, K | 1 |
| Quatraro, A | 1 |
| Consoli, G | 1 |
| Minei, A | 1 |
| Ceriello, A | 1 |
| Letiexhe, MR | 2 |
| Lefèbvre, PJ | 2 |
| Holman, RR | 2 |
| Turner, RC | 2 |
| Worm, D | 1 |
| Hoppe, E | 1 |
| Utiger, RD | 1 |
| Minchoff, LE | 1 |
| Grandin, JA | 1 |
| Waterman, PE | 1 |
| Kosegawa, I | 1 |
| Katayama, S | 2 |
| Kikuchi, C | 1 |
| Kashiwabara, H | 1 |
| Negishi, K | 1 |
| Ishii, J | 1 |
| Inukai, K | 1 |
| Oka, Y | 1 |
| Fontbonne, A | 2 |
| Charles, MA | 3 |
| Juhan-Vague, I | 5 |
| Bard, JM | 2 |
| Isnard, F | 2 |
| Cohen, JM | 1 |
| Grandmottet, P | 1 |
| Vague, P | 5 |
| Safar, ME | 1 |
| Eschwège, E | 4 |
| Signore, A | 1 |
| Fiore, V | 1 |
| Procaccini, E | 1 |
| Barone, R | 1 |
| Ronga, G | 1 |
| Negri, M | 1 |
| Pozzilli, P | 1 |
| Fanghänel, G | 1 |
| Sánchez-Reyes, L | 1 |
| Trujillo, C | 1 |
| Sotres, D | 1 |
| Espinosa-Campos, J | 1 |
| D'Argenzio, R | 1 |
| Cavallo, P | 1 |
| Merante, D | 1 |
| Morelli, A | 1 |
| Santos, RF | 1 |
| Nomizo, R | 1 |
| Bopsco, A | 1 |
| Wajchenberg, BL | 1 |
| Reaven, GM | 2 |
| Azhar, S | 1 |
| Grosskopf, I | 1 |
| Ringel, Y | 1 |
| Charach, G | 1 |
| Maharshak, N | 1 |
| Mor, R | 1 |
| Iaina, A | 1 |
| Weintraub, M | 1 |
| Carlsen, SM | 1 |
| Waage, A | 1 |
| Grill, V | 1 |
| Følling, I | 1 |
| Lee, A | 1 |
| Morley, JE | 2 |
| Kouli, C | 1 |
| Tsianateli, T | 1 |
| Bergiele, A | 1 |
| Koivunen, RM | 4 |
| Martikainen, HK | 4 |
| Mehnert, H | 1 |
| Sir, T | 1 |
| Castillo, T | 1 |
| Muñoz, S | 1 |
| López, G | 1 |
| Calvillán, M | 1 |
| Savontaus, E | 1 |
| Boss, O | 1 |
| Tomás, C | 1 |
| Amato, L | 1 |
| Eccellente, R | 1 |
| Gambardella, A | 1 |
| Tagliamonte, MR | 1 |
| Varricchio, G | 1 |
| Carella, C | 1 |
| Damsbo, P | 1 |
| Hermann, LS | 2 |
| Vaag, A | 1 |
| Nathan, DM | 1 |
| Morange, P | 1 |
| Roeleveld-Versteegh, AB | 1 |
| Jansen, M | 1 |
| De Vroede, M | 1 |
| Relimpio, F | 1 |
| Pumar, A | 1 |
| Losada, F | 1 |
| Mangas, MA | 1 |
| Acosta, D | 1 |
| Astorga, R | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Oleandri, SE | 1 |
| Maccario, M | 1 |
| Rossetto, R | 1 |
| Procopio, M | 1 |
| Grottoli, S | 1 |
| Avogadri, E | 1 |
| Gauna, C | 1 |
| Ganzaroli, C | 1 |
| Ghigo, E | 1 |
| Fontaine, R | 2 |
| Tracy, T | 2 |
| Sieve-Smith, L | 3 |
| Pinhas-Hamiel, O | 1 |
| Chan, NN | 1 |
| Feher, MD | 1 |
| Bridges, NA | 1 |
| Selby, JV | 1 |
| Ettinger, B | 1 |
| Swain, BE | 1 |
| Brown, JB | 1 |
| Smith, RB | 1 |
| Mann, JI | 1 |
| Avilés-Santa, L | 1 |
| Sinding, J | 1 |
| Raskin, P | 1 |
| Morel, Y | 1 |
| Perneger, T | 1 |
| Lehmann, T | 1 |
| Vadas, L | 1 |
| Pasik, C | 1 |
| Ritzmann, P | 1 |
| Ducluzeau, PH | 1 |
| Pirwany, IR | 1 |
| Yates, RW | 1 |
| Cameron, IT | 1 |
| Sánchez-Barba Izquierdo, MI | 1 |
| Ibarra Rueda, JM | 1 |
| Ruiz de Adana Pérez, R | 1 |
| Flechtner-Mors, M | 1 |
| Ditschuneit, HH | 1 |
| Jenkinson, CP | 1 |
| Alt, A | 1 |
| Adler, G | 1 |
| Genuth, S | 1 |
| Stades, AM | 2 |
| Heikens, JT | 1 |
| Holleman, F | 2 |
| Hoekstra, JB | 2 |
| Riemens, SC | 1 |
| Sluiter, WJ | 1 |
| Dullaart, RP | 1 |
| Gougeon, R | 1 |
| Styhler, K | 1 |
| Morais, JA | 1 |
| Jones, PJ | 1 |
| Marliss, EB | 1 |
| Wilding, J | 1 |
| Fritsche, A | 1 |
| Schmülling, RM | 1 |
| Janka, HU | 1 |
| Le Berre, MA | 1 |
| Grangé, V | 1 |
| Biscotti, D | 1 |
| Gagliardi, L | 1 |
| Colitta, D | 1 |
| Fiorini, S | 1 |
| Cognigni, GE | 1 |
| Filicori, M | 1 |
| Palmer, AJ | 1 |
| Sendi, PP | 1 |
| Spinas, GA | 1 |
| Lin, HZ | 1 |
| Yang, SQ | 1 |
| Chuckaree, C | 1 |
| Kuhajda, F | 1 |
| Ronnet, G | 1 |
| Diehl, AM | 1 |
| Vauhkonen, I | 1 |
| Janssen, JA | 1 |
| Kenyon, CJ | 1 |
| Pavlović, D | 1 |
| Kocić, R | 1 |
| Kocić, G | 1 |
| Jevtović, T | 1 |
| Radenković, S | 1 |
| Mikić, D | 1 |
| Stojanović, M | 1 |
| Djordjević, PB | 1 |
| Safar, M | 1 |
| Fruchart, JC | 1 |
| Mencucci, A | 1 |
| Pierazzuoli, E | 1 |
| Timsit, J | 1 |
| Dubois-Laforgue, D | 1 |
| Clarke, P | 1 |
| Gray, A | 1 |
| Adler, A | 1 |
| Stevens, R | 1 |
| Raikou, M | 1 |
| Cull, C | 1 |
| Stratton, I | 1 |
| Malacara, JM | 1 |
| Fajardo, ME | 1 |
| Nava, LE | 1 |
| Kowalska, I | 1 |
| Kinalski, M | 1 |
| Straczkowski, M | 1 |
| Wolczyski, S | 1 |
| Kinalska, I | 1 |
| Bursey, D | 1 |
| Fontaine, RN | 1 |
| Subbiah, MT | 1 |
| Weber, K | 1 |
| Illig, E | 1 |
| Streicher, P | 1 |
| Tracy, TM | 1 |
| Lang, JE | 1 |
| McCullough, P | 1 |
| Burrull-Madero, MA | 1 |
| Del-Villar-Ruiz, A | 1 |
| Grau-Cerrato, S | 1 |
| Andreu-Garcia, M | 1 |
| Goday-Arno, A | 1 |
| Boland, EA | 1 |
| Greenway, F | 1 |
| Larkin, M | 1 |
| Prieto, LA | 1 |
| Boyero, EC | 1 |
| Parsanezhad, ME | 1 |
| Alborzi, S | 1 |
| Zarei, A | 1 |
| Dehbashi, S | 1 |
| Omrani, G | 1 |
| Gokcel, A | 2 |
| Karakose, H | 2 |
| Ertorer, EM | 1 |
| Tanaci, N | 2 |
| Tutuncu, NB | 1 |
| Guvener, N | 2 |
| Ozata, M | 1 |
| Oktenli, C | 1 |
| Bingol, N | 1 |
| Ozdemir, IC | 1 |
| Kumar, VB | 1 |
| Bernardo, AE | 1 |
| Vyas, K | 1 |
| Franko, M | 1 |
| Farr, S | 1 |
| Lakshmanan, L | 1 |
| Buddhiraju, C | 1 |
| Nardo, LG | 1 |
| Rai, R | 1 |
| González-Clemente, JM | 1 |
| Giménez-Pérez, G | 1 |
| Caixàs, A | 1 |
| Mauricio, D | 1 |
| Jaber, LA | 1 |
| Nowak, SN | 1 |
| Slaughter, RR | 1 |
| Baysal, B | 1 |
| Batukan, M | 1 |
| Batukan, C | 1 |
| Gumurdulu, Y | 1 |
| Melek Ertorer, E | 1 |
| BascilTutuncu, N | 1 |
| Bischoff, A | 1 |
| Kalén, J | 1 |
| Katzman, P | 1 |
| Lager, I | 1 |
| Nilsson, A | 1 |
| Norrhamn, O | 1 |
| Sartor, G | 1 |
| Ugander, L | 1 |
| Fruehwald-Schultes, B | 1 |
| Oltmanns, KM | 1 |
| Toschek, B | 1 |
| Sopke, S | 1 |
| Kern, W | 1 |
| Born, J | 1 |
| Fehm, HL | 1 |
| Peters, A | 1 |
| Arslanian, SA | 1 |
| Lewy, V | 1 |
| Danadian, K | 1 |
| Saad, R | 1 |
| Christiansen, AL | 1 |
| Suzuki, M | 1 |
| Odaka, H | 1 |
| Suzuki, N | 1 |
| Sugiyama, Y | 1 |
| Ikeda, H | 1 |
| Brousseau, VJ | 1 |
| Miles, JM | 1 |
| Leiter, L | 1 |
| Wadden, T | 1 |
| Anderson, JW | 1 |
| Doyle, M | 1 |
| Foreyt, J | 1 |
| Aronne, L | 1 |
| Klein, S | 1 |
| Caporicci, D | 1 |
| Mori, A | 1 |
| Pepi, R | 1 |
| Lapi, E | 1 |
| Schaffalitzky de Muckadell, OB | 1 |
| Mortensen, H | 1 |
| Lyngsøe, J | 1 |
| Junien, JL | 1 |
| Brohon, J | 1 |
| Guillaume, M | 1 |
| Sterne, J | 1 |
| Borsey, DQ | 1 |
| Fraser, DM | 1 |
| Duncan, LJ | 4 |
| Shenfield, GM | 1 |
| Bhalla, IP | 1 |
| Steel, JM | 1 |
| Dieterle, C | 1 |
| Bolzano, K | 1 |
| Lütjens, A | 1 |
| Smit, JL | 1 |
| Munk, W | 1 |
| Hausmann, VL | 1 |
| Schubotz, R | 1 |
| Chlouverakis, C | 1 |
| Brun, JM | 1 |
| Italia, S | 1 |
| Mazzarino, S | 1 |
| Buscema, M | 1 |
| Rabuazzo, AM | 1 |
| Sangiorgio, L | 1 |
| Squatrito, S | 2 |
| Laurenti, O | 1 |
| Bravi, MC | 1 |
| Faldetta, MC | 1 |
| De Mattia, G | 1 |
| Barzilai, N | 1 |
| Simonson, DC | 1 |
| Benzi, L | 1 |
| Ciccarone, A | 1 |
| Cecchetti, P | 1 |
| Brunetti, A | 1 |
| Marchetti, P | 1 |
| Navalesi, R | 1 |
| Pedersen, O | 2 |
| Nielsen, O | 1 |
| Bak, J | 1 |
| Richelsen, B | 1 |
| Sørensen, N | 1 |
| Schmitz, O | 1 |
| Andersen, PH | 1 |
| Gawler, DJ | 1 |
| Wilson, A | 1 |
| Houslay, MD | 1 |
| Menzies, DG | 1 |
| Campbell, IW | 1 |
| McBain, A | 1 |
| Brown, IR | 1 |
| Alessi, MC | 2 |
| Badier, C | 2 |
| Valadier, J | 2 |
| Aillaud, MF | 1 |
| Atlan, C | 1 |
| Rizkalla, SW | 1 |
| Elgrably, F | 1 |
| Tchobroutsky, G | 1 |
| Slama, G | 1 |
| Clarke, BF | 1 |
| Lawson, AA | 2 |
| Strong, JA | 1 |
| Peattie, P | 2 |
| Roscoe, P | 1 |
| Gibson, A | 1 |
| Sapeika, N | 1 |
| Anderson, J | 1 |
| Penick, SB | 1 |
| Stunkard, AJ | 1 |
| Bloom, A | 1 |
| Mirouze, J | 1 |
| Jaffiol, C | 1 |
| Mary, P | 1 |
| Munro, JF | 1 |
| MacCuish, AC | 1 |
| Marshall, A | 1 |
| Wilson, EM | 1 |
| Weinhaus, RS | 1 |
| Cucurachi, L | 1 |
| Strata, A | 1 |
| Zuliani, U | 1 |
| Cucurachi, P | 1 |
| Dell'Anna, A | 1 |
| Schatz, H | 1 |
| Doci, S | 1 |
| Höfer, R | 1 |
| Vermeulen, A | 1 |
| Stowers, JM | 1 |
| Bewsher, PD | 1 |
| Berchtold, P | 1 |
| Bolli, P | 1 |
| Arbenz, U | 1 |
| Keiser, G | 1 |
| Lavieuville, M | 1 |
| Félix, H | 1 |
| Freyria, J | 1 |
| Irsigler, K | 2 |
| Rigas, AN | 1 |
| Bittles, AH | 1 |
| Hadden, DR | 1 |
| Montgomery, DA | 1 |
| Olesen, ES | 1 |
| Bigozzi, U | 1 |
| Conti, C | 1 |
| Guazzelli, R | 1 |
| Salti, F | 1 |
| Montali, E | 1 |
| Gibson, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)[NCT04029272] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-07-20 | Recruiting | ||
| Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study[NCT05702905] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors[NCT02431676] | Phase 2 | 121 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)[NCT02614859] | Phase 2 | 29 participants (Actual) | Interventional | 2015-12-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome[NCT04973891] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2021-04-07 | Completed | ||
| Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome[NCT04867252] | Phase 2 | 88 participants (Actual) | Interventional | 2021-05-03 | Completed | ||
| Personalized Technology-Supported Counseling to Reduce Glycemic Response in Dietary Weight Loss: The Personal Diet Study[NCT03336411] | 269 participants (Actual) | Interventional | 2017-12-12 | Completed | |||
| Pilot Study of Pharmacist-Coordinated Implementation of the Diabetes Prevention Program (DPP) for Women With a History of Gestational Diabetes Mellitus (GDM)[NCT03766256] | 33 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program[NCT02384109] | 521 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients[NCT05463627] | 1,440 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer[NCT01911247] | Early Phase 1 | 28 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)[NCT01234649] | Phase 3 | 153 participants (Actual) | Interventional | 2011-08-11 | Completed | ||
| Impact of a Diet Rich in Inulin-type Fructans Combined With Inulin Supplementation on Gut Microbiota Composition and Metabolic Parameters in Obese Patients[NCT03852069] | 106 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| Effect of Dapagliflozin, Metformin and Physical Activity on Glucose Variability, Body Composition and Cardiovascular Risk in Pre-diabetes[NCT02695810] | Phase 2 | 120 participants (Actual) | Interventional | 2016-02-24 | Completed | ||
| Investigation of Association Between Single Nucleotide Polymorphisms in Genes of the Apelin/ APJ System (-1860T>C & G212A) and CAD Risk and Hypertension in Syrian Patients[NCT05562687] | 230 participants (Actual) | Observational | 2019-12-15 | Completed | |||
| Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin[NCT03925714] | Phase 3 | 90 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women[NCT02635386] | Phase 3 | 119 participants (Actual) | Interventional | 2016-03-22 | Completed | ||
| A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS[NCT03538743] | Phase 1 | 98 participants (Actual) | Interventional | 2018-06-25 | Completed | ||
| Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk[NCT02028221] | Phase 2 | 151 participants (Actual) | Interventional | 2014-03-07 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)[NCT03862950] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-05-24 | Recruiting | ||
| Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity[NCT01960205] | Phase 4 | 80 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)[NCT01952145] | Phase 3 | 557 participants (Actual) | Interventional | 2013-09-20 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial[NCT00375388] | Phase 3 | 400 participants | Interventional | 1998-01-31 | Completed | ||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study[NCT02910817] | 102 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic[NCT04884776] | 453 participants (Actual) | Interventional | 2021-06-01 | Active, not recruiting | |||
| Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau[NCT05591339] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women a Randomized Control Trial.[NCT05554679] | Phase 4 | 178 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial[NCT05215990] | Phase 1/Phase 2 | 80 participants (Anticipated) | Interventional | 2022-01-15 | Recruiting | ||
| Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III[NCT00631033] | Phase 2 | 51 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Beta Cell Restoration Through Fat Mitigation[NCT01763346] | 88 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients[NCT02546609] | Phase 2 | 91 participants (Actual) | Interventional | 2015-11-19 | Completed | ||
| The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study.[NCT03008551] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2017-08-18 | Completed | ||
| The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome: A Randomized, Open Label Trial[NCT04700839] | Phase 4 | 68 participants (Actual) | Interventional | 2020-05-01 | Completed | ||
| Preventing Injured Knees From osteoArthritis: Severity Outcomes (PIKASO)[NCT06096259] | Phase 2 | 512 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Prospective, Randomized, Open Label, Parallel, 12-month Study to Explore and Evaluate the Therapeutic Effects ofLiraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients [NCT05313529] | 324 participants (Anticipated) | Interventional | 2022-10-08 | Recruiting | |||
| A Prospective, Randomized, Open Label, Parallel, 6-month Study to Explore and Evaluate the Therapeutic Effects of Henagliflozin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairmen[NCT06085703] | 60 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | |||
| The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients[NCT02738671] | 250 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| Early Diagnosis and Risk Evaluation of Mild Cognitive Impairment in Diabetes[NCT05590442] | 500 participants (Anticipated) | Observational | 2022-09-01 | Recruiting | |||
| Non-Pharmacologic Alternatives for the Treatment of Childhood Obesity in Mexico[NCT03670875] | 300 participants (Actual) | Interventional | 2021-07-31 | Completed | |||
| Effect of Two Omega 3 Polyunsaturated Fatty Acid Schemes on Insulin Resistance and the Inflammatory and Lipid Profile in Obese Children[NCT05488223] | 133 participants (Actual) | Interventional | 2014-02-17 | Completed | |||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| Effect of Acupuncture on Insulin Sensitivity in Women With Polycystic Ovary Syndrome and Insulin Resistance: Study Protocol of a Prospective Observational Study[NCT02026323] | 112 participants (Anticipated) | Interventional | 2014-01-31 | Enrolling by invitation | |||
| Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome[NCT02491320] | Phase 3 | 384 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Prevalence of Metabolic Syndrome and Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients[NCT01300637] | 60 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | |||
| Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study[NCT00816907] | Phase 4 | 146 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Ultrasonographic Evaluation of Ovarian Stroma in PCOS Women[NCT05418595] | 42 participants (Actual) | Observational | 2022-06-13 | Completed | |||
| Short Term Weight Loss With Liraglutide and Metformin Before IVF in Infertile Obese PCOS Patients[NCT03034941] | Phase 4 | 35 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study[NCT03353948] | Phase 4 | 30 participants (Actual) | Interventional | 2014-09-01 | Completed | ||
| Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients[NCT03151005] | Phase 4 | 70 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation[NCT00930579] | Phase 2 | 35 participants (Actual) | Interventional | 2009-10-16 | Completed | ||
| Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome[NCT02198417] | 20 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | |||
| Polycystic Ovary Syndrome Genetics and Treatment Response[NCT01389778] | 200 participants (Anticipated) | Interventional | 2011-06-30 | Active, not recruiting | |||
| Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi[NCT04698122] | 75 participants (Actual) | Observational | 2021-05-27 | Completed | |||
| An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents[NCT01487993] | Phase 3 | 62 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.[NCT05419726] | 20 participants (Anticipated) | Observational | 2023-02-01 | Recruiting | |||
| SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)[NCT02798744] | Phase 4 | 68 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes[NCT04183868] | Phase 4 | 26 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on[NCT01306214] | Phase 3 | 566 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF) Prospective, Randomized, Multicenter, Placebo-Controlled Trial[NCT04792190] | Phase 4 | 25 participants (Actual) | Interventional | 2021-07-27 | Completed | ||
| Physicians Committee for Responsible Medicine, A Randomized, Crossover Trial of the Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes[NCT04088981] | 60 participants (Anticipated) | Interventional | 2024-07-31 | Suspended (stopped due to The study was not initiated due to COVID-19 restrictions.) | |||
| MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease[NCT02226510] | Phase 4 | 68 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance[NCT00443755] | Phase 2 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome[NCT02280057] | Phase 4 | 56 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| Implementation of a Pragmatic Approach to Lower Diabetes Mellitus Risk After a Diagnosis of Gestational Diabetes Mellitus[NCT05280496] | Phase 3 | 36 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome[NCT02187250] | Phase 4 | 45 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients[NCT05840068] | Phase 4 | 107 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen[NCT01334125] | Phase 3 | 28 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrom[NCT00618072] | Phase 2 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?[NCT01273584] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.[NCT01648153] | Phase 2 | 37 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Investigation of the Effect of Calisthenic Exercise Training Combined With Aerobic Exercise on Exercise Tolerance, Physical Fitness and Plasma Lipid Profile in Patients With Dyslipidemia[NCT06008912] | 24 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India[NCT01283308] | 599 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus[NCT01099618] | Phase 4 | 48 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533] | Phase 2 | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | ||
| Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients[NCT02063802] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Fit-One: A Randomized Waitlist Controlled Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes[NCT03459573] | 500 participants (Anticipated) | Interventional | 2018-02-23 | Active, not recruiting | |||
| [NCT02909933] | Phase 4 | 30 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study[NCT02303470] | 47 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance[NCT00667498] | Phase 4 | 28 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study[NCT02457286] | Phase 1 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to patients do not want to participate) | ||
| Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)[NCT05196958] | 20 participants (Anticipated) | Interventional | 2022-01-25 | Recruiting | |||
| Chinese People's Liberation Army General Hospital[NCT02930265] | 400 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | |||
| Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With[NCT00318461] | Phase 3 | 1,091 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients[NCT04529278] | Phase 2 | 18 participants (Actual) | Interventional | 2021-01-18 | Active, not recruiting | ||
| A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)[NCT03421119] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-06-20 | Not yet recruiting | ||
| The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives[NCT00428311] | Phase 4 | 50 participants | Interventional | 2004-04-30 | Completed | ||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women.[NCT00292799] | 36 participants (Actual) | Interventional | 2006-02-28 | Completed | |||
| Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat[NCT00156897] | Phase 2 | 600 participants | Interventional | 2004-12-31 | Completed | ||
| Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease[NCT00934570] | Phase 4 | 60 participants (Anticipated) | Interventional | 2009-04-30 | Completed | ||
| Effects of Metformin on Energy Intake, Energy Expenditure, and Body Weight in Overweight Children With Insulin Resistance[NCT00005669] | Phase 2 | 100 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Multi-Center, Randomized, Placebo Controlled, Double Blind Trial of Metformin in Obese Adolescents.[NCT00209482] | Phase 2/Phase 3 | 76 participants | Interventional | 2003-10-31 | Active, not recruiting | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Four-Period Crossover Study to Assess the Effects of Concomitant Administration of MK0431 and Metformin Alone and in Combination on Post-Meal Incretin Hormone Concentrations in Healthy Adult Su[NCT00975052] | Phase 1 | 16 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus: a Randomized Controlled Study[NCT01087866] | Phase 2/Phase 3 | 97 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age[NCT02417090] | 173 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635] | Phase 3 | 173 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes[NCT02303730] | Phase 4 | 76 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)[NCT00682890] | Phase 4 | 28 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Lack of recruitment) | ||
| Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Understanding the Effects of Therapeutic Intervention on Cardiovascular Risk Markers, Insulin Resistance, and Intra-Hepatic Fat Contents in Obese Children at High Risk for the Metabolic Syndrome.[NCT00139477] | 66 participants (Actual) | Interventional | 2003-11-30 | Completed | |||
| Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1)[NCT00538486] | Phase 4 | 360 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial[NCT01410604] | Phase 4 | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial[NCT06105060] | Early Phase 1 | 160 participants (Anticipated) | Interventional | 2023-12-17 | Not yet recruiting | ||
| Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome[NCT02695186] | 180 participants (Anticipated) | Observational | 2016-02-29 | Recruiting | |||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689] | 97 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Cost Analysis of Bariatric Surgery in an Employee-based Healthcare System[NCT02381704] | 100 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Metformin in Children With Motor Deficit[NCT00720161] | 42 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Topiramate and Severe Obesity in Children and Adolescents[NCT02273804] | Phase 3 | 18 participants (Actual) | Interventional | 2016-06-01 | Completed | ||
| Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome[NCT00471523] | Phase 4 | 80 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389] | Phase 1 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity[NCT02438020] | Phase 4 | 30 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial[NCT02823691] | Early Phase 1 | 20 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus[NCT00111540] | Phase 3 | 456 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects[NCT00856609] | Phase 3 | 150 participants (Actual) | Interventional | 2009-03-03 | Completed | ||
| Liraglutide in the Treatment of Type 1 Diabetes Mellitus[NCT01722266] | Phase 3 | 72 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease[NCT00529204] | Phase 2 | 1 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Lack of recruitment) | ||
| ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study.[NCT05032001] | 30 participants (Anticipated) | Interventional | 2021-08-01 | Enrolling by invitation | |||
| Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb[NCT04625985] | Phase 2 | 20 participants (Actual) | Interventional | 2020-07-14 | Completed | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| Evaluation of Longevity Diet and Fasting Mimicking Diet Programs on Body Composition, Disease Risk Factors, and Aging Markers: a Randomized Clinical Trial[NCT05698654] | 501 participants (Anticipated) | Interventional | 2023-01-30 | Recruiting | |||
| The Experience of Living With Polycystic Ovary Syndrome in the Military[NCT03876665] | 24 participants (Actual) | Observational | 2019-08-15 | Completed | |||
| A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer[NCT03086005] | Phase 3 | 24 participants (Actual) | Interventional | 2011-10-12 | Completed | ||
| Body Fat Index as a Novel Sonographic Tool to Predict High Risk Pregnancy (BFiORS Trial)[NCT05533996] | 206 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | |||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Gastric Tolerability and Pharmacokinetics of an Extended Release Metformin and an Immediate Release Metformin[NCT00941239] | Phase 1 | 24 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Pulsatile GnRH in Anovulatory Infertility[NCT00383656] | Phase 2 | 270 participants (Anticipated) | Interventional | 1989-01-31 | Recruiting | ||
| Financial Incentives and SMS to Improve African American Womens' Glycemic Control: Friends & Relatives Improving the Effectiveness of Networks for Diabetes Support Through Text Messaging (FRIENDS Text)[NCT02384265] | 41 participants (Actual) | Interventional | 2012-06-21 | Completed | |||
| A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity[NCT04101669] | 240 participants (Anticipated) | Interventional | 2019-09-09 | Recruiting | |||
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Pilot Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes[NCT05514080] | 10 participants (Actual) | Interventional | 2019-12-06 | Completed | |||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The TELE-DD Project: a Nurse-led Randomised Controlled Trial on Treatment Adherence in Patients With Type 2 Diabetes and Comorbid Depression[NCT04097483] | 428 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism[NCT03398356] | Phase 4 | 47 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Medication Safety[NCT00256386] | 800 participants | Interventional | 2004-01-31 | Completed | |||
| New Electrophoretic Approaches in Studies of Obesity and Diabetes[NCT03189732] | 10 participants (Actual) | Interventional | 2015-10-01 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Different Variables Predicting Ovulatory Response Among Clomiphene Citrate Resistance and Clomiphene Citrate Sensitive Patients With Polycystic Ovarian Syndrome.[NCT04887402] | 100 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
IGF-1 at 12 months (NCT02431676)
Timeframe: 12 months
| Intervention | ng/ml (Mean) |
|---|---|
| Self-Directed | 73.4 |
| Coach Directed Behavioral Weight Loss | 76.6 |
| Metformin | 76.2 |
Insulin-like growth factor (IGF)-1 levels (ng/ml) at 6 months. (NCT02431676)
Timeframe: 6 months
| Intervention | ng/ml (Mean) |
|---|---|
| Self-Directed | 73.2 |
| Coach Directed Behavioral Weight Loss | 73.6 |
| Metformin | 71.2 |
IGF-1 level to IGFBP3 level ratio (molar ratio) at 6 months. (NCT02431676)
Timeframe: 6 months
| Intervention | ratio (Mean) |
|---|---|
| Self-Directed | 0.18 |
| Coach Directed Behavioral Weight Loss | 0.18 |
| Metformin | 0.17 |
Participants with undetectable PSA after 32 weeks (NCT02614859)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bicalutamide | 3 |
| Metformin and Bicalutamide | 5 |
Number of patients with BMI decline after 32 weeks (NCT02614859)
Timeframe: 32 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 4 |
| Arm B | 12 |
Median PSA decline after 8 weeks % (range) (NCT02614859)
Timeframe: 8 weeks
| Intervention | percent change (Median) |
|---|---|
| Bicalutamide | NA |
| Metformin and Bicalutamide | 9 |
Number of patients with PSA decline after 8 weeks (observation vs metformin) (NCT02614859)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bicalutamide | 1 |
| Metformin and Bicalutamide | 8 |
Number of patients with PSA decline ≥ 85% after 32 weeks (NCT02614859)
Timeframe: 32 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 6 |
| Arm B | 10 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
Body weight in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | kilograms (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.2 |
| Metformin XR Plus Placebo | 91.3 |
Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 32.3 |
| Metformin XR Plus Placebo | 31 |
ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of ALT (U/L)/ AST (U/L) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 1.2 |
| Metformin XR Plus Placebo | 1.18 |
The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 27 |
| Metformin XR Plus Placebo | 28 |
BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | weight (kg) /height (m) squared (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 33.8 |
| Metformin XR Plus Placebo | 32.8 |
Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent. (NCT01234649)
Timeframe: Change from baseline (time 0) to study end (84 weeks)
| Intervention | percent change in weight from baseline (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | -7.2 |
| Metformin XR Plus Placebo | -3.1 |
DBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 77.6 |
| Metformin XR Plus Placebo | 77 |
Fasting glucose levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 90 |
| Metformin XR Plus Placebo | 91.7 |
HDL-C levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 51 |
| Metformin XR Plus Placebo | 48.7 |
HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.2 |
| Metformin XR Plus Placebo | 2.45 |
IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET) (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 418.4 |
| Metformin XR Plus Placebo | 333 |
IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 0.8 |
| Metformin XR Plus Placebo | 0.62 |
LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 110 |
| Metformin XR Plus Placebo | 107 |
OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 5.9 |
| Metformin XR Plus Placebo | 5.4 |
MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 121.6 |
| Metformin XR Plus Placebo | 118.8 |
SBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 122 |
| Metformin XR Plus Placebo | 123 |
CHOL levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 183.7 |
| Metformin XR Plus Placebo | 183.8 |
TRG concentrations in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 120 |
| Metformin XR Plus Placebo | 125 |
TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of TRG (mg/dL)/HDL-C (mg/dl) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.56 |
| Metformin XR Plus Placebo | 2.95 |
Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.3 |
| Metformin XR Plus Placebo | 95.3 |
Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist /height (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .56 |
| Metformin XR Plus Placebo | .57 |
Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist/hip circumference (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .81 |
| Metformin XR Plus Placebo | .81 |
Treatment effect on body weight at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 100.4 |
| Dapagliflozin (DAPA) | 102.6 |
| EQW Plus DAPA | 99 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.2 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
treatment impact on measure of central adiposity as determined by android/gynoid ratio (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.07 |
| Dapagliflozin (DAPA) | 1.02 |
| EQW Plus DAPA | 1.04 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.04 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.03 |
Treatment efficacy in reducing body mass at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram/meter squared (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 37.3 |
| Dapagliflozin (DAPA) | 37.4 |
| EQW Plus DAPA | 36.7 |
| Dapagliflozin Plus Glucophage (MET ER) | 37 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 35.3 |
Treatment effect on loss of central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 104 |
| Dapagliflozin (DAPA) | 101 |
| EQW Plus DAPA | 106 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
Treatment effect on change in percent body weight from baseline (NCT02635386)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | percentage change in body weight (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.8 |
| Dapagliflozin (DAPA) | 1.5 |
| EQW Plus DAPA | 6.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 8.1 |
Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | 0.6 |
| EQW Plus DAPA | 0.91 |
| Dapagliflozin Plus Glucophage (MET ER) | 0.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.1 |
Treatment effect on blood concentrations of DHEA-S (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mcg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 165 |
| Dapagliflozin (DAPA) | 187 |
| EQW Plus DAPA | 169 |
| Dapagliflozin Plus Glucophage (MET ER) | 189 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 201 |
Treatment effect on DBP after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 81 |
| Dapagliflozin (DAPA) | 79.8 |
| EQW Plus DAPA | 76 |
| Dapagliflozin Plus Glucophage (MET ER) | 82 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 83.6 |
Treatment impact on fasting concentration of glucose in the blood (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 91 |
| Dapagliflozin (DAPA) | 93 |
| EQW Plus DAPA | 86.5 |
| Dapagliflozin Plus Glucophage (MET ER) | 89 |
| Phentermine /Topiramate (PHEN/ TPM ER | 91.4 |
Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.7 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 2.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 3.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 3.4 |
Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 5.3 |
| Dapagliflozin (DAPA) | 4.7 |
| EQW Plus DAPA | 5.2 |
| Dapagliflozin Plus Glucophage (MET ER) | 5.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 5 |
The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.1 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 3.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 4.8 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 4.7 |
Treatment effect on MBG measured during the oral glucose tolerance test (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 118 |
| Dapagliflozin (DAPA) | 126.4 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 119 |
| Phentermine /Topiramate (PHEN/ TPM ER | 113 |
An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 471 |
| Dapagliflozin (DAPA) | 311 |
| EQW Plus DAPA | 503 |
| Dapagliflozin Plus Glucophage (MET ER) | 395 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 545 |
Treatment effect on SBP after 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 123.6 |
| Dapagliflozin (DAPA) | 123 |
| EQW Plus DAPA | 122 |
| Dapagliflozin Plus Glucophage (MET ER) | 128 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 124 |
Treatment impact on percent total body fat by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | percent fat mass (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 46.1 |
| Dapagliflozin (DAPA) | 46.4 |
| EQW Plus DAPA | 45.8 |
| Dapagliflozin Plus Glucophage (MET ER) | 46.1 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.2 |
Treatment effect on blood concentrations of total cholesterol (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 189 |
| Dapagliflozin (DAPA) | 186 |
| EQW Plus DAPA | 185 |
| Dapagliflozin Plus Glucophage (MET ER) | 192 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 178 |
Treatment impact on total fat mass by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 47.6 |
| Dapagliflozin (DAPA) | 47.8 |
| EQW Plus DAPA | 45.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 48 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 44.5 |
Treatment effect on blood concentrations of total testosterone (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ng/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 38.8 |
| Dapagliflozin (DAPA) | 35 |
| EQW Plus DAPA | 42.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 39.5 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.5 |
Treatment effect on blood concentrations of triglycerides (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 130 |
| Dapagliflozin (DAPA) | 132 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 105 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 110 |
Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | .95 |
| EQW Plus DAPA | .93 |
| Dapagliflozin Plus Glucophage (MET ER) | .98 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .99 |
Treatment impact on WHtR which is a measure of central adiposity (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .64 |
| Dapagliflozin (DAPA) | .61 |
| EQW Plus DAPA | .65 |
| Dapagliflozin Plus Glucophage (MET ER) | .61 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .59 |
Treatment impact on central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .83 |
| Dapagliflozin (DAPA) | .79 |
| EQW Plus DAPA | .86 |
| Dapagliflozin Plus Glucophage (MET ER) | .83 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .81 |
Percent of dose recovered in urine as unchanged drug. Ae24% = 100* Ae24/Dose (NCT03538743)
Timeframe: 0 to 24 hours post-dose on Day 28
| Intervention | Percentage (Geometric Mean) |
|---|---|
| PF-06882961 15mg BID (Cohort 1) | 0.05747 |
| PF-06882961 50mg BID (Cohort 2) | 0.03360 |
| PF-06882961 70mg BID (Cohort 3) | 0.02942 |
| PF-06882961 120mg BID (Cohort 4) | NA |
| PF-06882961 10mg BID (Cohort 5) | 0.07483 |
| PF-06882961 120mg BID ST (Cohort 6) | 0.02607 |
| PF-06882961 200mg QD CR (Cohort 7) | 0.03652 |
| PF-06882961 120mg QD (Cohort 8) | 0.04094 |
Ae was the cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval was 24 hours. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram [g]/1.020), where 1.020 g/mL was the approximate specific gravity of urine. (NCT03538743)
Timeframe: 0 to 24 hours post-dose on Day 28
| Intervention | microgram (Geometric Mean) |
|---|---|
| PF-06882961 15mg BID (Cohort 1) | 17.25 |
| PF-06882961 50mg BID (Cohort 2) | 33.60 |
| PF-06882961 70mg BID (Cohort 3) | 41.16 |
| PF-06882961 120mg BID (Cohort 4) | NA |
| PF-06882961 10mg BID (Cohort 5) | 14.97 |
| PF-06882961 120mg BID ST (Cohort 6) | 62.63 |
| PF-06882961 200mg QD CR (Cohort 7) | 72.98 |
| PF-06882961 120mg QD (Cohort 8) | 49.09 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin). (NCT03538743)
Timeframe: From baseline to up to 14 days after last dose for a total of approximately 42 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 24 |
| PF-06882961 10mg BID | 7 |
| PF-06882961 15mg BID | 8 |
| PF-06882961 50mg BID | 10 |
| PF-06882961 70mg BID | 8 |
| PF-06882961 120mg BID | 8 |
| PF-06882961 120mg BID ST | 9 |
| PF-06882961 120mg QD | 7 |
| PF-06882961 200mg QD CR | 10 |
CLr was calculated as Ae divided by AUCtau, where dosing interval is 24 hours. (NCT03538743)
Timeframe: 0 to 24 hours post-dose on Day 28
| Intervention | mL/min (Geometric Mean) |
|---|---|
| PF-06882961 15mg BID (Cohort 1) | 0.3273 |
| PF-06882961 50mg BID (Cohort 2) | 0.3385 |
| PF-06882961 70mg BID (Cohort 3) | 0.3094 |
| PF-06882961 120mg BID (Cohort 4) | NA |
| PF-06882961 10mg BID (Cohort 5) | 0.5470 |
| PF-06882961 120mg BID ST (Cohort 6) | 0.2006 |
| PF-06882961 200mg QD CR (Cohort 7) | 0.2895 |
| PF-06882961 120mg QD (Cohort 8) | 0.3178 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT03538743)
Timeframe: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 28
| Intervention | hours (Mean) |
|---|---|
| PF-06882961 15mg BID (Cohort 1) | 5.100 |
| PF-06882961 50mg BID (Cohort 2) | 5.067 |
| PF-06882961 70mg BID (Cohort 3) | 4.681 |
| PF-06882961 120mg BID (Cohort 4) | 6.203 |
| PF-06882961 10mg BID (Cohort 5) | 8.090 |
| PF-06882961 120mg BID ST (Cohort 6) | 6.730 |
| PF-06882961 200mg QD CR (Cohort 7) | 5.773 |
| PF-06882961 120mg QD (Cohort 8) | 4.954 |
Area under the concentration-time profile from time zero to time 24 hours (AUC24) was calculated as AUCtau1 +AUCtau2, where AUCtau was area under the plasma concentration-time profile from time zero to time tau (tau1 = 0 to 10 hours and tau2=10 to 24 hours). AUCtau was determined using linear/log trapezoidal method. (NCT03538743)
Timeframe: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28
| Intervention | nanogram.hours/milliliter (ng.h/mL) (Geometric Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| AUC24 on Day 1 | AUCtau1 on Day 1 | AUCtau2 on Day 1 | AUC24 on Day 14 or 21 | AUCtau1 on Day 14 or 21 | AUCtau2 on Day 14 or 21 | AUC24 on Day 28 | AUCtau1 on Day 28 | AUCtau2 on Day 28 | |
| PF-06882961 10mg BID (Cohort 5) | 178.7 | 74.50 | 103.7 | 201.6 | 85.57 | 115.4 | 455.9 | 190.8 | 261.0 |
| PF-06882961 120mg BID (Cohort 4) | 666.1 | 260.3 | 401.9 | 8149 | 3772 | 4361 | 8368 | 3534 | 4852 |
| PF-06882961 120mg BID ST (Cohort 6) | 324.0 | 147.7 | 176.4 | 2660 | 957.3 | 1693 | 5973 | 2249 | 3668 |
| PF-06882961 120mg QD (Cohort 8) | 184.6 | NA | NA | 1204 | NA | NA | 2723 | NA | NA |
| PF-06882961 15mg BID (Cohort 1) | 707.5 | 288.1 | 414.8 | 853.8 | 348.6 | 500.1 | 876.7 | 331.1 | 534.7 |
| PF-06882961 200mg QD CR (Cohort 7) | 393.9 | NA | NA | 1291 | NA | NA | 4372 | NA | NA |
| PF-06882961 50mg BID (Cohort 2) | 1502 | 741.4 | 678.5 | 2092 | 880.3 | 1175 | 1653 | 671.1 | 960.1 |
| PF-06882961 70mg BID (Cohort 3) | 645.8 | 279.7 | 364.9 | 2988 | 1462 | 1517 | 3171 | 1153 | 1970 |
"For BID dosing, parameters were calculated for both dosing intervals (0-10 hr = interval 1 and 10-24 hr = interval 2) and were displayed as Cmax1, Cmax2.~Cmax1: maximum plasma concentration during the dosing interval τ1 =0 to 10 hours.~Cmax2: maximum plasma concentration during the dosing interval τ2=10 to 24 hours." (NCT03538743)
Timeframe: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1, 14 or 21, and 28
| Intervention | nanogram/milliliter (ng/mL) (Geometric Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cmax on Day 1 | Cmax1 on Day 1 | Cmax2 on Day 1 | Cmax on Day 14 or 21 | Cmax1 on Day 14 or 21 | Cmax2 on Day 14 or 21 | Cmax on Day 28 | Cmax1 on Day 28 | Cmax2 on Day 28 | |
| PF-06882961 10mg BID (Cohort 5) | 15.02 | 12.82 | 13.98 | 18.63 | 15.31 | 17.16 | 38.38 | 30.42 | 35.01 |
| PF-06882961 120mg BID (Cohort 4) | 51.61 | 36.51 | 44.97 | 788.4 | 682.7 | 505.3 | 685.2 | 649.2 | 617.9 |
| PF-06882961 120mg BID ST (Cohort 6) | 26.02 | 24.06 | 21.64 | 188.5 | 143.0 | 178.4 | 437.6 | 357.1 | 410.3 |
| PF-06882961 120mg QD (Cohort 8) | 20.40 | NA | NA | 100.7 | NA | NA | 192.2 | NA | NA |
| PF-06882961 15mg BID (Cohort 1) | 50.58 | 42.69 | 40.63 | 65.78 | 55.00 | 63.89 | 81.56 | 50.24 | 74.22 |
| PF-06882961 200mg QD CR (Cohort 7) | 28.67 | NA | NA | 98.11 | NA | NA | 303.9 | NA | NA |
| PF-06882961 50mg BID (Cohort 2) | 124.4 | 119.1 | 68.77 | 149.8 | 130.2 | 127.9 | 133.7 | 103.8 | 117.2 |
| PF-06882961 70mg BID (Cohort 3) | 49.75 | 45.01 | 42.33 | 253.6 | 235.1 | 202.8 | 328.8 | 197.9 | 306.5 |
"ECG categorical summarization criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (>=) 300 millisecond (msec), b) >=25% increase when baseline is > 200 msec or >=50% increase when baseline is less than or equal to (<=) 200 msec.~2. QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) >=140 msec, b) >=50% increase from baseline.~3. QTcF interval (QT corrected using the Fridericia formula): a) >450 msec and <=480 msec, b) >480 msec and <=500 msec, c) >500 msec, d) >30 msec and <=60 msec increase from baseline, e) >60 msec increase from baseline" (NCT03538743)
Timeframe: From baseline to up to 14 days after last dose for a total of approximately 42 days
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| PR interval ≥300 msec | %Change in PR interval ≥25/50% | QRS duration ≥140 msec | %Change in QRS duration ≥50% | QTcF interval >450 and ≤480 msec | QTcF interval >480 and ≤500 msec | QTcF interval >500 msec | Change in QTcF interval >30 and ≤60 msec | Change in QTcF interval >60 msec | |
| PF-06882961 10mg BID | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| PF-06882961 120mg BID | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| PF-06882961 120mg BID ST | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-06882961 120mg QD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-06882961 15mg BID | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| PF-06882961 200mg QD CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-06882961 50mg BID | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-06882961 70mg BID | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Vital signs categorical summarization criteria: 1) supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) <50 mmHg; 3) supine pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP >= 20 mmHg. (NCT03538743)
Timeframe: From baseline to up to 14 days after last dose for a total of approximately 42 days
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Supine SBP <90 mmHg | Supine SBP increase >=30 mmHg | Supine SBP decrease >=30 mmHg | Supine DBP <50 mmHg | Supine DBP increase >=20 mmHg | Supine DBP decrease >=20 mmHg | Supine pulse rate <40 bpm | Supine pulse rate >120 bpm | |
| PF-06882961 10mg BID | 3 | 0 | 2 | 1 | 1 | 2 | 0 | 0 |
| PF-06882961 120mg BID | 0 | 1 | 3 | 0 | 1 | 3 | 0 | 0 |
| PF-06882961 120mg BID ST | 3 | 2 | 3 | 2 | 2 | 4 | 0 | 0 |
| PF-06882961 120mg QD | 0 | 2 | 5 | 0 | 2 | 2 | 0 | 0 |
| PF-06882961 15mg BID | 2 | 0 | 5 | 2 | 1 | 1 | 0 | 0 |
| PF-06882961 200mg QD CR | 1 | 1 | 4 | 0 | 1 | 3 | 0 | 0 |
| PF-06882961 50mg BID | 1 | 2 | 3 | 1 | 0 | 2 | 0 | 0 |
| PF-06882961 70mg BID | 3 | 3 | 5 | 1 | 4 | 1 | 0 | 0 |
| Placebo | 3 | 4 | 9 | 1 | 1 | 6 | 0 | 0 |
Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent. (NCT03538743)
Timeframe: From baseline to up to 35 days after last dose for a total of approximately 63 days
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| All-causality AE | All-causality SAE | Treatment-related AE | Treatment-related SAE | |
| PF-06882961 10mg BID | 6 | 0 | 4 | 0 |
| PF-06882961 120mg BID | 8 | 0 | 8 | 0 |
| PF-06882961 120mg BID ST | 9 | 1 | 9 | 0 |
| PF-06882961 120mg QD | 8 | 0 | 8 | 0 |
| PF-06882961 15mg BID | 8 | 0 | 4 | 0 |
| PF-06882961 200mg QD CR | 9 | 0 | 9 | 0 |
| PF-06882961 50mg BID | 10 | 0 | 10 | 0 |
| PF-06882961 70mg BID | 8 | 0 | 7 | 0 |
| Placebo | 17 | 0 | 14 | 0 |
Time for Cmax, Cmax1 and Cmax2 (Tmax, Tmax1 and Tmax2) of PF-06293620 was observed directly from data as time of first occurrence. (NCT03538743)
Timeframe: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28
| Intervention | hours (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tmax on Day 1 | Tmax1 on Day 1 | Tmax2 on Day 1 | Tmax on Day 14 or 21 | Tmax1 on Day 14 or 21 | Tmax2 on Day 14 or 21 | Tmax on Day 28 | Tmax1 on Day 28 | Tmax2 on Day 28 | |
| PF-06882961 10mg BID (Cohort 5) | NA | 2.00 | 12.0 | NA | 6.00 | 12.0 | NA | 4.00 | 12.0 |
| PF-06882961 120mg BID (Cohort 4) | NA | 4.00 | 14.0 | NA | 1.54 | 12.0 | NA | 4.00 | 12.0 |
| PF-06882961 120mg BID ST (Cohort 6) | NA | 2.00 | 14.0 | NA | 6.00 | 14.0 | NA | 6.00 | 12.0 |
| PF-06882961 120mg QD (Cohort 8) | 3.00 | NA | NA | 6.00 | NA | NA | 10.0 | NA | NA |
| PF-06882961 15mg BID (Cohort 1) | NA | 4.00 | 14.0 | NA | 4.00 | 13.0 | NA | 5.00 | 12.0 |
| PF-06882961 200mg QD CR (Cohort 7) | 13.0 | NA | NA | 12.0 | NA | NA | 14.0 | NA | NA |
| PF-06882961 50mg BID (Cohort 2) | NA | 4.00 | 14.0 | NA | 4.00 | 13.0 | NA | 3.00 | 12.0 |
| PF-06882961 70mg BID (Cohort 3) | NA | 2.00 | 14.0 | NA | 1.05 | 12.0 | NA | 6.00 | 12.0 |
Change in dense breast volume at 12 months (NCT02028221)
Timeframe: Baseline, 12 months
| Intervention | cm^3 (Mean) |
|---|---|
| Placebo | -12.11 |
| Metformin | -14.75 |
change of dense breast volume at 6 months (NCT02028221)
Timeframe: baseline, 6 months
| Intervention | cm^3 (Mean) |
|---|---|
| Placebo | -5.45 |
| Metformin | -13.71 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | kg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 101.5 | 99.6 | 99.3 |
| Placebo | 102.3 | 102.1 | 103.2 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | data presented as ratio; no unit (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 0.170 | 0.169 | 0.165 |
| Placebo | 0.178 | 0.178 | 0.171 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | uIU/ml (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 13.5 | 11.9 | 11.7 |
| Placebo | 14.6 | 14.0 | 13.1 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | data presented as ratio; no unit (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 0.028 | 0.025 | 0.026 |
| Placebo | 0.023 | 0.022 | 0.021 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | cm (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 111.2 | 108.9 | 108.3 |
| Placebo | 110.3 | 111.6 | 111.8 |
Change from baseline in body weight after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Kg (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.4 |
| Insulin Glargine (IGlar) | 1.8 |
Change from baseline in HbA1c after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Percentage (%) (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.81 |
| Insulin Glargine (IGlar) | -1.13 |
Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia. (NCT01952145)
Timeframe: During 26 weeks of treatment
| Intervention | Number of episodes (Number) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | 289 |
| Insulin Glargine (IGlar) | 683 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
HbA1C (NCT01763346)
Timeframe: 24 months
| Intervention | percent of hemoglobin (Mean) |
|---|---|
| Metformin | 5.84 |
| Gastric Banding | 5.73 |
mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity (NCT01763346)
Timeframe: 24 months
| Intervention | (nmol/L) adjusted for M/I (Geometric Mean) |
|---|---|
| Metformin | 3.01 |
| Gastric Banding | 3.19 |
fasting and 2-hour OGTT glucose levels (NCT01763346)
Timeframe: 24 months
| Intervention | mmol/l (Mean) | |
|---|---|---|
| fasting glucose | 2-hour glucose | |
| Gastric Banding | 5.85 | 9.92 |
| Metformin | 5.95 | 10.87 |
Lipid levels such as cholesterol will be examined by standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | -0.8 |
| Leu Met Sil 0.5mg | -20.5 |
| Leu Met Sil 1.0mg | -5.9 |
Lipid levels such as HDL will be examined by standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | -1.0 |
| Leu Met Sil 0.5mg | -13.3 |
| Leu Met Sil 1.0mg | 1.2 |
CRP levels will be examined by standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mg/L (Geometric Mean) |
|---|---|
| Placebo | 1.02 |
| Leu Met Sil 0.5mg | 1.27 |
| Leu Met Sil 1.0mg | 1.08 |
Change in Circulating Cytokeratin 18 Fragments (M30) from Baseline to Week 16 will be examined through standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | U/L (Mean) |
|---|---|
| Placebo | 70.685 |
| Leu Met Sil 0.5mg | 55.386 |
| Leu Met Sil 1.0mg | 37.847 |
Fasting glucose will be examined through standard fasting blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.8 |
| Leu Met Sil 0.5mg | -2.7 |
| Leu Met Sil 1.0mg | -6.3 |
HbA1c will be examined through standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | percentage (Mean) |
|---|---|
| Placebo | 0.07 |
| Leu Met Sil 0.5mg | -0.15 |
| Leu Met Sil 1.0mg | -0.11 |
To evaluate the change in hepatic fat content assessed by proton-density-fat-fraction (PDFF) employing magnetic resonance imaging (MRI). (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | percentage (Mean) |
|---|---|
| Placebo | -10.046 |
| Leu Met Sil 0.5mg | 3.083 |
| Leu Met Sil 1.0mg | -4.013 |
Insulin levels will be examined through standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | μIU/mL (Mean) |
|---|---|
| Placebo | -8.30 |
| Leu Met Sil 0.5mg | -6.60 |
| Leu Met Sil 1.0mg | -5.30 |
HOMA-IR levels will be examined by standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mU/L (Geometric Mean) |
|---|---|
| Placebo | 0.89 |
| Leu Met Sil 0.5mg | 0.80 |
| Leu Met Sil 1.0mg | 0.85 |
Lipid levels such as LDL will be examined by standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | -1.0 |
| Leu Met Sil 0.5mg | -13.3 |
| Leu Met Sil 1.0mg | 1.2 |
Serum AlanineAminotransferase (ALT) will be examined through standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | U/L (Mean) |
|---|---|
| Placebo | -4.1 |
| Leu Met Sil 0.5mg | 1.8 |
| Leu Met Sil 1.0mg | -2.7 |
Lipid levels such as triglycerides will be examined by standard blood chemistry (NCT02546609)
Timeframe: Baseline, Day 112
| Intervention | mg/dL (Geometric Mean) |
|---|---|
| Placebo | 1.0 |
| Leu Met Sil 0.5mg | 0.8 |
| Leu Met Sil 1.0mg | 0.9 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
fasting blood glucose (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| Metformin | -2.3 |
Fasting insulin (NCT00816907)
Timeframe: 16 weeks
| Intervention | mU/L (Mean) |
|---|---|
| Placebo | 5.5 |
| Metformin | 1.6 |
high-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Metformin | -0.6 |
glycosylated hemoglobin (NCT00816907)
Timeframe: 16 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Metformin | -0.06 |
low-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Metformin | -7.1 |
Total cholesterol (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.2 |
| Metformin | -8.9 |
serum triglycerides (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 13.2 |
| Metformin | -7.0 |
Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks) (NCT00816907)
Timeframe: Measured at the last study visit
| Intervention | kilograms (Mean) |
|---|---|
| Placebo | -1.0 |
| Metformin | -3.0 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
Systolic blood pressure was measured in mmHg. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 122.83 |
| Metformin-Oral Contraceptive(OC) | 122.40 |
Alanine transaminase was measured in IU/L. (NCT03151005)
Timeframe: 12 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 39.09 |
| Metformin-Oral Contraceptive(OC) | 36.73 |
Changes in testosterone levels were measured (NCT03151005)
Timeframe: 12 weeks
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 1.82 |
| Metformin-Oral Contraceptive(OC) | 2.14 |
Concentration of LH was measured in mIU/ml. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mIU/ml (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 5.52 |
| Metformin-Oral Contraceptive(OC) | 5.33 |
Weight and height will be combined to report BMI in kg/m^2. (NCT03151005)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 26.26 |
| Metformin-Oral Contraceptive(OC) | 27.12 |
This outcome measure examines the changes in tumor proliferation as measured by the amount of Ki-67 protein in the tumor. (NCT00930579)
Timeframe: Baseline, up to 4 weeks
| Intervention | percentage of ki-67 positive cells (Mean) | |
|---|---|---|
| Premetformin Tumor Sample | Post Metformin Tumor Sample | |
| Metformin | 2.17 | 2.165 |
The secondary endpoint was the change from baseline in body weight after 52 weeks of treatment (NCT01306214)
Timeframe: Baseline and 52 weeks
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | 0.44 |
| Empagliflozin 10 mg | -1.95 |
| Empagliflozin 25 mg | -2.04 |
The primary endpoint was the change from baseline in HbA1c after 18 weeks of treatment. (NCT01306214)
Timeframe: Baseline and 18 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) |
|---|---|
| Placebo | -0.50 |
| Empagliflozin 10 mg | -0.94 |
| Empagliflozin 25 mg | -1.02 |
The secondary endpoint was the change from baseline in HbA1c after 52 weeks of treatment (NCT01306214)
Timeframe: Baseline and 52 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) |
|---|---|
| Placebo | -0.81 |
| Empagliflozin 10 mg | -1.18 |
| Empagliflozin 25 mg | -1.27 |
The secondary endpoint is change from baseline in insulin dose after 52 weeks of treatment (NCT01306214)
Timeframe: Baseline and 52 weeks
| Intervention | IU/day (Least Squares Mean) |
|---|---|
| Placebo | 10.16 |
| Empagliflozin 10 mg | 1.33 |
| Empagliflozin 25 mg | -1.06 |
Body fat is reported as a percentage of body weight. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage of body weight (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 1.73 |
| Placebo | -0.01 |
Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 0.37 |
| Placebo | -0.21 |
Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -19.96 |
| Placebo | 8.39 |
FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kilograms (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -1.13 |
| Placebo | -0.34 |
HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.35 |
| Placebo | 0.19 |
TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL). (NCT00443755)
Timeframe: Baseline, 3 month
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.13 |
| Placebo | 0.18 |
Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | microIU/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -8.13 |
| Placebo | 1.38 |
Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit & was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | micromols/kg of FFM/minute (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 17.95 |
| Placebo | 1.68 |
Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 9.10 |
| Placebo | 0.46 |
CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.19 |
| Placebo | -0.15 |
IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.99 |
| Placebo | -1.42 |
Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 14.00 |
| Placebo | -18.62 |
PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | ng/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -34.17 |
| Placebo | 8.15 |
Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Triglycerides | HDL-C-Cholesterol | Non-HDL-Cholesterol | |
| Insulin Sensitizer Therapy | -15.58 | 4.33 | -7.50 |
| Placebo | 17.77 | -0.31 | 4.62 |
Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model). (NCT01334125)
Timeframe: Baseline, 3mo, 6 mo, and 9 months
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 2.0 |
| Placebo | 1.2 |
Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model). (NCT01334125)
Timeframe: Baseline, 3mo, 6mo, and 9 months
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 3.5 |
| Placebo | 4 |
Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model). (NCT01334125)
Timeframe: Baseline, 3mo, 6mo, and 9 months
| Intervention | percentage of HbA1c (Mean) |
|---|---|
| Metformin | 9.46 |
| Placebo | 9.85 |
Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of <60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of ≤60 mg/dL between 11PM and 6AM). (NCT01334125)
Timeframe: 12 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major hypoglycemia | Minor hypoglycemia | Nocturnal hypoglycemia | |
| Metformin | 1 | 3 | 2 |
| Placebo | 0 | 2 | 2 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
Total adiponectin was measured with a commercial ELISA kit (Millipore/Linco Research, St. Charles, MO) in the laboratory of Dr. Philipp Scherer. (NCT00618072)
Timeframe: 6 months
| Intervention | ug/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 10.6 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 10.9 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 18.5 |
Body weight measurement was performed three times and averaged by a single study coordinator. (NCT00618072)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 80.0 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 80.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 77.5 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 71.7 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 72.7 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 74.3 |
Insulin was determined with a Siemens Immulite assay with respective intra-and inter-CV's 5.7 and 5.9%, and no cross reactivity to pro-insulin. (NCT00618072)
Timeframe: 6 months
| Intervention | uIU/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 8.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 8.0 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 6.3 |
HDL was measured using two reagents homogeneous systems with selective detergents to homogenize the lipoprotein of interest. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 56.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 70.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 68.3 |
HOMA-IR was calculated by the formula: fasting insulin (uU/mL) times fasting glucose (mg/L) divided by 22.5. (NCT00618072)
Timeframe: 6 months
| Intervention | HOMA-IR score (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 1.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 1.6 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 1.3 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 113.8 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 107.2 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 114.2 |
Triglycerides were measured by enzymatic immunoassay on an AU400 chemistry auto-analyzer with commercially available enzymatic reagents. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 95.2 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 103.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 109.2 |
(NCT00618072)
Timeframe: 6 months
| Intervention | cm (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 93.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 90.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 87.5 |
For those patients that are able to discontinue insulin therapy at or <12 weeks, how long were they able to well controlled with an A1c <7% on the agent that they were randomized to. (NCT01099618)
Timeframe: 3 years
| Intervention | days (Median) |
|---|---|
| Metformin | 472 |
| Sitagliptin | 589 |
| Placebo | 111 |
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 104
| Intervention | percentage point (%point) (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | 64.48 |
| Lira 1.2 + Met | 27.30 |
| Lira 1.8 + Met | 17.81 |
| Met Mono | -7.89 |
| Met + Glim | 11.25 |
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 26
| Intervention | percentage point (%point) (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | 20.45 |
| Lira 1.2 + Met | 20.33 |
| Lira 1.8 + Met | 26.12 |
| Met Mono | -1.63 |
| Met + Glim | 24.68 |
Change in body weight from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -2.07 |
| Lira 1.2 + Met | -3.03 |
| Lira 1.8 + Met | -2.91 |
| Met Mono | -1.80 |
| Met + Glim | 0.70 |
Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.78 |
| Lira 1.2 + Met | -2.58 |
| Lira 1.8 + Met | -2.79 |
| Met Mono | -1.51 |
| Met + Glim | 0.95 |
Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.80 |
| Lira 1.2 + Met | -1.20 |
| Lira 1.8 + Met | -1.18 |
| Met Mono | 0.75 |
| Met + Glim | -0.64 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.13 |
| Lira 1.2 + Met | -1.63 |
| Lira 1.8 + Met | -1.68 |
| Met Mono | 0.40 |
| Met + Glim | -1.31 |
Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | percentage of total haemoglobin (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.36 |
| Lira 1.2 + Met | -0.56 |
| Lira 1.8 + Met | -0.58 |
| Met Mono | 0.25 |
| Met + Glim | -0.50 |
Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | Percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.69 |
| Lira 1.2 + Met | -0.97 |
| Lira 1.8 + Met | -1.00 |
| Met Mono | 0.09 |
| Met + Glim | -0.98 |
Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.59 |
| Lira 1.2 + Met | -2.22 |
| Lira 1.8 + Met | -2.10 |
| Met Mono | -0.43 |
| Met + Glim | -1.80 |
Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.68 |
| Lira 1.2 + Met | -2.33 |
| Lira 1.8 + Met | -2.57 |
| Met Mono | -0.62 |
| Met + Glim | -2.46 |
"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.27 |
| Lira 1.2 + Met | -0.56 |
| Lira 1.8 + Met | -0.44 |
| Met Mono | -0.20 |
| Met + Glim | -0.29 |
"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/l (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.23 |
| Lira 1.2 + Met | -0.40 |
| Lira 1.8 + Met | -0.56 |
| Met Mono | -0.44 |
| Met + Glim | -0.44 |
Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-104
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| All | Major | Minor | Symptoms only | |
| Lira 0.6 + Met | 52 | 0 | 23 | 29 |
| Lira 1.2 + Met | 51 | 1 | 26 | 24 |
| Lira 1.8 + Met | 49 | 0 | 22 | 27 |
| Met + Glim | 524 | 0 | 284 | 240 |
| Met Mono | 18 | 0 | 6 | 12 |
Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-26
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Lira 0.6 + Met | 0 | 15 | 17 |
| Lira 1.2 + Met | 0 | 3 | 7 |
| Lira 1.8 + Met | 0 | 9 | 22 |
| Met + Glim | 0 | 136 | 175 |
| Met Mono | 0 | 6 | 10 |
Change in body fat mass measured by air displacement plethysmography (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -1.51 |
| Placebo Plus Weight Reduction Counseling | 1.81 |
Change in body fat mass by Dual Energy X-Ray Absorptiometry (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 0.48 |
| Placebo Plus Weight Reduction Counseling | 1.88 |
Change in body weight (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 1.47 |
| Placebo Plus Weight Reduction Counseling | 4.85 |
Change in body weight as determined by body mass index (kg/m2) (NCT00005669)
Timeframe: 6 months
| Intervention | kg/m2 (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.78 |
| Placebo Plus Weight Reduction Counseling | 0.32 |
Change in Body Mass Index standard deviation score (BMI-SDS) determined using tables created by the CDC in 2000. BMI-SDS is a unitless transformation of the body mass index (measured in kg divided by the squared height in meters) using the L M S method. Possible values range from -3 to +3. See http://www.cdc.gov/growthcharts/percentile_data_files.htm for details. (NCT00005669)
Timeframe: 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.11 |
| Placebo Plus Weight Reduction Counseling | -0.07 |
(NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | kg/m-squared (Mean) |
|---|---|
| Metformin | 1.3 |
| Vitamin E | 2.1 |
| Placebo | 1.9 |
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | -1.1 |
| Vitamin E | -1.8 |
| Placebo | -0.7 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 4.0 |
| Vitamin E | 6.0 |
| Placebo | 5.6 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 5.4 |
| Vitamin E | 7.6 |
| Placebo | 5.4 |
(NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin | -21.5 |
| Vitamin E | -22.8 |
| Placebo | -20.4 |
Change in alpha-Tocopherol (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | mg/L (Mean) |
|---|---|
| Metformin | -0.5 |
| Vitamin E | 9.4 |
| Placebo | -0.9 |
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 22 |
| Vitamin E | 22 |
| Placebo | 10 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 22 |
| Vitamin E | 18 |
| Placebo | 19 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 23 |
| Vitamin E | 22 |
| Placebo | 20 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 26 |
| Vitamin E | 27 |
| Placebo | 19 |
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 9 |
| Vitamin E | 15 |
| Placebo | 10 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | min-1/(µlU/L) (Mean) | ||
|---|---|---|---|
| SI at baseline | SI at 3 months | SI change vs baseline | |
| Metformin | 3.83 | 2.11 | -1.72 |
| Placebo | 2.26 | 2.8 | 0.544 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| ISI at baseline | ISI at month 3 | ISI change vs baseline | |
| Metformin | 7.3 | 5.9 | -1.4 |
| Placebo | 4.7 | 4.4 | -0.3 |
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year
| Intervention | percent of liver fat (Mean) |
|---|---|
| Pioglitazone and Exenatide | 4.7 |
| Pioglitazone | 6.5 |
the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year
| Intervention | microgram per ml (Mean) |
|---|---|
| Pioglitazone and Exenatide | 23.2 |
| Pioglitazone | 15.8 |
Value at 6 months minus value at baseline. Fibrinogen is a hepatic-derived factor directly involved in clotting and in the viscosity characteristics of blood flow. It binds to platelets and contributes to their aggregation, promotes fibrin formation and is also an acute phase reactant that is increased in inflammatory states. Fibrinogen concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA). (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | 58.5 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -105 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | 0.00 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | -33 |
Value at 6 months minus value at baseline. HsCRP is an acute phase protein which is a sensitive marker for systemic inflammation. HsCRP concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA), with an hsCRP lower sensitivity of 0.156 mg/L. (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | -0.37 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -1.78 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | -0.29 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | 0.00 |
Value at 6 months minus value at baseline. IL-6 is a pro-inflammatory cytokine thought to produce a state of low-grade inflammation in obese individuals. IL-6 stimulates hepatic production of C-reactive protein (CRP), an acute phase protein which is a sensitive marker for systemic inflammation. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA). (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | pg/mL (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | -0.66 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -0.99 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | 0.2 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | -0.35 |
Value at 6 months minus value at baseline. PAI-1 is the primary physiological inhibitor of fibrinolysis and proteolysis. High PAI-1 levels have been linked to thrombosis and fibrosis, insulin resistance and obesity. PAI-1 was measured by ELISA (American Diagnostica, Stamford, CT, USA). (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | ng/ML (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | 6.98 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -46.84 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | 0.55 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | -34.42 |
Change from baseline in Adiponectin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µg/mL (Mean) |
|---|---|
| Metformin | -0.71 |
| Placebo | -7.52 |
Change from baseline in Body Mass Index after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin | -0.74 |
| Placebo | -0.71 |
Change from baseline in Fasting insulin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µU/mL (Mean) |
|---|---|
| Metformin | -3.97 |
| Placebo | 11.03 |
Change from baseline in Fasting plasma glucose after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.08 |
| Placebo | 1.71 |
Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.26 |
| Placebo | -1.35 |
Change from baseline in Interleukin 6 after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.09 |
| Placebo | 16.42 |
Change from baseline in Tumour necrosis factor alpha after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.08 |
| Placebo | -4.01 |
Change from baseline in Waist circumference after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | cm (Mean) |
|---|---|
| Metformin | -0.57 |
| Placebo | -3.29 |
Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months
| Intervention | min^-1 (Mean) |
|---|---|
| Oral Contraceptive - 1 | 1653 |
| Flutamide - 2 | 194 |
| Placebo - 3 | -184 |
Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months
| Intervention | percentage of body mass (Mean) |
|---|---|
| Oral Contraceptive - 1 | 0.4 |
| Flutamide - 2 | -1.9 |
| Placebo - 3 | -1.9 |
Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | 6 |
| Flutamide - 2 | -5 |
| Placebo - 3 | -2 |
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | -6 |
| Flutamide - 2 | -9 |
| Placebo - 3 | -7 |
Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months
| Intervention | L/min (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.5 |
| Flutamide - 2 | -1.6 |
| Placebo - 3 | 1.1 |
Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months
| Intervention | Kcal/day (Mean) |
|---|---|
| Oral Contraceptive - 1 | 7 |
| Flutamide - 2 | -79 |
| Placebo - 3 | -88 |
Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months
| Intervention | L (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.1 |
| Flutamide - 2 | -0.1 |
| Placebo - 3 | 0.1 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
Mean decrease between pre- and post-randomization in 5 Weeks between the exenatide and placebo groups. (NCT00856609)
Timeframe: 5 weeks
| Intervention | kg (Mean) |
|---|---|
| Exenatide | 1.6 |
| Placebo | 0.27 |
Mean of 3-day food intake change between 3 days (Day 6-7-8) at baseline assessment and 3 days (Day 12-13-14) during the intervention period between the exenatide and placebo groups (NCT00856609)
Timeframe: Day 6-7-8 (at baseline) and Day 12-13-14 (3 days after starting study intervention)
| Intervention | kcal/day (Mean) |
|---|---|
| Exenatide | 1016.1 |
| Placebo | 245.1 |
Change of twenty-four-hour energy expenditure between at Day 5 at baseline assessment and at Day 11 two days after starting study medication between the exenatide and placebo groups (NCT00856609)
Timeframe: Day 5 and Day 11
| Intervention | kcal/day (Mean) |
|---|---|
| Exenatide | 51.6 |
| Placebo | 28.9 |
(NCT01722266)
Timeframe: 12 weeks
| Intervention | grams (Mean) |
|---|---|
| Placebo | -13.4 |
| Liraglutide 1.8mg | -46.4 |
| Liraglutide 1.2mg | -47.6 |
| Liraglutide 0.6 mg | -23.7 |
(NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Kg (Mean) |
|---|---|
| Placebo | -0.3 |
| Liraglutide 1.8mg | -4.8 |
| Liraglutide 1.2mg | -5.0 |
| Liraglutide 0.6 mg | -2.7 |
(NCT01722266)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Mean) |
|---|---|
| Placebo | -0.30 |
| Liraglutide 1.8mg | -0.42 |
| Liraglutide 1.2mg | -0.78 |
| Liraglutide 0.6 mg | -0.26 |
The primary endpoint of the study is to detect a difference from baseline in mean weekly blood glucose concentrations before and after 12 weeks of treatment in each of the Liraglutide groups. (NCT01722266)
Timeframe: 12 Weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | 1 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -10 |
| Liraglutide 0.6 mg | -0.3 |
Total insulin dose = Basal insulin dose plus bolus insulin dose. (NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Units (Mean) |
|---|---|
| Placebo | -3.4 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -12.1 |
| Liraglutide 0.6 mg | -2.8 |
(NCT00529204)
Timeframe: 24 weeks
| Intervention | IU (Number) |
|---|---|
| Exenatide | 61 |
(NCT00529204)
Timeframe: 24 weeks
| Intervention | adverse events (Number) |
|---|---|
| Exenatide | 0 |
"Steatosis was grades on a scale of 0 (< 5%); 1 (5%- 33%); 2 (> 33% - 66%); and 3 (> 66%).~Inflammation was graded on a scale of 0 (No foci); 1 (< 2 foci per 200 X field); 2 (2-4 foci per 200 X field); and 3 (>4 foci per 200 X field) Fibrosis was graded on a scale of 0 (None); 1 (Mild periportal or perisinusoidal); 2 (Moderate periportal or perisinusoidal); 3 (Bridging fibrosis); and 4 (cirrhosis)" (NCT00529204)
Timeframe: 24 weeks
| Intervention | units on a scale (Number) | ||
|---|---|---|---|
| steatosis | inflammation | fibrosis | |
| Exenatide | -1 | -1 | 0 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
ADMA- asymmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.51 | 0.52 | 0.50 |
| Group B | 0.57 | 0.55 | 0.52 |
arginine serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 112.18 | 107.72 | 104.72 |
| Group B | 111.72 | 97.69 | 103.76 |
serum concentration of the citrulline (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 21.73 | 25.95 | 26.93 |
| Group B | 28.08 | 27.01 | 29.77 |
DMA- dimethylamine, serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 1.71 | 1.63 | 1.62 |
| Group B | 2.07 | 1.89 | 1.84 |
the serum concentration of the studied drug-metformin (NCT03398356)
Timeframe: 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 4.36 | 5.09 | 4.66 |
| Group B | 4.25 | 7.42 | 4.01 |
SDMA-symmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.40 | 0.41 | 0.39 |
| Group B | 0.45 | 0.42 | 0.39 |
267 reviews available for metformin and Obesity
| Article | Year |
|---|---|
Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19.
Topics: Adipose Tissue; Adrenergic beta-3 Receptor Agonists; Aged; Aging; Angiotensin-Converting Enzyme 2; A | 2021 |
Obesity and Diabetes.
Topics: Behavior Therapy; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Gastric Bypass; Humans; Hypo | 2021 |
Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside.
Topics: COVID-19; Diabetes Mellitus; Humans; Metformin; Obesity; SARS-CoV-2 | 2022 |
Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport.
Topics: Animals; Female; Gene Expression; Glucose; Glucose Transport Proteins, Facilitative; Glucose Transpo | 2022 |
Polycystic ovary syndrome.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2022 |
Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Child; Exenatide; Humans; Liraglutide; Metformin; Obesity; Orlistat | 2022 |
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mass | 2022 |
Enhancing Metformin Effects by Adding Gut Microbiota Modulators to Ameliorate the Metabolic Status of Obese, Insulin-Resistant Hosts.
Topics: Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin; Metformin; Obesity; Prebiot | 2022 |
Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity.
Topics: Animals; COVID-19; Glucose; Humans; Metformin; Mice; Obesity; Oxidative Stress; Pandemics; SARS-CoV- | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Research Progress of Population Pharmacokinetic of Metformin.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Models, Biological; Obesity; Polymorphism, Genetic | 2022 |
Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials.
Topics: Breast Neoplasms; Cancer Survivors; Female; Humans; Metabolomics; Metformin; Obesity; Overweight; Ph | 2022 |
Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Energy Metabolism; Feasibility Studies; Glucose; Human | 2023 |
Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Humans; Insulin; Metformin; Obesity | 2022 |
The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Female; Humans; Infertility, Female; Live Birth; Metformin; Netwo | 2023 |
Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Obesity | 2023 |
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin; Obesity; Risk Factors | 2023 |
Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy.
Topics: Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant | 2023 |
Lights and shadows on the use of metformin in pregnancy: from the preconception phase to breastfeeding and beyond.
Topics: Abortion, Spontaneous; Breast Feeding; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Hum | 2023 |
The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Topics: Alanine Transaminase; Child; Humans; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liv | 2023 |
Review of Prediabetes and Hypertensive Disorders of Pregnancy.
Topics: Blood Glucose Self-Monitoring; Diet Therapy; Exercise; Female; Glycated Hemoglobin; Humans; Hyperten | 2021 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Metformin: An old drug against old age and associated morbidities.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Mo | 2020 |
Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin.
Topics: Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neoplasms; Obesi | 2020 |
The Bacterium
Topics: Akkermansia; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Dysbiosis; Gram-Negative Bacterial | 2020 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.
Topics: Adult; Aspirin; Cardiovascular Diseases; Child; Diet; Dietary Supplements; Humans; Hydroxymethylglut | 2020 |
COVID-19 in diabetic patients: Related risks and specifics of management.
Topics: Acidosis, Lactic; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Critical Illness; | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
Topics: Adult; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; | 2020 |
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Topics: Diabetes Complications; Drug Resistance, Neoplasm; Endometrial Neoplasms; Estrogens; Female; Glucose | 2020 |
Pharmacotherapeutic options for prediabetes.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2021 |
Time course and dose effect of metformin on weight in patients with different disease states.
Topics: Antipsychotic Agents; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Huma | 2020 |
Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials.
Topics: Adipokines; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Sy | 2021 |
NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.
Topics: Angiotensin-Converting Enzyme 2; Cardiovascular Diseases; Comorbidity; COVID-19; COVID-19 Drug Treat | 2020 |
Lipid Metabolism and Relevant Disorders to Female Reproductive Health.
Topics: Diet, Reducing; Female; Humans; Insulin Resistance; Lipid Metabolism; Metformin; Obesity; Polycystic | 2021 |
The Fatty Acid Lipid Metabolism Nexus in COVID-19.
Topics: AMP-Activated Protein Kinases; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Digestive System | 2021 |
Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients.
Topics: Anti-Obesity Agents; COVID-19; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Ag | 2021 |
Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cardiovascular Diseases; COVID-19; COVID-19 D | 2021 |
Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses.
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2021 |
Pharmacological and non-pharmacological strategies for obese women with subfertility.
Topics: Abortion, Spontaneous; Appetite Depressants; Bias; Carnitine; Clomiphene; Dexfenfluramine; Drug Ther | 2021 |
The therapeutic potentials of apelin in obesity-associated diseases.
Topics: Animals; Anti-Obesity Agents; Apelin; Apelin Receptors; Diabetes Mellitus, Type 2; Diabetic Cardiomy | 2021 |
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Topics: Administration, Oral; Body Weight; Cardiovascular Diseases; Comorbidity; Decision Making; Diabetes M | 2021 |
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Human | 2021 |
Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycem | 2021 |
The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
Topics: Drug Synergism; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; | 2022 |
Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis.
Topics: Adult; Androgens; C-Reactive Protein; Female; Humans; Metformin; Obesity; Polycystic Ovary Syndrome; | 2017 |
Optimizing diabetes treatment in the presence of obesity.
Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Gly | 2017 |
Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Randomize | 2018 |
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Topics: Bariatric Surgery; Diet Therapy; Diuretics; Exercise Therapy; Female; Gout; Humans; Hypoglycemic Age | 2017 |
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review.
Topics: Body Mass Index; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fatty Liver; Femal | 2017 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials.
Topics: Bayes Theorem; Diabetes, Gestational; Female; Glyburide; Humans; Hypertension, Pregnancy-Induced; In | 2018 |
Why AMPK agonists not known to be stressors may surprisingly contribute to miscarriage or hinder IVF/ART.
Topics: Abortion, Spontaneous; Adenosine Triphosphate; AMP-Activated Protein Kinase Kinases; Blastocyst; Die | 2018 |
Treatment of 'Diabesity': Beyond Pharmacotherapy.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; | 2018 |
Metformin in Pregnancy: Mechanisms and Clinical Applications.
Topics: Adult; Animals; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Insulin; Me | 2018 |
[Polycystic ovary syndrome - current state of knowledge].
Topics: Adult; Clomiphene; Diabetes Mellitus, Type 2; Female; Fertility Agents, Female; Humans; Infertility, | 2018 |
Review of Metformin Use for Type 2 Diabetes Prevention.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
The effects of metformin on simple obesity: a meta-analysis.
Topics: Body Mass Index; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Treatment Outcome | 2018 |
Metformin: An Old Drug with New Applications.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metform | 2018 |
Type 2 Diabetes Mellitus in Children.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypoglycemic Agents; Ins | 2018 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.
Topics: Aspirin; Cardiovascular Diseases; Diet; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reduc | 2018 |
Topics: Body Weight; Child; Humans; Metformin; Obesity | 2018 |
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
Topics: Animals; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com | 2019 |
Body Weight Considerations in the Management of Type 2 Diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2019 |
Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.
Topics: Adult; Body Mass Index; Body Weight; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2018 |
Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Obesity; Overweigh | 2019 |
Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Overwei | 2019 |
Metformin for Improving Maternal and Infant Outcomes in Pregnant Women Who are Obese.
Topics: Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Obesity; Pregnancy; Pregnancy Compl | 2019 |
Anti-diabetic treatment leads to changes in gut microbiome.
Topics: alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase | 2019 |
Metformin: Mechanisms in Human Obesity and Weight Loss.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastrointestinal Microbiome; Huma | 2019 |
Metformin reduces maternal weight gain in obese pregnant women: A systematic review and meta-analysis of two randomized controlled trials.
Topics: Female; Gestational Weight Gain; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; Pregnan | 2019 |
Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Topics: Alcoholism; Case-Control Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Gly | 2020 |
Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis.
Topics: Child; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Long Term Adve | 2019 |
The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases.
Topics: Animals; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Metfor | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
Diabetes and cancer: placing the association in perspective.
Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications | 2013 |
[Diabetes drugs and body weight].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Prognosis; R | 2013 |
Interventions for the metabolic dysfunction in polycystic ovary syndrome.
Topics: Diabetes Mellitus; Diet; Dyslipidemias; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Ob | 2013 |
[Management of type 2 diabetes: new or previous agents, how to choose?].
Topics: Administration, Oral; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Pep | 2013 |
Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplas | 2013 |
Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review.
Topics: Adult; Clinical Trials as Topic; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin | 2013 |
The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Combined Modality Therapy; Drug Administration S | 2014 |
Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Neop | 2013 |
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thick | 2013 |
Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
Topics: Abscess; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bandages; Biofilms; Combined Modality Ther | 2013 |
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.
Topics: Androgen Antagonists; Androgens; Bariatric Surgery; Female; Hair Removal; Hirsutism; Humans; Metform | 2014 |
Polycystic ovary syndrome: current status and future perspective.
Topics: Androgens; Disease Management; Female; Humans; Hyperandrogenism; Infertility, Female; Insulin Resist | 2014 |
Endocrine basis for recurrent pregnancy loss.
Topics: Abortion, Habitual; Female; Humans; Hyperinsulinism; Hyperprolactinemia; Hypoglycemic Agents; Lutein | 2014 |
Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
Topics: Adolescent; Female; Humans; Insulin Resistance; Life Style; Menopause; Metabolic Syndrome; Metformin | 2014 |
Microbiota and diabetes: an evolving relationship.
Topics: Diabetes Mellitus, Type 2; Diet Therapy; Feces; Humans; Hypoglycemic Agents; Immunity, Innate; Intes | 2014 |
Cancer risks from diabetes therapies: evaluating the evidence.
Topics: Animals; Diabetes Mellitus; Drug Design; Endocannabinoids; Glucose; Humans; Hypoglycemic Agents; Ins | 2014 |
The therapy of insulin resistance in other diseases besides type 2 diabetes.
Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic | 2014 |
Effects of metformin on weight loss: potential mechanisms.
Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Hypothalamus; | 2014 |
Metformin and gynecologic cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hu | 2014 |
Novel therapeutic strategies for adult obese asthmatics.
Topics: Adenylate Kinase; Adult; Airway Remodeling; Arginine; Asthma; Dietary Supplements; Humans; Hydroxyme | 2014 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
Placental dysfunction in obese women and antenatal surveillance strategies.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Inflammation; Metform | 2015 |
Medical and surgical interventions to improve outcomes in obese women planning for pregnancy.
Topics: Bariatric Surgery; Exercise; Feeding Behavior; Female; Humans; Hypoglycemic Agents; Infertility, Fem | 2015 |
Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
Topics: Androgens; Anovulation; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2015 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoprevention; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; | 2015 |
Chemoprevention in Barrett's Esophagus: Current Status.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Bile Acids and Salts; Cy | 2015 |
[Metformin: new data for an old molecule].
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2015 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Metabolic Syndrome: Insulin Resistance and Prediabetes.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Humans; Hypoglycemic Agent | 2015 |
Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Female; Hirsutism; Hormones; Humans; Hyperan | 2015 |
Metformin: risk-benefit profile with a focus on cancer.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Incidence; Insulin Resistance; Metformin; Neoplasms; | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Mechanisms of obesity in the development of breast cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Breast Neoplasms; Disease Progression | 2015 |
[Evidence-based therapy of polycystic ovarian syndrome].
Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace | 2015 |
[Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management].
Topics: Biomarkers; Counseling; Dermatology; Diabetes Mellitus, Type 2; Disease Management; Endocrinology; E | 2015 |
Obesity and Cancer: An Angiogenic and Inflammatory Link.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Inflammation; Metformin; Neoplasms; Neovascularization, | 2016 |
Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metformin; Neoplasms; Obesi | 2016 |
Metabolic syndrome, diet and exercise.
Topics: Bariatric Surgery; Diet; Diet Therapy; Exercise; Exercise Therapy; Female; Humans; Hydroxymethylglut | 2016 |
Endocrine and metabolic characteristics in polycystic ovary syndrome.
Topics: Biomarkers; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic S | 2016 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
The cardiovascular phenotype: impact on choice of glucose- lowering therapy.
Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2016 |
Hypothalamic AMPK: a canonical regulator of whole-body energy balance.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anti-Obesity Agents; Di | 2016 |
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
Topics: Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Clozapine; Fasting; Humans; Hypog | 2016 |
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Consensus; Female; Fertility Agents, Female; Fertiliz | 2016 |
Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Blood Pressure; Female; Humans; Male; Metformin; Middle Aged; Obesity; Rand | 2017 |
Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2.
Topics: Animals; Aryldialkylphosphatase; Chemokine CCL2; Diabetes Mellitus, Type 2; Gene Expression Regulati | 2016 |
EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Topics: Animals; Bariatric Surgery; Bile Acids and Salts; Cholecystokinin; Diabetes Mellitus, Type 2; Gastri | 2016 |
Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities.
Topics: Child; Clinical Trials as Topic; Comorbidity; Diabetes Complications; Diabetes Mellitus, Type 2; Hum | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Pharmacotherapy for obesity in menopausal women.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; | 2008 |
Current and emerging therapies in nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics | 2008 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis.
Topics: Androgens; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; | 2009 |
Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Clinical Trials as Topic; Double-Blind Method; Femal | 2009 |
Metformin for obesity in children and adolescents: a systematic review.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Child; Female; Humans; Male; Metformin; Obesit | 2009 |
Diabetes medications and body weight.
Topics: Abdominal Fat; Benzamides; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipepti | 2009 |
Pharmacotherapy in pediatric obesity: current agents and future directions.
Topics: Anti-Obesity Agents; Child; Cyclobutanes; Drug Therapy; Humans; Metformin; Obesity | 2009 |
[Adipose tissue inflammation and atherosclerosis].
Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; H | 2009 |
Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insuli | 2009 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; E | 2010 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Fructose; Humans; Hypoglycemic Agents; Metformin; Obesity | 2010 |
Insulin, insulin resistance, obesity, and cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Metformin; Neoplasms; Obesity | 2010 |
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Topics: Adiponectin; AMP-Activated Protein Kinases; Breast Neoplasms; Clinical Trials as Topic; Female; Huma | 2010 |
Metabolic syndrome with the atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Clozapine; Humans; Metabolic Syndrom | 2010 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
Topics: Antipsychotic Agents; Blood Glucose; Body Weight; Humans; Hypoglycemic Agents; Metformin; Obesity; O | 2010 |
[New clinical data with metformin therapy in patients with diabetes mellitus].
Topics: Administration, Oral; Adult; Aged; Biomarkers; Clinical Trials as Topic; Diabetes Complications; Dia | 2010 |
Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Glucose Metabolism Disorders; Humans; Hypoglycemic Ag | 2011 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros | 2011 |
Pharmacotherapy for obese adolescents.
Topics: Adolescent; Amphetamines; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Central Nervo | 2011 |
Insulin resistance: pathophysiology and rationale for treatment.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Hyperinsulin | 2011 |
Use of metformin in pediatric age.
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty | 2011 |
Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials.
Topics: Anovulation; Body Mass Index; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Fe | 2011 |
Management of metabolic syndrome in children and adolescents.
Topics: Adolescent; Antioxidants; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2011 |
[Colorectal cancer and diabetes].
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Ri | 2011 |
How can primary care providers manage pediatric obesity in the real world?
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Body Mass Index; Child; Humans; Hypoglycemic Age | 2011 |
[Diabetes and cancer risk: oncologic considerations].
Topics: Adipokines; Age Factors; Animals; Cytokines; Diabetes Complications; Diabetes Mellitus, Type 2; Feed | 2011 |
Weight beneficial treatments for type 2 diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insuli | 2011 |
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Topics: Animals; Breast Neoplasms; Chemoprevention; Cohort Studies; Comorbidity; Disease Models, Animal; Fem | 2011 |
Gestational diabetes: implications for cardiovascular health.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetes, Ge | 2012 |
Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Diabetes Mellitus, Type 2; Estrogens; Female; Human | 2012 |
Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hyp | 2012 |
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones; | 2012 |
Metformin use among individuals at risk for type 2 diabetes.
Topics: Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Early Diagnosis; Fasting; Female; Humans; | 2012 |
Metformin in obesity, cancer and aging: addressing controversies.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metform | 2012 |
The treatment of infertility in polycystic ovary syndrome: a brief update.
Topics: Adult; Anovulation; Clomiphene; Evidence-Based Medicine; Female; Fertility Agents, Female; Gonadotro | 2012 |
Endometrial carcinoma tumorigenesis and pharmacotherapy research.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Endom | 2012 |
Insulin resistance in type 2 diabetic youth.
Topics: Adolescent; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Exercise Tolerance; Female | 2012 |
Endocrine-related cancers and the role of AMPK.
Topics: AMP-Activated Protein Kinases; Biological Factors; Cell Transformation, Neoplastic; Colonic Neoplasm | 2013 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
Diabetes and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen | 2012 |
The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
Topics: Animals; Continuous Positive Airway Pressure; Electroacupuncture; Female; Heart Rate; Humans; Insuli | 2012 |
Obesity and diabetes.
Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metfor | 2012 |
Reproductive impact of polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Clomiphene; Female; Fertilization in Vitro; Humans; Infant, Newborn; Infertil | 2012 |
Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hypoglycemic Agents; Life Style; M | 2012 |
Metformin: the hidden chronicles of a magic drug.
Topics: Animals; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Metformin; Neo | 2013 |
Polycystic ovarian syndrome management options.
Topics: Clomiphene; Contraceptives, Oral, Hormonal; Estrogen Antagonists; Exercise; Female; Humans; Infertil | 2012 |
Evaluation and treatment of anovulatory and unexplained infertility.
Topics: Anovulation; Clomiphene; Diet; Evidence-Based Medicine; Exercise; Female; Fertility Agents, Female; | 2012 |
The complexities of epidemiology and prevention of gastrointestinal cancers.
Topics: Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Folic Acid; Gastrointesti | 2012 |
Diabetes and pancreatic cancer.
Topics: Age Factors; Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Early Detection o | 2012 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; | 2002 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertrigly | 2002 |
Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome.
Topics: Body Mass Index; Clomiphene; Diet; Female; Humans; Hypoglycemic Agents; Menotropins; Menstrual Cycle | 2003 |
Combination of drugs in the management of diabetes mellitus.
Topics: Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypogl | 2002 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double- | 2003 |
Insulin resistance syndrome in children : pathophysiology and potential management strategies.
Topics: Child; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Metformin; Obes | 2003 |
[Insulin resistance and polycystic ovary syndrome].
Topics: Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metf | 2003 |
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mell | 2003 |
Type 2 diabetes mellitus in youth.
Topics: Adolescent; Behavior Therapy; Blood Glucose; Blood Glucose Self-Monitoring; Child; Comorbidity; Diab | 2003 |
Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes?
Topics: Acarbose; Diabetes Complications; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss | 2003 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
Antiatherogenic properties of metformin: the experimental evidence.
Topics: Animals; Aortic Diseases; Arteries; Arteriosclerosis; Diabetes Mellitus, Type 2; Disease Models, Ani | 2003 |
Insulin-lowering agents in the management of polycystic ovary syndrome.
Topics: Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnanc | 2003 |
[Drug treatment of type 2 diabetes].
Topics: Administration, Oral; Cause of Death; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab | 2004 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diab | 2003 |
Polycystic ovary syndrome in adolescence--a therapeutic conundrum.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome | 2004 |
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Topics: Anti-Obesity Agents; Behavior Therapy; Caloric Restriction; Cost-Benefit Analysis; Cyclobutanes; Die | 2004 |
Endothelial dysfunction, inflammation and diabetes.
Topics: Acarbose; Animals; Cardiovascular Agents; Diabetes Mellitus; Diabetic Angiopathies; Endothelium, Vas | 2004 |
Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Drug Resistance; Electrocoagulation; Female; Fertility Agents, Femal | 2004 |
Nonalcoholic fatty liver disease in the pediatric population.
Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Female; Histocytochemistry; Humans; Hypoglycem | 2004 |
Current indications for metformin therapy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin R | 2003 |
[Oral diabetes treatment. Which substance is indicated at which time?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Germany; Glucagon; Glucagon-Like Peptide 1; Glucago | 2004 |
Alpha-lipoic acid, an anti-obesity agent?
Topics: AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Disease Models, Animal; Humans; Lipid M | 2004 |
Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.
Topics: Antihypertensive Agents; Comorbidity; Diabetes Mellitus; Glucosidases; Humans; Hypercholesterolemia; | 2004 |
Polycystic ovary syndrome--a management update.
Topics: Contraceptives, Oral; Family Practice; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Inf | 2005 |
The fatty liver and insulin resistance.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Animals; Antiretroviral Therapy, Highly Active; C | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; | 2005 |
Insulin-sensitisers in the treatment of polycystic ovary syndrome.
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Drug Approval; Exercise; Fema | 2005 |
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipogenesis; Allosteric Regulation; AMP-Activated | 2006 |
Insulin resistance and improvements in signal transduction.
Topics: Adiponectin; AMP-Activated Protein Kinases; Appetite Regulation; Diabetes Mellitus, Type 2; Enzyme A | 2006 |
Pregnancy complications in PCOS.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperinsulinism; Hypertension, Pregnan | 2006 |
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; | 2006 |
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
Topics: Administration, Oral; Adult; Aged; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, | 2006 |
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Topics: Adult; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2006 |
The treatment of type 2 diabetes mellitus in youth : which therapies?
Topics: Adipose Tissue; Adolescent; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic | 2006 |
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathie | 2006 |
Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped?
Topics: Adolescent; Anti-Obesity Agents; Behavior Therapy; Child; Humans; Hyperinsulinism; Hypoglycemic Agen | 2006 |
[The metabolic syndrome and sports].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Clinical Trials as Topic; Diabetes Mellitus; Ener | 2006 |
AMP-activated protein kinase in metabolic control and insulin signaling.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; Amino Acid Sequence; Aminoimidazole Car | 2007 |
Polycystic ovary syndrome update in adolescence.
Topics: Adolescent; Algorithms; Androgen Antagonists; Disease Progression; Female; Humans; Hypoglycemic Agen | 2007 |
Pharmacotherapeutic options for overweight adolescents.
Topics: Adolescent; Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Hypoglycemic Agents | 2007 |
Metformin and body weight.
Topics: Adolescent; Adult; Body Weight; Child; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agent | 2008 |
Managing anovulatory infertility and polycystic ovary syndrome.
Topics: Anovulation; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Obesity; Ovulation | 2007 |
Obesity and the polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Cardiovascular Diseases; Contraceptives, Oral, Hormonal; Diet; Fem | 2007 |
Unmet needs in controlling metabolic disease.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Hyp | 2007 |
FPIN's clinical inquiries. Metformin therapy and diabetes prevention in adolescents who are obese.
Topics: Adolescent; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metform | 2007 |
Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Endothelium, Vascular; Exercise | 2008 |
Management of type 2 diabetes in the obese patient: current concerns and emerging therapies.
Topics: Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; | 2008 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adult; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity | 2008 |
Metformin beyond diabetes: new life for an old drug.
Topics: Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglyc | 2006 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
Topics: Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Life Style; Metfor | 2007 |
Pharmacotherapy for obesity.
Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclo | 2007 |
An overview of obesity in children with psychiatric disorders taking atypical antipsychotics.
Topics: Adolescent; Antipsychotic Agents; Appetite Depressants; Child; Child, Preschool; Cognitive Behaviora | 2008 |
Pediatric obesity: parallels with addiction and treatment recommendations.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Child; C | 2008 |
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Topics: Algorithms; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitu | 2008 |
Role of metformin for weight management in patients without type 2 diabetes.
Topics: Adolescent; Adult; Anti-Obesity Agents; Body Weight; Clinical Trials as Topic; Humans; Hypoglycemic | 2008 |
Metformin as a weight-loss tool in "at-risk" obese adolescents: a magic bullet?
Topics: Adolescent; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Risk Factors | 2008 |
[Action of metformin at and beyond insulin receptors. Studies in humans].
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Erythrocytes; Humans; Insulin; Metformin; Mono | 1983 |
[Metformin -- biguanid of choice].
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Humans; Metformin; Obesity | 1995 |
Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Diabetes Mell | 1994 |
Effects of metformin in obese patients with impaired glucose tolerance.
Topics: Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Ob | 1995 |
Insulin therapy in type II diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Com | 1995 |
Syndrome X. Recognition and management of this metabolic disorder in primary care.
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypertension; Metabolic Diseases; Metformin; Ob | 1996 |
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Topics: Adult; Aged; Chromans; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
[Metformin in diabetes therapy].
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Metformin; Obe | 1998 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
Insulin resistance, polycystic ovary syndrome and metformin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Res | 1999 |
Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2000 |
[++UKPDS Study. Metformin in obese patients with Type 2 diabetes (UKPDS 340].
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; | 2000 |
Drug treatment of obesity.
Topics: Androgen Antagonists; Androgens; Anti-Obesity Agents; Appetite Depressants; Caffeine; Central Nervou | 1999 |
[Metformin efficacious in poorly controlled diabetes mellitus type 2].
Topics: Abdominal Pain; Acidosis, Lactic; Aged; Blood Glucose; Contraindications; Diabetes Mellitus; Diabete | 2000 |
[Current role of metformin in treatment of diabetes mellitus type 2].
Topics: Acidosis, Lactic; Contraindications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglyce | 2000 |
The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovar | 1999 |
[Should the occurrence of a first coronary event change the management of diabetes?].
Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Antagonists; Blood Glucose; Cardiovascular Agents; | 2000 |
Obesity medications and the treatment of type 2 diabetes.
Topics: Acarbose; Anti-Obesity Agents; Appetite Depressants; Diabetes Mellitus; Diabetes Mellitus, Type 2; D | 1999 |
Intensive therapies for pediatric obesity.
Topics: Adolescent; Appetite Depressants; Child; Diet, Reducing; Gastric Bypass; Gastrointestinal Agents; Hu | 2001 |
Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
Topics: Endocrine System; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Menstrual | 2001 |
[The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H | 2002 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
[Identification and prevention of vascular risk. Significance of metformin].
Topics: Anthropometry; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; I | 1990 |
Obesity.
Topics: Adolescent; Adult; Appetite Depressants; Child; Diagnosis; Diet, Reducing; Fasting; Female; Humans; | 1972 |
The treatment of obesity.
Topics: Amphetamine; Behavior Therapy; Chorionic Gonadotropin; Dextroamphetamine; Exercise Therapy; Hospital | 1972 |
The management of obesity: some recent concepts.
Topics: Adaptation, Psychological; Adipose Tissue; Appetite Depressants; Attitude; Chlorphentermine; Defense | 1969 |
370 trials available for metformin and Obesity
| Article | Year |
|---|---|
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Body Composition; Body Mass Index; Female; Gonadal Steroid Hormon | 2022 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
[Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Orlist | 2021 |
A behavioral weight-loss intervention, but not metformin, decreases a marker of gut barrier permeability: results from the SPIRIT randomized trial.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Lipopolysaccharides; Male; Metformin; | 2022 |
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed C | 2022 |
Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Bariatric Surgery; Female; Humans; Metformin; Obesity; Polycystic Ovary Syndrome; | 2022 |
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglyc | 2022 |
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Topics: Exenatide; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; O | 2022 |
Metformin, testosterone, or both in men with obesity and low testosterone: A double-blind, parallel-group, randomized controlled trial.
Topics: Double-Blind Method; Erectile Dysfunction; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2022 |
Effect of sodium alginate supplementation on weight management and reproductive hormones in polycystic females.
Topics: Adult; Alginates; Blood Glucose; Body Mass Index; Dietary Fiber; Dietary Supplements; Estrogens; Fem | 2022 |
Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
Topics: Female; Follicle Stimulating Hormone; Glucose; Humans; Liraglutide; Metabolome; Metformin; Obesity; | 2022 |
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind M | 2022 |
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Female; Humans; Insulin; Insulin Resistance; Metabo | 2022 |
Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.
Topics: Adiponectin; Adult; Female; Follicle Stimulating Hormone; Humans; Inositol; Insulin; Luteinizing Hor | 2023 |
Effect of a Personalized Diet to Reduce Postprandial Glycemic Response vs a Low-fat Diet on Weight Loss in Adults With Abnormal Glucose Metabolism and Obesity: A Randomized Clinical Trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Female; Glucose; Glycated Hem | 2022 |
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr
Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Fema | 2022 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Metformin; Obesity; Polyethy | 2022 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans | 2023 |
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastrointestinal Microbiome; Gl | 2023 |
Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; | 2023 |
Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial.
Topics: Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Metformin; Multicenter Studies | 2023 |
[Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity].
Topics: Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Humans; Liraglutid | 2023 |
Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes.
Topics: Adolescent; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemi | 2023 |
Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years.
Topics: Adipokines; Adiponectin; Adiposity; Child; Diabetes, Gestational; Female; Humans; Inflammation; Insu | 2023 |
Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
Topics: Female; Humans; Insulin Resistance; Metformin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; W | 2023 |
Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial.
Topics: Adult; Aged; Decision Making, Shared; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents | 2019 |
Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels.
Topics: Adult; Anti-Mullerian Hormone; Clomiphene; Cross-Over Studies; Diabetes Mellitus, Type 2; Dihydrotes | 2020 |
Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Re | 2020 |
Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study.
Topics: Adolescent; Body Mass Index; Body Weight; C-Reactive Protein; Carotid Intima-Media Thickness; Child; | 2019 |
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Longitudina | 2020 |
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Energy Met | 2020 |
Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Anthropometry; Blood Pressure; Body Mass Index; Caloric Restriction; Energy | 2020 |
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Topics: Adolescent; Adult; Blood Glucose; China; Drug Therapy, Combination; Exenatide; Female; Glucose Intol | 2021 |
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Topics: Adult; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2020 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Gl | 2021 |
An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hy | 2021 |
Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial.
Topics: Body Mass Index; Cancer Survivors; Female; Health Behavior; Humans; Insulin-Like Growth Factor Bindi | 2021 |
Nigella sativa as a promising intervention for metabolic and inflammatory disorders in obese prediabetic subjects: A comparative study of Nigella sativa versus both lifestyle modification and metformin.
Topics: Blood Glucose; Humans; Inflammation; Life Style; Metformin; Nigella sativa; Obesity; Plant Preparati | 2021 |
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial.
Topics: Adult; Fatty Acids, Volatile; Feces; Female; Gastrointestinal Microbiome; Humans; Metformin; Middle | 2021 |
Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women.
Topics: Administration, Oral; Adolescent; Adult; China; Cholesterol; Cyproterone Acetate; Drug Administratio | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female | 2021 |
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Rece | 2021 |
Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood.
Topics: Cardiovascular Diseases; Child; Child, Preschool; Female; Follow-Up Studies; Heart Disease Risk Fact | 2022 |
A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
Topics: Adiposity; Breast Density; Breast Neoplasms; Feasibility Studies; Female; Humans; Mammography; Metab | 2021 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Retrospective Evaluation of Metformin and/or Metformin Plus a New Polysaccharide Complex in Treating Severe Hyperinsulinism and Insulin Resistance in Obese Children and Adolescents with Metabolic Syndrome.
Topics: Adolescent; Child; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; M | 2017 |
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; D | 2018 |
Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Estradiol; Female; Glucose Intolerance; Gonadal Steroid Hor | 2017 |
Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Diabetes | 2018 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study.
Topics: Adult; Biomarkers; Body Weights and Measures; Clomiphene; Energy Metabolism; Hormones; Humans; Hypog | 2017 |
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Topics: Adipocytes; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide | 2017 |
Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Fem | 2017 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as | 2018 |
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Double-Bli | 2018 |
Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility | 2019 |
Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Topics: Adipose Tissue; Adult; Androgen Antagonists; Androgens; Cyproterone Acetate; Drug Combinations; Ethi | 2018 |
Effectiveness of Metformin in the Prevention of Gestational Diabetes Mellitus in Obese Pregnant Women.
Topics: Adolescent; Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Incidence; Metformin; | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer.
Topics: Adiposity; Biomarkers; Body Composition; Body Mass Index; Endometrial Neoplasms; Endometrium; Female | 2018 |
Metformin added to intensive insulin therapy improves metabolic control in patients with type 1 diabetes and excess body fat.
Topics: Adipose Tissue; Adolescent; Adult; Body Mass Index; Diabetes Mellitus, Type 1; Drug Therapy, Combina | 2018 |
Effect of a nonsystemic, orally administered hydrogel, GS100, on metformin pharmacokinetics.
Topics: Administration, Oral; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Fasti | 2018 |
High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Diazoxide; Dose-Response Relationship, Drug; Dou | 2018 |
Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastroplasty; Glucose Intolerance; Gl | 2018 |
Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters.
Topics: Body Weight; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Leucine; Male; Metformin; Mid | 2019 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2019 |
The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance.
Topics: Adult; Anti-Obesity Agents; Caloric Restriction; Diet; Female; Humans; Hypoglycemic Agents; Insulin | 2018 |
l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.
Topics: Adult; Blood Glucose; Carnitine; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Horm | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
Topics: Adipokines; Adult; Biomarkers; Blood Glucose; Carrier Proteins; Exenatide; Female; Glycoproteins; Hu | 2019 |
Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double- | 2019 |
The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cancer Survivors; Cognitive Dysfunction; Combined Modalit | 2019 |
Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study.
Topics: Adiposity; Adolescent; Blood Glucose; Body Fat Distribution; Child; Combined Modality Therapy; Diabe | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; De | 2019 |
Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Typ | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults.
Topics: Adiposity; Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Dou | 2013 |
Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program.
Topics: Adult; Alleles; Body Mass Index; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Genotype; Humans | 2013 |
Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Body Mass Index; Child; Child Behavior; Combined Modality Therapy; | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Topics: Adult; Body Weight; Clozapine; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Metabol | 2013 |
Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Female; Follow-Up Studies; Gonadal Steroid Hormones; Hu | 2014 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study.
Topics: Adult; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glycation End Products, Advance | 2013 |
Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention.
Topics: Adult; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Male; Metabolic Syndrome; | 2013 |
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female; | 2013 |
Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.
Topics: Adult; Blood Glucose; Body Composition; Body Mass Index; Carrier Proteins; Diabetes Mellitus, Type 2 | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Diet; Energy Intake; Glucose Tolerance Test; G | 2015 |
Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment.
Topics: Adiponectin; Adolescent; Adult; C-Reactive Protein; Female; Humans; Insulin Resistance; Metformin; O | 2014 |
Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program.
Topics: Adipose Tissue; Adiposity; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellit | 2014 |
Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women.
Topics: Adult; Anti-Mullerian Hormone; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Metfor | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes | 2013 |
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Cell Proliferatio | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ene | 2014 |
Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy | 2014 |
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Topics: Adult; Aminopyridines; Benzamides; Body Weight; Cyclopropanes; Drug-Related Side Effects and Adverse | 2014 |
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidas | 2014 |
METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study.
Topics: Adolescent; Body Composition; Child; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypogly | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Effect of fat loss on arterial elasticity in obese adolescents with clinical insulin resistance: RESIST study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Body Composition; Child; Diabetes Mellitus, Type | 2014 |
Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Diet; Endometrial Neoplasms; Exercise; Female; Humans; Intrauteri | 2014 |
Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Double-Blind Method; Fasting; Female; Humans; Hypoglyce | 2015 |
Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.
Topics: Adolescent; Adult; Biomarkers; Cardiac Output; Coronary Artery Disease; Delayed-Action Preparations; | 2015 |
Efficacy of metformin in pregnant obese women: a randomised controlled trial.
Topics: Adolescent; Adult; Birth Weight; Blood Glucose; Clinical Protocols; Diabetes, Gestational; Double-Bl | 2015 |
Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Topics: Adult; Cross-Sectional Studies; Female; Fibronectins; Glucose Tolerance Test; Humans; Hypoglycemic A | 2015 |
Effect of insulin sensitizer therapy on amino acids and their metabolites.
Topics: Adult; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose C | 2015 |
Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Body Mass Index; Cohort Studies; Cross-Over Studies; Doub | 2015 |
Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc | 2015 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2015 |
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Fema | 2015 |
Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity.
Topics: Adult; Black or African American; Cholesterol, HDL; Cohort Studies; Ethnicity; Female; Hispanic or L | 2015 |
The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aldose-Ketose Isomerases; Alleles; Antipsychotic Agents | 2015 |
Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial.
Topics: Biomarkers; Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasm Staging; Obes | 2015 |
Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program Cohort.
Topics: Adiponectin; Adult; Albuminuria; Creatinine; Cross-Sectional Studies; Diabetes Mellitus; Female; Hum | 2015 |
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.
Topics: Adolescent; Adult; Blood Glucose; Chemotherapy, Adjuvant; Child; Diabetes Mellitus, Type 1; Double-B | 2015 |
Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Topics: Amylases; Blood Glucose; Body Fat Distribution; Body Weight; Diabetes Mellitus, Type 2; Drug Adminis | 2015 |
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
Topics: Adult; Body Mass Index; Cross-Sectional Studies; Female; Gonadal Steroid Hormones; Humans; Hypoglyce | 2016 |
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Topics: Adolescent; Blood Glucose; Body Mass Index; Body Weight; Child; Diabetes Mellitus, Type 1; Double-Bl | 2015 |
Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
Topics: Aged; Aged, 80 and over; Blood Glucose; Breast Neoplasms; C-Reactive Protein; Estradiol; Exercise; F | 2016 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinat | 2016 |
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Female; | 2016 |
Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
Topics: Aged; Anemia; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypoglyce | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program.
Topics: Adult; Betaine; Biomarkers; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Diabete | 2016 |
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
Topics: Adiposity; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Typ | 2016 |
A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus.
Topics: Aged; Antibodies, Monoclonal, Humanized; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Com | 2016 |
Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; | 2016 |
Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Drug Therapy | 2016 |
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Bli | 2016 |
Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients.
Topics: Acupuncture Therapy; Adiponectin; Adult; Biomarkers; Body Mass Index; Body Weight; Cholesterol, HDL; | 2016 |
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Huma | 2016 |
Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.
Topics: Adiposity; Body Weight; Child; Double-Blind Method; Female; Genotype; Glomerular Filtration Rate; Hu | 2017 |
The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study.
Topics: Adult; Female; Humans; Hydroxycholecalciferols; Hyperandrogenism; Hypoglycemic Agents; Insulin Resis | 2016 |
Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
Topics: Adiponectin; Adult; Body Weight; Breast; Breast Neoplasms; Double-Blind Method; Humans; Hypoglycemic | 2016 |
Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Comorbidity; Cross-Over Studies; Diabetes Mellitus, Typ | 2016 |
The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diet; Female; Follow-Up Studies; Glucose I | 2016 |
Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial.
Topics: Adolescent; Body Composition; Child; Double-Blind Method; Exercise; Female; Humans; Hypoglycemic Age | 2016 |
Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises.
Topics: Adolescent; Adult; Black or African American; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic K | 2016 |
Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Carotid Artery, Common; Carotid Intima-Media | 2016 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammat | 2017 |
Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial.
Topics: Adiponectin; Aged; Caloric Restriction; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Lactone | 2016 |
Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Blood Glucose; Body Composition; Cardiovascular Diseases; Child; Double-Blin | 2017 |
Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study.
Topics: Adolescent; Blood Glucose; Caloric Restriction; Child; Diabetes Mellitus, Type 2; Diet, Reducing; Fa | 2017 |
Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.
Topics: Adult; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Obesity; Outcom | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Bone Density Conservation Agents; Female; Follow- | 2017 |
Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Body Weight; Child; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic A | 2008 |
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-Obesity Agents; Biomarkers; Female; gamma-Gl | 2008 |
Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Topics: Adult; Contraceptives, Oral, Combined; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estra | 2008 |
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.
Topics: Behavior Therapy; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Fe | 2008 |
The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials.
Topics: Adolescent; Androgens; Behavior Therapy; C-Reactive Protein; Child; Cholesterol; Contraceptives, Ora | 2008 |
Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance.
Topics: Adolescent; Body Mass Index; Carbohydrate Metabolism; Cardiovascular Diseases; Exercise Test; Female | 2008 |
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Fatty Liver; Female; Glycated Hemoglobi | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; | 2009 |
Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Androgen Antagonists; Area Under Curve; Body Weight; | 2009 |
An RCT of metformin versus orlistat for the management of obese anovulatory women.
Topics: Adolescent; Adult; Androgens; Anovulation; Anti-Obesity Agents; Female; Humans; Hypoglycemic Agents; | 2009 |
Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Topics: Adult; Androgen Antagonists; Blood Coagulation; Blood Platelets; Case-Control Studies; Contraceptive | 2009 |
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double | 2009 |
Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance.
Topics: Adipokines; Adolescent; Body Mass Index; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2 | 2009 |
Changes in health state utilities with changes in body mass in the Diabetes Prevention Program.
Topics: Activities of Daily Living; Adult; Cost-Benefit Analysis; Diabetes Mellitus; Diet, Reducing; Exercis | 2009 |
Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
Topics: Adult; Case-Control Studies; Cell Movement; Cells, Cultured; Culture Media, Conditioned; Down-Regula | 2009 |
Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Topics: Adolescent; Adult; Aged; Benzoxazines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2010 |
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
Topics: Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; | 2010 |
Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Female; Humans; Hypoglycemic Agents; Insulin; Ins | 2010 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Alcohol consumption and diabetes risk in the Diabetes Prevention Program.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Cholesterol, HDL; Diabetes Mellitus, Type 2; Energ | 2009 |
Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans.
Topics: Adipocytes; Adiponectin; Adult; Aged; CD36 Antigens; Cell Line; Coculture Techniques; Down-Regulatio | 2009 |
Intraperitoneal fat and insulin resistance in obese adolescents.
Topics: Abdominal Fat; Absorptiometry, Photon; Adiposity; Adolescent; Anthropometry; Biomarkers; Black or Af | 2010 |
Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin.
Topics: Adolescent; Combined Modality Therapy; Contraceptives, Oral; Female; Humans; Hypoglycemic Agents; Li | 2010 |
Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Topics: Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Drug Therapy, Combination; Female; Hu | 2010 |
Lifestyle modification and metformin as long-term treatment options for obese adolescents: study protocol.
Topics: Adolescent; Behavior Therapy; Child; Exercise; Female; Humans; Life Style; Male; Metformin; Obesity; | 2009 |
The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome.
Topics: Blood Glucose; Caloric Restriction; Drug Administration Schedule; Endocrine System; Female; Follow-U | 2010 |
Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome.
Topics: Abortion, Habitual; Adult; Body Mass Index; Case-Control Studies; Diabetes, Gestational; Female; Fet | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
The effect of comprehensive lifestyle intervention or metformin on obesity in young women.
Topics: Adolescent; Adult; Behavior Therapy; Body Composition; Body Mass Index; Body Weight; Double-Blind Me | 2011 |
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.
Topics: Adult; Body Mass Index; Diet; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Non | 2010 |
Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile.
Topics: Adult; Body Weight; Female; Hormones; Humans; Hypoglycemic Agents; Lipids; Metformin; Obesity; Polyc | 2010 |
Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study.
Topics: Adolescent; Body Mass Index; Body Weight; Child; Female; Humans; Hypoglycemic Agents; Insulin; Insul | 2010 |
[Sonographic ovarian vascularization and volume in women with polycystic ovary syndrome treated with clomiphene citrate and metformin].
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hyperglycemi | 2010 |
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
Topics: Adolescent; Adult; Animals; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Met | 2010 |
A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metformin; Obesity | 2010 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Topics: Adult; Arginine; Body Mass Index; Cardiovascular Diseases; Contraceptives, Oral; Female; Homocystein | 2011 |
Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial.
Topics: Body Composition; Body Weight; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insu | 2011 |
Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.
Topics: Adult; Algorithms; Androgens; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Fem | 2011 |
In vitro and in vivo effects of metformin on human adipose tissue adiponectin.
Topics: Adiponectin; Adipose Tissue; Adult; Cells, Cultured; Female; Humans; Hypoglycemic Agents; Intra-Abdo | 2011 |
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Body Weight; Female; Humans; Hypoglycemic Agents; Lacto | 2011 |
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Child; Double-Blind Method; Fatty Liver; Female; Hum | 2011 |
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Gl | 2011 |
Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Topics: Administration, Oral; Adult; Anthropometry; Asian People; Body Composition; China; Diabetes Mellitus | 2011 |
Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Ora | 2011 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, | 2011 |
Lifestyle intervention improves fitness independent of metformin in obese adolescents.
Topics: Absorptiometry, Photon; Adiponectin; Adolescent; Analysis of Variance; Biomarkers; Body Composition; | 2012 |
Combination therapy with metformin and fenofibrate for insulin resistance in obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; | 2011 |
[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Topics: Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Combined Modality Therapy; | 2012 |
Weight loss/maintenance as an effective tool for controlling type 2 diabetes: novel methodology to sustain weight reduction.
Topics: Behavior Therapy; Cardiovascular Diseases; Computers; Diabetes Mellitus, Type 2; Feedback; Humans; L | 2012 |
Effects of a group-based exercise and self-regulatory intervention on obese adolescents' physical activity, social cognitions, body composition and strength: a randomized feasibility study.
Topics: Adolescent; Body Composition; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cooper | 2012 |
[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
Topics: Adolescent; Adult; Body Composition; Combined Modality Therapy; Drug Therapy, Combination; Female; H | 2012 |
Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; China; Cholesterol; Double-Blind Method; Female; Humans; | 2012 |
The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial.
Topics: Adiponectin; Adolescent; Body Mass Index; C-Reactive Protein; Double-Blind Method; Female; Humans; H | 2012 |
Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat.
Topics: Abdominal Fat; Adolescent; Biomarkers; C-Reactive Protein; Child; Female; Fibrinogen; Glucose Tolera | 2012 |
Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Humans; Life Style; M | 2012 |
Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Topics: Adult; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypo | 2012 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Metho | 2013 |
Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycysti | 2012 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 2013 |
Metformin in obese children and adolescents: the MOCA trial.
Topics: Adolescent; Age of Onset; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up S | 2013 |
Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; C-Reactive Protein; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Ins | 2013 |
Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.
Topics: Adult; Androgens; Androstenedione; Diet, Reducing; Female; Ghrelin; Homeostasis; Humans; Hypoglycemi | 2002 |
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cyclobutanes; Diabetes Mellitus; D | 2003 |
Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
Topics: Acarbose; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Dr | 2003 |
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Biopsy; Chromans; Culture Media, Conditioned; | 2003 |
Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Topics: Adolescent; Adult; Blood Pressure; Body Mass Index; Double-Blind Method; Female; Follicle Stimulatin | 2003 |
Effect of metformin on insulin sensitivity and insulin secretion in female obese patients with normal glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cross-Over Studies; Female; Glucose Clamp Techniqu | 2003 |
Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
Topics: Adult; C-Reactive Protein; Cyproterone Acetate; Estradiol Congeners; Ethinyl Estradiol; Female; Huma | 2003 |
Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids.
Topics: Adult; Androstenedione; Estrone; Feedback, Physiological; Female; Gonadal Steroid Hormones; Gonadotr | 2003 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellit | 2003 |
Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fema | 2004 |
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated | 2004 |
Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Area Under Curve; Blood Glucose; C-Peptide; Es | 2004 |
Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Body Weight; Female; Glucose Tolerance Test; H | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Topics: Administration, Oral; Adult; Body Mass Index; Body Weight; Double-Blind Method; Female; Hormones; Hu | 2004 |
Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Topics: Aged; Arginine; Blood Glucose; Blood Pressure; Body Composition; Body Constitution; Body Weight; Dia | 2004 |
Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration.
Topics: Aged; Anthropometry; Autonomic Nervous System; Biomarkers; Blood Glucose; Blood Pressure; Diabetes M | 2004 |
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
Topics: Aged; Amyloid; Body Mass Index; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Bl | 2004 |
Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women.
Topics: Adult; Dietary Fats; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypogl | 2004 |
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Therapy | 2004 |
A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Body Mass Index; Double-Blind Method; Electr | 2004 |
Metformin ameliorates treatment of obese type 2 diabetic patients with mental retardation; its effects on eating behavior and serum leptin levels.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Energy Intake; Feedin | 2004 |
Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: a placebo-controlled, 24-month randomized study.
Topics: Black or African American; Blood Glucose; Humans; Hypoglycemic Agents; Metformin; Obesity | 2004 |
Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals.
Topics: Adult; Anthropometry; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
Topics: Adiponectin; Blood Glucose; Body Composition; C-Reactive Protein; Cross-Over Studies; Diabetes Melli | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Topics: Adiponectin; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2005 |
Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cardiovascular Diseases; Cholesterol; Cyproterone Acetate; Ethinyl Estr | 2005 |
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
Topics: Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type | 2005 |
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.
Topics: Blood Coagulation; Blood Glucose; Body Mass Index; Diabetes Mellitus; Female; Glucose Intolerance; H | 2005 |
Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
Topics: Administration, Oral; Androstenedione; Blood Glucose; Dehydroepiandrosterone Sulfate; Female; Humans | 2005 |
The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
Topics: Adult; Apolipoproteins B; Biomarkers; Blood Glucose; Fatty Acids, Nonesterified; Humans; Hypoglycemi | 2005 |
Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglob | 2005 |
Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Chemokin | 2005 |
Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus.
Topics: C-Reactive Protein; Complement C3; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglyce | 2005 |
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Topics: Adult; Anthropometry; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Child; Contraceptives, Oral; Female; Humans; Hyperinsulinism; Hypoglyc | 2005 |
Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Topics: Adiposity; Adult; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hyperinsulini | 2005 |
Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children.
Topics: Adolescent; Black People; Blood Glucose; Body Mass Index; Central Nervous System Diseases; Child; Ch | 2006 |
Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Administration Schedule; Drug Combinations; Female; Fertility Agents, Female | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Typ | 2006 |
Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type | 2007 |
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
Topics: Adult; Aged; Biopsy; Blood Glucose; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Female | 2006 |
Metformin treatment is effective in obese teenage girls with PCOS.
Topics: Adolescent; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin Re | 2006 |
Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Lipids; Menstru | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
The effects of combined insulin and metformin therapy in obese patients with diabetes mellitus type 2 in the early stage of the disease.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; | 2006 |
An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Drug Therapy, Combination; Female; | 2007 |
Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
Topics: Acanthosis Nigricans; Administration, Oral; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Ins | 2006 |
Relationship of body size and shape to the development of diabetes in the diabetes prevention program.
Topics: Adult; Body Composition; Body Mass Index; Body Size; Diabetes Mellitus, Type 2; Ethnicity; Female; G | 2006 |
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Diabetes Melli | 2006 |
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Appetite Depressa | 2006 |
Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Grow | 2008 |
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
Topics: Adult; Aged; Anti-Obesity Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diet, Redu | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Hum | 2008 |
Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics.
Topics: Adult; Blood Pressure; Caloric Restriction; Exercise; Humans; Hypoglycemic Agents; Metformin; Middle | 2007 |
[Medical treatment of type 2 diabetes. Recommendations for good practice].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; France; Glycated Hemoglobin; Humans; Hypoglycemic Agents; | 2007 |
Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; | 2007 |
Metformin treatment does not affect total leptin levels and free leptin index in obese patients with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Leptin; Metformin; Obesity; Po | 2008 |
Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Colorimetry; Diabetes Mellitus, Type | 2007 |
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Topics: Adolescent; Adult; Body Weight; Cross-Over Studies; Double-Blind Method; Female; Humans; Insulin; Me | 2007 |
The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
Topics: Adult; Alanine; Amino Acid Substitution; Body Composition; Chromans; Diabetes Mellitus, Type 2; Diet | 2007 |
Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study.
Topics: Adult; Chi-Square Distribution; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Menstruation; M | 2007 |
Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agen | 2007 |
[Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; M | 2007 |
Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects.
Topics: Adult; Albuminuria; Blood Pressure; Caloric Restriction; Cardiovascular Diseases; Creatinine; Exerci | 2008 |
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; G | 2008 |
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug | 2008 |
Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Topics: Adult; Female; Ghrelin; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypoglycemic Agents; Insuli | 2008 |
The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hy | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2008 |
Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Topics: Adolescent; Adult; Body Mass Index; Cross-Sectional Studies; Cyproterone Acetate; Drug Combinations; | 2008 |
Metformin and parameters of physical health.
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias | 2008 |
Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program.
Topics: Adult; Body Composition; Body Height; Body Mass Index; Diabetes Mellitus, Type 2; Ethnicity; Female; | 2008 |
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
Topics: Adult; Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Metf | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.
Topics: Adult; Aged; Appetite Depressants; Body Weight; Diabetes Mellitus; Female; Glucose Tolerance Test; H | 1983 |
Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.
Topics: Androgens; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Composition; Cholesterol; Chol | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Cross-Over Studies; Double-Blind Method; Hum | 1994 |
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
Topics: Adult; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type | 1995 |
Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, No | 1994 |
Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, No | 1994 |
Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, No | 1994 |
Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, No | 1994 |
Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.
Topics: Blood Glucose; Blood Pressure; Calorimetry; Cholesterol; Double-Blind Method; Echocardiography; Fema | 1993 |
The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.
Topics: Adult; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Glyco | 1993 |
Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Topics: Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1993 |
Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Constitution; C-Peptide; Cross-Over Studies; Double-Blind Method; Female; | 1995 |
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Female; Humans; Hydroxyprogesterones | 1996 |
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diabetes Mellit | 1996 |
Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes | 1996 |
The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hype | 1996 |
Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Dietary Fats; Female; Glucose Intoler | 1997 |
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Pro
Topics: Adult; Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Female; Follow-Up | 1998 |
Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Ene | 1998 |
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucose Clamp Technique; Humans; Hyperandrogenism; Hy | 1998 |
Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Blood Glucose; Cohort Studies; Dehydroepiandro | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Lept | 1998 |
Effect of metformin on food intake in obese subjects.
Topics: Adolescent; Adult; Basal Metabolism; Body Mass Index; Double-Blind Method; Energy Intake; Female; Hu | 1998 |
Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.
Topics: Adult; Blood Glucose; Body Weight; Calorimetry, Indirect; Diabetes Mellitus; Diabetes Mellitus, Type | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.
Topics: Adult; Aged; Female; Fibrinolysis; Hemostasis; Humans; Hypoglycemic Agents; Insulin; Male; Metformin | 1998 |
Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LD | 1998 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 1999 |
Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity.
Topics: Abdomen; Appetite Depressants; Blood Glucose; Blood Pressure; Body Composition; Body Constitution; B | 1999 |
Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.
Topics: Adult; Amenorrhea; Blood Glucose; Blood Pressure; Body Mass Index; Female; Hormones; Humans; Hypogly | 1999 |
Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, | 1999 |
Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance.
Topics: Blood Glucose; C-Peptide; Double-Blind Method; Female; Fructosamine; Glucose Intolerance; Glycated H | 1999 |
[Controversial aspects regarding metformin in type 2 diabetic patient: reduction of late complications in early, single drug administration; increased risk of death in later administration in combination with sulfonylurea compounds].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dr | 1999 |
Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.
Topics: Adult; Endocrine Glands; Fasting; Female; Hormones; Humans; Insulin; Longitudinal Studies; Metformin | 1999 |
[The combination of insulin and metformin in obese patients with type-2 diabetes mellitus].
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 1999 |
Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
Topics: Body Mass Index; Body Weight; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2000 |
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
Topics: Acarbose; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 2000 |
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Topics: Abdomen; Adipose Tissue; Adult; Androgens; Body Composition; Combined Modality Therapy; Diet, Reduci | 2000 |
Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
Topics: Blood Glucose; Cause of Death; Cost-Benefit Analysis; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2000 |
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Androgen Antagonists; Area Under Curve; Blood Glucose; Calorimetry; Cyproterone Acetate; Estr | 2000 |
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
Topics: Adolescent; Adult; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose | 2001 |
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Body Mass Index; | 2001 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona | 2001 |
Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistan | 2001 |
The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Body Weight; Child; Comorbidity; Diabetes Mellitus; Diab | 2001 |
Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Amenorrhea; Blood Glucose; Case-Control Studies; Cohort Studies; Dietary Carbohydrates; | 2001 |
Metformin in obesity associated with antipsychotic drug administration: a pilot study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Area Under Curve; Blood Glucose; Body Mass Index; Brie | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclo | 2002 |
Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Diabetes Mellitus; Diabete | 2001 |
Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.
Topics: Adipose Tissue; Adult; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus; Glucagon; Humans; | 2002 |
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
Topics: Adult; Aged; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes | 2002 |
Metabolic effects of glucocorticoid and ethanol administration in phenformin- and metformin-treated obese diabetics.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Drug Synergism; Ethanol; Humans; Hydrocortisone; Lactates; M | 1979 |
[Treatment of obese diabetic patients using glucophage retard].
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus; Drug Evaluation; Humans; M | 1975 |
[Antidiabetic efficacy of benfluorex. Clinical data].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypolipidemic A | 1992 |
Comparison of combined therapies in treatment of secondary failure to glyburide.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administra | 1992 |
[Evaluation of the efficacy of metformin-glibenclamide treatment in overweight non-insulin dependent diabetics].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glybu | 1992 |
BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.
Topics: Adult; Aged; Arteriosclerosis; Data Collection; Data Interpretation, Statistical; Diabetes Mellitus; | 1991 |
The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Bli | 1989 |
Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dou | 1989 |
U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gl | 1985 |
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.
Topics: Adolescent; Adult; Female; Fibrinolysis; Glycoproteins; Humans; Insulin; Male; Metformin; Middle Age | 1987 |
Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.
Topics: Adolescent; Adult; Blood Glucose; Clinical Trials as Topic; Female; Fibrinolysis; Glycoproteins; Hum | 1987 |
Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Doubl | 1986 |
Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics.
Topics: Adult; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Diet Therapy; Female; Hu | 1968 |
Comparison of fenfluramine and metformin in treatment of obesity.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Female; Fenfluramine; Fluorine; | 1970 |
Weight-reducing effect of diguanides in obese non-diabetic women.
Topics: Adult; Appetite; Bicarbonates; Body Weight; Clinical Trials as Topic; Female; Glucose Tolerance Test | 1969 |
[Biguanides in treatment of obesity. II. Controlled clinical research with placebos, metformin and phenformin in obesity with normal and reduced tolerance to carbohydrates].
Topics: Adolescent; Adult; Aged; Biguanides; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mel | 1968 |
[Effect of metformin on glucose utilization and body weight].
Topics: Biguanides; Blood Glucose; Body Weight; Glucose; Glucose Tolerance Test; Humans; Injections, Intrave | 1970 |
Circadian variation of glucose, insulin, and free fatty acids during long-term use of oral hypoglycaemic agents in diabetes mellitus.
Topics: Aged; Blood Glucose; Chlorpropamide; Circadian Rhythm; Diabetes Mellitus; Diet, Diabetic; Fatty Acid | 1968 |
Weight reduction in obesity.
Topics: Appetite Depressants; Female; Fenfluramine; Fluorine; Humans; Metformin; Obesity; Phenethylamines | 1969 |
601 other studies available for metformin and Obesity
| Article | Year |
|---|---|
8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.
Topics: Animals; Berberine; Diabetes Mellitus; Electron Transport; Glucose; Humans; Hypoglycemic Agents; Mal | 2010 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cho | 2012 |
Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors.
Topics: Animals; Body Weight; Cell Line; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Inh | 2019 |
Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders.
Topics: 3T3-L1 Cells; Animals; Anti-Obesity Agents; Cell Differentiation; Cells, Cultured; Cholesterol; Diet | 2020 |
Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Female; Hyperinsulinism; Hypoglycemic Agents; Insu | 2021 |
Hypoglycemic and lipid lowering effects of theaflavins in high-fat diet-induced obese mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Biflavonoids; Blood Glucose; Catechin; Cholesterol, H | 2021 |
Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Diet, High-Fat; Disease Models, Animal; Drinking Water; Dy | 2021 |
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States.
Topics: Aged; Aging; COVID-19; COVID-19 Drug Treatment; Critical Care; Diabetes Complications; Diabetes Mell | 2021 |
Obesity and altered angiogenic-related gene expression in endometrial cancer.
Topics: AMP-Activated Protein Kinases; Animals; Body Mass Index; Calcium-Binding Proteins; Cell Adhesion Mol | 2021 |
Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce.
Topics: Adipocytes; Adipose Tissue; Cell Cycle; Cell Differentiation; Cellular Senescence; Cyclin D1; Humans | 2021 |
Restoration of mRNA Expression of Solute Carrier Proteins in Liver of Diet-Induced Obese Mice by Metformin.
Topics: Animals; Diet, High-Fat; Gene Expression Regulation; Glucose; Glucose Tolerance Test; Hepatocytes; I | 2021 |
Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple mechanisms in obese rats with induced type 2 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Curcumin; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2021 |
Metformin prevents airway hyperreactivity in rats with dietary obesity.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; Bronchoconstrictor Agents; Diet, Hi | 2021 |
Screening for Vitamin D Deficiency in Adults.
Topics: Antihypertensive Agents; Asymptomatic Diseases; Body Mass Index; Diabetes Mellitus, Type 2; Humans; | 2021 |
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metfor | 2022 |
Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin.
Topics: Adult; Animals; Cell Line; Cells, Cultured; Female; Gene Expression Profiling; Gene Expression Regul | 2022 |
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.
Topics: Animals; Diet, High-Fat; Female; Kidney Diseases; Liraglutide; Male; Metabolic Syndrome; Metformin; | 2021 |
Deciphering metformin action in obese mice: A critical re-evaluation of established protocols.
Topics: Animals; Blood Glucose; Homeostasis; Hypoglycemic Agents; Liver; Male; Metformin; Mice; Mice, Inbred | 2022 |
Metainflammation in COVID-19.
Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans; | 2022 |
Combination of metformin and exercise alleviates osteoarthritis in ovariectomized mice fed a high-fat diet.
Topics: Animals; Diet, High-Fat; Estrogens; Female; Humans; Male; Metformin; Mice; Mice, Inbred C57BL; Obesi | 2022 |
Screening for Prediabetes and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetes, Gestational; Exercise; Female; Humans; Hypoglycemi | 2022 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Sub | 2022 |
Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Disease Susceptibility; Embryonic Development; Epig | 2022 |
Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.
Topics: Animals; Glucose; Inflammation; Insulin; Insulin Resistance; Male; Metformin; Muscle, Skeletal; Obes | 2022 |
Osteocalcin serum levels in obese patients with type 2 diabetes mellitus: The virtual points observed in a case control study.
Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated | 2021 |
Association of gene polymorphisms with body weight changes in prediabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genotype; Humans; Metformin; M | 2022 |
Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS.
Topics: Adiponectin; Endometrium; Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycysti | 2022 |
Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model.
Topics: Breast Neoplasms; Cell Proliferation; Cell Survival; Female; Humans; In Vitro Techniques; Insulin Re | 2022 |
[INFLUENCE OF METFORMIN ON THE DIAMETER AND NUMBER OF DNA BREAKS IN BLOOD LYMPHOCYTES IN OBESITY].
Topics: DNA; DNA Breaks; DNA Damage; Humans; Lymphocytes; Metformin; Obesity | 2022 |
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2022 |
Metformin-induced reductions in tumor growth involves modulation of the gut microbiome.
Topics: Animals; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Microbiom | 2022 |
Metformin combats obesity by targeting FTO in an m
Topics: 3T3-L1 Cells; Adipocytes; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Cyclin D1; Cyclin- | 2022 |
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Obesity; Prospective Studies; Prostatic Hyperplasia; Pro | 2022 |
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Hypothalamus; Leptin; Metformin; Mice; Neurons; | 2022 |
Impact Of Prepregnancy Overweight And Obesity On Treatment Modality And Pregnancy Outcome In Women With Gestational Diabetes Mellitus.
Topics: Cesarean Section; Diabetes, Gestational; Female; Glucose; Humans; Insulin, Short-Acting; Metformin; | 2022 |
PDIA4, a novel ER stress chaperone, modulates adiponectin expression and inflammation in adipose tissue.
Topics: Adiponectin; Adipose Tissue; Animals; Cytokines; Endoplasmic Reticulum Stress; Glucose; Humans; Infl | 2022 |
Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Humans; Lipid Droplets; Lipids; Metformin; Obesit | 2022 |
Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice.
Topics: Adipose Tissue; Adipose Tissue, White; Animals; Diet, High-Fat; Female; Humans; Intra-Abdominal Fat; | 2022 |
Monoamine oxidase is a source of cardiac oxidative stress in obese rats: the beneficial role of metformin.
Topics: Animals; Diabetes Mellitus, Type 2; Metformin; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Obes | 2023 |
Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Humans; Inpatients; Insulin Resistance; Metfor | 2022 |
Effects of metformin on lymphocyte DNA damage in obese individuals among Kazakh population.
Topics: China; DNA Damage; Histones; Humans; Lymphocytes; Metformin; Obesity | 2022 |
The ameliorating effects of metformin on disarrangement ongoing in gastrocnemius muscle of sarcopenic and obese sarcopenic mice.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Fatty Acids, Nonesterified; Interl | 2022 |
Metformin improves neurobehavioral impairments of streptozotocin-treated and western diet-fed mice: Beyond glucose-lowering effects.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2023 |
The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance.
Topics: Animals; Glial Cell Line-Derived Neurotrophic Factor Receptors; Growth Differentiation Factor 15; Hu | 2022 |
Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice.
Topics: Animals; Diet, High-Fat; HMGB1 Protein; Metformin; Mice; Mice, Inbred C57BL; Neoplasms; Obesity | 2022 |
Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.
Topics: Adult; Animals; Body Composition; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Hig | 2022 |
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Pept | 2022 |
Knockdown of Endogenous Nucb2/Nesfatin-1 in the PVN Leads to Obese-Like Phenotype and Abolishes the Metformin- and Stress-Induced Thermogenic Response in Rats.
Topics: Animals; Calcium-Binding Proteins; DNA-Binding Proteins; Gene Knockdown Techniques; Male; Metformin; | 2022 |
Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
Topics: Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemo | 2022 |
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Mellitus; Hepatitis C, C | 2023 |
Metformin alleviates HFD-induced oxidative stress in hepatocyte via activating SIRT6/PGC-1α/ENDOG signaling.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Hepatocytes; Humans; Lipids; Metformin; Mice; Ob | 2022 |
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male | 2022 |
Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation.
Topics: Adult; Body Mass Index; Female; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; O | 2022 |
Gene Expression Profiling of Peripheral Blood Mononuclear Cells in Type 2 Diabetes: An Exploratory Study.
Topics: Adult; ATP Binding Cassette Transporter 1; Cholesterol; Diabetes Mellitus, Type 2; Gene Expression P | 2022 |
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Estradiol; Female; Humans; Insulin; Leptin; Letrozole; | 2023 |
Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Exenatide; Exercise Therapy; Humans; Hypoglycem | 2023 |
Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.
Topics: Animals; Female; Humans; Insulin Resistance; Letrozole; Lipids; Metformin; Mitochondria; Nanoparticl | 2023 |
The Synergistic Action of Metformin and
Topics: Animals; Diet, High-Fat; Glycyrrhiza uralensis; Liver; Metabolic Diseases; Metformin; Mice; Mice, In | 2023 |
Obesity management: Attitudes and practice of Italian endocrinologists.
Topics: Anti-Obesity Agents; Endocrinologists; Humans; Metformin; Obesity; Orlistat | 2022 |
Past and present: a bibliometric study on polycystic ovary syndrome.
Topics: Bibliometrics; Female; Humans; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2023 |
Using Artificial Intelligence to Develop a Multivariate Model with a Machine Learning Model to Predict Complications in Mexican Diabetic Patients without Arterial Hypertension (National Nested Case-Control Study): Metformin and Elevated Normal Blood Press
Topics: Aged; Aged, 80 and over; Artificial Intelligence; Blood Pressure; Case-Control Studies; Diabetes Mel | 2023 |
The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank.
Topics: Back Pain; Biological Specimen Banks; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, T | 2023 |
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki | 2023 |
Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
Topics: Blood Glucose; Child; Diabetes Mellitus; Dwarfism, Pituitary; Glycated Hemoglobin; Human Growth Horm | 2023 |
Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Extracellular Traps; Metfo | 2023 |
The Medicinal Mushroom Ganoderma neo-japonicum (Agaricomycetes) Polysaccharide Extract Prevents Obesity-Induced Diabetes in C57BL/6J Mice.
Topics: Agaricales; Animals; Basidiomycota; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Insuli | 2023 |
[Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; | 2023 |
Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases.
Topics: Animals; Berberine; Cricetinae; Hyperlipidemias; Lipids; Metformin; Mice; Obesity | 2023 |
Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice.
Topics: Animals; Diet, High-Fat; Inflammation; Liver; Metformin; Mice; Mice, Inbred C57BL; Non-alcoholic Fat | 2023 |
Clinical and metabolic characteristics of endometrial lesions in polycystic ovary syndrome at reproductive age.
Topics: Contraceptives, Oral; Female; Gonadal Steroid Hormones; Humans; Metformin; Obesity; Polycystic Ovary | 2023 |
Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.
Topics: Biomarkers; Blood Glucose; Cohort Studies; Cross-Sectional Studies; Female; Hedgehog Proteins; Human | 2023 |
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Topics: Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA R | 2023 |
Utilization and Predictors of Adjuvant Metformin for Children and Adolescents on Mixed Receptor Antagonists (Second-Generation Antipsychotics).
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus; Humans; Hyperglycemia; Metformin; Obesit | 2023 |
Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity.
Topics: Animals; Bulimia; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Male; M | 2023 |
Role of serum- and glucocorticoid-inducible kinase 1 in the regulation of hepatic gluconeogenesis.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucocorticoids; Gluconeogenesi | 2023 |
Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone.
Topics: Exenatide; Female; Gastrointestinal Microbiome; Humans; Metagenomics; Metformin; Obesity; Polycystic | 2023 |
Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose Intolerance; High Fructose Corn Syrup; M | 2023 |
[Investigation of glycaemic and nutritional status of patients suffering from cancer.]
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms; N | 2023 |
Role of metformin in the management of type 2 diabetes: recent advances.
Topics: Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metform | 2023 |
Management of Type 2 Diabetes in Frail Older Adults.
Topics: Aged; Diabetes Mellitus, Type 2; Frail Elderly; Frailty; Humans; Hypoglycemic Agents; Metformin; Obe | 2023 |
Effect of Human Adenovirus 36 on Response to Metformin Monotherapy in Obese Mexican Patients with Type 2 Diabetes: A Prospective Cohort Study.
Topics: Adenoviruses, Human; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Obe | 2023 |
Targeting BCAA metabolism to potentiate metformin's therapeutic efficacy in the treatment of diabetes in mice.
Topics: Amino Acids, Branched-Chain; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose; Humans; Me | 2023 |
Effect of Metformin Treatment on Serum Metabolic Profile Changes in Lean and Obese Zucker Rat Model for Fatty Liver Disease.
Topics: Animals; Female; Metabolome; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Rats; Rats, Zuck | 2023 |
Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Immune System; Immunoglobulins; Insulin; In | 2023 |
Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases | 2023 |
Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Gestational Weight Gain; Humans; Hypoglycemic A | 2019 |
Type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cardiovascular Nursing; Diabetes Mellitus, Type 2; | 2019 |
Resveratrol and Metformin Recover Prefrontal Cortex AMPK Activation in Diet-Induced Obese Mice but Reduce BDNF and Synaptophysin Protein Content.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Autophagy; Blood Glucose; Brain-Derived Neurot | 2019 |
Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Humans; Mesenchymal Stem Cell Trans | 2019 |
Effect of high-fat diet-induced obesity on thyroid gland structure in female rats and the possible ameliorating effect of metformin therapy.
Topics: Animals; Body Weight; Diet, High-Fat; Female; Hormones; Lipids; Metformin; Obesity; Rats; Thyroid Gl | 2020 |
[The effect of high-dose metformin on the metabolic parameters and functional state of the liver of agouti-mice with the melanocortin obesity.]
Topics: Animals; Liver; Melanocortins; Metformin; Mice; Mice, Inbred C57BL; Obesity | 2019 |
[Effect of the management of class I obesity with metformin on metalloproteinase activity in patients with chronic periodontitis].
Topics: Adult; Chronic Periodontitis; Female; Humans; Hypoglycemic Agents; Metalloproteases; Metformin; Obes | 2019 |
Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2019 |
Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Diet, High-Fat; Fatty Liver; Gastrointestinal Microbiome | 2019 |
Metformin Improves Fertility in Obese Males by Alleviating Oxidative Stress-Induced Blood-Testis Barrier Damage.
Topics: Animals; Blood-Testis Barrier; Disease Models, Animal; Fertility; Humans; Hypoglycemic Agents; Male; | 2019 |
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeo | 2019 |
Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Carcinoma, Endometrioid; Cell Cycle Proteins; Cell Line, | 2020 |
Urinary sulphated glycosaminoglycans excretion in obese patients with type 2 diabetes mellitus treated with metformin.
Topics: Diabetes Mellitus, Type 2; Glycosaminoglycans; Humans; Metformin; Obesity | 2022 |
The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Topics: Adult; AMP-Activated Protein Kinases; Cells, Cultured; Endometrium; Enzyme Activation; Female; Gluco | 2020 |
Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Latin | 2020 |
Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone | 2020 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female | 2020 |
Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Gluconeogenesis; Glucose-6-Phosphatase; Glucosides; H | 2020 |
Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis.
Topics: Aging; Animals; Cognition; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Micro | 2020 |
Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Diet; Female; Humans; Hypoglycemic Agents; | 2020 |
Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Diet, High-Fat; Epoprostenol; Heart | 2020 |
Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Therapy, Combination; Hypoglycemic Age | 2020 |
Impact of Isoorientin on Metabolic Activity and Lipid Accumulation in Differentiated Adipocytes.
Topics: 3T3-L1 Cells; Adenosine Triphosphate; Adipocytes; AMP-Activated Protein Kinase Kinases; Animals; Dio | 2020 |
Stress-induced intestinal barrier dysfunction is exacerbated during diet-induced obesity.
Topics: Animals; Cecum; Colon; Corticosterone; Diet, High-Fat; Gastrointestinal Microbiome; Humans; Hypoglyc | 2020 |
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency.
Topics: Animals; Antineoplastic Agents; Cyclin D1; Cyclin-Dependent Kinase 4; Diabetes Mellitus, Type 2; Hyp | 2020 |
Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity.
Topics: Animals; Antioxidants; Blood Glucose; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Sup | 2020 |
Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance.
Topics: Adipose Tissue; Child; Humans; Insulin Resistance; Metformin; Obesity; Pericardium | 2020 |
Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
Topics: Adult; Aged; Asian People; Biological Specimen Banks; Blood Glucose; Body Mass Index; Cholesterol, H | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
[Novel role of intracellular ATP in obesity pathology].
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Energy Metabolism; | 2020 |
Pilosocereus gounellei (Cactaceae) stem extract decreases insulin resistance, inflammation, oxidative stress, and cardio-metabolic risk in diet-induced obese mice.
Topics: Animals; Cactaceae; Cardiovascular Diseases; Cytokines; Diet, High-Fat; Hyperglycemia; Inflammation; | 2021 |
Successful IVF outcome after repeat laparoscopic ovarian drilling in a case of resistant PCOS.
Topics: Abortion, Habitual; Adult; Female; Fertilization in Vitro; Glucose Metabolism Disorders; Humans; Hyp | 2020 |
The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesi
Topics: Adipokines; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fibr | 2020 |
Metformin effectively restores the HPA axis function in diet-induced obese rats.
Topics: Animals; Body Weight; Corticosterone; Diet, High-Fat; Hypothalamo-Hypophyseal System; Male; Metformi | 2021 |
Growth arrest-specific 6 modulates adiponectin expression and insulin resistance in adipose tissue.
Topics: Adipocytes; Adipogenesis; Adiponectin; Adipose Tissue; Animals; Humans; Hypoglycemic Agents; Insulin | 2021 |
Histological, immunohistochemical and biochemical effects of bee bread on stomach tissue of obese rats.
Topics: Animals; Female; Ghrelin; Hypoglycemic Agents; Leptin; Metformin; Necrosis; Obesity; Propolis; Rats; | 2020 |
Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Body Mass Index; C-Peptide; Cholecalciferol; Cross-Sectional Studies; Diabe | 2020 |
Targeting T-cell oxidative metabolism to improve influenza survival in a mouse model of obesity.
Topics: Adipose Tissue; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Di | 2020 |
Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood.
Topics: Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Composition; Body Weight; Fema | 2020 |
Not only metformin, but also D-allulose, alleviates metabolic disturbance and cognitive decline in prediabetic rats.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Drinking Water; Fructose; Insulin Resistance; Insuli | 2022 |
Metformin alters peripheral blood mononuclear cells (PBMC) senescence biomarkers gene expression in type 2 diabetic patients.
Topics: Biomarkers; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Diabetes Mellitus, Type 2; G | 2021 |
Higher ACE2 expression levels in epicardial cells than subcutaneous stromal cells from patients with cardiovascular disease: Diabetes and obesity as possible enhancer.
Topics: ADAM17 Protein; Adipogenesis; Adipose Tissue; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme | 2021 |
The effect of Nigella sativa oil and metformin on male seminal parameters and testosterone in Wistar rats exposed to an obesogenic diet.
Topics: Animals; Anti-Obesity Agents; Biomarkers; Disease Models, Animal; Fertility; Fertility Agents, Male; | 2021 |
Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Body Weight; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte | 2021 |
A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistance.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Cell Line, Transformed; Diet, Hi | 2021 |
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.
Topics: Cohort Studies; COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Obesity; Retro | 2021 |
Deletion of intestinal epithelial AMP-activated protein kinase alters distal colon permeability but not glucose homeostasis.
Topics: AMP-Activated Protein Kinases; Animals; Bacteria; Colon; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2021 |
Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Body Mass Index; COVID-19 Drug Treatment; Glycated Hemog | 2021 |
Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, | 2021 |
Metformin restores hippocampal neurogenesis and learning and memory via regulating gut microbiota in the obese mouse model.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Microbiome; Hippocampus; Metfor | 2021 |
Genetically proxied growth-differentiation factor 15 levels and body mass index.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Humans; Metformin; Obesity; Weight Loss | 2021 |
MicroRNAs modulation and clinical outcomes at 1 year of follow-up in obese patients with pre-diabetes treated with metformin vs. placebo.
Topics: Diet, Reducing; Follow-Up Studies; Humans; Metformin; MicroRNAs; Obesity; Prediabetic State | 2021 |
Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Mellitus, Experimental; Female; | 2021 |
Metformin Improves Autonomic Nervous System Imbalance and Metabolic Dysfunction in Monosodium L-Glutamate-Treated Rats.
Topics: Acetylcholine; Animals; Autonomic Nervous System; Glucose; Hypoglycemic Agents; Insulin-Secreting Ce | 2021 |
Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.
Topics: Animals; Antioxidants; Catalase; Female; Glutathione Peroxidase; Liraglutide; Male; Metformin; Obesi | 2021 |
Metformin alleviates monoamine oxidase-related vascular oxidative stress and endothelial dysfunction in rats with diet-induced obesity.
Topics: Animals; Aorta; Disease Models, Animal; Endothelium, Vascular; Hypoglycemic Agents; Male; Metformin; | 2021 |
Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes.
Topics: Age Factors; Blood Glucose; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Hum | 2021 |
Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats.
Topics: Animals; Diet, High-Fat; Imidazoles; Indoles; Insulin Resistance; Male; Metformin; Mitochondria, Hea | 2021 |
Metabolic benefits of novel histamine H
Topics: Adipose Tissue; Animals; Body Weight; C-Peptide; Carrier Proteins; Cholesterol; Energy Intake; Feedi | 2021 |
Obesity increases neuropathic pain via the AMPK-ERK-NOX4 pathway in rats.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Butadienes; Diet, Hig | 2021 |
Metformin and tBHQ Treatment Combined with an Exercise Regime Prevents Osteosarcopenic Obesity in Middle-Aged Wistar Female Rats.
Topics: Animals; Bone Diseases, Metabolic; Female; Hydroquinones; Metformin; Obesity; Physical Conditioning, | 2021 |
Combined metformin and insulin treatment reverses metabolically impaired omental adipogenesis and accumulation of 4-hydroxynonenal in obese diabetic patients.
Topics: Adipocytes; Adipogenesis; Adult; Aldehydes; Bariatric Surgery; Cells, Cultured; Diabetes Mellitus, T | 2017 |
Collaboration Is Key for Successful Treatment of Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Adolescent Health; Diabetes Mellitus, Type 2; Diet; Exercise; Family Relations; Healthy | 2017 |
Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Dose-Response Relationship, Drug; Hypoglycemic Agents; Infl | 2017 |
Metformin improves in vivo and in vitro B cell function in individuals with obesity and Type-2 Diabetes.
Topics: Antibodies, Viral; B-Lymphocytes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Im | 2017 |
Metformin and sulodexide restore cardiac microvascular perfusion capacity in diet-induced obese rats.
Topics: Animals; Coronary Vessels; Diet, High-Fat; Glycosaminoglycans; Hypoglycemic Agents; Male; Metformin; | 2017 |
Metformin as targeted treatment in fragile X syndrome.
Topics: Adult; Animals; Child; Child, Preschool; Diabetes Mellitus, Type 2; Female; Fragile X Syndrome; Gluc | 2018 |
The Landscape of Histone Modifications in a High-Fat Diet-Induced Obese (DIO) Mouse Model.
Topics: Acylation; Animals; Diet, High-Fat; Disease Models, Animal; Epigenesis, Genetic; Histone Code; Histo | 2017 |
Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Autophagy; Body Weight; Diet, High-Fat; Dise | 2017 |
Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
Topics: Adult; Androgens; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Ag | 2017 |
Diabetes-related weight change in a Canadian First Nation cohort.
Topics: Anthropometry; Body Weight; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Femal | 2017 |
Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis.
Topics: Animals; Anti-Obesity Agents; Butyrates; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Hor | 2017 |
Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Humans; Mental Disorders; Metformin; Obesity; Risk Fa | 2017 |
Is There a Role for Metformin in the Treatment of Childhood Obesity?
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pediatric Obesity | 2017 |
Diabetes: Systemic effects of metformin revealed.
Topics: Adiposity; Animals; Bone Marrow; Cortical Bone; Diet; Humans; Hypoglycemic Agents; Male; Metformin; | 2017 |
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female | 2017 |
A Western diet-induced mouse model reveals a possible mechanism by which metformin decreases obesity.
Topics: Animals; Diet, High-Fat; Diet, Western; Disease Models, Animal; Hypoglycemic Agents; Metformin; Mice | 2017 |
Metformin improves obesity-associated inflammation by altering macrophages polarization.
Topics: Adenylate Kinase; Adipose Tissue; Animals; Cell Polarity; Cytokines; Diet, High-Fat; Glucose; Inflam | 2018 |
Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver.
Topics: Adult; Cells, Cultured; Diabetes Mellitus, Type 2; DNA Methylation; Epigenesis, Genetic; Female; Gen | 2017 |
Metformin influences on respiratory system in obese mice induced by postnatal overnutrition.
Topics: Animals; Bronchoalveolar Lavage Fluid; Diet; Disease Models, Animal; Hypoglycemic Agents; Lung; Male | 2018 |
Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice.
Topics: Absorptiometry, Photon; Adipose Tissue, White; Adiposity; Animals; Body Composition; Bone Marrow; Ce | 2017 |
Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice.
Topics: Age Factors; Animals; Bacteria; Blood Glucose; Body Weight; Diet, High-Fat; Disease Models, Animal; | 2018 |
Gestational diabetes-Predictors of response to treatment and obstetric outcome.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Diet, Carbohydrate-Restricted; Female; Humans; Hypogl | 2018 |
Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Topics: Adult; Anti-Obesity Agents; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethin | 2018 |
RE: Statistical Interpretation Error in Metformin Trial Article.
Topics: Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity | 2017 |
Authors' Response.
Topics: Child; Humans; Metformin; Obesity | 2017 |
Exercise and reproductive function in polycystic ovary syndrome: protocol of a systematic review.
Topics: Diet; Exercise; Female; Fertility; Humans; Hyperandrogenism; Insulin Resistance; Menstrual Cycle; Me | 2017 |
Metabolic parameters and functional state of hypothalamic signaling systems in A
Topics: Animals; Genetic Predisposition to Disease; Hypothalamus; Metformin; Mice; Obesity; Proto-Oncogene P | 2017 |
[Metformin reduces plasma triglycerides in ob/ob obese mice via inhibiting the hepatic apoA5 expression].
Topics: Animals; Apolipoprotein A-V; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Metformin; Mice; Mic | 2017 |
Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation.
Topics: Adipocytes, Brown; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthri | 2018 |
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidy | 2018 |
Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, | 2017 |
The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter.
Topics: Adolescent; Adult; Aged; Female; Goiter, Nodular; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2018 |
Update on off label use of metformin for obesity.
Topics: Administration, Oral; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agent | 2018 |
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Fibrobl | 2018 |
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Insulin; | 2018 |
Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
Topics: Humans; Lung Neoplasms; Metformin; Obesity; Risk Factors | 2018 |
Stimulating effect of palmitate and insulin on cell migration and proliferation in PNT1A and PC3 prostate cells: Counteracting role of metformin.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2018 |
Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
Topics: Acyltransferases; Administration, Oral; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Chemo | 2018 |
Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic Effects of Metformin in Correlation with Modulating Gut Microbiota.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, C | 2018 |
Inflammatory signatures distinguish metabolic health in African American women with obesity.
Topics: Biomarkers; Black or African American; Chemokines; Cytokines; Diabetes Mellitus, Type 2; Female; Gly | 2018 |
The effect of high fat diet and metformin treatment on liver lipids accumulation and their impact on insulin action.
Topics: Animals; Blood Glucose; Ceramides; Diet, High-Fat; Diglycerides; Fatty Liver; Humans; Insulin Resist | 2018 |
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Com | 2018 |
Metabolomic analysis and biochemical changes in the urine and serum of streptozotocin-induced normal- and obese-diabetic rats.
Topics: Amino Acids; Animals; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experime | 2018 |
Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
Topics: Biomarkers; Breast Neoplasms; Humans; Life Style; Metformin; Obesity; Weight Loss | 2018 |
A novel mutation in the proopiomelanocortin (POMC) gene of a Hispanic child: metformin treatment shows a beneficial impact on the body mass index.
Topics: Adrenal Insufficiency; Adult; Body Mass Index; Child; Child, Preschool; Female; Hispanic or Latino; | 2018 |
Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Proliferation; Diet, High-Fat; Disease Models, Animal | 2018 |
Complete androgen insensitivity syndrome in a young woman with metabolic disorder and diabetes: A case report.
Topics: Amenorrhea; Androgen-Insensitivity Syndrome; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydro | 2018 |
Metformin Plus Caloric Restriction Show Anti-epileptic Effects Mediated by mTOR Pathway Inhibition.
Topics: AMP-Activated Protein Kinases; Animals; Anticonvulsants; Caloric Restriction; Combined Modality Ther | 2018 |
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase.
Topics: Adenosine Monophosphate; Aminoimidazole Carboxamide; Animals; Base Sequence; Chickens; Disease Model | 2018 |
Beneficial effects of metformin on muscle atrophy induced by obesity in rats.
Topics: Animals; Diet, High-Fat; Forkhead Box Protein O3; Gene Expression Regulation; Hypoglycemic Agents; M | 2019 |
Prenatal metformin treatment improves ovarian function in offspring of obese rats.
Topics: Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Lactation; Metfo | 2018 |
Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Apolipoprotein E2; Apolipoprotein E4; Carbonated B | 2019 |
Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Hypoglycemic | 2019 |
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.
Topics: Bacteroides; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Micro | 2018 |
Reassessing strategies to improve pregnancy outcomes in overweight and obese women.
Topics: Double-Blind Method; Female; Humans; Life Style; Metformin; Obesity; Overweight; Pregnancy; Pregnanc | 2019 |
Type 2 diabetes mellitus in pregnancy: The impact of maternal weight and early glycaemic control on outcomes.
Topics: Adult; Case-Control Studies; Cesarean Section; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; | 2019 |
What protects against pre-diabetes progressing to diabetes? Observational study of integrated health and social data.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Delivery of Health Care, Integrated; Diabetes Melli | 2019 |
Methodological issues in meta-analysis of the metformin effects on simple obesity.
Topics: Humans; Hypoglycemic Agents; Metformin; Obesity | 2019 |
Long-term diabetes outcomes after bariatric surgery-managing medication withdrawl.
Topics: Adult; Bariatric Surgery; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Human | 2019 |
Metformin use in polycystic ovary syndrome pregnancy impacts on offspring obesity.
Topics: Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Metformin; Obesity; Polycystic Ovary Syn | 2019 |
Atypical presentation of Crimean-Congo haemorrhagic fever: Lessons learned.
Topics: Acidosis; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Dr | 2019 |
The evidence of metabolic-improving effect of metformin in Ay/a mice with genetically-induced melanocortin obesity and the contribution of hypothalamic mechanisms to this effect.
Topics: Agouti-Related Protein; Animals; Body Weight; Female; Gene Expression Regulation; Hypoglycemic Agent | 2019 |
A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats.
Topics: 3T3 Cells; Adipogenesis; Adipose Tissue, White; Animals; Berberine; Diabetes Mellitus, Type 2; Femal | 2019 |
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression | 2019 |
Advising Patients on How to Achieve Long-Term Weight Loss.
Topics: Diabetes Mellitus, Type 2; Humans; Life Style; Metformin; Obesity; Weight Loss | 2019 |
Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative-a prospective cohort study.
Topics: Aged; Cartilage, Articular; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Female; | 2019 |
Reply to "Methodological issues in meta-analysis of the metformin effects on simple obesity".
Topics: Humans; Hypoglycemic Agents; Metformin; Obesity | 2019 |
Epicardial adipose tissue: An important therapeutic target.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Metformin; Obesity; Pericardium | 2019 |
MODERN ASPECTS OF SUGAR-REDUCING EFFECT OF THICK BEAN EXTRACT BASED ON A TYPE II DIABETES MODEL ON THE BACKGROUND OF OBESITY.
Topics: Animals; Cell Size; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; | 2019 |
Hyperosmolar hyperglycaemic state (HHS) as the first manifestationof type 2 diabetes in a child.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemic Hyperosmolar Non | 2019 |
Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.
Topics: Adipose Tissue; Blood Glucose; Body Mass Index; Brachial Artery; Carotid Arteries; Diabetes Mellitus | 2013 |
Chemopreventive effects of metformin on obesity-associated endometrial proliferation.
Topics: Analysis of Variance; Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Endometrial Ne | 2013 |
Effect of metformin on the urinary metabolites of diet-induced-obese mice studied by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-TOF/MS).
Topics: Animals; Blood Glucose; Body Weight; Chromatography, High Pressure Liquid; Diet, High-Fat; Male; Mas | 2013 |
The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic | 2013 |
Update in endocrinology: evidence published in 2012.
Topics: Biliopancreatic Diversion; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2013 |
Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome.
Topics: Animals; Diet, High-Fat; Dietary Carbohydrates; Female; Fetus; Inflammation; Interleukin-6; Male; Me | 2013 |
Metformin use in adolescents.
Topics: Adolescent; Age of Onset; Body Mass Index; Child; Diabetes Mellitus; Female; Humans; Hypoglycemic Ag | 2013 |
[Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients].
Topics: Biomarkers; Body Mass Index; C-Reactive Protein; Case-Control Studies; Diabetes Mellitus, Type 2; Hu | 2012 |
Diabetes update: screening and diagnosis.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2013 |
Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties.
Topics: Adolescent; Adolescent Medicine; Androgen Antagonists; Contraceptives, Oral, Hormonal; Diabetes Mell | 2013 |
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
Topics: Adamantane; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2014 |
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
Topics: Adipose Tissue, White; Animals; Anticarcinogenic Agents; Carcinogenesis; Carcinoma, Hepatocellular; | 2013 |
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Analysis of Variance; Animals; Bariatric Surgery; Diet, Hi | 2014 |
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2013 |
Reply: To PMID 23659985.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Maternal metformin, obesity, and metabolic syndrome: the contribution of autonomic nervous system function.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Imaging, Three-Di | 2014 |
Metformin inhibits skin tumor promotion in overweight and obese mice.
Topics: Adenylate Kinase; Adiponectin; Animals; Body Weight; Carcinogenesis; Carcinoma, Squamous Cell; Diet; | 2014 |
Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice.
Topics: AMP-Activated Protein Kinases; Animals; Asthma; Blotting, Western; Bronchoalveolar Lavage Fluid; Die | 2013 |
Management and treatment goals in Polish patients with type 2 diabetes of short duration: results of the ARETAEUS2-Grupa study.
Topics: Blood Glucose; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycated Hem | 2013 |
[Оptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
Topics: Adult; Aged; Angina, Stable; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Body Weight; | 2013 |
[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2013 |
Metformin and Alzheimer's disease risk.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Response to Rosenfeld.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Diabetes Mellitus; Diet, High-Fat; Disease Mod | 2014 |
Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats.
Topics: Adiponectin; Animals; Cytokines; Drug Combinations; Exenatide; Metformin; Obesity; Peptides; Rats; T | 2013 |
Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans.
Topics: Adipokines; Adult; Blood Glucose; Carotid Intima-Media Thickness; Case-Control Studies; Cross-Sectio | 2014 |
Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose; Glucose Intol | 2014 |
Potential biomarker of metformin action.
Topics: Adolescent; Adult; Animals; Biomarkers; Cells, Cultured; CREB-Binding Protein; Fasting; Female; Gluc | 2014 |
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.
Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Endometrial Hyperplasia; Endom | 2014 |
Metformin for weight loss in schizophrenia: safe but not a panacea.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats.
Topics: Adipose Tissue; Animals; Cholesterol; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Hypog | 2014 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Topics: Adipose Tissue, Brown; Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinase Kinases; Animals | 2014 |
[The secret world of the microbiom. Do bacteria make us fat?].
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Intestines; Metabolic Syndrome; Metformin; Microbiota; O | 2014 |
Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Insulin; M | 2014 |
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
Topics: Adipocytes; Adipokines; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; C | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol | 2014 |
Metformin suppresses lipid accumulation in skeletal muscle by promoting fatty acid oxidation.
Topics: Animals; Body Weight; Cell Line; Fatty Acids; Female; Lipid Metabolism; Male; Metformin; Mice; Mice, | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhi | 2014 |
Effect of metformin on metabolic improvement and gut microbiota.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Clostridium; Diabetes Mellitus, Experimental; Diabe | 2014 |
Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Th | 2015 |
[European guidelines on diabetes, pre-diabetes and cardiovascular diseases: what's new?].
Topics: Arrhythmias, Cardiac; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type | 2014 |
Advanced onset of puberty after metformin therapy in swine with thrifty genotype.
Topics: Adiposity; Age Factors; Animals; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; | 2014 |
[Effect of Mudan Granule on islets beta cell function in monosodium glutamate induced obese mice with insulin resistance: an experimental study].
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Female; Insulin Resistance; Insulin-Secretin | 2014 |
How does obesity affect fertility in men - and what are the treatment options?
Topics: Adiposity; Androgens; Aromatase Inhibitors; Body Mass Index; Clomiphene; Erectile Dysfunction; Estro | 2015 |
Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
Topics: Adenocarcinoma, Papillary; Aged; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Comorbidity | 2014 |
The effect of lifestyle change and metformin therapy on serum arylesterase and paraoxonase activity in obese children.
Topics: Adult; Aryldialkylphosphatase; Carboxylic Ester Hydrolases; Child; Humans; Life Style; Metformin; Ob | 2015 |
Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways.
Topics: Adenylate Kinase; Animals; Diet, High-Fat; Enzyme Activators; Male; Metformin; Mice; Mice, Inbred C5 | 2014 |
Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis.
Topics: Animals; Diet, High-Fat; Dietary Fats; Disease Models, Animal; Drosophila melanogaster; Feeding Beha | 2014 |
Urban, obese, allergic, and breathless: the shape of things to come?
Topics: Adult; Animals; Anti-Inflammatory Agents; Asthma; Child; Dyspnea; Feeding Behavior; Humans; Insulin | 2014 |
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Endometrial Neoplasms; Fe | 2015 |
Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity.
Topics: Adult; Aged; Body Mass Index; C-Reactive Protein; Case-Control Studies; Diabetes Mellitus, Type 2; F | 2015 |
TallyHO obese female mice experience poor reproductive outcomes and abnormal blastocyst metabolism that is reversed by metformin.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; AMP-Activated Protein Kinases; Animals; Apoptosis; Blastocyst; Blo | 2014 |
Polycystic ovaries and obesity.
Topics: Adipokines; Adiponectin; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Inf | 2015 |
Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a.
Topics: Animals; Carcinoma 256, Walker; Cyclic AMP-Dependent Protein Kinases; Female; Food Additives; Forkhe | 2015 |
(5) Prevention or delay of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exercise; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Ob | 2015 |
Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
Topics: Age Factors; Animals; Behavior, Animal; Biomarkers; Blood Glucose; Caloric Restriction; Combined Mod | 2015 |
Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference.
Topics: Asian People; Blood Glucose; CA-19-9 Antigen; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 2015 |
Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2014 |
Obesity, metformin and prostate cancer risk.
Topics: Humans; Insulin; Male; Metformin; Obesity; Prostatic Neoplasms; Risk Factors | 2014 |
The brighter (and evolutionarily older) face of the metabolic syndrome: evidence from Trypanosoma cruzi infection in CD-1 mice.
Topics: Adipose Tissue, White; Adiposity; Animals; Cell Line; Chagas Disease; Cytokines; Energy Metabolism; | 2015 |
[Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Metformin | 2014 |
PRDM16 sustains white fat gene expression profile in human adipocytes in direct relation with insulin action.
Topics: Adipocytes, White; Adipogenesis; Adipose Tissue, White; Adult; Case-Control Studies; Cells, Cultured | 2015 |
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Topics: Animals; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Synergism; Eating; Gast | 2015 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Gene Exp | 2015 |
Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes.
Topics: Adipose Tissue; Adult; Biomarkers; Caspase 1; Connexins; Diabetes, Gestational; Endoplasmic Reticulu | 2015 |
Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice.
Topics: Adipocytes; AMP-Activated Protein Kinases; Animals; Blood Glucose; Diet, High-Fat; Fasting; Glucose; | 2015 |
Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice.
Topics: Adipokines; Animals; Animals, Newborn; Carcinogenesis; Diabetes Mellitus, Experimental; Diethylnitro | 2015 |
Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study.
Topics: Adult; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insurance, Health; Life Style; Male; | 2015 |
Tetrapleura tetraptera spice attenuates high-carbohydrate, high-fat diet-induced obese and type 2 diabetic rats with metabolic syndrome features.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Fruit; Hypoglycemic Agents; | 2015 |
Protective effects of metformin on reproductive function in obese male rats induced by high-fat diet.
Topics: Animals; Apoptosis; Diet, High-Fat; Hypoglycemic Agents; Male; Metformin; Obesity; Protective Agents | 2015 |
Total Antioxidant Status in Type 2 Diabetic Patients in Palestine.
Topics: Antioxidants; Arabs; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Educational Status; | 2015 |
Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Topics: Abortion, Spontaneous; Adult; Androgen Antagonists; Blood Glucose; Body Mass Index; Clomiphene; Cypr | 2015 |
Treatment With Metformin Improves Erectile Dysfunction in a Murine Model of Obesity Associated With Insulin Resistance.
Topics: Animals; Disease Models, Animal; Erectile Dysfunction; Hypoglycemic Agents; Insulin Resistance; Male | 2015 |
Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.
Topics: Adipose Tissue; Adiposity; Adolescent; Adult; Aged; Body Composition; Diabetes Mellitus, Type 2; Dru | 2016 |
Spontaneous Regression of Lumbar Disc Herniation After Weight Loss: Case Report.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Intervertebral Disc Displacem | 2015 |
Alpha-lipoic acid reduces body weight and regulates triglycerides in obese patients with diabetes mellitus.
Topics: Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Middle Aged; O | 2015 |
[THE EFFECTS OF LONG-TERM METFORMIN TREATMENT ON THE ACTIVITY OF ADENYLYL CYCLASE SYSTEM AND NO-SYNTHASES IN THE BRAIN AND THE MYOCARDIUM OF RATS WITH OBESITY].
Topics: Adenylyl Cyclases; Adipose Tissue; Adrenergic Agonists; Animals; Body Weight; Brain; Cardiotonic Age | 2015 |
Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice.
Topics: Animals; Cell Line, Tumor; Diet, High-Fat; Humans; Hyperlipidemias; Leucine; Lipid Metabolism; Liver | 2015 |
Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats.
Topics: Animals; Blotting, Western; Caloric Restriction; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2015 |
Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats.
Topics: Animals; Anti-Obesity Agents; Bacteria; Base Sequence; Berberine; Diet, High-Fat; Fatty Acids, Volat | 2015 |
IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
Topics: Aged; Asian People; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Humans; Hypogl | 2015 |
Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erectile Dysfunctio | 2015 |
Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2015 |
Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence.
Topics: Adult; Aged; Aged, 80 and over; Arkansas; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents | 2016 |
Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate.
Topics: Cytokines; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Ketoglutari | 2015 |
Metformin in obese teenagers does not improve glycaemic control, study finds.
Topics: Diabetes Mellitus, Type 1; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Obesity | 2015 |
HL271, a novel chemical compound derived from metformin, differs from metformin in its effects on the circadian clock and metabolism.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle Proteins; Cell Line; Circadian Clocks; Energy Met | 2016 |
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Topics: Adenocarcinoma; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Body | 2016 |
[New aspects in prevention and therapy of diabetic nephropathy].
Topics: Acidosis, Lactic; Diabetic Nephropathies; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; | 2016 |
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.
Topics: Animals; Breast Neoplasms; Diet, High-Fat; Female; Glucose; Humans; Hypoglycemic Agents; Macrophages | 2016 |
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
Topics: Adipokines; Anti-Inflammatory Agents; Brain; Cohort Studies; Cytokines; Disability Evaluation; Dose- | 2016 |
Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agent | 2016 |
[Treatment of type 2 diabetes with metformin].
Topics: Administration, Oral; Body Mass Index; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglyce | 2015 |
Metformin stimulates IGFBP-2 gene expression through PPARalpha in diabetic states.
Topics: Adenylate Kinase; Aged; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2016 |
Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Topics: Acarbose; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hum | 2016 |
Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21.
Topics: 3T3-L1 Cells; Adipose Tissue; Adiposity; Animals; Body Weight; CD4-Positive T-Lymphocytes; Diet, Hig | 2016 |
Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
Topics: Adult; Atorvastatin; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Female; Huma | 2016 |
A challenge in the management of women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anti-Mullerian Hormone; Female; Ferritins; Humans; Hypoglycemic Agents; Insul | 2016 |
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.
Topics: Adenocarcinoma, Follicular; Anaplasia; Animals; Antineoplastic Agents; Cell Proliferation; Diet, Hig | 2016 |
Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination.
Topics: Adamantane; Animals; beta-Alanine; Diabetes Mellitus, Type 2; Diet; Glucose Tolerance Test; Hypoglyc | 2016 |
AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity.
Topics: Adipose Tissue; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Coll | 2016 |
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cause of Death; Databases, Factual; | 2016 |
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estroge | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body | 2016 |
Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.
Topics: Animals; Cell Line; Diet, High-Fat; Female; Gentamicins; HEK293 Cells; Humans; Kidney; Kidney Diseas | 2016 |
[Assessment of efficiency of the personalized therapy of patients with obesity and diabetes mellitus 2 types appointed on the basis of studying rs5219 polymorphism of KCNJ11 gene].
Topics: Adult; Aged; Caloric Restriction; Case-Control Studies; Combined Modality Therapy; Diabetes Mellitus | 2016 |
The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agen | 2016 |
Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway.
Topics: Animals; Apolipoprotein A-V; Body Weight; Hep G2 Cells; Humans; Hypertriglyceridemia; Male; Metformi | 2016 |
Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes.
Topics: Adolescent; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Gain | 2016 |
Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats.
Topics: Adiposity; Animals; Central Nervous System Depressants; Circadian Rhythm; Glucose Intolerance; Hypog | 2016 |
[Woman 19-old with hirsutism, obesity and acanthosis nigricans].
Topics: Acanthosis Nigricans; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Ob | 2016 |
Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Docosahexaenoic Acids; Dr | 2017 |
Metformin Reduces Lipogenesis Markers in Obese Mice Fed a Low-Carbohydrate and High-Fat Diet.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Administration, Oral; Animals; Biomarkers; Body Weight; Diet | 2016 |
Metformin preconditioned adipose derived mesenchymal stem cells is a better option for the reversal of diabetes upon transplantation.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Diet, Hig | 2016 |
Duodenal endoluminal barrier sleeve alters gut microbiota of ZDF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Dysbiosis; Gastric Bypass; Gas | 2017 |
Metformin with insulin does not improve the glycaemic control of overweight/obese adolescents with type 1 diabetes.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Metformi | 2017 |
The Effects of Metformin on Obesity-Induced Dysfunctional Retinas.
Topics: Animals; Blood Glucose; Blotting, Western; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mell | 2017 |
Transcriptomic effects of metformin in skeletal muscle arteries of obese insulin-resistant rats.
Topics: Animals; Arteries; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Muscle | 2017 |
Insulin use increases risk of asthma but metformin use reduces the risk in patients with diabetes in a Taiwanese population cohort.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Asthma; Case-Control Studies; Diabetes Mellitus; F | 2017 |
Exercise timing and blood lactate concentrations in individuals with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diet; Female; Humans; Hypoglycemic | 2017 |
Should family physicians prescribe medication for obesity? NO.
Topics: Anti-Obesity Agents; Body Mass Index; Family Practice; Humans; Lactones; Liraglutide; Male; Metformi | 2017 |
A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage.
Topics: Abortion, Habitual; Androgens; Anovulation; Female; Gonadotropins; Humans; Infertility, Female; Insu | 2008 |
Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
Topics: Adiponectin; Adult; Body Mass Index; C-Reactive Protein; Cytokines; Fasting; Female; Humans; Insulin | 2008 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F | 2008 |
Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness.
Topics: Adipocytes; Adult; Aged; Animals; Female; Gene Expression Regulation, Enzymologic; Glucose Tolerance | 2008 |
No effect of metformin on the innate airway hyperresponsiveness and increased responses to ozone observed in obese mice.
Topics: Administration, Oral; Animals; Asthma; Blood Glucose; Body Weight; Bronchial Hyperreactivity; Bronch | 2008 |
Considerations regarding the use of metformin with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Drug Administration Schedule; Huma | 2008 |
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
Topics: Antipsychotic Agents; Asian People; Benzodiazepines; Energy Intake; Exercise; Humans; Hypoglycemic A | 2008 |
Metformin: effective in the prevention of new-onset type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Early Diagnosis; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug?
Topics: Adolescent; Behavior Therapy; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; L | 2008 |
Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes.
Topics: Androgen Antagonists; Diabetes Mellitus, Type 2; Humans; Male; Metabolic Syndrome; Metformin; Obesit | 2009 |
The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Topics: Body Mass Index; Body Size; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Greece; | 2009 |
O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.
Topics: Adult; Aged; Apolipoprotein C-III; Bariatric Surgery; Biomarkers; Diabetes Mellitus; Female; Glycosi | 2009 |
Treatment of white coat hypertension with metformin.
Topics: Adolescent; Adult; Aged; Anorexia; Appetite Depressants; Blood Glucose; Dyslipidemias; Female; Human | 2008 |
Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascula | 2008 |
Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes.
Topics: Activins; Adiponectin; Aged; Cells, Cultured; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2009 |
Treatment of non-alcoholic fatty liver disease in children: swim at your own risk.
Topics: Adolescent; Child; Fatty Liver; Humans; Metformin; Obesity; Patient Education as Topic; Randomized C | 2009 |
Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gastric Inhibitory Polypeptide; Glucagon-Like | 2009 |
[Effect of the Gly972Arg, SNP43 and Prol2Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatán, México].
Topics: Aged; Anthropometry; Body Mass Index; Calpain; Diabetes Mellitus, Type 2; Drug Resistance; Female; G | 2009 |
Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity.
Topics: Adiponectin; Adult; Aminoimidazole Carboxamide; Antigens, CD; Antigens, Differentiation, Myelomonocy | 2009 |
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme | 2009 |
Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes.
Topics: Adipocytes; Adult; Aged; Animals; Blotting, Western; Body Mass Index; Cells, Cultured; Diabetes Mell | 2010 |
Reproductive endocrinology: live birth prediction in polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Live Birth; Metformin; | 2010 |
The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression.
Topics: Agouti-Related Protein; Animals; Blood Glucose; Body Weight; Eating; Humans; Hypoglycemic Agents; Hy | 2011 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fat | 2010 |
Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combina | 2010 |
Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Energy Intake; Glucagon-Like Peptide 1; Glucose I | 2010 |
Incorporating practical lifestyle management for obesity.
Topics: Appetite Depressants; Attitude to Health; Bariatric Surgery; Diabetes Mellitus, Type 2; Diet; Exerci | 2010 |
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Topics: Animals; Diet; Dietary Carbohydrates; Dietary Fats; Gluconeogenesis; Hypoglycemic Agents; Insulin; I | 2010 |
Generation, validation and humanisation of a novel insulin resistant cell model.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; | 2010 |
Evaluation of a focal lesion in the liver. answer to the clinical challenges and images in GI question: image 3: Focal fatty infiltration.
Topics: Diabetes Mellitus; Diet, Reducing; Exercise Therapy; Fatty Liver; Female; Humans; Hypoglycemic Agent | 2010 |
Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats.
Topics: Animals; Diabetes Mellitus, Type 2; Electron Transport Complex I; Hydrogen Peroxide; Male; Metformin | 2010 |
Analysis of metformin treatment for adolescent obesity at 48 rather than 24 weeks after treatment cessation.
Topics: Adolescent; Body Mass Index; Humans; Life Style; Metformin; Obesity | 2010 |
Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Fatty Liver; Humans; Hypoglycemic | 2010 |
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Genetic Predisposition to Diseas | 2010 |
National survey on management of weight reduction in PCOS women in the United Kingdom.
Topics: Anti-Obesity Agents; Body Mass Index; Diet, Reducing; Exercise; Female; Guideline Adherence; Health | 2010 |
Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice.
Topics: Animals; Dietary Fats; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Leptin; Liver; Male; Metf | 2010 |
Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.
Topics: Animals; Body Weight; Cardiomegaly; Drug Therapy, Combination; Eating; Male; Metformin; Mice; Mice, | 2010 |
OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects.
Topics: Acetyl-CoA Carboxylase; Acetyltransferases; Adenylate Kinase; Adipocytes; Azo Compounds; Cell Differ | 2011 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Rem | 2010 |
Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant.
Topics: Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2011 |
Abnormal metabolism flexibility in response to high palmitate concentrations in myotubes derived from obese type 2 diabetic patients.
Topics: Acetyl-CoA Carboxylase; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Cells, Cultured; | 2011 |
Successful strategy to improve glucose tolerance in Thai obese youth.
Topics: Adolescent; Asian People; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Diet; Ex | 2010 |
The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents.
Topics: Adolescent; Age Factors; Child; Diet; Exercise; Female; Humans; Male; Metformin; Obesity; Sex Factor | 2011 |
The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androgens; Androstenedione; Anti-Mullerian Hormone; Body Mass I | 2011 |
[Expression of aquaporin 7 in perirenal adipose tissue of Otsuka Long-Evans Tokushima Fatty diabetic rats].
Topics: Adipose Tissue; Animals; Aquaporins; Diabetes Mellitus, Type 2; Kidney; Metformin; Obesity; Rats; Ra | 2011 |
Anti-diabetic effects of mildronate alone or in combination with metformin in obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Cell Nucleus; Drug Combinations; Eating; Gene Expression Regula | 2011 |
Metformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor development and increases the area of tumor necrosis.
Topics: Animals; Carcinoma 256, Walker; Male; Metformin; Necrosis; Obesity; Random Allocation; Rats; Rats, W | 2011 |
[Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
Topics: Acne Vulgaris; Adult; Body Mass Index; Caloric Restriction; Case-Control Studies; Drug Administratio | 2011 |
Should metformin be our antiglycemic agent of choice post-transplantation?
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type | 2011 |
Weight-reducing effects of metformin are sustained over 40 weeks for psychiatric inpatients receiving polypharmacy.
Topics: Exercise; Hospitalization; Hospitals, Psychiatric; Humans; Metformin; Obesity; Polypharmacy; Schizop | 2011 |
Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment.
Topics: Adipocytes; Adrenergic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Ob | 2011 |
Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Analysis of Variance; Animals; Blood Glucose; | 2011 |
Unlicensed use of metformin in children and adolescents in the UK.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus; Drug Prescriptions; Drug Uti | 2012 |
Metformin after bariatric surgery--an acid problem.
Topics: Acids; Adult; Bariatric Surgery; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Administ | 2012 |
Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats.
Topics: Animals; Endomyocardial Fibrosis; Hypoglycemic Agents; Male; Metformin; Obesity; Rats; Rats, Wistar; | 2013 |
Unlicensed use of metformin in children and adolescents in Germany and France.
Topics: Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Male; Metformin; Obesity | 2012 |
Drug treatment of obesity.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupro | 2011 |
Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist.
Topics: AMP-Activated Protein Kinases; Animals; C-Reactive Protein; Caloric Restriction; Cells, Cultured; En | 2012 |
Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats.
Topics: Acetylcholine; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Dyslipidemias; Epoprost | 2012 |
Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats.
Topics: Acetyl-CoA Carboxylase; Adenylate Kinase; Animals; Blood Glucose; Body Composition; Dietary Fiber; D | 2012 |
Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2012 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2012 |
Menopausal obesity and metabolic syndrome - PolSenior study.
Topics: Age of Onset; Aged; Aged, 80 and over; Anthropometry; Cardiovascular Diseases; Cohort Studies; Diabe | 2012 |
Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Ghrelin; Glucagon-Like | 2012 |
Non-alcoholic fatty liver disease in children.
Topics: Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver; Metformin; Obesity; Piog | 2012 |
Reproductive endocrinology: Infertility treatment in PCOS--is metformin in from the cold?
Topics: Comorbidity; Female; Humans; Infertility, Female; Metformin; Obesity; Polycystic Ovary Syndrome; Tre | 2012 |
[Metformin improves epididymal sperm quality and antioxidant function of the testis in diet-induced obesity rats].
Topics: Animals; Epididymis; Glutathione Peroxidase; Male; Malondialdehyde; Metformin; Obesity; Rats; Rats, | 2012 |
Obesity and metformin.
Topics: Humans; Hypoglycemic Agents; Metformin; Obesity | 2012 |
Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Case-Control Studies; Endometrium; Female; Glucose Transporter Type 4; Human | 2012 |
Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
Topics: Adiponectin; Adolescent; Cholesterol, LDL; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin | 2011 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Considering metformin in cardiometabolic protection in psychosis.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agent | 2012 |
What's preventing us from preventing type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Approval; Glucose Intolerance; Humans; Hypoglycemic Agents; Insuranc | 2012 |
TAp63 is a master transcriptional regulator of lipid and glucose metabolism.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Energy Metabolism; Fatty Acids; Fatty Liver; Gluc | 2012 |
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Case-Control Studies; | 2013 |
Fitness, fatness, and metformin.
Topics: Diet, Reducing; Exercise Therapy; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; | 2012 |
Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Behavior Therapy; Body Mass Index; Child; Dietetics; Endocrinology; Feeding Behav | 2012 |
Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography.
Topics: Adult; Case-Control Studies; Endometrium; Female; Humans; Hypoglycemic Agents; Imaging, Three-Dimens | 2013 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
Effectiveness of metformin on weight loss in non-diabetic individuals with obesity.
Topics: Adult; Age Factors; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; | 2013 |
Metformin decreases meal size and number and increases c-Fos expression in the nucleus tractus solitarius of obese mice.
Topics: Animals; Avoidance Learning; Body Weight; Circadian Rhythm; Dietary Fats; Eating; Energy Intake; Ene | 2013 |
Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes.
Topics: Adipocytes; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Transporter Type 4; Humans; Insulin; | 2013 |
Seeking sweet relief for diabetes.
Topics: Behavior Control; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Exe | 2002 |
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus].
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypercholesterolemia; Hyperli | 2002 |
Therapeutic approach in insulin resistance with acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Body Mass Index; Body Weight; Diabetes Complications; Diabe | 2002 |
Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.
Topics: Abdomen; Adolescent; Anovulation; Body Composition; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity.
Topics: Adolescent; Child; Child, Preschool; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; H | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug T | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insu | 2003 |
Beta2-adrenergic receptor polymorphism and obesity in type 2 diabetes: response to van Tilburg et al.
Topics: Amino Acid Substitution; Diabetes Mellitus; Humans; Metformin; Middle Aged; Obesity; Polymorphism, G | 2003 |
Type 2 diabetes presenting as diabetic ketoacidosis in adolescence.
Topics: Acanthosis Nigricans; Adolescent; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; | 2003 |
Metformin use as an adjunct to insulin treatment.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Age | 2003 |
Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
Topics: Acetylglucosaminidase; Administration, Oral; Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Fem | 2003 |
[Metformin-associated lactic acidosis remains a serious complication of metformin therapy].
Topics: Acidosis, Lactic; Acute Kidney Injury; Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type | 2003 |
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
Topics: Adolescent; Adult; Diet, Reducing; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; M | 2003 |
Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents.
Topics: Adolescent; Black or African American; Blood Glucose; Body Mass Index; Caribbean Region; Child; Diab | 2003 |
Management of the overweight patient with Type 2 diabetes.
Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hum | 2003 |
[BIGUANIDES AND SULFONAMIDES IN SMALL DOSES IN THE INITIAL TREATMENT OF THE DIABETES OF THE OBESE PERSON].
Topics: Biguanides; Chlorpropamide; Diabetes Mellitus; Humans; Metformin; Obesity; Sulfanilamide; Sulfanilam | 1963 |
THE EFFECT OF METFORMIN ON WEIGHT LOSS IN OBESITY.
Topics: Diabetes Mellitus; Diet; Diet, Reducing; Drug Therapy; Humans; Metformin; Obesity; Weight Loss | 1965 |
Hyperglycaemic hyperosmolar syndrome in young obese Afro-Caribbean adults--a diagnostic dilemma. Report of two cases.
Topics: Adolescent; Adult; Black People; Diagnosis, Differential; Female; Humans; Hyperglycemic Hyperosmolar | 2003 |
Acarbose for the prevention of diabetes.
Topics: Acarbose; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss | 2003 |
Acarbose for the prevention of diabetes.
Topics: Acarbose; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss | 2003 |
Diabetes in a nonpancreatectomized child with nesidioblastosis.
Topics: Adolescent; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Pancreatecto | 2004 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Longitudinal metabolic observation of metformin effects during pregnancy in hyperinsulinemic women with polycystic ovary syndrome: a case report.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glucose Tolerance Test; Humans; Hyperinsulinism | 2004 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Protei | 2004 |
Understanding the rising incidence of type 2 diabetes in adolescence.
Topics: Adolescent; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Age | 2004 |
[Primary prevention of diabetes mellitus type 2].
Topics: Acarbose; Cardiovascular Diseases; Cross-Cultural Comparison; Cross-Sectional Studies; Diabetes Mell | 2004 |
Fatty acid composition of erythrocyte phospholipids is related to insulin levels, secretion and resistance in obese type 2 diabetics on Metformin.
Topics: Adult; Age Factors; Aged; Biomarkers; Diabetes Mellitus, Type 2; Dietary Fats; Erythrocytes; Fatty A | 2004 |
Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin.
Topics: Adult; Blood Glucose; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insu | 2004 |
[Current concept of polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Insulin Resistance; Leptin; Metformin; Obesity; Polycystic Ovary Sy | 2004 |
Metformin in the treatment of obesity in subjects with normal glucose tolerance.
Topics: Adult; Body Weights and Measures; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insul | 2003 |
Metformin monotherapy in lean women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Thinness | 2005 |
Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hydroxymethylgl | 2005 |
AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
Topics: Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Cardiovascular Diseases; Citrates; Diabetes | 2005 |
Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; G | 2004 |
Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice.
Topics: Adiponectin; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglyc | 2005 |
Metformin in the treatment of clomiphene citrate-resistant women with high BMI and primary infertility: clinical results and reproductive outcome.
Topics: Adult; Body Mass Index; Clomiphene; Drug Resistance; Female; Humans; Hypoglycemic Agents; Infertilit | 2005 |
[The rehabilitation of metformin].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyp | 2005 |
Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization.
Topics: Animals; Cholestenone 5 alpha-Reductase; Glucocorticoids; Hypoglycemic Agents; Insulin; Liver; Metfo | 2005 |
Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Metformin; Obes | 2005 |
The "worried-well", insulin resistance and metformin therapy.
Topics: Anti-Obesity Agents; Body Mass Index; Cholesterol; Humans; Metformin; Obesity; Waist-Hip Ratio | 2005 |
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Femal | 2006 |
[Metformin in the treatment of type 2 diabetes in overweighted or obese patients].
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; | 2005 |
Clinical Research Network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children.
Topics: Adolescent; Antioxidants; Child; Clinical Trials as Topic; Data Collection; Fatty Liver; Female; Hum | 2006 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu | 2005 |
Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Corticotropin-Releasing Hormone; Dietary Fat | 2006 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Heal | 2006 |
[Metformin hydrochloride ameliorates adiponectin levels and insulin sensitivity in adolescents with metabolic syndrome].
Topics: Adiponectin; Adolescent; Alanine Transaminase; Blood Glucose; Blood Pressure; Case-Control Studies; | 2006 |
Ovulation induction in women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Diathermy; Drug Therapy, Combination; Female; Fertility Agents, Fema | 2006 |
[Factors influencing homocysteineamia in type 2 diabetic patients].
Topics: Diabetes Mellitus, Type 2; Female; Folic Acid; Glycated Hemoglobin; Homocysteine; Humans; Hyperhomoc | 2006 |
Obesity is associated with altered metabolic and reproductive activity in the mare: effects of metformin on insulin sensitivity and reproductive cyclicity.
Topics: Animals; Breeding; Dose-Response Relationship, Drug; Estrous Cycle; Female; Food Deprivation; Horse | 2006 |
Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention.
Topics: Adiponectin; Adolescent; Body Mass Index; Body Size; Child; China; Exercise Therapy; Feeding Behavio | 2007 |
The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.
Topics: Androgens; Body Weight; Chromogranins; Female; Genotype; GTP-Binding Protein alpha Subunits, Gs; Hum | 2006 |
Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Body Weight; Databases, Factual; Diabete | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
[The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypog | 2006 |
Gaining: pediatric patients and use of atypical antipsychotics.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Child; Dia | 2006 |
[Metformine hydrochloride reduces both acanthosis nigricans and insulin resistance in Japanese young female].
Topics: Acanthosis Nigricans; Adult; Asian People; Diet, Diabetic; Female; Humans; Hypoglycemic Agents; Insu | 2006 |
Ovulation induction management of PCOS.
Topics: Aromatase Inhibitors; Clomiphene; Endometrial Neoplasms; Female; Fertility Agents, Female; Glucocort | 2007 |
CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice.
Topics: Adiposity; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Diabetes Mellitus; Energy Metabo | 2007 |
Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
Topics: Age Factors; Aged; Blood Glucose; Comorbidity; Databases, Factual; Diabetes Complications; Diabetes | 2007 |
C-reactive protein in obese PCOS women and the effect of metformin therapy.
Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Administration Schedule; Female | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mas | 2007 |
Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Clozapine; Female; Humans; Insulin Resistance; Metfor | 2007 |
Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Topics: Adolescent; Analysis of Variance; Behavior Therapy; Body Mass Index; Child; Combined Modality Therap | 2007 |
Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Insulin Res | 2003 |
Preventing diabetes, Part II: an action plan.
Topics: Diabetes Mellitus; Diet; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Rosi | 2007 |
Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes.
Topics: Animals; Fatty Acids; Hepatocytes; Insulin Resistance; Liver; Male; Metformin; Obesity; Phosphorylat | 2007 |
[Insulin resistance in type 2 diabetes patients].
Topics: Aged; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, | 2007 |
Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is ....
Topics: Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformi | 2007 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Topics: Body Weight; Female; Humans; Insulin Resistance; Metformin; Obesity; Overweight; Polycystic Ovary Sy | 2007 |
[Fat cells becoming ever more prolific--editorial].
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Met | 2007 |
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; H | 2007 |
Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes.
Topics: Administration, Oral; Aged; Biphasic Insulins; Diabetes Mellitus, Type 2; Female; Humans; Hyperglyce | 2007 |
[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Topics: Adolescent; Adult; Capillary Permeability; Case-Control Studies; Diabetes Mellitus, Type 2; Endothel | 2007 |
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gl | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Re: "Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome", Sinha SK et al., JPEM 2007; 20: 1045-1052.
Topics: Child; Deafness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; | 2008 |
Treatment of impaired glucose tolerance in childhood.
Topics: Child; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Insulin Resistance; Metformin; Obesit | 2008 |
Acarbose for polycystic ovary syndrome.
Topics: Acarbose; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Metformi | 2008 |
A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery.
Topics: Adult; Antihypertensive Agents; Breast Feeding; Diabetes Mellitus, Type 2; Female; Gastric Bypass; G | 2008 |
Treatment options in insulin resistance obesity-related acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Calcitriol; Humans; Hyperinsulinism; Hypoglycemic Agents; I | 2008 |
[On the use of ER 102 in the treatment of diabetes mellitus].
Topics: Adolescent; Adult; Aged; Diabetes Mellitus; Female; Humans; Insulin; Liver Cirrhosis; Male; Metformi | 1967 |
Metformin in the treatment of obese diabetics.
Topics: Adult; Aged; Diabetes Mellitus; Humans; Metformin; Middle Aged; Obesity | 1967 |
Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients.
Topics: Acetates; Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Female; Humans; Insulin; | 1983 |
Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Erythrocytes; Female; Hemoglobin A; Humans; Male; Metformin; | 1983 |
Reduction of the absorption of the fatty acid and glycerol moieties of ingested triglycerides by biguanides: a possible contribution to their anti-obesity, anti-hypertriglyceridaemic and anti-diabetes properties.
Topics: Adipose Tissue; Animals; Carbon Radioisotopes; Fatty Acids; Glycerol; Hypoglycemic Agents; Intestina | 1982 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metformin.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Metformin; Obesity | 1995 |
Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y.
Topics: Administration, Oral; Animals; Appetite Depressants; Blood Glucose; Body Weight; Drinking; Eating; H | 1995 |
The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema.
Topics: Adult; Albumins; Capillary Permeability; Edema; Female; Humans; Metformin; Middle Aged; Obesity | 1995 |
The American Diabetes Association annual meeting, 1994: treatment issues for NIDDM.
Topics: Diabetes Mellitus, Type 2; Fats; Health Services Accessibility; Humans; Insulin; Managed Care Progra | 1994 |
Elevated GLUT 1 level in crude muscle membranes from diabetic Zucker rats despite a normal GLUT 1 level in perineurial sheaths.
Topics: Animals; Blood Glucose; Cell Membrane; Diabetes Mellitus; Electrophoresis, Polyacrylamide Gel; Femor | 1994 |
Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Humans; Hypertension; Insulin; Lipids | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin ameliorates diabetes but does not normalize the decreased GLUT 4 content in skeletal muscle of obese (fa/fa) Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Cell Membrane; Diabetes Mellitus; Diabetes Mellitus, Type 1; Fru | 1993 |
Metformin and brown adipose tissue thermogenetic activity in genetically obese Zucker rats.
Topics: Adipose Tissue, Brown; Animals; Blood Glucose; Body Temperature Regulation; Carrier Proteins; Eating | 1993 |
In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Biological Transport; Drug Synergism; Enzyme Activation; | 1993 |
Metformin and liver glycogen synthase activity in obese Zucker rats.
Topics: Animals; Blood Glucose; Glycogen Synthase; Hyperinsulinism; Insulin Resistance; Liver; Liver Glycoge | 1993 |
Decreased skeletal muscle phosphotyrosine phosphatase (PTPase) activity towards insulin receptors in insulin-resistant Zucker rats measured by delayed Europium fluorescence.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Europium; Fluorescent Ant | 1996 |
Insulin and the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Hyperandrogenism; Insulin; Lutei | 1996 |
Metformin as an adjunctive therapy for NIDDM.
Topics: Adult; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabe | 1996 |
Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
Topics: Aging; Animals; Blood Glucose; Blood Pressure; Blotting, Northern; Body Weight; Diabetes Mellitus, T | 1996 |
Conference report: renal disease, metformin, and the adipocyte.
Topics: Adipocytes; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabet | 1996 |
The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Circul | 1996 |
[Comparison of two treatment models in type-II diabetic patients with poor metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinatio | 1996 |
Effect of metformin on insulin-stimulated tyrosine kinase activity of erythrocytes from obese women with normal glucose tolerance.
Topics: Adult; Blood Glucose; Erythrocyte Membrane; Erythrocytes; Female; Glucose Tolerance Test; Humans; Hy | 1997 |
Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease.
Topics: Adult; Coronary Disease; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obe | 1998 |
[Effects of metformin on insulin resistance in obese and hyperandrogenic women].
Topics: Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity | 1997 |
Differential regulation of uncoupling proteins by chronic treatments with beta 3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats.
Topics: Adipose Tissue; Adrenergic beta-Agonists; Analysis of Variance; Animals; Carrier Proteins; Eating; E | 1998 |
Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; M | 1998 |
Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics.
Topics: Adipose Tissue; Body Composition; Carnitine; Citrates; Diabetes Mellitus; Humans; Hypoglycemic Agent | 1998 |
[A twelve-year old girl with diabetes mellitus type 2].
Topics: Acanthosis Nigricans; Candidiasis, Vulvovaginal; Child; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1998 |
Clinical problem-solving. The importance of a name.
Topics: Acanthosis Nigricans; Adolescent; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 1999 |
Metformin therapy for diabetes in Prader-Willi syndrome.
Topics: Adolescent; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Obesity; Prader | 1998 |
First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization.
Topics: Adolescent; Adult; Aged; California; Child; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Ty | 1999 |
The treatment of type 2 diabetes: good news from the UK.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Combined Modality | 1999 |
[Renaissance of metformin].
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Metformin; Obesity | 1999 |
Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study.
Topics: Adipose Tissue; Adult; Body Mass Index; Electric Impedance; Epinephrine; Female; Glycerol; Humans; H | 1999 |
Metformin: a useful adjunct to insulin therapy?
Topics: Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combina | 2000 |
Effect of metformin on glycaemic control in type 2 diabetes in daily practice: a retrospective study.
Topics: Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glyca | 2000 |
Enhanced escape of non-esterified fatty acids from tissue uptake: its role in impaired insulin-induced lowering of total rate of appearance in obesity and Type II diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hydro | 2000 |
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati | 2000 |
Obesity and Type 2 diabetes mellitus.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; G | 2000 |
[Early control of diabetic sequelae. Combined insulin treatment also in type 2].
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents | 2000 |
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Topics: Adenosine Triphosphate; Adipose Tissue; Animals; Body Weight; Energy Intake; Energy Metabolism; Fatt | 2000 |
Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adrenal Glands; Adrenalectomy; Analysis of Va | 2000 |
Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Catalase; Diabetes Mellitus; Diabetes Mellitus, Type 2; Erythrocytes; Fruc | 2000 |
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.
Topics: Abdomen; Adult; Aged; Biguanides; Biomarkers; Cardiovascular Diseases; Endothelium, Vascular; Female | 2001 |
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Topics: Adult; Aged; Body Mass Index; Body Weight; Cholesterol, LDL; Coronary Disease; Fasting; Female; Huma | 2001 |
Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?
Topics: Adult; Gastrointestinal Hemorrhage; Humans; Hypoglycemic Agents; Male; Meckel Diverticulum; Metformi | 2001 |
Continuous glucose monitoring in youth with type 2 diabetes: overcoming barriers to successful treatment.
Topics: Adolescent; Adult; Blood Glucose; Blood Glucose Self-Monitoring; Child; Circadian Rhythm; Diabetes M | 2000 |
Diet and exercise delay onset of type 2 diabetes, say US experts.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Behavior Therapy; Diabetes Mellitus, Type 2; Diet; Exer | 2001 |
The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
Topics: Adult; Body Constitution; Body Mass Index; Dehydroepiandrosterone Sulfate; Diabetes Mellitus; Diabet | 2001 |
Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice.
Topics: Adipose Tissue, Brown; Animals; Blood Glucose; Blotting, Western; Dose-Response Relationship, Drug; | 2001 |
Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Blood Glucose; Chorionic Gonadotropin; Estradi | 2001 |
[Metabolism control in overweight type 2 diabetics. High metformin dosage brings more].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity | 2001 |
[Thus to avoid complications of diabetes. To combine early].
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Humans; Hypo | 2001 |
[Some considerations on the Consensus of the Spanish Diabetes Society and the Spanish Society of Family and Community Medicine on the criteria and guidelines for combined therapy for type 2 diabetes].
Topics: Acarbose; Blood Glucose; Community Medicine; Consensus Development Conferences as Topic; Controlled | 2001 |
Insulin-metformin combination therapy in obese patients with type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2002 |
Biochemical and body weight changes with metformin in polycystic ovary syndrome.
Topics: Adult; Body Weight; Female; Humans; Hypoglycemic Agents; Insulin; Menstruation; Metformin; Obesity; | 2001 |
[Fatty liver and raised gamma-GT: it can happen to abstainers, too].
Topics: Cholagogues and Choleretics; Clinical Enzyme Tests; Diabetes Complications; Diagnosis, Differential; | 2002 |
Metformin for weight loss in pediatric patients taking psychotropic drugs.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Child; Dose-R | 2002 |
Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Androgens; Body Composition; Female; Glucos | 2002 |
Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Eating; Glycogen | 2002 |
Diabetes prevention.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metfo | 2002 |
[Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus].
Topics: Cholesterol; Diabetes Mellitus; Humans; Hyperlipidemias; Insulin; Lipids; Male; Metformin; Middle Ag | 1979 |
DBM mice as a pharmacological model of maturity onset diabetes. Studies with metformin.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, A | 1979 |
The treatment and progress of obese insulin independent diabetics.
Topics: Diabetes Mellitus; Female; Humans; Male; Metformin; Middle Aged; Obesity | 1979 |
Metformin in the treatment of obese diabetics.
Topics: Diabetes Mellitus; Female; Glycosuria; Humans; Hyperglycemia; Male; Metformin; Obesity | 1977 |
Treatment of normal-weight diabetics.
Topics: Aged; Body Weight; Diabetes Mellitus; Humans; Metformin; Middle Aged; Obesity | 1978 |
[Therapy of diabetes mellitus with oral drugs].
Topics: Acidosis; Body Weight; Diabetes Mellitus; Drug Tolerance; Humans; Metformin; Obesity; Sulfonylurea C | 1978 |
[Biguanides: reasons for withdrawal of drugs and remaining indications].
Topics: Acidosis; Austria; Biguanides; Buformin; Diabetes Mellitus; Humans; Lactates; Legislation, Drug; Met | 1978 |
Effect of biguanide treatment in obese children.
Topics: Adolescent; Blood Glucose; Child; Fasting; Glucose Tolerance Test; Humans; Insulin; Metformin; Obesi | 1977 |
[Proinsulin and insulin secretion in obese females before and after administration of metformin].
Topics: Adult; Blood Glucose; Body Weight; Cholesterol; Diet, Reducing; Female; Glucose Tolerance Test; Huma | 1975 |
Dietary and medical treatments of obesity: an evaluative review.
Topics: Amphetamines; Appetite Depressants; Behavior Therapy; Chorionic Gonadotropin; Diet, Reducing; Evalua | 1975 |
Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats.
Topics: Animals; Appetite Depressants; Blood Glucose; Body Weight; Corticosterone; Digestive System; Eating; | 1992 |
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Female; Glucose; | 1991 |
Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients.
Topics: Biological Transport; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Insulin; | 1990 |
Metformin treatment of lean and obese Zucker rats modulates the ability of glucagon and insulin to regulate hepatocyte adenylate cyclase activity.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Cell Membrane; Enzyme Activation; Glucagon; | 1989 |
Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Tolerance; | 1989 |
Drugs in obesity.
Topics: Amphetamine; Appetite Depressants; Diet, Reducing; Diuretics; Ephedrine; Fenfluramine; Health Educat | 1974 |
Oral therapy in diabetes.
Topics: Acetohexamide; Administration, Oral; Animals; Chlorpropamide; Diabetes Mellitus; Diet Therapy; Evalu | 1972 |
[Extragonadal endocrine manifestations of Klinefelter's disease].
Topics: Adrenal Gland Diseases; Adult; Antibodies; Autoantibodies; Blood Glucose; Diabetes Mellitus; Diazoxi | 1973 |
The effect of dimethylbiguanide on glucose tolerance, serum insulin and growth hormone in obese patients.
Topics: Blood Glucose; Diabetes Mellitus; Glucose Tolerance Test; Growth Hormone; Humans; Insulin; Insulin S | 1972 |
Influence of dimethylbiguanide (Metformin) on carbohydrate metabolism in obese, non-diabetic women.
Topics: Blood Glucose; Carbohydrate Metabolism; Female; Humans; Insulin; Insulin Resistance; Insulin Secreti | 1972 |
[Round-table discussion on the value of the association of chlorpropamide with metformin in the treatment of diabetes mellitus].
Topics: Aged; Chlorpropamide; Diabetes Mellitus; Dosage Forms; Drug Combinations; Humans; Metformin; Obesity | 1972 |
Diabetes mellitus--refractory obesity.
Topics: Biguanides; Diabetes Mellitus; Diet Therapy; Female; Fetal Death; Glucose Tolerance Test; Glycosuria | 1972 |
Studies on the mechanism of weight reduction by phenformin.
Topics: Biguanides; Diabetes Mellitus; Female; Humans; Metformin; Obesity; Phenformin | 1969 |
[Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides].
Topics: Body Weight; Diabetes Mellitus; Humans; Intestinal Absorption; Lipids; Metformin; Obesity; Vitamin B | 1969 |
[Effects of glucophage on insulin secretion and insulin activity].
Topics: Diabetes Mellitus; Humans; Insulin; Insulin Antagonists; Insulin Secretion; Metformin; Obesity | 1969 |
[Double aim in the treatment of diabetes in obese patients: glycemia equilibration, lipid constant normalization. Trial of delayed-action N,N-dimethyl-biguanide].
Topics: Adult; Aged; Appetite Depressants; Diabetes Mellitus; Female; Humans; Lipid Metabolism; Male; Metfor | 1970 |
Observations on the mechanism of increased weight loss during metformin administration in obesity.
Topics: Body Weight; Carbohydrate Metabolism; Diet Therapy; Female; Humans; Lipid Metabolism; Metformin; Met | 1968 |
[Effect of dimethylbiguanide on plasmatic NEFA after carbohydrate administration in obese subjects].
Topics: Diabetes Mellitus; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Humans; Metformin; O | 1968 |
[Glucose utilization and plasma lipids in obese patients under the effect of dimethylbiguanide (glucophage)].
Topics: Blood Glucose; Cholesterol; Fatty Acids, Nonesterified; Glucose Tolerance Test; Humans; Metformin; O | 1969 |